FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Laporte, M
   Becerra, A
   Castro, L
   Veiga, N
   Espejo-Arce, X
   Bahamondes, L
AF Laporte, Montas
   Becerra, Alejandra
   Castro, Lester
   Veiga Jr, Nelio
   Espejo-Arce, Ximena
   Bahamondes, Luis
TI Evaluation of clinical performance when intrauterine devices are
   inserted by different categories of healthcare professional
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Early Access
DE Clinical performance; Copper intrauterine device; Levonorgestrel
   intrauterine system; Medical residents; Nurses; Physicians
ID AUXILIARY NURSE-MIDWIVES; IUD SERVICES; PROVIDERS; OUTCOMES; TURKEY;
   WOMEN
AB Objective We evaluated clinical performance when the TCu380A intrauterine device (IUD) and the levonorgestrel (LNG) 52-mg intrauterine system (IUS) were inserted by different categories of healthcare professionals. Methods A retrospective study was conducted at the University of Campinas, Brazil. The medical records were reviewed of all women in whom an IUD was inserted between January 1980 and December 2018, with data for at least 1 year, and for whom information on the healthcare provider who inserted the device was available. Results Overall, 19 132 (76.9%) IUD and 5733 (23.1%) LNG-IUS insertions were included, with residents/interns performing 13 853 (55.8%), nurses 7024 (28.2%), and physicians 3988 (16.0%). Removals for pregnancy and infection were significantly higher when physicians inserted the device, while removals for bleeding/pain and other medical reasons were more common when nurses performed the insertion. Expulsion and removals for personal reasons were similar for all three categories. Conclusion Clinical outcomes were similar regardless of whether trained nurses, residents/interns, or physicians inserted the device, and were irrespective of users' age and parity. These results could stimulate other healthcare services, particularly in regions where there is a shortage of physicians, to invest in training nurses to perform insertions of IUDs.
C1 [Laporte, Montas; Becerra, Alejandra; Castro, Lester; Veiga Jr, Nelio; Espejo-Arce, Ximena; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynecol, Fac Med Sci, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Fundacao de Apoio a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Brazilian National Research
   CouncilNational Council for Scientific and Technological Development
   (CNPq)
FX Fundacao de Apoio a Pesquisa do Estado de Sao Paulo; Brazilian National
   Research Council
CR Adeyemi-Fowode OA, 2019, J PEDIATR ADOL GYNEC, V32, pS2, DOI 10.1016/j.jpag.2019.07.001
   AKIN A, 1980, STUD FAMILY PLANN, V11, P178, DOI 10.2307/1965760
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 2018, CONTRACEPTION, V97, P205, DOI 10.1016/j.contraception.2017.10.007
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Brasil. Ministerio da Saude; Secretaria de Politicas de Saude area Tecnica de Saude da Mulher, 2002, ASS PLAN FAM MAN TEC
   EREN N, 1983, STUD FAMILY PLANN, V14, P43, DOI 10.2307/1965401
   Guttmacher Institute, 2017, FACT SHEET ADD IT IN
   Kemeny F, 2016, AUST NZ J OBSTET GYN, V56, P92, DOI 10.1111/ajo.12427
   Lassner K J, 1995, Bull Pan Am Health Organ, V29, P206
   Lohr PA, 2017, CONTRACEPTION, V95, P529, DOI 10.1016/j.contraception.2016.08.011
   Madden T, 2014, OBSTET GYNECOL, V124, P718, DOI 10.1097/AOG.0000000000000475
   Mhlanga FG, 2019, INT PERSPECT SEX R H, V45, P61, DOI 10.1363/45e8019
   de Leon RGP, 2019, LANCET GLOB HEALTH, V7, pE227, DOI 10.1016/S2214-109X(18)30481-9
   Thompson KMJ, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2018.03.016
   Viellas Elaine Fernandes, 2014, Cad Saude Publica, V30 Suppl 1, pS1
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Health Organization (WHO), 2017, TASK SHAR IMPR ACC F
   Yadav V, 2016, CONTRACEPTION, V93, P347, DOI 10.1016/j.contraception.2015.12.012
   ZHANG J, 1992, CONTRACEPTION, V46, P427, DOI 10.1016/0010-7824(92)90146-K
NR 21
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
DI 10.1002/ijgo.13396
EA OCT 2020
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OC4SD
UT WOS:000579147200001
PM 32981045
DA 2020-12-01
ER

PT J
AU Ferreira, LS
   de Nadai, MN
   Poli-Neto, OB
   Franceschini, SA
   Juliato, CRT
   Monteiro, IMU
   Bahamondes, L
   Vieira, CS
AF Ferreira, Leticia Sanchez
   de Nadai, Mariane Nunes
   Poli-Neto, Omero B.
   Franceschini, Silvio A.
   Juliato, Cassia R. T.
   Monteiro, Ilza Maria U.
   Bahamondes, Luis
   Vieira, Carolina Sales
TI Predictors of severe pain during insertion of the levonorgestrel 52 mg
   intrauterine system among nulligravid women
SO CONTRACEPTION
LA English
DT Article
DE Pain; Contraception; Levonorgestrel intrauterine system; Nulligravid
   women
ID DEVICE INSERTION; IUD INSERTION; PRIMARY DYSMENORRHEA; LIDOCAINE GEL;
   TRIAL
AB Objective: To identify sociodemographic and clinical variables associated with severe pain with levonorgestrel 52 mg intrauterine system (IUS) placement among nulligravid women.
   Study design: We performed a secondary analysis of a randomized trial that evaluated intracervical anesthesia before IUS insertion. We assessed factors associated with severe pain (visual analog scale pain score >= 7) immediately after insertion using bivariate and multiple regression analyses.
   Results: Overall, 137/300 (45.7%) subjects reported severe pain. In multiple regression analysis, only intracervical anesthesia [RR 0.55, 95% CI 0.37-0.80] and a history of dysmenorrhea [RR 1.36, 95% CI 1.08-1.72)] were associated with severe pain.
   Conclusions: Among nulligravid women, a history of dysmenorrhea increases, and intracervical block decreases severe pain during levonorgestrel IUS insertion. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Ferreira, Leticia Sanchez; de Nadai, Mariane Nunes; Poli-Neto, Omero B.; Franceschini, Silvio A.; Vieira, Carolina Sales] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Obstet & Gynecol, Ave Bandeirantes 3900,Campus Univ Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Juliato, Cassia R. T.; Monteiro, Ilza Maria U.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Vieira, CS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Obstet & Gynecol, Ave Bandeirantes 3900,Campus Univ Monte Alegre, BR-14049900 Ribeirao Preto, SP, Brazil.
EM carol.sales@uol.com.br
OI Bahamondes, Luis/0000-0002-7356-8428
FU Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo-FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2017/12938-4]
FX This study was funded by the Sao Paulo Research Foundation (Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo-FAPESP), research grant
   #2017/12938-4. The LNG IUS were donated by the International
   Contraceptive Access Foundation, Finland, under an unrestricted grant.
CR Akers AY, 2017, OBSTET GYNECOL, V130, P795, DOI 10.1097/AOG.0000000000002242
   Allen RH, 2014, J OBSTET GYNAECOL, V34, P263, DOI 10.3109/01443615.2013.868424
   Allen RH, 2013, CONTRACEPTION, V88, P730, DOI 10.1016/j.contraception.2013.07.009
   Bednarek PH, 2015, CONTRACEPTION, V91, P193, DOI 10.1016/j.contraception.2014.11.012
   Botega NJ, 1995, REV SAUDE PUBL, V29, P355, DOI 10.1590/S0034-89101995000500004
   Castro TVB, 2014, HUM REPROD, V29, P2439, DOI 10.1093/humrep/deu233
   Chen CX, 2015, EUR J PAIN, V19, P377, DOI 10.1002/ejp.556
   CHI I, 1986, CONTRACEPTION, V34, P483, DOI 10.1016/0010-7824(86)90057-0
   Conti JA, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.11.1085
   da Silva AL, 2017, POSTGRAD MED J, V93, P376, DOI 10.1136/postgradmedj-2016-134247
   De Nadai MN, 2020, AM J OBSTET GYNECOL, V222, DOI 10.1016/j.ajog.2019.09.013
   Dina B, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.10.017
   Doty N, 2015, CONTRACEPTION, V92, P567, DOI 10.1016/j.contraception.2015.05.009
   Santos ARG, 2013, CONTRACEPTION, V88, P164, DOI 10.1016/j.contraception.2012.10.015
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Hubacher D, 2015, CONTRACEPTION, V91, P185, DOI 10.1016/j.contraception.2014.11.006
   Jensen MP, 2001, PAIN, V91, P317, DOI 10.1016/S0304-3959(00)00459-0
   Kaislasuo J, 2014, OBSTET GYNECOL, V124, P345, DOI 10.1097/AOG.0000000000000362
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   Maguire K, 2012, CONTRACEPTION, V86, P214, DOI 10.1016/j.contraception.2012.01.005
   Mody SK, 2018, OBSTET GYNECOL, V132, P575, DOI 10.1097/AOG.0000000000002790
   Morrow N, 2009, MED PHYS, V36, DOI 10.1118/1.3181375
   Payne LA, 2017, J PAIN RES, V10, P2233, DOI 10.2147/JPR.S143512
   Vincent K, 2011, PAIN, V152, P1966, DOI 10.1016/j.pain.2011.03.029
   Wiebe ER, 2015, INT J GYNECOL OBSTET, V129, P172, DOI 10.1016/j.ijgo.2014.11.004
   World Health Organization, 2015, WHO MED EL CRIT CONT
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2020
VL 102
IS 4
BP 267
EP 269
DI 10.1016/j.contraception.2020.07.004
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA OD4GG
UT WOS:000579810300009
PM 32679045
DA 2020-12-01
ER

PT J
AU Adanu, R
   Bahamondes, L
   Brizuela, V
   Gitau, E
   Kouanda, S
   Lumbiganon, P
   Nguyen, TTH
   Saleem, S
   Thorson, A
   Torpey, K
AF Adanu, Richard
   Bahamondes, Luis
   Brizuela, Vanessa
   Gitau, Evelyn
   Kouanda, Seni
   Lumbiganon, Pisake
   Nguyen, Thi Thuy Hanh
   Saleem, Sarah
   Thorson, Anna
   Torpey, Kwasi
TI Strengthening research capacity through regional partners: the HRP
   Alliance at the World Health Organization
SO REPRODUCTIVE HEALTH
LA English
DT Editorial Material
DE Research capacity strengthening; Research; Sexual and reproductive
   health; LMIC
ID TRENDS
AB Background: Improvements in health cannot occur without cutting-edge research informing the design and implementation of health programmes and policies, highlighting the need for qualified and capable researchers and institutions in countries where disease burden is high and resources are limited.
   Main body: Research capacity strengthening efforts in low- and middle-income countries have included provision of training scholarships for postgraduate degrees, often in high-income countries, internships at research universities/centres, short courses, as well as involvement with research groups for hands-on experience, among others. The HRP Alliance provides opportunities for developing local research capacity in sexual and reproductive health and rights through institutions based in low- and middle-income countries linked with ongoing and past collaborative studies. It is a network of HRP research partner institutions, World Health Organization (WHO) country and regional offices, WHO special programmes and partnerships, and WHO collaborating centres.
   Conclusion: It is through the HRP Alliance that HRP seeks to improve population health by strengthening local research capacity in sexual and reproductive health across the globe, with focus in low- and middle-income countries, in alignment with WHO's quest of promoting healthier populations.
C1 [Adanu, Richard; Torpey, Kwasi] Univ Ghana, Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Accra, Ghana.
   [Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Fac, Campinas, SP, Brazil.
   [Brizuela, Vanessa; Thorson, Anna] WHO, UNDP UNFPA UNICEF WHO World Bank Special Program, Dept Sexual & Reprod Hlth & Res, Ave Appia 20, CH-1211 Geneva, Switzerland.
   [Gitau, Evelyn] African Populat & Hlth Res Ctr, Nairobi, Kenya.
   [Kouanda, Seni] Inst Rech Sci Sante IRSS, Ouagadougou, Burkina Faso.
   [Lumbiganon, Pisake] Khon Kaen Univ, Dept Obstet & Gynaecol, Fac Med, Khon Kaen, Thailand.
   [Nguyen, Thi Thuy Hanh] Hanoi Med Univ, Inst Prevent Med & Publ Hlth, Hanoi, Vietnam.
   [Saleem, Sarah] Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan.
RP Brizuela, V (corresponding author), WHO, UNDP UNFPA UNICEF WHO World Bank Special Program, Dept Sexual & Reprod Hlth & Res, Ave Appia 20, CH-1211 Geneva, Switzerland.
EM brizuelav@who.int
OI Lumbiganon, Pisake/0000-0001-9372-0071; Brizuela,
   Vanessa/0000-0002-4860-0828
FU UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP)
FX The HRP Alliance is funded by the UNDP/UNFPA/UNICEF/WHO/World Bank
   Special Programme of Research, Development and Research Training in
   Human Reproduction (HRP). The views of the funding body have not
   influenced the content of this manuscript. This article represents the
   views of the named authors only and does not represent the views of WHO.
CR Aman MI, 2020, LANCET GLOB HEALTH, V8, pE661, DOI 10.1016/S2214-109X(20)30109-1
   Belizan JM, 2017, LANCET, V389, P1697, DOI 10.1016/S0140-6736(17)31064-4
   Bohren MA, 2019, LANCET, V394, P1750, DOI 10.1016/S0140-6736(19)31992-0
   Bowsher G, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/s12992-019-0465-y
   Chu KM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001612
   Hedt-Gauthier BL, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001853
   Iyer AR, 2018, LANCET GLOB HEALTH, V6, pE142, DOI 10.1016/S2214-109X(17)30497-7
   Kabra R, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-016-0222-0
   Kelaher M, 2016, INT J EPIDEMIOL, V45, P2174, DOI 10.1093/ije/dyw313
   Kim CR, 2016, BMJ GLOB HEALTH, V1, DOI 10.1136/bmjgh-2016-000113
   Matus J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3518-7
   Maung TM, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-0907-2
   Thorson A, 2020, INT J GYNECOL OBSTET, V148, P1, DOI 10.1002/ijgo.13040
   Tran NT, 2019, LANCET GLOB HEALTH, V7, pE1109, DOI 10.1016/S2214-109X(19)30202-5
   Tulloch-Reid M, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k2456
   WHO, WHO HRP ALL
   World Health Organization, 2013, RES U HLTH COV, P146
NR 17
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-4755
J9 REPROD HEALTH
JI Reprod. Health
PD AUG 26
PY 2020
VL 17
IS 1
AR 131
DI 10.1186/s12978-020-00965-0
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NJ3WK
UT WOS:000565977600001
PM 32847605
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Fernandes, A
   Monteiro, I
   Bahamondes, MV
AF Bahamondes, Luis
   Fernandes, Arlete
   Monteiro, Ilza
   Bahamondes, M. Valeria
TI Long-acting reversible contraceptive (LARCs) methods
SO BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
LA English
DT Review
DE Contraception; Long acting contraceptives; Copper intrauterine device;
   Levonorgestrel-releasing intrauterine system; Subdermal implants; LARCs
ID INTRAUTERINE-DEVICE; CERVICAL-MUCUS; EXTENDED USE; CLINICAL-PERFORMANCE;
   ETONOGESTREL IMPLANT; UNINTENDED PREGNANCY; ECTOPIC PREGNANCY; PROLONGED
   USE; LEVONORGESTREL; SYSTEM
AB Unplanned pregnancy (UP) is a public health problem, which affects millions of women worldwide. Providing long-acting reversible contraceptive (LARC) methods is an excellent strategy to avoid or at least reduce UP, because the effectiveness of these methods is higher than other methods, and is indeed comparable to that of permanent contraception. As the initial introduction of the inert plastic intrauterine device (IUD) and of the six-rod implant, pharmaceutical companies have introduced a copper IUD (Cu-IUD), different models of levonorgestrel-releasing intrauterine system (LNG IUS), and one and two-rod implants, which certainly improved women's LARC options. The main characteristic of LARCs is that they provide high contraceptive effectiveness with a single intervention, and that they can be used for a long time. Emerging evidence from the last few years has demonstrated that it is possible to extend the use of the 52 mg LNG IUS and of the etonogestrel-implant beyond five- and three years, respectively, which adds new value to these LARCs. (C) 2019 Published by Elsevier Ltd.
C1 [Bahamondes, Luis; Fernandes, Arlete; Monteiro, Ilza] Univ Estadual Campinas, Fac Med Sci UNICAMP, Dept Obstet & Gynecol, BR-61811308 Campinas, SP, Brazil.
   [Bahamondes, M. Valeria] Ctr Latinoamer Perinatol Salud Mujer & Reproduct, Montevideo, Uruguay.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci UNICAMP, Dept Obstet & Gynecol, BR-61811308 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI ; Fernandes, Arlete/I-7561-2018
OI Bahamondes, Luis/0000-0002-7356-8428; Fernandes,
   Arlete/0000-0001-5872-0017
CR Ali M, 2017, GLOB HEALTH-SCI PRAC, V5, P534, DOI 10.9745/GHSP-D-17-00296
   Ali M, 2016, HUM REPROD, V31, P2491, DOI 10.1093/humrep/dew222
   ALVAREZ F, 1988, FERTIL STERIL, V49, P768
   [Anonymous], 2018, Obstet Gynecol, V131, pe130, DOI 10.1097/AOG.0000000000002632
   [Anonymous], 1994, Contraception, V49, P543
   [Anonymous], 2017, TRACKING PROGR UNIVE
   Apter D, 2014, FERTIL STERIL, V101, P1656, DOI 10.1016/j.fertnstert.2014.03.004
   AREF I, 1983, CONTRACEPT DELIV SYS, V4, P203
   Backman T, 2004, AM J OBSTET GYNECOL, V190, P50, DOI 10.1016/j.ajog.2003.07.021
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 2018, HUM REPROD OPEN, V1
   Bahamondes L, 2019, EUR J CONTRACEP REPR, V24, P97, DOI 10.1080/13625187.2019.1586872
   Bahamondes L, 2018, CONTRACEPTION, V97, P205, DOI 10.1016/j.contraception.2017.10.007
   Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023
   Bahamondes L, 2015, INT J WOMENS HEALTH, V7, P717, DOI 10.2147/IJWH.S84173
   Bahamondes L, 2013, FERTIL STERIL, V100, P445, DOI 10.1016/j.fertnstert.2013.03.039
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Barnett C, 2017, EUR J CONTRACEP REPR, V22, P424, DOI 10.1080/13625187.2017.1412427
   Bayer Ltd, ATR BLACKTH ROAD SAN
   BERGINK EW, 1981, J STEROID BIOCHEM, V14, P175, DOI 10.1016/0022-4731(81)90171-0
   Borders AE, 2016, OBSTET GYNECOL, V128, pE32
   BRACHE V, 1985, CONTRACEPTION, V31, P261, DOI 10.1016/0010-7824(85)90096-4
   Brahmi D, 2012, CONTRACEPTION, V85, P131, DOI 10.1016/j.contraception.2011.06.010
   Brunson MR, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.02.036
   Carvalho N, 2018, FERTIL STERIL, V110, P1129, DOI 10.1016/j.fertnstert.2018.07.003
   Castellsague X, 2011, LANCET ONCOL, V12, P1023, DOI 10.1016/S1470-2045(11)70223-6
   Croxatto HB, 1998, CONTRACEPTION, V58, p91S, DOI 10.1016/S0010-7824(98)00118-8
   Curtis KM, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6504a1
   Daniels K, 2015, CURRENT CONTRACEPTIV
   Darney P, 2009, FERTIL STERIL, V91, P1646, DOI 10.1016/j.fertnstert.2008.02.140
   Darroch JE, 2017, ADDING IT INVESTING
   DIAZ S, 1991, CONTRACEPTION, V44, P393, DOI 10.1016/0010-7824(91)90030-J
   Diedrich JT, 2017, AM J OBSTET GYNECOL, V216, P364, DOI 10.1016/j.ajog.2016.12.024
   Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575
   Ganacharya S, 2003, EUR J OBSTET GYN R B, V111, P78, DOI 10.1016/S0301-2115(03)00208-2
   Gavin L, 2017, CONTRACEPTION, V96, P149, DOI 10.1016/j.contraception.2017.05.013
   Gemzell-Danielsson K, 2017, EUR J OBSTET GYN R B, V210, P22, DOI 10.1016/j.ejogrb.2016.11.022
   Gemzell-Danielsson K, 2012, FERTIL STERIL, V97, P616, DOI 10.1016/j.fertnstert.2011.12.003
   Goldstuck ND, 2017, EXPERT REV MED DEVIC, V14, P593, DOI 10.1080/17434440.2017.1350169
   Goldthwaite LM, 2019, CONTRACEPTION, V100, P128, DOI 10.1016/j.contraception.2019.03.044
   Grimes DA, 2000, LANCET, V356, P1013, DOI 10.1016/S0140-6736(00)02699-4
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   Heinemann K, 2015, CONTRACEPTION, V91, P280, DOI 10.1016/j.contraception.2015.01.011
   Heller R, 2016, J FAM PLAN REPROD H, V42, P93, DOI 10.1136/jfprhc-2014-101165
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hidalgo MM, 2006, CONTRACEPTION, V73, P532, DOI 10.1016/j.contraception.2005.12.012
   Hopkins MR, 2009, CONTRACEPTION, V79, P323, DOI 10.1016/j.contraception.2008.10.008
   Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438
   Huber J, 1998, CONTRACEPTION, V58, p85S, DOI 10.1016/S0010-7824(98)00120-6
   Itriyeva K, 2018, CURR PROB PEDIATR AD, V48, P321, DOI 10.1016/j.cppeds.2018.11.002
   Jackson E, 2011, OBSTET GYNECOL, V117, P657, DOI 10.1097/AOG.0b013e31820ce18c
   Jatlaoui TC, 2018, OBSTET GYNECOL, V132, P895, DOI 10.1097/AOG.0000000000002822
   Kapp N, 2009, CONTRACEPTION, V80, P327, DOI 10.1016/j.contraception.2009.03.024
   KIRKINEN P, 1992, ULTRASOUND OBST GYN, V2, P345, DOI 10.1046/j.1469-0705.1992.02050345.x
   Kulier R, 2007, COCHRANE DB SYST REV, V4
   Le J, 2001, ANN PHARMACOTHER, V35, P329
   Luukkainen T, 2001, SEMIN REPROD MED, V19, P355, DOI 10.1055/s-2001-18643
   LUUKKAINEN T, 1983, AM J OBSTET GYNECOL, V147, P885, DOI 10.1016/0002-9378(83)90240-5
   MacIsaac L, 2007, OBSTET GYN CLIN N AM, V34, P91, DOI 10.1016/j.ogc.2007.02.004
   Madden T, 2014, OBSTET GYNECOL, V124, P718, DOI 10.1097/AOG.0000000000000475
   Makarainen L, 1998, FERTIL STERIL, V69, P714, DOI 10.1016/S0015-0282(98)00015-6
   Mansour D, 2010, EUR J CONTRACEP REPR, V15, P4, DOI 10.3109/13625180903427675
   McNicholas C, 2015, OBSTET GYNECOL, V125, P599, DOI 10.1097/AOG.0000000000000690
   Meirik O, 2009, CONTRACEPTION, V80, P133, DOI 10.1016/j.contraception.2009.02.006
   Mishell DR, 1992, FERTILITY CONTROL RE, V3, P3
   Moraes LG, 2016, EUR J CONTRACEP REPR, V21, P318, DOI 10.1080/13625187.2016.1193139
   Morgan IA, 2019, J PEDIATR ADOL GYNEC, V32, P402, DOI 10.1016/j.jpag.2019.01.007
   Natavio MF, 2013, CONTRACEPTION, V87, P426, DOI 10.1016/j.contraception.2012.09.034
   NILSSON CG, 1981, LANCET, V1, P577
   Pam V C, 2016, Niger Med J, V57, P314
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Phillips SJ, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.03.005
   Phillips SJ, 2016, CONTRACEPTION, V94, P226, DOI 10.1016/j.contraception.2015.09.010
   Rivera R, 1999, CONTRACEPTION, V60, P155, DOI 10.1016/S0010-7824(99)00077-3
   Schiesser M, 2004, ULTRASOUND OBST GYN, V23, P486, DOI 10.1002/uog.1036
   Seeber B, 2012, CONTRACEPTION, V86, P345, DOI 10.1016/j.contraception.2012.01.015
   SIVIN I, 1991, OBSTET GYNECOL, V78, P291
   SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X
   SIVIN I, 1989, STUD FAMILY PLANN, V20, P355, DOI 10.2307/1966438
   SIVIN I, 1981, FERTIL STERIL, V36, P159
   SIVIN I, 1993, CONTRACEPTION, V47, P37
   Steenland MW, 2013, CONTRACEPTION, V87, P625, DOI 10.1016/j.contraception.2012.09.018
   Taneepanichskula S, 2006, CONTRACEPTION, V73, P368, DOI 10.1016/j.contraception.2005.10.010
   TREDWAY DR, 1975, AM J OBSTET GYNECOL, V123, P734, DOI 10.1016/0002-9378(75)90497-4
   Trussell J, 2007, CONTRACEPTIVE TECHNO, P747
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Whitaker AK, 2018, CONTRACEPTION, V97, P2, DOI 10.1016/j.contraception.2017.09.014
   Wildemeersch Dirk, 2016, Clin Med Insights Reprod Health, V10, P19, DOI 10.4137/CMRH.S40087
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2005, REP WHO TECHN CONS B
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Health Organization, 1987, TECHN REP SER WHO, V753, P91
   Wu JP, 2018, JAMA-J AM MED ASSOC, V320, P397, DOI 10.1001/jama.2018.8877
   Yisa SB, 2005, J FAM PLAN REPROD H, V31, P67, DOI 10.1783/0000000052972799
   Zhu HL, 2013, CONTRACEPTION, V87, P416, DOI 10.1016/j.contraception.2012.11.002
NR 97
TC 5
Z9 5
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6934
EI 1532-1932
J9 BEST PRACT RES CL OB
JI Best Pract. Res. Clin. Obstet. Gynaecol.
PD JUL
PY 2020
VL 66
SI SI
BP 28
EP 40
DI 10.1016/j.bpobgyn.2019.12.002
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA MO6PR
UT WOS:000551645800004
PM 32014434
DA 2020-12-01
ER

PT J
AU Barbieri, MM
   Juliato, CRT
   Bahamondes, L
   Surita, FG
AF Barbieri, M. M.
   Juliato, C. R. T.
   Bahamondes, L.
   Surita, F. G.
TI ENG-releasing subdermal implants in postpartum teenagers - an open-label
   trial study protocol
SO REPRODUCTIVE HEALTH
LA English
DT Article
DE Subdermal implant; Contraception; Puerperium; Teenagers
ID ADOLESCENT PREGNANCY; ETONOGESTREL IMPLANT; REPEAT PREGNANCY; EARLY
   INITIATION; CONTRACEPTION; EXPERIENCE
AB Background: Higher than expected adolescent pregnancy high rates continue globally, with repeated unplanned pregnancy (UP) in this age group is a public health problem. In Brazil, 16% of pregnancies occur in adolescents under 18 years old, with high maternal morbidity and mortality rates in this age group. Effective and safe contraception is required to reduce UP rates. The objective of our study is to evaluate acceptance of etonogestrel (ENG)-releasing subdermal contraceptive implant after childbirth, before discharge, as well as clinical performance up to one year after placement. Comparison between teenagers who opt for ENG-implant versus other contraceptive methods after childbirth will be also evaluated, specifically regarding UP, continuation and discontinuation rates and reasons, body composition, pelvic ultrasound characteristics and user satisfaction.
   Methods: A non-randomized open-label trial will be conducted with teenagers after childbirth and followed up to one year at the Women's Hospital, University of Campinas (UNICAMP), Campinas, Brazil. The study group will consist of patients who accepted to use ENG-implant and placed before discharge. The comparison group will include adolescents who choose to use other contraceptive methods at the first postpartum visit (42 +/- 3 days after childbirth). All women will follow-up at 40-60 days postpartum, as well as, at 6 and 12 months post-enrollment. Patient satisfaction, contraceptive effectiveness, reasons of discontinuation, continuation rate and body composition will be evaluated. Transvaginal ultrasound and electric bio impedance tests will be performed at all follow-up appointments. A 5% significance level was assumed, as well as, a sampling error (absolute) for 10% prevalence. The sample size was calculated atn = 100, obtaining an estimate of 50 to 70 adolescents who would accept the method offered, according to the prevalence and sample error assumed.
   Discussion: Long-acting reversible contraceptive (LARC) methods include subdermal implants and intrauterine contraceptives, are considered first line contraception for teenagers. Immediate postpartum use is a safe option, which significantly reduces rates of repeated UP and all the undesirable consequences inherent to this process.
C1 [Barbieri, M. M.; Juliato, C. R. T.; Bahamondes, L.; Surita, F. G.] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Ave Alexander Fleming, BR-101 Campinas, SP, Brazil.
RP Surita, FG (corresponding author), Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Ave Alexander Fleming, BR-101 Campinas, SP, Brazil.
EM surita@unicamp.br
RI Surita, Fernanda/H-9575-2012
OI Surita, Fernanda/0000-0003-4335-0337
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2018/20868-9]
FX Financial support for this study was obtained from the Sao Paulo
   Research Foundation (FAPESP), grant number 2018/20868-9.
CR Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   Borovac-Pinheiro A, 2016, REV BRAS GINECOL OBS, V38, P545, DOI 10.1055/s-0036-1593971
   Brito MB, 2009, CONTRACEPTION, V80, P519, DOI 10.1016/j.contraception.2009.05.124
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chen MJ, 2017, INT J GYNECOL OBSTET, V136, P113, DOI 10.1002/ijgo.12064
   Coles MS, 2011, CONTRACEPTION, V84, P578, DOI 10.1016/j.contraception.2011.03.008
   Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group The American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P983
   Damle LF, 2015, J PEDIATR ADOL GYNEC, V28, P57, DOI 10.1016/j.jpag.2014.04.005
   Galvao RBD, 2018, REV BRAS GINECOL OBS, V40, P437, DOI 10.1055/s-0038-1666811
   Carmo LSDP, 2017, OBSTET GYNECOL, V130, P100, DOI 10.1097/AOG.0000000000002092
   Diedrich JT, 2017, AM J OBSTET GYNECOL, V216, P364, DOI 10.1016/j.ajog.2016.12.024
   Diedrich JT, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.07.025
   Eliscu AH, 2016, J PEDIATR-US, V175, P22, DOI 10.1016/j.jpeds.2016.05.007
   Fleming N, 2015, J OBSTET GYNAECOL CA, V37, P740, DOI 10.1016/S1701-2163(15)30180-8
   Fridy RL, 2018, J PEDIATR ADOL GYNEC, V31, P394, DOI 10.1016/j.jpag.2018.01.004
   Kirbas A, 2016, J PEDIATR ADOL GYNEC, V29, P367, DOI 10.1016/j.jpag.2015.12.010
   Kozuki N, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S2
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Levine JP, 2008, CONTRACEPTION, V78, P409, DOI 10.1016/j.contraception.2008.06.016
   Obijuru L, 2016, J ADOLESCENT HEALTH, V58, P284, DOI 10.1016/j.jadohealth.2015.10.254
   Oliveira FC, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-77
   Oringanje C, 2016, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD005215.PUB3
   Ott MA, 2014, PEDIATRICS, V134, pE1244, DOI 10.1542/peds.2014-2299
   Tejada CAO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171888
   Silva JLPE, 2017, REV BRAS GINECOL OBS, V39, P41, DOI 10.1055/s-0037-1600899
   Pritt NM, 2017, J PEDIATR ADOL GYNEC, V30, P18, DOI 10.1016/j.jpag.2016.07.002
   Sedgh G, 2015, J ADOLESCENT HEALTH, V56, P223, DOI 10.1016/j.jadohealth.2014.09.007
   Speroff L, 2008, CONTRACEPTION, V78, P90, DOI 10.1016/j.contraception.2008.04.005
   Tocce K, 2012, J PEDIATR ADOL GYNEC, V25, P59, DOI 10.1016/j.jpag.2011.09.003
   Wilson S, 2014, CONTRACEPTION, V90, P259, DOI 10.1016/j.contraception.2014.05.006
NR 30
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-4755
J9 REPROD HEALTH
JI Reprod. Health
PD JUN 23
PY 2020
VL 17
IS 1
AR 100
DI 10.1186/s12978-020-00952-5
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA ME7UN
UT WOS:000544860200001
PM 32576199
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Ferreira, ES
   de Melo, NR
   Sorpreso, ICE
   Bahamondes, L
   Simoes, RD
   Soares, JM
   Baracat, EC
AF Ferreira-Filho, Edson Santos
   de Melo, Nilson Roberto
   Sorpreso, Isabel Cristina Esposito
   Bahamondes, Luis
   Simoes, Ricardo Dos Santos
   Soares-Junior, Jose Maria
   Baracat, Edmund Chada
TI Contraception and reproductive planning during the COVID-19 pandemic
SO EXPERT REVIEW OF CLINICAL PHARMACOLOGY
LA English
DT Review
DE Contraception; coronavirus; COVID-19; SARS-CoV-2; reproductive health;
   family planning
ID ORAL-CONTRACEPTIVES; HORMONAL CONTRACEPTION; ETHINYL ESTRADIOL;
   DRUG-INTERACTIONS; EXTENDED USE; WOMEN; PHARMACOKINETICS; HEALTH;
   LOPINAVIR/RITONAVIR; AZITHROMYCIN
AB Introduction The coronavirus disease (COVID-19) is a global health emergency. Major disruption to healthcare services during the current COVID-19 pandemic will last even after its peak. Sexual and reproductive health (SRH), specially contraception, needs to be understood as an essential service. Areas covered This paper is a narrative review. Data from PubMed/MEDLINE, Scopus, and websites of scientific societies were screened during the months of April and May 2020. It addresses the main aspects related to contraception during the COVID-19 pandemic, with special emphasis on family planning services, extended use of long-acting reversible contraceptive (LARC) methods, drug interactions, and thromboembolism risk. We also specified some issues focused on the Brazilian reality. Expert opinion Ensuring proper contraception use in the COVID-19 time is very important. We encourage women, healthcare providers, policymakers, and the society to consider SRH services as priority.
C1 [Ferreira-Filho, Edson Santos; de Melo, Nilson Roberto; Sorpreso, Isabel Cristina Esposito; Simoes, Ricardo Dos Santos; Soares-Junior, Jose Maria; Baracat, Edmund Chada] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Gynecol Div, Sao Paulo, Brazil.
   [Bahamondes, Luis] Univ Campinas Unicamp, Dept Obstet & Gynecol, Family Planning Clin, Fac Med Sci, Campinas, Brazil.
RP Ferreira, ES (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Gynecol Div, Sao Paulo, Brazil.
EM edson.f@fm.usp.br
RI Ferreira-Filho, Edson S/C-6136-2012; Sorpreso, Isabel Cristina
   Esposito/C-4054-2013; Soares-Jr, Jose Maria/G-1467-2012
OI Ferreira-Filho, Edson S/0000-0002-0017-3273; Sorpreso, Isabel Cristina
   Esposito/0000-0002-5475-5957; Soares-Jr, Jose Maria/0000-0003-0774-9404;
   Bahamondes, Luis/0000-0002-7356-8428
CR Ali M, 2016, HUM REPROD, V31, P2491, DOI 10.1093/humrep/dew222
   Anderson FA, 2003, CIRCULATION, V107, pI9, DOI 10.1161/01.CIR.0000078469.07362.E6
   Asociacion Espanola para el Estudio de la Menopausia; Sociedad Espanola de Ginecologia y Obstetricia; Sociedad Espanola de Trombosis y Hemostasia, 2020, RIESG GIN OBST SOC E
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 2018, CONTRACEPTION, V97, P205, DOI 10.1016/j.contraception.2017.10.007
   Bearak J, 2018, LANCET, V6, pe380
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bellizzi S, 2020, CONTRACEPTION, V101, P26, DOI 10.1016/j.contraception.2019.09.006
   Bietsch K, 2020, STUD FAMILY PLANN, DOI 10.1111/sifp.12110
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   British Association of Sexual Health and HIV, 2020, CONT PLANN OUTP GEN
   Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6
   College National des Enseignants de Gynecologie Medicale; L'Unite d'Hemostase Clinique de Cochin, 2020, PREV RISQ THROMB VEI
   ComissAo Nacional de AnticoncepcAo da Febrasgo, 2020, ANT DUR PAND COVID 1
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Costanzo G, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X19899296
   Curtis KM, 2016, MMWR RECOMM REP, V2016, P65, DOI DOI 10.15585/MMWR.RR6504A1
   de Bastos M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010813.pub2
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Sorpreso ICE, 2015, REV BRAS GINECOL OBS, V37, P395, DOI 10.1590/SO100-720320150005456
   Faculty of Sexual and Reproductive Healthcare, 2020, FSRH CEU CLIN ADV SU
   Faculty of Sexual and Reproductive Healthcare, 2020, FSRH GUID CONTR PROV
   Fischer JH, 2012, ANTIMICROB AGENTS CH, V56, P715, DOI 10.1128/AAC.00717-11
   Guilhem D, 2007, DEV WORLD BIOETH, V7, P68, DOI 10.1111/j.1471-8847.2007.00201.x
   Hall KS, 2020, LANCET, V395, P1175, DOI 10.1016/S0140-6736(20)30801-1
   Hendrix CW, 2004, CLIN PHARMACOL THER, V75, P464, DOI 10.1016/j.clpt.2004.01.003
   Kinyanjui N, 2020, COVID 19 DOUBLE BURD
   Jacomini LCL, 2011, REV BRAS REUMATOL, V51, P161
   Landolt NK, 2016, JAIDS-J ACQ IMM DEF, V72, P507, DOI 10.1097/QAI.0000000000000997
   Lazorwitz A, 2020, CONTRACEPTION, VS0010-7824
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Liu X, 2016, AM J THER, V23, pe388
   Luque AE, 2015, ANTIMICROB AGENTS CH, V59, P2094, DOI 10.1128/AAC.04701-14
   da Silva ATM, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-017-0498-4
   McNicholas C, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.01.036
   Ministerio da Saude, 2019, REL NAC MED ESS REN
   Nahata M, 1996, J ANTIMICROB CHEMOTH, V37, P133, DOI 10.1093/jac/37.suppl_C.133
   Nanda K, 2020, GLOB HEALTH-SCI PRAC, V8, P166, DOI 10.9745/GHSP-D-20-00119
   NIH, 2020, COVID 19 TREATM GUID
   Ramirez I, 2020, MATURITAS, V137, P57, DOI 10.1016/j.maturitas.2020.04.019
   Raps M, 2012, J THROMB HAEMOST, V10, P992, DOI 10.1111/j.1538-7836.2012.04720.x
   Riley Taylor, 2020, Int Perspect Sex Reprod Health, V46, P73, DOI 10.1363/46e9020
   Rowe PJ, 1997, CONTRACEPTION, V56, P341
   Sanchez LA, 2007, FERTIL STERIL, V87, P713, DOI 10.1016/j.fertnstert.2006.07.1507
   Sanofi-aventis Canada Inc, 2017, SAR PROD MON
   Short M, 2020, EUR J CONTRACEP REPR, V25, P167, DOI 10.1080/13625187.2020.1754036
   Sitruk-Ware R, 2016, FERTIL STERIL, V106, P1289, DOI 10.1016/j.fertnstert.2016.08.039
   Skala SL, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.020
   Slayter KL, 1996, CLIN PHARMACOL THER, V59, P312, DOI 10.1016/S0009-9236(96)80009-9
   Stelzig KE, 2020, AM J PHYSIOL-LUNG C, V318, pL1280, DOI 10.1152/ajplung.00153.2020
   Tang K, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-0900-9
   Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014
   Thaxton L, 2019, INT J GYNECOL OBSTET, V144, P2, DOI 10.1002/ijgo.12696
   The American College of Obstetricians and Gynecologists (ACOG), 2020, COVID 19 FAQS OBST G
   Thomas CM, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003815
   Ti AJ, 2020, AM J OBSTET GYNECOL, V223, P24, DOI 10.1016/j.ajog.2020.01.014
   U.S. Food and Drug Administration, 2010, LEFL PACK INS
   Bustamante LHU, 2016, REV BRAS PSIQUIATR, V38, P263, DOI 10.1590/1516-4446-2015-1883
   United Nations Population Fund, 2020, SEX REPR HLTH RIGHTS
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Vieira CS, 2014, JAIDS-J ACQ IMM DEF, V66, P378, DOI 10.1097/QAI.0000000000000189
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   WHO Health Emergency, 2020, DASHB WHO COVID 19 H
   World Health Organization, 2020, CONTR FAM PLANN COVI
   World Health Organization, 2015, MED EL CRIT CONTR US
   Zhang XP, 2014, INT J CLIN PHARM TH, V52, P27, DOI 10.5414/CP201951
   2016, OBSTET GYNECOL, V127
NR 68
TC 4
Z9 4
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1751-2433
EI 1751-2441
J9 EXPERT REV CLIN PHAR
JI Expert Rev. Clin. Pharmacol.
PD JUN 2
PY 2020
VL 13
IS 6
BP 615
EP 622
DI 10.1080/17512433.2020.1782738
EA JUN 2020
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA MR6FQ
UT WOS:000547281600001
PM 32538185
OA Bronze
DA 2020-12-01
ER

PT J
AU Miranda, L
   Townsend, J
   Faundes, A
   Bahamondes, L
AF Miranda, Laura
   Townsend, John
   Faundes, Anibal
   Bahamondes, Luis
TI The benefits and limitations of donating new contraceptive technology:
   The case of the International Contraceptive Access (ICA) Foundation and
   the LNG IUS Program in Brazil
SO CONTRACEPTION
LA English
DT Editorial Material
DE Levonorgestrel-intrauterine system; inequity; Women's health; Brazil;
   ICA Foundation
ID INTRAUTERINE SYSTEM
C1 [Miranda, Laura; Faundes, Anibal; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Townsend, John] Populat Council, Washington, DC USA.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
OI Bahamondes, Luis/0000-0002-7356-8428
CR [Anonymous], 2011, RESPOND PROJECT TECH
   Bahamondes L, 2018, CONTRACEPTION, V97, P205, DOI 10.1016/j.contraception.2017.10.007
   Ferreira JM, 2017, J FAM PLAN REPROD H, V43, P181, DOI 10.1136/jfprhc-2016-101569
   Juliato CRT, 2018, CONTRACEPTION, V98, P252, DOI 10.1016/j.contraception.2018.04.017
   Kaunitz AM, 2009, OBSTET GYNECOL, V113, P1104, DOI 10.1097/AOG.0b013e3181a1d3ce
   Stover J, 2000, EVALUATION REV, V24, P3, DOI 10.1177/0193841X0002400101
   Bahamondes MV, 2012, CONTRACEPTION, V86, P244, DOI 10.1016/j.contraception.2011.12.005
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2020
VL 101
IS 6
BP 367
EP 369
DI 10.1016/j.contraception.2020.01.003
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA LO3JJ
UT WOS:000533524600002
PM 32007419
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Makuch, MY
AF Bahamondes, Luis
   Makuch, Maria Y.
TI Family planning: an essential health activity in the pandemic of
   SARS-CoV-2
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Editorial Material
C1 [Bahamondes, Luis; Makuch, Maria Y.] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, Brazil.
EM bahamond@caism.unicamp.br
CR Ali M, 2017, GLOB HEALTH-SCI PRAC, V5, P534, DOI 10.9745/GHSP-D-17-00296
   Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226
   Faculty of Sexual and Reproductive Health, 2020, FSRH CEU CLIN ADV SU
   [Faculty of Sexual and Reproductive Healthcare. Faculty of Sexual and Reproductive Healthcare], FSRH CEU REC EXT US
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   World Bank, 2019, TRENDS MAT MORT 2000, V2
NR 6
TC 2
Z9 3
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD JUL 3
PY 2020
VL 25
IS 4
BP 319
EP 320
DI 10.1080/13625187.2020.1768368
EA MAY 2020
PG 2
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA MR8NV
UT WOS:000538327800001
PM 32436743
DA 2020-12-01
ER

PT J
AU Laporte, M
   Marangoni, M
   Surita, F
   Juliato, CT
   Miadaira, M
   Bahamondes, L
AF Laporte, Montas
   Marangoni, Marcos, Jr.
   Surita, Fernanda
   Juliato, Cassia T.
   Miadaira, Mariana
   Bahamondes, Luis
TI Postplacental placement of intrauterine devices: A randomized clinical
   trial
SO CONTRACEPTION
LA English
DT Article
DE Copper IUD; Levonorgestrel intrauterine system; Postpartum placement;
   Randomized trial
ID INSERTION; EXPERIENCE; HEALTH; NEED
AB Objective: To compare the expulsion rate of the TCu380A intrauterine device (IUD) or levonorgestrel (LNG) 52 mg intrauterine system (IUS) up to 90 days after postplacental placement (10 min after delivery of the placenta).
   Study design: Randomized trial (1:1) of women aged 18-43 years and >= 37 weeks pregnant enrolled during early or prodromal labor at the University of Campinas, Brazil. Follow-up was scheduled at 42 and 90 days after device placement. We confirmed the IUD or IUS location using ultrasonography. Multivariate logistic regression was used to assess variables associated with expulsion.
   Results: We enrolled 140 women, and assigned 70 to the TCu380A IUD and 70 to the IUS groups. By the 90-day follow-up visit, 22/60 women (36.7%) in the TCu380A IUD group had expelled the device, as had 12/60 women in the IUS group (20%). Thirty-three of the 34 expulsions had occurred by the 42-day visit. Multivariate analysis demonstrated that the expulsion odds ratio ([OR]; 95% confidence interval [CI]) was higher after vaginal delivery than after Cesarean delivery (OR 5.60; 95% CI 2.08-15.10; P < 0.00) and higher among women with one (OR 4.38; 95% CI 1.33-14.43: P 0.00) or three or more deliveries (including the present one) (OR 6.08; 95% CI 1.78-20.77; P 0.00) than those with two deliveries.
   Conclusions: Postplacental TCu380A IUD placement had a higher expulsion rate than the IUS, and the expulsion rate was higher among women who had a vaginal delivery than those who had a Cesarean delivery. Most of the expulsions occurred within 42 days. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Laporte, Montas; Marangoni, Marcos, Jr.; Surita, Fernanda; Juliato, Cassia T.; Miadaira, Mariana; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Laporte, Montas/AAL-7757-2020; Surita, Fernanda/H-9575-2012
OI Laporte, Montas/0000-0002-9906-4367; Surita,
   Fernanda/0000-0003-4335-0337; Bahamondes, Luis/0000-0002-7356-8428
FU Organization of American States; Fundacao de Apoio a Pesquisa do Estado
   de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2015/20504-9]; Brazilian National Research Council
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [573747/2008-3]; International Contraceptive Access Foundation,
   Turku, Finland
FX ML is PhD student with a fellowship funded by the Organization of
   American States. This study received partial financial support from the
   Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP) award No.
   2015/20504-9 and from the Brazilian National Research Council (CNPq)
   grant No. 573747/2008-3. The TCu380A IUDs were donated by Pregna,
   Mumbai, India. Since 2007, the LNG-IUSs used at our clinic have been
   donated by the International Contraceptive Access Foundation, Turku,
   Finland, under an unrestricted grant.
CR Bahamondes L, 2018, HUM REPROD OPEN, V2018
   Chen BA, 2010, OBSTET GYNECOL, V116, P1079, DOI 10.1097/AOG.0b013e3181f73fac
   Conde-Agudelo A, 2012, STUD FAMILY PLANN, V43, P93, DOI 10.1111/j.1728-4465.2012.00308.x
   Dahlke JD, 2011, CONTRACEPTION, V84, P244, DOI 10.1016/j.contraception.2011.01.007
   Darroch JE, 2013, LANCET, V381, P1756, DOI 10.1016/S0140-6736(13)60597-8
   Eluwa GIE, 2016, GLOB HEALTH-SCI PRAC, V4, P276, DOI 10.9745/GHSP-D-16-00072
   Goldthwaite LM, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.08.001
   Heller R, 2016, J FAM PLAN REPROD H, V42, P93, DOI 10.1136/jfprhc-2014-101165
   Hinz EK, 2019, CONTRACEPTION
   Jatlaoui TC, 2018, OBSTET GYNECOL, V132, P895, DOI 10.1097/AOG.0000000000002822
   Jatlaoui TC, 2014, CONTRACEPTION, V89, P528, DOI 10.1016/j.contraception.2013.10.008
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Lopez LM, 2015, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD003036.PUB3
   Pakarinen P, 2005, CONTRACEPTION, V72, P342, DOI 10.1016/j.contraception.2005.05.013
   Rossier C, 2015, STUD FAMILY PLANN, V46, P355, DOI 10.1111/j.1728-4465.2015.00037.x
   Singh S, 2016, GLOB HEALTH-SCI PRAC, V4, P132, DOI 10.9745/GHSP-D-15-00355
   Sonalkar S, 2015, EUR J CONTRACEP REPR, V20, P4, DOI 10.3109/13625187.2014.971454
   Theme-Filha MM, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0227-8
   Washington CI, 2015, FERTIL STERIL, V103, P131, DOI 10.1016/j.fertnstert.2014.09.032
   Whitaker AK, 2018, CONTRACEPTION, V97, P2, DOI 10.1016/j.contraception.2017.09.014
   World Health Organization, 2015, MED EL CRIT CONTR US
   Xu JX, 1996, CONTRACEPTION, V54, P33, DOI 10.1016/0010-7824(96)00117-5
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD MAR
PY 2020
VL 101
IS 3
BP 153
EP 158
DI 10.1016/j.contraception.2019.12.006
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KW1QV
UT WOS:000520946900003
PM 31927027
DA 2020-12-01
ER

PT J
AU De Nadai, MN
   Poli-Neto, OB
   Franceschini, SA
   Yamaguti, EMM
   Monteiro, IMU
   Troncon, JK
   Juliato, CRT
   Santana, LF
   Bahamondes, L
   Vieira, CS
AF De Nadai, Mariane N.
   Poli-Neto, Omero B.
   Franceschini, Silvio A.
   Yamaguti, Erciliene M. M.
   Monteiro, Ilza M. U.
   Troncon, Julia K.
   Juliato, Cassia R. T.
   Santana, Laura F.
   Bahamondes, Luis
   Vieira, Carolina Sales
TI Intracervical block for levonorgestrel-releasing intrauterine system
   placement among nulligravid women: a randomized double-blind controlled
   trial
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE insertion; intracervical block; levonorgestrel-releasing intrauterine
   system; lidocaine; nulligravid women; pain
ID IUD INSERTION EXPERIENCE; CARE PROVIDER ATTITUDES; DEVICE INSERTION;
   NULLIPAROUS WOMEN; PAIN; ADOLESCENTS; MISOPROSTOL; CONTRACEPTION;
   LIDOCAINE; PATIENT
AB BACKGROUND: Fear of pain during the insertion of intrauterine contraceptives is a barrier to using these methods, especially for nulligravidas. An intracervical block may be easier and more reproducible than a paracervical block; however, this intervention has not been evaluated in nulligravid women to reduce pain with intrauterine contraceptive insertion.
   OBJECTIVE: To evaluate whether a 3.6-mL 2% lidocaine intracervical block reduces pain at tenaculum placement and levonorgestrel-releasing intrauterine system insertion among nulligravidas; and, in addition, to assess whether the intracervical block has any effect on the ease of device insertion and on the overall experience with the procedure.
   MATERIALS AND METHODS: In this randomized double-blind controlled trial, nulligravidas were block-randomized to 1 of 3 arms prior to 52-mg levonorgestrel-releasing intrauterine system insertion: 3.6-mL 2%-lidocaine intracervical block, sham injection (intracervical dry-needling), or no intervention. The primary outcome was pain at levonorgestrel-releasing intrauterine system insertion. Secondary outcomes were pain at tenaculum placement, ease of insertion (assessed by healthcare providers), and the overall experience with the procedure (pain with levonorgestrel-releasing intrauterine system insertion compared with expectations, discomfort level, wish to undergo another device insertion in the future, and recommendation of the procedure to others). Participants' pain was measured with a 10-cm visual analogue scale and a 5-point Faces Pain Scale. Pain was summarized into categories (none, mild, moderate, severe) and also analyzed as a continuous variable (mean and 95% confidence interval). Our sample size had 80% power (alpha = 0.05) to detect a 15% difference in pain score measured by visual analogue scale (mean [standard deviation] visual analogue scale score = 5.9 [2.0] cm) and an absolute difference of 20% in the proportion of women reporting severe pain at levonorgestrel-releasing intrauterine system insertion among groups. We used a chi(2) test and a mixed-effects linear regression model. We calculated the number needed to treat for the intracervical block to avert severe pain at tenaculum placement and levonorgestrel-releasing intrauterine system insertion.
   RESULTS: A total of 302 women were randomized (99 to the intracervical block, 101 to the intracervical sham, and 102 to no intervention), and 300 had a successful device insertion. The intracervical block group had fewer women reporting severe pain than the other groups, both at tenaculum placement (intracervical block: 2% vs sham: 30.2% vs no intervention: 15.2%, P < .0001) and at levonorgestrel-releasing intrauterine system insertion (intracervical block: 26.5% vs sham: 59.4% vs no intervention: 50.5%, P < .0001). The mean (95% confidence interval) pain score reported at levonorgestrel-releasing intrauterine system insertion was lower in the intracervical block group than in the other groups (intracervical block: 4.3 [3.8-4.9] vs sham: 6.6 [6.2-7.0], P < .0001; intracervical block: 4.3 [3.8-4.9] vs no intervention: 5.8 [5.3-6.4], P < .0001). Women from the intracervical block group reported less pain than expected (P < .0001), rated the insertion as less uncomfortable (P <.0001), and were more willing to undergo another device insertion in the future (P < .01) than women in the other groups. The ease of insertion were similar among groups. The number needed to treat for the intracervical block to avert severe pain at tenaculum placement and levonorgestrel-releasing intrauterine system insertion was 2 and 4, respectively.
   CONCLUSION: A 3.6-mL 2% lidocaine intracervical block decreased pain at tenaculum placement and levonorgestrel-releasing intrauterine system insertion among nulligravidas. It also provided a better overall experience during the procedure.
C1 [De Nadai, Mariane N.; Poli-Neto, Omero B.; Franceschini, Silvio A.; Yamaguti, Erciliene M. M.; Troncon, Julia K.; Santana, Laura F.; Vieira, Carolina Sales] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Obstet & Gynecol, Ribeirao Preto, SP, Brazil.
   [Monteiro, Ilza M. U.; Juliato, Cassia R. T.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
RP Vieira, CS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Obstet & Gynecol, Ribeirao Preto, SP, Brazil.
EM carol.sales@uol.com.br
RI Juliato, Cassia R T/D-4447-2012; Vieira, Carolina Sales/N-6855-2015; de
   Nadai, Mariane Nunes/I-6829-2019; monteiro, ilza m u/F-4871-2014;
   Poli-Neto, Omero Benedicto/E-1392-2012
OI Juliato, Cassia R T/0000-0003-3197-1195; Vieira, Carolina
   Sales/0000-0003-2933-5755; monteiro, ilza m u/0000-0002-9536-0564;
   Poli-Neto, Omero Benedicto/0000-0003-0270-5496
FU Sao Paulo Research Foundation (Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo - FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2017/12938-4]; International Contraceptive Access
   Foundation in Turku, Finland
FX This study was funded by the Sao Paulo Research Foundation (Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo - FAPESP), research grant
   #2017/12938-4. The LNG-IUS were donated by the International
   Contraceptive Access Foundation in Turku, Finland, under an unrestricted
   grant.
CR Akers AY, 2017, OBSTET GYNECOL, V130, P795, DOI 10.1097/AOG.0000000000002242
   Allen RH, 2014, J OBSTET GYNAECOL, V34, P263, DOI 10.3109/01443615.2013.868424
   [Anonymous], 2017, BRAZILS FAILED ED SY
   [Anonymous], 2020, MED EL CRIT CONTR US
   Anthoulakis C, 2018, J PEDIATR ADOL GYNEC, V31, P549, DOI 10.1016/j.jpag.2018.05.008
   Bahamondes MV, 2015, HUM REPROD, V30, P1861, DOI 10.1093/humrep/dev137
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Bednarek PH, 2013, CONTRACEPTION, V87, P421, DOI 10.1016/j.contraception.2012.10.030
   Castro TVB, 2014, HUM REPROD, V29, P2439, DOI 10.1093/humrep/deu233
   Citrome Leslie, 2014, Innov Clin Neurosci, V11, P26
   Committee on Gynecologic Practice Long-Acting Reversible Contraception Working Group, 2015, Obstet Gynecol, V126, pe44, DOI 10.1097/AOG.0000000000001106
   da Silva AL, 2017, POSTGRAD MED J, V93, P376, DOI 10.1136/postgradmedj-2016-134247
   Diedrich JT, 2015, AM J OBSTET GYNECOL, V213, P822, DOI 10.1016/j.ajog.2015.08.077
   Dina B, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.10.017
   Dunning J, 2014, PHYS THER REV, V19, P252, DOI 10.1179/108331913X13844245102034
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Edelman AB, 2011, CONTRACEPTION, V84, P234, DOI 10.1016/j.contraception.2011.01.016
   Espey E, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.11.018
   Gemzell-Danielsson K, 2012, FERTIL STERIL, V97, P616, DOI 10.1016/j.fertnstert.2011.12.003
   Santos ARG, 2013, CONTRACEPTION, V88, P164, DOI 10.1016/j.contraception.2012.10.015
   Harvey C, 2012, AUST NZ J OBSTET GYN, V52, P534, DOI 10.1111/ajo.12007
   Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Hubacher D, 2015, CONTRACEPTION, V91, P185, DOI 10.1016/j.contraception.2014.11.006
   Kaislasuo J, 2014, OBSTET GYNECOL, V124, P345, DOI 10.1097/AOG.0000000000000362
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   Kavanaugh ML, 2013, J PEDIATR ADOL GYNEC, V26, P86, DOI 10.1016/j.jpag.2012.10.006
   Lathrop E, 2013, CONTRACEPTION, V88, P725, DOI 10.1016/j.contraception.2013.07.011
   LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605
   Lopez N, 2015, J RENEW SUSTAIN ENER, V7, DOI 10.1063/1.4939192
   Mankowski JL, 2009, OBSTET GYNECOL, V113, P1052, DOI 10.1097/AOG.0b013e31819ec97e
   Mansy AA, 2018, MIDDLE EAST FERTIL S, V23, P72, DOI 10.1016/j.mefs.2017.08.007
   MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934
   Micks EA, 2014, CONTRACEPTION, V90, P60, DOI 10.1016/j.contraception.2014.03.012
   Mody SK, 2018, OBSTET GYNECOL, V132, P575, DOI 10.1097/AOG.0000000000002790
   Ngo LL, 2016, OBSTET GYNECOL, V128, P1306, DOI 10.1097/AOG.0000000000001746
   Perez-Lopez FR, 2018, EUR J CONTRACEP REPR, V23, P207, DOI 10.1080/13625187.2018.1469124
   PNUD Brasil, 2010, RANK HDI MUN BRAS 20
   Pradhan R, 2015, J EPIDEMIOL COMMUN H, V69, P918, DOI 10.1136/jech-2014-205128
   Rapkin RB, 2016, OBSTET GYNECOL, V128, P621, DOI 10.1097/AOG.0000000000001596
   Singh RH, 2016, INT J GYNECOL OBSTET, V135, P145, DOI 10.1016/j.ijgo.2016.04.014
   Sinning KM, 2018, J PEDIATR ADOL GYNEC, V31, P400, DOI 10.1016/j.jpag.2018.02.127
   Swenson C, 2012, OBSTET GYNECOL, V120, P341, DOI 10.1097/AOG.0b013e31825d9ec9
   Tornblom-Paulander S, 2015, FERTIL STERIL, V103, P422, DOI 10.1016/j.fertnstert.2014.10.026
   Tyler CP, 2012, OBSTET GYNECOL, V119, P762, DOI 10.1097/AOG.0b013e31824aca39
   WHO, 2018, FAMILY PLANNING GLOB
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Zapata LB, 2016, CONTRACEPTION, V94, P407, DOI 10.1016/j.contraception.2016.07.092
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 49
TC 1
Z9 1
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD MAR
PY 2020
VL 222
IS 3
AR 245.e1-10
DI 10.1016/j.ajog.2019.09.013
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KS5TD
UT WOS:000518369800008
PM 31541635
OA Bronze
DA 2020-12-01
ER

PT J
AU Munuce, MJ
   Gomez-Elias, MD
   Caille, AM
   Bahamondes, L
   Cuasnicu, PS
   Cohen, DJ
AF Jose Munuce, Maria
   Gomez-Elias, Matias D.
   Caille, Adriana M.
   Bahamondes, Luis
   Cuasnicu, Patricia S.
   Cohen, Debora J.
TI Mechanisms involved in the contraceptive effects of ulipristal acetate
SO REPRODUCTION
LA English
DT Review
ID PROGESTERONE-RECEPTOR MODULATOR; HUMAN FALLOPIAN-TUBE; IN-VITRO;
   EMERGENCY CONTRACEPTION; ANTIPROGESTIN CDB-2914; CATSPER CHANNEL;
   GENE-EXPRESSION; SPERM TRANSPORT; MICE LACKING; LEVONORGESTREL
AB The use of emergency contraception (EC) methods is increasing worldwide as it constitutes an effective way to prevent unplanned pregnancy after unprotected sexual intercourse. During the last decade, ulipristal acetate (UPA), a selective progesterone receptor modulator, has emerged as the most effective EC pill, and it is now recommended as first-line hormonal treatment for EC in several countries. Its principal mechanism of action involves inhibition or delay of follicular rupture, but only when administered during the follicular phase before the luteinizing hormone (LH) peak. However, considering the high efficacy of UPA, it is possible that it also exerts contraceptive effects besides ovulation. In the present review, we summarize and discuss the existing evidence obtained on the effect of UPA on sperm function and post-ovulatory events as potential additional mechanisms to prevent pregnancy. The bulk of evidence collected so far indicates that UPA would not affect gamete function; however, it could impair embryo-uterine interaction. Thus, besides the described effects on ovarian function, UPA contraceptive effectiveness might also be attributed to post-ovulatory effects, depending on the moment of the female cycle in which the drug is administered.
C1 [Jose Munuce, Maria; Caille, Adriana M.] Natl Univ Rosario, Sch Biochem & Pharmaceut Sci, Lab Reprod Med, Biochem Chem Area, Rosario, Argentina.
   [Gomez-Elias, Matias D.; Cuasnicu, Patricia S.; Cohen, Debora J.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Buenos Aires, DF, Argentina.
   [Bahamondes, Luis] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, UNICAMP, Campinas, Brazil.
RP Cohen, DJ (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Buenos Aires, DF, Argentina.
EM dcohen@dna.uba.ar
OI Caille, Agnes/0000-0003-4715-6144
FU University of Rosario [BIO 486 (1480/2016), BIO 565 (5601/2018)];
   National Agency of Scientific and Technological Promotion (ANPCyT),
   ArgentinaANPCyT [PICT 2016-1057]
FX The project is partially supported by grants BIO 486 (1480/2016) and BIO
   565 (5601/2018) from the University of Rosario to M J M and PICT
   2016-1057 to D J C from the National Agency of Scientific and
   Technological Promotion (ANPCyT), Argentina.
CR Palomino WA, 2010, FERTIL STERIL, V94, P1589, DOI 10.1016/j.fertnstert.2009.09.013
   Baird DT, 2015, HUM REPROD, V30, P751, DOI 10.1093/humrep/dev019
   Baldi E, 2009, MOL CELL ENDOCRINOL, V308, P39, DOI 10.1016/j.mce.2009.02.006
   Berger C, 2015, HUM REPROD, V30, P800, DOI 10.1093/humrep/dev030
   BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   Brache V, 2013, CONTRACEPTION, V88, P611, DOI 10.1016/j.contraception.2013.05.010
   Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Cheng LN, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001324.pub4, 10.1002/14651858.CD001324.pub4.]
   Chung JJ, 2014, CELL, V157, P808, DOI 10.1016/j.cell.2014.02.056
   Cleland K, 2012, HUM REPROD, V27, P1994, DOI 10.1093/humrep/des140
   Croxatto HB, 2004, CONTRACEPTION, V70, P442, DOI 10.1016/j.contraception.2004.05.007
   Da Ros VG, 2008, DEV BIOL, V320, P12, DOI 10.1016/j.ydbio.2008.03.015
   Durand M, 2001, CONTRACEPTION, V64, P227, DOI 10.1016/S0010-7824(01)00250-5
   Esber N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140795
   Fine P, 2010, OBSTET GYNECOL, V115, P257, DOI 10.1097/AOG.0b013e3181c8e2aa
   Brukman NG, 2019, J CELL PHYSIOL, V234, P5276, DOI 10.1002/jcp.27337
   Gemzell-Danielsson K, 2014, GYNECOL ENDOCRINOL, V30, P685, DOI 10.3109/09513590.2014.950648
   Gemzell-Danielsson K, 2010, INT J WOMENS HEALTH, V2, P53
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Goldstuck ND, 2014, GYNECOLOGY OBSTET, V4, P224, DOI [10.4172/2161-0932.1000224, DOI 10.4172/2161-0932.1000224]
   Gomez-Elias MD, 2019, MOL HUM REPROD, V25, P257, DOI 10.1093/molehr/gaz013
   Gomez-Elias MD, 2016, HUM REPROD, V31, P53, DOI 10.1093/humrep/dev287
   Guidobaldi HA, 2017, HUM REPROD, V32, P1560, DOI 10.1093/humrep/dex232
   Hild SA, 2000, HUM REPROD, V15, P822, DOI 10.1093/humrep/15.4.822
   Holt WV, 2010, MOL REPROD DEV, V77, P934, DOI 10.1002/mrd.21234
   Jesam C, 2016, CONTRACEPTION, V93, P310, DOI 10.1016/j.contraception.2015.12.015
   Munuce MJ, 2013, EUR J CONTRACEP REPR, V18, P355, DOI 10.3109/13625187.2013.813930
   Ko JKY, 2014, ANDROLOGY-US, V2, P868, DOI 10.1111/j.2047-2927.2014.00261.x
   Kunz G, 1996, HUM REPROD, V11, P627, DOI 10.1093/HUMREP/11.3.627
   Lalitkumar PGL, 2007, HUM REPROD, V22, P3031, DOI 10.1093/humrep/dem297
   Larner JM, 2000, HUM REPROD, V15, P1100, DOI 10.1093/humrep/15.5.1100
   Leonhardt SA, 2002, EXP BIOL MED, V227, P969
   Levens ED, 2008, OBSTET GYNECOL, V111, P1129, DOI 10.1097/AOG.0b013e3181705d0e
   Levy DP, 2014, CONTRACEPTION, V89, P431, DOI 10.1016/j.contraception.2014.01.003
   Li HWR, 2016, HUM REPROD, V31, P1200, DOI 10.1093/humrep/dew055
   Li HWR, 2014, HUM REPROD, V29, P2156, DOI 10.1093/humrep/deu210
   Li HWR, 2017, HUM REPROD, V32, P2414, DOI 10.1093/humrep/dex328
   Li S, 2017, J ENDOCRINOL, V232, pR1, DOI [10.1530/JOE-16-0302, 10.1530/joe-16-0302]
   LIBERSKY EA, 1995, BIOL REPROD, V53, P483, DOI 10.1095/biolreprod53.3.483
   Lira-Albarran S, 2018, MOL CELL ENDOCRINOL, V476, P70, DOI 10.1016/j.mce.2018.04.010
   Lira-Albarran S, 2017, MOL CELL ENDOCRINOL, V447, P1, DOI 10.1016/j.mce.2017.02.024
   Lishko PV, 2011, NATURE, V471, P387, DOI 10.1038/nature09767
   Lyons RA, 2006, HUM REPROD UPDATE, V12, P363, DOI 10.1093/humupd/dml012
   Mahmood T, 1998, HUM REPROD, V13, P2991, DOI 10.1093/humrep/13.11.2991
   Mangal RK, 1997, J STEROID BIOCHEM, V63, P195, DOI 10.1016/S0960-0760(97)00119-2
   Meng CX, 2009, FERTIL STERIL, V91, P256, DOI 10.1016/j.fertnstert.2007.11.007
   Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963
   Mozzanega B, 2013, TRENDS PHARMACOL SCI, V34, P195, DOI 10.1016/j.tips.2013.02.003
   Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751
   Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100
   Munuce MJ, 2012, EUR J CONTRACEP REPR, V17, P428, DOI 10.3109/13625187.2012.725877
   Munuce MJ, 2005, CONTRACEPTION, V72, P71, DOI 10.1016/j.contraception.2004.12.003
   Nallasamy S, 2013, REPROD SCI, V20, P371, DOI 10.1177/1933719112459239
   Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200
   Palanisamy GS, 2006, MOL ENDOCRINOL, V20, P2784, DOI 10.1210/me.2006-0093
   Passaro MD, 2003, HUM REPROD, V18, P1820, DOI 10.1093/humrep/deg342
   Patel B, 2015, HUM REPROD UPDATE, V21, P155, DOI 10.1093/humupd/dmu056
   Ramathal CY, 2010, SEMIN REPROD MED, V28, P17, DOI 10.1055/s-0029-1242989
   Reel JR, 1998, CONTRACEPTION, V58, P129, DOI 10.1016/S0010-7824(98)00067-5
   ROBLERO LS, 1987, CONTRACEPTION, V36, P549, DOI 10.1016/0010-7824(87)90007-2
   Sagare-Patil V, 2012, INT J ANDROL, V35, P633, DOI 10.1111/j.1365-2605.2012.01291.x
   Singh AP, 2015, REPROD BIOMED ONLINE, V30, P28, DOI 10.1016/j.rbmo.2014.09.014
   Snow SE, 2011, ANN PHARMACOTHER, V45, P780, DOI 10.1345/aph.1P704
   Stratton P, 2000, HUM REPROD, V15, P1092, DOI 10.1093/humrep/15.5.1092
   Stratton P, 2010, FERTIL STERIL, V93, P2035, DOI 10.1016/j.fertnstert.2008.12.057
   Strunker T, 2011, NATURE, V471, P382, DOI 10.1038/nature09769
   Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047
   TASK FORC POS, 1998, LANCET, V352, P428, DOI DOI 10.1016/S0140-6736(98)05145-9)
   Teilmann SC, 2006, J ENDOCRINOL, V191, P525, DOI 10.1677/joe.1.06565
   Teves ME, 2006, FERTIL STERIL, V86, P745, DOI 10.1016/j.fertnstert.2006.02.080
   Trussell J, 1998, CONTRACEPTION, V57, P363, DOI 10.1016/S0010-7824(98)00042-0
   WANG C, 1995, CONTRACEPTION, V51, P215, DOI 10.1016/0010-7824(95)00020-B
   Wanggren K, 2008, HUM REPROD, V23, P2359, DOI 10.1093/humrep/den260
   Whitaker LHR, 2017, HUM REPROD, V32, P531, DOI 10.1093/humrep/dew359
   WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301
   Williams ARW, 2012, INT J GYNECOL PATHOL, V31, P556, DOI 10.1097/PGP.0b013e318251035b
   YANG YQ, 1990, CONTRACEPTION, V41, P551, DOI 10.1016/0010-7824(90)90063-2
   Zumoffen C, 2017, CONTRACEPTION, V95, P586, DOI 10.1016/j.contraception.2017.02.019
NR 81
TC 0
Z9 0
U1 2
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 1470-1626
J9 REPRODUCTION
JI Reproduction
PD MAR
PY 2020
VL 159
IS 3
BP R139
EP R149
DI 10.1530/REP-19-0355
PG 11
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA KM6AL
UT WOS:000514220800003
PM 31689233
OA Bronze
DA 2020-12-01
ER

PT J
AU Margatho, D
   Carvalho, NM
   Bahamondes, L
AF Margatho, Deborah
   Carvalho, Nelsilene Mota
   Bahamondes, Luis
TI Endometriosis-associated pain scores and biomarkers in users of the
   etonogestrel-releasing subdermal implant or the 52-mg
   levonorgestrel-releasing intrauterine system for up to 24 months
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Biomarkers; CA-125; chronic pelvic pain; endometriosis; etonogestrel
   implant; 52-mg levonorgestrel-releasing intrauterine system; soluble
   CD23
ID BONE-MINERAL DENSITY; SYMPTOMATIC ENDOMETRIOSIS; CONTRACEPTIVE IMPLANT;
   CLASSIFICATION; WOMEN; DYSMENORRHEA; PATHOGENESIS; SUPPRESSION;
   MANAGEMENT; QUALITY
AB Objectives: The aims of the study were to correlate endometriosis-associated pain, evaluated by visual analogue scale (VAS) scores, with serum levels of etonogestrel (ENG), levonorgestrel (LNG), CA-125 and soluble CD23 in users of the ENG implant or the 52-mg LNG-releasing intrauterine system (52 mg LNG-IUS) for up to 2 years after device placement. Methods: A randomised trial was conducted at the University of Campinas Medical School, Brazil. All participants (n = 103) had had endometriosis-associated chronic pelvic pain or dysmenorrhoea, or both, for more than 6 months. Participants were randomly assigned to use an ENG implant (experimental treatment) or a 52-mg LNG-IUS (active comparator). Follow-up was conducted 6 monthly for up to 24 months after device placement. Dysmenorrhoea and chronic pelvic pain were evaluated using a VAS and the scores were correlated with serum levels of ENG, LNG, CA-125 and soluble CD23. Results: Both progestin-only contraceptives significantly reduced VAS scores for dysmenorrhoea and chronic pelvic pain and reduced serum levels of soluble CD23 (p < 0.001). Serum levels of CA-125 decreased only in the ENG implant group after 24 months' use of the device (p < 0.001). No correlation was found between pain scores and ENG or LNG serum levels over time (p > 0.005). Conclusion: Both contraceptives improved dysmenorrhoea and chronic pelvic pain scores in women with endometriosis-associated pain and they reduced serum levels of soluble CD23; however, serum levels of CA-125 were reduced only in ENG implant users over the 24-month study period.
C1 [Margatho, Deborah; Carvalho, Nelsilene Mota; Bahamondes, Luis] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
FU Fundacao de Apoio a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9, 2015/10021];
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq) [573747/2008-3]; MSD
FX The study received partial financial support from the Fundacao de Apoio
   a Pesquisa do Estado de Sao Paulo [awards 2015/20504-9 and 2015/10021]
   and from CNPq, the Brazilian National Council for Scientific and
   Technological Development [grant 573747/2008-3]. ENG implants and
   financial assistance for the study were provided by MSD. The donors did
   not participate in the protocol design, conduct of the study, analysis
   of the data or drafting of the manuscript.
CR Ahn SH, 2017, FERTIL STERIL, V107, P523, DOI 10.1016/j.fertnstert.2017.01.009
   Apter D, 2014, FERTIL STERIL, V101, P1656, DOI 10.1016/j.fertnstert.2014.03.004
   Bahamondes MV, 2010, HUM REPROD, V25, P1158, DOI 10.1093/humrep/deq043
   Bayer HealthCare Pharmaceuticals, 2017, MIR LEV REL INTR SYS
   Bedaiwy MA, 2017, FERTIL STERIL, V107, P555, DOI 10.1016/j.fertnstert.2016.12.025
   Beerthuizen R, 2000, HUM REPROD, V15, P118, DOI 10.1093/humrep/15.1.118
   Bennink H J, 2000, Eur J Contracept Reprod Health Care, V5 Suppl 2, P12
   Brown J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009590.pub2
   Canis M, 1997, FERTIL STERIL, V67, P817
   Carvalho N, 2018, FERTIL STERIL, V110, P1129, DOI 10.1016/j.fertnstert.2018.07.003
   Chamie LP, 2009, INT J GYNECOL OBSTET, V106, P198, DOI 10.1016/j.ijgo.2009.04.013
   Goncalves MOD, 2010, HUM REPROD, V25, P665, DOI 10.1093/humrep/dep433
   Donnez J, 2017, FERTIL STERIL, V108, P869, DOI 10.1016/j.fertnstert.2017.10.015
   Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
   Fedele L, 2001, FERTIL STERIL, V75, P485, DOI 10.1016/S0015-0282(00)01759-3
   Grandi G, 2019, EUR J CONTRACEP REPR, V24, P61, DOI 10.1080/13625187.2018.1550576
   Guo SW, 2009, HUM REPROD UPDATE, V15, P441, DOI 10.1093/humupd/dmp007
   Gupta D, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012165
   Haas D, 2013, ACTA OBSTET GYN SCAN, V92, P3, DOI 10.1111/aogs.12026
   Johnson NP, 2017, HUM REPROD, V32, P315, DOI 10.1093/humrep/dew293
   Louis GMB, 2011, FERTIL STERIL, V96, P360, DOI 10.1016/j.fertnstert.2011.05.087
   Margatho D, 2018, EUR J CONTRACEP REPR, V23, P344, DOI 10.1080/13625187.2018.1531117
   Matalliotakis IM, 2000, OBSTET GYNECOL, V95, P810, DOI 10.1016/S0029-7844(99)00635-3
   Moraes LG, 2016, EUR J CONTRACEP REPR, V21, P318, DOI 10.1080/13625187.2016.1193139
   MSD, 2009, IMPL ET IMPL 68 MG S
   Odukoya O, 1996, ACTA OBSTET GYN SCAN, V75, P927, DOI 10.3109/00016349609055030
   Odukoya OA, 1996, HUM REPROD, V11, P2018
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014
   Schulz KF, 2005, LANCET, V365, P1348, DOI 10.1016/S0140-6736(05)61034-3
   Vandever MA, 2008, CONTRACEPTION, V77, P162, DOI 10.1016/j.contraception.2007.11.005
   Vercellini P, 2003, FERTIL STERIL, V80, P305, DOI 10.1016/S0015-0282(03)00608-3
   Vercellini P, 1999, FERTIL STERIL, V72, P505, DOI 10.1016/S0015-0282(99)00291-5
   Vercellini P, 2014, NAT REV ENDOCRINOL, V10, P261, DOI 10.1038/nrendo.2013.255
   Walch K, 2009, CONTRACEPTION, V79, P29, DOI 10.1016/j.contraception.2008.07.017
   World Health Organization Department of Reproductive Health, 2015, MED EL CRIT CONTR US
   Yucel N, 2018, AUST NZ J OBSTET GYN, V58, P560, DOI 10.1111/ajo.12773
NR 37
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD MAR 3
PY 2020
VL 25
IS 2
BP 133
EP 140
DI 10.1080/13625187.2020.1725461
EA FEB 2020
PG 8
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA KV3OU
UT WOS:000514738000001
PM 32069126
DA 2020-12-01
ER

PT J
AU Conz, L
   Mota, BS
   Bahamondes, L
   Doria, MT
   Derchain, SFM
   Rieira, R
   Sarian, LO
AF Conz, Livia
   Mota, Bruna Salani
   Bahamondes, Luis
   Doria, Maira Teixeira
   Mauricette Derchain, Sophie Francoise
   Rieira, Rachel
   Sarian, Luis Otavio
TI Levonorgestrel-releasing intrauterine system and breast cancer risk: A
   systematic review and meta-analysis
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Review
DE breast cancer; contraception; dysmenorrhea; levonorgestrel;
   levonorgestrel-releasing intrauterine system; menopause
ID HORMONE-THERAPY; PROGESTINS
AB Introduction Epidemiological studies have shown that some hormonal contraceptive methods are associated with increased breast cancer risk, especially if used over long periods. Our objective was to conduct a systematic review and meta-analysis of the literature on the risk of breast cancer development in women using the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS).
   Material and methods We performed a thorough review of peer-reviewed publications from 10 January 1999, through 31 July 2019, using combinations of search terms for breast cancer risk and LNG-IUS in the Medline, EMBASE, LILACS (Latin American and Caribbean Health Sciences Literature), and Scielo databases. This review was registered in PROSPERO (CRD42017059076). Studies reporting breast cancer risk estimates among healthy users of LNG-IUS were included according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) criteria. Two authors performed data extraction, and a third author resolved disagreements. The quality of evidence was evaluated using the Downs and Black instrument. A funnel plot was generated, and a linear regression test of funnel plot asymmetry was used to assess publication bias. Finally, we performed a random-effects model (owing to high study heterogeneity) meta-analysis of 7 suitable studies, stratified by the age distribution of patients (<50 years, >= 50 years, and mixed).
   Results We identified 96 studies and manually cross-referenced and excluded duplicate articles. Seventy articles were excluded on the basis of the inclusion and exclusion criteria, resulting in the assessment of 26 full-text articles. Eight articles were considered adequate for inclusion in this systematic review, and 7 studies were included in the meta-analysis. Three publications were case-control studies and 5 were cohort studies. According to the Downs and Black instrument, 5 studies were rated as "good" and 3 studies were deemed "fair". Our meta-analysis results indicated increased breast cancer risk in LNG-IUS users: for all women, odds ratio (OR) = 1.16 (95% CI 1.06-1.28, I-2 = 78%, P < .01); for women aged <50 years, OR = 1.12 (95% CI 1.02-1.22, I-2 = 66%, P = .02); and for women aged >= 50 years, OR = 1.52 (95% CI 1.34-1.72, I-2 = 0%, P = .84).
   Conclusions Current evidence suggests that LNG-IUS users have an increased breast cancer risk regardless of age and indication. The effect of LNG-IUS on breast cancer risk seems to be larger in older users. However, our systematic review detected methodological issues across the available studies, and confounding factors may be responsible for at least a fraction of the risk effects associated with LNG-IUS use. Nevertheless, users of LNG-IUS should be aware of these trends. We believe that caution is needed, and risks should be balanced against proven health benefits (eg effective treatment of heavy menstrual bleeding and avoidance of surgical interventions), when prescribing LNG-IUS for long periods of use, especially in women with other known breast cancer risk factors such as old age, obesity, and familial predisposition.
C1 [Conz, Livia; Bahamondes, Luis; Doria, Maira Teixeira; Mauricette Derchain, Sophie Francoise; Sarian, Luis Otavio] Univ Estadual Campinas, UNICAMP, Dept Obstet & Gynecol, Med Sch, Campinas, SP, Brazil.
   [Conz, Livia; Doria, Maira Teixeira; Mauricette Derchain, Sophie Francoise; Sarian, Luis Otavio] Univ Estadual Campinas, Div Gynecol & Breast Oncol, Womens Hosp CAISM, Campinas, SP, Brazil.
   [Mota, Bruna Salani] Univ Sao Paulo, Setor Mastol Clin Ginecol, ICESP, Hosp Clin,Fac Med, Sao Paulo, Brazil.
   [Rieira, Rachel] Univ Fed Sao Paulo UNIFESP, Ctr Hlth Tecnol, Hosp Sirio Libanes, Sao Paulo, Brazil.
RP Sarian, LO (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Obstet & Gynecol, Med Sch, Campinas, SP, Brazil.
EM sarian@unicamp.br
RI Sarian, Luis O/C-4150-2013; Mota, Bruna/J-9833-2015; CONZ,
   LIVIA/H-6955-2018
OI Sarian, Luis O/0000-0002-9554-6131; Riera, Rachel/0000-0002-9522-1871;
   Mota, Bruna/0000-0001-9567-1066; Bahamondes, Luis/0000-0002-7356-8428;
   Doria, Maira Teixeira/0000-0002-8671-2863; CONZ,
   LIVIA/0000-0002-8277-3554
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9];
   Brazilian National Council for Scientific and Technological
   DevelopmentNational Council for Scientific and Technological Development
   (CNPq) [CNPq 308888/2017-0]
FX This study received partial financial support from the Fundacao de Apoio
   a Pesquisa do Estado de Sao Paulo (FAPESP; award no. 2015/20504-9). Luis
   Sarian received a research stipend from the Brazilian National Council
   for Scientific and Technological Development (CNPq 308888/2017-0).
CR Backman T, 2005, OBSTET GYNECOL, V106, P813, DOI 10.1097/01.AOG.0000178754.88912.b9
   Backman T, 2001, EUR J CONTRACEP REPR, V6, P23, DOI 10.3109/ejc.6.s1.23.26
   Banks E, 2003, LANCET, V362, P419, DOI 10.1016/s0140-6736(03)14065-2
   Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/s0140-6736(97)08233-0
   Chlebowski RT, 2012, JNCI-J NATL CANCER I, V104, P517, DOI 10.1093/jnci/djs014
   Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407
   Collaborative Grp Hormonal Factors, 2019, LANCET, V394, P1159, DOI 10.1016/S0140-6736(19)31709-X
   Dinger J, 2011, CONTRACEPTION, V83, P211, DOI 10.1016/j.contraception.2010.11.009
   Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377
   Eden J, 2003, AM J OBSTET GYNECOL, V188, P1123, DOI 10.1067/mob.2003.201
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502
   Heikkinen S, 2016, CANCER CAUSE CONTROL, V27, P249, DOI 10.1007/s10552-015-0702-5
   Inumaru LE, 2011, CAD SAUDE PUBLICA, V27, P1259, DOI 10.1590/S0102-311X2011000700002
   Jareid M, 2018, GYNECOL ONCOL, V149, P127, DOI 10.1016/j.ygyno.2018.02.006
   Jones ME, 2016, BRIT J CANCER, V115, P1
   Lyytinen HK, 2010, INT J CANCER, V126, P483, DOI 10.1002/ijc.24738
   Morch LS, 2017, NEW ENGL J MED, V377, P2228, DOI 10.1056/NEJMoa1700732
   MUSGROVE EA, 1991, MOL CELL BIOL, V11, P5032, DOI 10.1128/MCB.11.10.5032
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   Okobia M N, 2005, Niger J Clin Pract, V8, P35
   Samson M, 2016, BREAST CANCER RES TR, V155, P3, DOI 10.1007/s10549-015-3663-1
   Siegelmann-Danieli N, 2018, BREAST CANCER RES TR, V167, P257, DOI 10.1007/s10549-017-4491-2
   Soini T, 2016, ACTA ONCOL, V55, P188, DOI 10.3109/0284186X.2015.1062538
   VANLEEUWEN FF, 1991, ACTA ENDOCRINOL-COP, V125, P13
   Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X
NR 26
TC 3
Z9 3
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6349
EI 1600-0412
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PD AUG
PY 2020
VL 99
IS 8
BP 970
EP 982
DI 10.1111/aogs.13817
EA FEB 2020
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA ML8PR
UT WOS:000512801800001
PM 31990981
DA 2020-12-01
ER

PT J
AU Zantut-Wittmann, DE
   Quintino-Moro, A
   dos Santos, PNS
   Melhado-Kimura, V
   Bahamondes, L
   Fernandes, A
AF Zantut-Wittmann, Denise Engelbrecht
   Quintino-Moro, Alessandra
   Silva dos Santos, Priscilla Nazare
   Melhado-Kimura, Vaneska
   Bahamondes, Luis
   Fernandes, Arlete
TI Lack of Influence of Thyroid Hormone on Bone Mineral Density and Body
   Composition in Healthy Euthyroid Women
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE thyroid hormone; bone mineral density; body composition; healthy women;
   euthyroidism
ID FRACTURE RISK; MASS INDEX; SERUM TSH; ADIPOSE-TISSUE; FREE-THYROXINE;
   NORMAL RANGE; FREE T4; WEIGHT; ASSOCIATION; CONSUMPTION
AB Objective: The objective of this study was to evaluate whether evolution of bone mineral density (BMD) is associated with the thyroid hormone profile in a cohort of euthyroid women with no other known diseases within 1 year. Methods: This was a prospective cohort study conducted at the University of Campinas, Brazil. We used a database with 52 women aged 20-39 who were followed for 1 year in a family planning outpatient clinic. The inclusion criteria were body mass index (BMI) <30 kg/m(2), no known diseases/medication use, fasting glucose <100 mg/dl, and 2 h glucose after a 75 g oral glucose load <140 mg/dl. The women were divided into groups of normal weight (n = 30) and overweight (n = 22). The main outcomes were BMD measured by dual-energy x-ray absorptiometry (DXA) and thyroid hormone profile (thyrotropin TSH, free triiodothyronine FT3, free thyroxine FT4, and T3/T4 ratio); other variables were body composition (DXA), calcium metabolism markers, and life habits. We used a repeated measures analysis of variance (ANOVA) and multiple regression analyses to evaluate associations. Results: At the baseline data collection, overweight women showed a higher T3/T4 ratio, leptin, calcium, BMD in the lumbar spine and total femur, total mass, mass, and percentage of fat mass than normal weight women. At 12 months, both groups had increased FT4, calcium, ALP, femoral neck BMD, and total mass by time effect. The normal weight group presented a decrease of vitamin D when compared to the baseline. Increased BMD of the femoral neck was associated with moderate coffee intake, and as such, there were no associations found between this increase and the thyroid hormone profile. Leptin and ALP were associated with total mass variation, while leptin and PTH were associated with fat mass variation. The normal BMI was inversely associated with the variation of total mass, mass, and percentage of fat mass, and engaging in regular physical activity was inversely associated with fat mass variation. Conclusions: In this sample of euthyroid healthy women who were both normal weight and overweight, the thyroid hormone profile was not associated with variations in bone mineral density and body composition after a 1 year follow-up.
C1 [Zantut-Wittmann, Denise Engelbrecht] Dept Internal Med, Div Endocrinol, Sao Paulo, Brazil.
   [Quintino-Moro, Alessandra; Silva dos Santos, Priscilla Nazare; Melhado-Kimura, Vaneska; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Famiy Planning Clin, Dept Obstet & Gynecol, Sch Med Sci, Sao Paulo, SP, Brazil.
RP Zantut-Wittmann, DE (corresponding author), Dept Internal Med, Div Endocrinol, Sao Paulo, Brazil.
EM zantutw@unicamp.br
RI Zantut-Wittmann, Denise Engelbrecht/ABE-5858-2020
OI Zantut-Wittmann, Denise Engelbrecht/0000-0002-7434-5701
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo Foundation
   for the Support of Research (Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo-FAPESP); Sao Paulo State Health Department (SES-SP) under
   Grant [PPSUS/2009], Brazil [2009/53293-0]
FX This work was supported by the Brazilian National Research Council
   (CNPq), the Sao Paulo Foundation for the Support of Research (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP), and the Sao Paulo
   State Health Department (SES-SP) under Grant [PPSUS/2009 #2009/53293-0],
   Brazil.
CR Agnihothri RV, 2014, THYROID, V24, P19, DOI 10.1089/thy.2013.0055
   Aubert CE, 2017, J CLIN ENDOCR METAB, V102, P2719, DOI 10.1210/jc.2017-00294
   Bassett JHD, 2016, ENDOCR REV, V37, P135, DOI 10.1210/er.2015-1106
   Blum MR, 2015, JAMA-J AM MED ASSOC, V313, P2055, DOI 10.1001/jama.2015.5161
   Camargo M. C. R., 1998, Ciencia e Tecnologia de Alimentos, V18, P421, DOI 10.1590/S0101-20611998000400012
   Carrelli A, 2017, J BONE MINER RES, V32, P237, DOI 10.1002/jbmr.2979
   Choi E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147762
   Clark MK, 2004, FERTIL STERIL, V82, P1580, DOI 10.1016/j.fertnstert.2004.04.064
   Cursino K, 2016, EUR J CONTRACEP REPR, V21, P22, DOI 10.3109/13625187.2015.1059415
   DOYLE F, 1970, LANCET, V1, P391, DOI 10.1016/S0140-6736(70)91520-5
   Dvornyk V, 2003, ANN HUM GENET, V67, P216, DOI 10.1046/j.1469-1809.2003.00037.x
   ERIKSEN EF, 1986, BONE, V7, P101, DOI 10.1016/8756-3282(86)90681-2
   Fisberg RM, 2009, ARQ BRAS ENDOCRINOL, V53, P617, DOI 10.1590/S0004-27302009000500014
   Flynn RW, 2010, J CLIN ENDOCR METAB, V95, P186, DOI 10.1210/jc.2009-1625
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Fox CS, 2008, ARCH INTERN MED, V168, P587, DOI 10.1001/archinte.168.6.587
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Hallstrom H, 2006, OSTEOPOROSIS INT, V17, P1055, DOI 10.1007/s00198-006-0109-y
   HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S, DOI 10.1093/ajcn/61.3.638S
   Hwangbo Y, 2016, OSTEOPOROSIS INT, V27, P457, DOI 10.1007/s00198-015-3270-3
   Klok MD, 2007, OBES REV, V8, P21, DOI 10.1111/j.1467-789X.2006.00270.x
   Knudsen N, 2005, J CLIN ENDOCR METAB, V90, P4019, DOI 10.1210/jc.2004-2225
   Makepeace AE, 2008, CLIN ENDOCRINOL, V69, P648, DOI 10.1111/j.1365-2265.2008.03239.x
   Manji N, 2006, CLIN ENDOCRINOL, V64, P125, DOI 10.1111/j.1365-2265.2006.02433.x
   MOSEKILDE L, 1978, ACTA PATH MICRO IM A, V86, P56
   Murphy E, 2010, J CLIN ENDOCR METAB, V95, P3173, DOI 10.1210/jc.2009-2630
   Nava-Gonzalez EJ, 2015, GAC MED MEX, V151, P731
   Noh HM, 2015, OSTEOPOROSIS INT, V26, P997, DOI 10.1007/s00198-014-2906-z
   Nyrnes A, 2006, INT J OBESITY, V30, P100, DOI 10.1038/sj.ijo.0803112
   Samuels MH, 2017, J CLIN ENDOCR METAB, V102, P2533, DOI 10.1210/jc.2017-00224
   Svare A, 2013, EUR J ENDOCRINOL, V169, P845, DOI 10.1530/EJE-13-0546
   van Rijn LE, 2014, EUR J ENDOCRINOL, V170, P461, DOI 10.1530/EJE-13-0769
   Wirth CD, 2014, ANN INTERN MED, V161, P189, DOI 10.7326/M14-0125
NR 33
TC 0
Z9 0
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JAN 10
PY 2020
VL 10
AR 890
DI 10.3389/fendo.2019.00890
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA KF4YG
UT WOS:000509248900001
PM 31998231
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Fava, M
   Peloggia, A
   Baccaro, LF
   Castro, S
   Carvalho, N
   Bahamondes, L
AF Fava, Mariana
   Peloggia, Alessandra
   Baccaro, Luiz F.
   Castro, Sara
   Carvalho, Nelsilene
   Bahamondes, Luis
TI A randomized controlled pilot study of ulipristal acetate for abnormal
   bleeding among women using the 52-mg levonorgestrel intrauterine system
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Abnormal bleeding; Levonorgestrel intrauterine system; Randomized
   clinical trial; Treatment; Ulipristal acetate
ID USER SATISFACTION; CONTROLLED-TRIAL; CONTRACEPTION; EXPERIENCE;
   MANAGEMENT; CDB-2914; PLACEBO
AB Objective To assess the efficacy of ulipristal acetate (UPA) for reducing abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system (LNG-IUS). Methods A randomized, double-blind, placebo-controlled pilot study conducted from September 1, 2016 to September 30, 2018, at the University of Campinas, Brazil. LNG-IUS users reporting prolonged or frequent uterine bleeding for at least 1 year were randomized to receive 5 mg UPA per day for 5 days or placebo at an identical regimen. Bleeding was recorded for 90 days after treatment began and was compared between the groups. Results Of 94 eligible women, 64 with abnormal bleeding associated with LNG-IUS use declined treatment or device removal after counselling regarding anticipated bleeding patterns. For the 25 study participants, differences were nonsignificant between the UPA and placebo groups for number of days before bleeding stopped and days free of bleeding; however, UPA users displayed a trend for shorter duration before bleeding stopped and longer time free of bleeding. A similar trend for mean number of bleeding days at 30-, 60-, and 90-day follow-up was observed. Conclusion A nonsignificant trend in reduction of abnormal bleeding was observed among LNG-IUS users taking 5 mg UPA per day for 5 days compared with placebo; however, further research is needed. ClinicalTrials.gov: NCT03186586
C1 [Fava, Mariana; Peloggia, Alessandra; Baccaro, Luiz F.; Castro, Sara; Carvalho, Nelsilene; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
RI Baccaro, Luiz Francisco/G-2858-2013
OI Baccaro, Luiz Francisco/0000-0002-8837-8061
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); National Research
   Council (CNPq)National Council for Scientific and Technological
   Development (CNPq); International Contraceptive Access Foundation
FX Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP); National
   Research Council (CNPq); International Contraceptive Access Foundation
CR Backman T, 2002, OBSTET GYNECOL, V99, P608, DOI 10.1016/S0029-7844(01)01764-1
   Barlow DH, 2014, HUM REPROD, V29, P480, DOI 10.1093/humrep/det467
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Carvalho NM, 2017, J OBSTET GYNAECOL RE, V43, P1732, DOI 10.1111/jog.13441
   Cohen MA, 2019, CONTRACEPTION
   Donnez J, 2012, NEW ENGL J MED, V366, P421, DOI 10.1056/NEJMoa1103180
   Donnez J, 2012, NEW ENGL J MED, V366, P409, DOI 10.1056/NEJMoa1103182
   Gemzell-Danielsson K, 2010, HUM REPROD, V25, P354, DOI 10.1093/humrep/dep426
   Guttinger A, 2007, CONTRACEPTION, V75, pS93, DOI 10.1016/j.contraception.2007.01.015
   Heikinheimo O, 2014, HUM REPROD, V29, P1182, DOI 10.1093/humrep/deu063
   Lal S, 2010, INT J GYNECOL OBSTET, V109, P128, DOI 10.1016/j.ijgo.2010.01.015
   Levy DP, 2014, CONTRACEPTION, V89, P431, DOI 10.1016/j.contraception.2014.01.003
   LUUKKAINEN T, 1991, ANN NY ACAD SCI, V626, P43, DOI 10.1111/j.1749-6632.1991.tb37898.x
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   Moher D, 2010, BMJ-BRIT MED J, V340, DOI [10.1136/bmj.c869, 10.1016/j.jclinepi.2010.03.004]
   PAKARINEN P, 1995, HUM REPROD, V10, P2390
   Phupong V, 2006, CONTRACEPTION, V73, P253, DOI 10.1016/j.contraception.2005.09.012
   Sitruk-Ware R, 2005, WOMENS HEALTH, V1, P171, DOI 10.2217/17455057.1.2.171
   Sordal T, 2013, OBSTET GYNECOL, V121, P934, DOI 10.1097/AOG.0b013e31828c65d8
   Suvisaari J, 1996, CONTRACEPTION, V54, P201, DOI 10.1016/S0010-7824(96)00189-8
   Talaulikar VS, 2012, ADV THER, V29, P655, DOI 10.1007/s12325-012-0042-8
   Warner P, 2010, HUM REPROD, V25, P345, DOI 10.1093/humrep/dep377
   Woodhead N, 2018, J OBSTET GYNAECOL, V38, P813, DOI 10.1080/01443615.2017.1405926
   Zigler RE, 2018, OBSTET GYNECOL, V132, P888, DOI 10.1097/AOG.0000000000002810
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD APR
PY 2020
VL 149
IS 1
BP 10
EP 15
DI 10.1002/ijgo.13068
EA DEC 2019
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA KR3ON
UT WOS:000502238700001
PM 31777949
DA 2020-12-01
ER

PT J
AU Vieira, CS
   Fraser, IS
   Plagianos, MG
   Burke, AE
   Westhoff, CL
   Jensen, J
   Brache, V
   Bahamondes, L
   Merkatz, R
   Sitruk-Ware, R
   Blithe, DL
AF Vieira, Carolina Sales
   Fraser, Ian S.
   Plagianos, Marlena G.
   Burke, Anne E.
   Westhoff, Carolyn L.
   Jensen, Jeffrey
   Brache, Vivian
   Bahamondes, Luis
   Merkatz, Ruth
   Sitruk-Ware, Regine
   Blithe, Diana L.
TI Bleeding profile associated with 1-year use of the segesterone
   acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis
   from Phase 3 trials
SO CONTRACEPTION
LA English
DT Article
DE Contraceptive vaginal system; Combined hormonal contraceptives;
   Segesterone acetate; Nestorone; Bleeding pattems
ID CYCLE CONTROL; RING; ACCEPTABILITY; EFFICACY; PATTERNS; TOLERABILITY;
   SAFETY
AB Objectives: To describe bleeding patterns among users of the segesterone acetate (SA) and ethinyl estradiol (EE) contraceptive vaginal system (CVS), and identify factors associated with unscheduled bleeding/spotting (B/S).
   Study design: We pooled results from two multicenter, single-arm, open-label, pivotal, phase 3 studies of the SA/EE CVS conducted in 17 US and 7 international sites. Participants (age 18-40 years; BMI <= 29 kg/m(2)) followed a 21/7-day in/out schedule of CVS use for up to 13 cycles and recorded vaginal bleeding daily in paper diaries. Scheduled and unscheduled B/S were summarized by cycle. We used multiple logistic regression to identify factors associated with unscheduled bleeding/spotting, based on the first 4 cycles only.
   Results: Analysis included data from 2070 participants (16,408 cycles). Ninety-eight percent documented scheduled B/S [mean (SD): 4.9 (1.1) days/cycle)]. Absence of scheduled B/S was 5-8% of women/cycle. Unscheduled B/S ranged from 13.2% to 21.7% of women per cycle. Few women (1.8%) discontinued prematurely due to unacceptable bleeding. Black women were more likely to report unscheduled B/S than White women [Adjusted odds ratio (AOR) = 1.49, 95% confidence interval (CI) = 1.14-1.94]. Women with fewer years of schooling [<high school (AOR=0.62, 95%CI=0.43-0.90); high school graduate (AOR: 0.76, 95% CI=0.60-0.97)] were less likely to report any episode of unscheduled B/S compared to college graduates.
   Conclusions: Participants using the SA/EE CVS up to 13 cycles reported good cycle control. Discontinuation due to unacceptable bleeding was very low. Further research into demographic/other differences with reported unscheduled bleeding is warranted. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Vieira, Carolina Sales] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ave Bandeirantes 3900,Campus Univ, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Vieira, Carolina Sales; Plagianos, Marlena G.; Merkatz, Ruth; Sitruk-Ware, Regine] Populat Council, 1230 York Ave, New York, NY 10065 USA.
   [Fraser, Ian S.] Univ New South Wales, Royal Hosp Women, Sch Womens & Childrens Hlth, Barker St, Randwick, NSW 2031, Australia.
   [Burke, Anne E.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Bayview Med Ctr, Baltimore, MD 21224 USA.
   [Westhoff, Carolyn L.] Columbia Univ, Dept Obstet & Gynecol, Irving Med Ctr, New York, NY 10032 USA.
   [Jensen, Jeffrey] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA.
   [Brache, Vivian] Profamilia, Santo Domingo, Dominican Rep.
   [Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
   [Blithe, Diana L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Contracept Dev Program, NIH, Bethesda, MD USA.
RP Vieira, CS (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Gynecol & Obstet, Ave Bandeirantes 3900,Campus Univ, BR-14049900 Ribeirao Preto, SP, Brazil.; Vieira, CS (corresponding author), Populat Council, 1230 York Ave, New York, NY 10065 USA.
EM carol.sales@uol.com.br
RI Vieira, Carolina Sales/N-6855-2015
OI Vieira, Carolina Sales/0000-0003-2933-5755
FU National Institute of Child Health and Human Development of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [HD43366003, HD43371003, HD43372003, HD43373003, HD43374003, HD43375003,
   HD43376003, HD43377003, HD43378003, HD43379003, HD43380003, HD43381003,
   HD43382003]; United States Agency for International DevelopmentUnited
   States Agency for International Development (USAID)
   [GPO-A-00-04-00019-00]; WHO's RHRP Division; Population Council
FX These trials were supported by the National Institute of Child Health
   and Human Development of the National Institutes of Health (Contract
   Numbers HD43366003, HD43371003, HD43372003, HD43373003, HD43374003,
   HD43375003, HD43376003, HD43377003, HD43378003, HD43379003, HD43380003,
   HD43381003, HD43382003), and the United States Agency for International
   Development (Grant Number GPO-A-00-04-00019-00), as well as financial
   support from WHO's RHRP Division for two clinical sites in Europe, and
   the Population Council.
CR Archer DF, 2019, LANCET GLOB HEALTH, V7, pE1054, DOI 10.1016/S2214-109X(19)30265-7
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   Bjarnadottir RI, 2002, AM J OBSTET GYNECOL, V186, P389, DOI 10.1067/mob.2002.121103
   Dieben TOM, 2002, OBSTET GYNECOL, V100, P585, DOI 10.1016/S0029-7844(02)02124-5
   Edelman A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub3
   Egarter C, 2013, BMC WOMENS HEALTH, V13, DOI 10.1186/1472-6874-13-9
   Endrikat J, 1999, CONTRACEPTION, V60, P269, DOI 10.1016/S0010-7824(99)00097-9
   Fan GS, 2016, EUR J CONTRACEP REPR, V21, P303, DOI 10.1080/13625187.2016.1186269
   FDA advisory committee briefing document, 2007, FDA ADVISORY COMMITT
   Fruzzetti F, 2016, EUR J CONTRACEP REPR, V21, P449, DOI 10.1080/13625187.2016.1234598
   Gemzell-Danielsson K, 2019, CONTRACEPTION, V99, P323, DOI 10.1016/j.contraception.2019.02.001
   Glasier AF, 2003, CONTRACEPTION, V67, P1, DOI 10.1016/S0010-7824(02)00474-2
   Heise L, 1997, ACCEPTABILITY USERS, P6
   Kayisli OG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137855
   Madden T, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.01.051
   Mansour D, 2008, EUR J CONTRACEP REPR, V13, P13, DOI 10.1080/13625180801959931
   Mansour D, 2017, CONTRACEPTION, V95, P390, DOI 10.1016/j.contraception.2016.12.001
   Merkatz RB, 2014, CONTRACEPTION, V90, P514, DOI 10.1016/j.contraception.2014.05.015
   Merki-Feld GS, 2014, EUR J CONTRACEP REPR, V19, P266, DOI 10.3109/13625187.2014.907398
   Milsom I, 2006, HUM REPROD, V21, P2304, DOI 10.1093/humrep/del162
   Mishell DR, 2007, CONTRACEPTION, V75, P11, DOI 10.1016/j.contraception.2006.08.012
   Nippita S, 2015, CONTRACEPTION, V92, P578, DOI 10.1016/j.contraception.2015.09.004
   Oddsson K, 2005, HUM REPROD, V20, P557, DOI 10.1093/humrep/deh604
   Polis CB, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0561-0
   Roumen FJME, 2001, HUM REPROD, V16, P469, DOI 10.1093/humrep/16.3.469
   Schafer JE, 2006, CONTRACEPTION, V73, P488, DOI 10.1016/j.contraception.2005.11.003
   Shapiro JP, 2015, CONTRACEPTION, V91, P253, DOI 10.1016/j.contraception.2014.11.005
   Sitruk-Ware R, 2008, MATURITAS, V61, P151, DOI 10.1016/j.maturitas.2004.01.001
   Thurman AR, 2013, INT J WOMENS HEALTH, V5, P695, DOI 10.2147/IJWH.S34030
   Westhoff C, 2005, OBSTET GYNECOL, V106, P89, DOI 10.1097/01.AOG.0000164483.13326.59
   WHO, 2018, GLOB HDB PROV
   Wieder DR, 2010, INT J WOMENS HEALTH, V2, P401, DOI 10.2147/IJWH.S6162
NR 32
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD DEC
PY 2019
VL 100
IS 6
BP 438
EP 444
DI 10.1016/j.contraception.2019.07.145
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA JW2JY
UT WOS:000502885200003
PM 31398307
DA 2020-12-01
ER

PT J
AU Gemzell-Danielsson, K
   Jensen, JT
   Monteiro, I
   Peers, T
   Rodriguez, M
   Sardo, AD
   Bahamondes, L
AF Gemzell-Danielsson, Kristina
   Jensen, Jeffrey T.
   Monteiro, Ilza
   Peers, Tina
   Rodriguez, Maria
   Sardo, Attilio Di Spiezio
   Bahamondes, Luis
TI Interventions for the prevention of pain associated with the placement
   of intrauterine contraceptives: An updated review
SO ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
LA English
DT Review
DE contraception; intrauterine contraception; intrauterine device;
   nonsteroidal anti-inflammatory drugs; pain; women
ID RANDOMIZED-CONTROLLED-TRIAL; DEVICE INSERTION; NULLIPAROUS WOMEN; IUD
   INSERTION; LIDOCAINE GEL; MISOPROSTOL PRIOR; REDUCING PAIN; PAROUS
   WOMEN; SYSTEM; PERCEPTION
AB A 2013 review found no evidence to support the routine use of pain relief for intrauterine contraceptive (IUC) placement; however, fear of pain with placement continues to be a barrier to use for some women. This narrative review set out to identify (1) new evidence that may support routine use of pain management strategies for IUC placement; (2) procedure-related approaches that may have a positive impact on the pain experience; and (3) factors that may help healthcare professionals identify women at increased risk of pain with IUC placement. A literature search of the PubMed and Cochrane library databases revealed 550 citations, from which we identified 43 new and pertinent studies for review. Thirteen randomized clinical trials, published since 2012, described reductions in placement-related pain with administration of oral and local analgesia (oral ketorolac, local analgesia with different lidocaine formulations) and cervical priming when compared with placebo or controls. Four studies suggested that ultrasound guidance, balloon dilation, and a modified placement device may help to minimize the pain experienced with IUC placement. Eight publications suggested that previous cesarean delivery, timing of insertion relative to menstruation, dysmenorrhea, expected pain, baseline anxiety, and size of insertion tube may affect the pain experienced with IUC placement. Oral and local analgesia and cervical priming can be effective in minimizing IUC placement-related pain when compared with placebo, but routine use remains subject for debate. Predictive factors may help healthcare professionals to identify women at risk of experiencing pain. Targeted use of effective strategies in these women may be a useful approach while research continues in this area.
C1 [Gemzell-Danielsson, Kristina] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, WHO Ctr, C1 05, S-17176 Stockholm, Sweden.
   [Jensen, Jeffrey T.; Rodriguez, Maria] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA.
   [Monteiro, Ilza; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynecol, Fac Med Sci, Campinas, SP, Brazil.
   [Peers, Tina] Clare Pk Hosp, Farnham, Surrey, England.
   [Sardo, Attilio Di Spiezio] Univ Naples Federico II, Sch Med, Dept Publ Hlth, Naples, Italy.
RP Gemzell-Danielsson, K (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, WHO Ctr, C1 05, S-17176 Stockholm, Sweden.
EM kristina.gemzell@ki.se
RI ; Saccone, Gabriele/K-2792-2018
OI Di Spiezio Sardo, Attilio/0000-0001-6485-5735; Saccone,
   Gabriele/0000-0003-0078-2113
CR Abbas AM, 2017, CONTRACEPTION, V95, P251, DOI 10.1016/j.contraception.2016.10.011
   Abd Ellah NH, 2018, INT J PHARMACEUT, V538, P279, DOI 10.1016/j.ijpharm.2018.01.033
   Abdellah MS, 2017, CONTRACEPTION, V95, P538, DOI 10.1016/j.contraception.2017.01.003
   Akers AY, 2017, OBSTET GYNECOL, V130, P795, DOI 10.1097/AOG.0000000000002242
   Aksoy H, 2016, J FAM PLAN REPROD H, V42, P83, DOI 10.1136/jfprhc-2014-100917
   Allen RH, 2014, J OBSTET GYNAECOL, V34, P263, DOI 10.3109/01443615.2013.868424
   Allen RH, 2013, CONTRACEPTION, V88, P730, DOI 10.1016/j.contraception.2013.07.009
   Arsenijevic S, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-196
   Bahamondes MV, 2015, HUM REPROD, V30, P1861, DOI 10.1093/humrep/dev137
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Bednarek PH, 2015, CONTRACEPTION, V91, P193, DOI 10.1016/j.contraception.2014.11.012
   Birgisson NE, 2015, J WOMENS HEALTH, V24, P349, DOI 10.1089/jwh.2015.5191
   Black KI, 2013, CONTRACEPTION, V88, P650, DOI 10.1016/j.contraception.2013.06.005
   Brockmeyer A, 2008, EUR J CONTRACEP REPR, V13, P248, DOI 10.1080/02699200802253706
   Cameron ST, 2013, J FAM PLAN REPROD H, V39, P207, DOI 10.1136/jfprhc-2012-100422
   Castro TVB, 2014, HUM REPROD, V29, P2439, DOI 10.1093/humrep/deu233
   Chi IC, 1996, CONTRACEPTION, V34, P483
   Collins JA, 2005, HUM REPROD UPDATE, V11, P103, DOI 10.1093/humupd/dmh058
   Conti JA, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.11.1085
   Crawford M, 2017, J OBSTET GYNAECOL CA, V39, P1143, DOI 10.1016/j.jogc.2017.05.014
   Dakhly DMR, 2017, EUR J CONTRACEP REPR, V22, P349, DOI 10.1080/13625187.2017.1381234
   Dina B, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.10.017
   Doty N, 2015, CONTRACEPTION, V92, P567, DOI 10.1016/j.contraception.2015.05.009
   Elkhouly NI, 2017, EUR J CONTRACEP REPR, V22, P222, DOI 10.1080/13625187.2017.1317340
   Espey E, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.11.018
   Ferrari R., 2015, MED WRITING, V24, P230, DOI DOI 10.1179/2047480615Z.000000000329
   Fouda UM, 2016, CONTRACEPTION, V93, P513, DOI 10.1016/j.contraception.2016.02.001
   Gemzell-Danielsson K, 2013, HUM REPROD UPDATE, V19, P419, DOI 10.1093/humupd/dmt022
   Gemzell-Danielsson K, 2017, CONTRACEPTION, V96, P426, DOI 10.1016/j.contraception.2017.08.004
   Gemzell-Danielsson K, 2012, FERTIL STERIL, V97, P616, DOI 10.1016/j.fertnstert.2011.12.003
   GOLDSTUCK N D, 1985, Clinical Reproduction and Fertility, V3, P65
   Santos ARG, 2013, CONTRACEPTION, V88, P164, DOI 10.1016/j.contraception.2012.10.015
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Kaislasuo J, 2014, OBSTET GYNECOL, V124, P345, DOI 10.1097/AOG.0000000000000362
   Karasu Y, 2017, J OBSTET GYNAECOL RE, V43, P1061, DOI 10.1111/jog.13308
   Lathrop E, 2013, CONTRACEPTION, V88, P725, DOI 10.1016/j.contraception.2013.07.011
   Lopez LM, 2015, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD001863
   Maged AM, 2018, EUR J CONTRACEP REPR, V23, P32, DOI 10.1080/13625187.2018.1428297
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   Micks EA, 2014, CONTRACEPTION, V90, P60, DOI 10.1016/j.contraception.2014.03.012
   Mody SK, 2018, OBSTET GYNECOL, V132, P575, DOI 10.1097/AOG.0000000000002790
   Moher D, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0087-2
   Murty J, 2003, J FAM PLAN REPROD H, V29, P150, DOI 10.1783/147118903101197539
   Narayan A, 2018, J ADOLESCENT HEALTH, V63, P37, DOI 10.1016/j.jadohealth.2018.02.001
   Nelson AL, 2013, CONTRACEPTION, V88, P37, DOI 10.1016/j.contraception.2012.12.009
   Ngo LL, 2016, OBSTET GYNECOL, V128, P1306, DOI 10.1097/AOG.0000000000001746
   Olsen MF, 2017, BMC MED, V15, DOI 10.1186/s12916-016-0775-3
   Oxford Centre for Evidence Based Medicine Levels of Evidence [cited, LEVELS EVIDENCE
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Rapkin RB, 2016, OBSTET GYNECOL, V128, P621, DOI 10.1097/AOG.0000000000001596
   Sayar GH, 2016, J NEUROBEHAVE SCI, V3, P65
   Scavuzzi A, 2013, HUM REPROD, V28, P2118, DOI 10.1093/humrep/det240
   Shahnazi Mahnaz, 2012, J Caring Sci, V1, P255, DOI 10.5681/jcs.2012.035
   Singh RH, 2016, INT J GYNECOL OBSTET, V135, P145, DOI 10.1016/j.ijgo.2016.04.014
   Sinning KM, 2018, J PEDIATR ADOL GYNEC, V31, P400, DOI 10.1016/j.jpag.2018.02.127
   Speedie JMM, 2016, J FAM PLAN REPROD H, V42, P241, DOI 10.1136/jfprhc-2016-101446
   Tavakolian Samira, 2015, Glob J Health Sci, V7, P399, DOI 10.5539/gjhs.v7n4p399
   The Cochrane Collaboration, 2011, HDB SYST REV INT
   Torky H, 2017, EUR J CONTRACEP REPR, V22, P159, DOI 10.1080/13625187.2017.1285881
   Tornblom-Paulander S, 2015, FERTIL STERIL, V103, P422, DOI 10.1016/j.fertnstert.2014.10.026
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Turok DK, 2019, BMJ SEX REPROD HEAL, V45, P47, DOI 10.1136/bmjsrh-2017-200031
   van der Heijden PAHH, 2017, BJOG-INT J OBSTET GY, V124, P299, DOI 10.1111/1471-0528.14445
NR 63
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6349
EI 1600-0412
J9 ACTA OBSTET GYN SCAN
JI Acta Obstet. Gynecol. Scand.
PD DEC
PY 2019
VL 98
IS 12
BP 1500
EP 1513
DI 10.1111/aogs.13662
PG 14
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA JN7UG
UT WOS:000497098500002
PM 31112295
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Quintino-Moro, A
   Zantut-Wittmann, DE
   dos Santos, PNS
   Silva, CA
   Bahamondes, L
   Fernande, A
AF Quintino-Moro, Alessandra
   Zantut-Wittmann, Denise E.
   Silva dos Santos, Priscilla N.
   Silva, Conceicao A.
   Bahamondes, Luis
   Fernande, Arlete
TI Changes in calcium metabolism and bone mineral density in new users of
   medroxyprogesterone acetate during the first year of use
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Body composition; Bone mineral density; Caffeine; Calcium metabolism;
   Contraception; Depot medroxyprogesterone acetate
ID BIOCHEMICAL MARKERS; PHYSICAL-ACTIVITY; 1ST-TIME USERS; RECOVERY;
   CONSUMPTION
AB Objective To evaluate calcium metabolism and bone mineral density (BMD) in new users of depot medroxyprogesterone acetate (DMPA) in the first year of use. Methods This prospective, non-randomized study, conducted at the University of Campinas, Sao Paulo, Brazil, was carried out between February 2011 and February 2013. Women aged from 18 to 40 with a body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters) DMPA were paired by age (+/- 1 year) and BMI (+/- 1) with women commencing the use of a copper intrauterine device (IUD). The primary outcomes were BMD measured by dual-energy X-ray absorptiometry and calcium metabolism markers; other variables were body composition and lifestyle habits. Repeated measures analysis of variance (ANOVA) and multiple regression analyses were used to evaluate associations. Results Twenty-seven women using DMPA and 24 using IUD were evaluated, with a mean age of 29.7 years and 28.6 years, respectively. The DMPA group presented with a 3.6% (P<0.001) loss of lumbar spine BMD, a 2.1% (P=0.100) loss of femoral neck BMD and higher phosphorus (P=0.014) concentrations at 12 months compared to the IUD group. The decreases in BMD were associated with the use of DMPA, while total mass and coffee intake were found to be protective factors. Conclusion Changes in calcium metabolism and a decrease in BMD were found in the DMPA group at 12 months.
C1 [Quintino-Moro, Alessandra; Silva dos Santos, Priscilla N.; Bahamondes, Luis; Fernande, Arlete] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Family Planning Clin, Sao Paulo, Brazil.
   [Zantut-Wittmann, Denise E.; Silva, Conceicao A.] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, Div Endocrinol, Sao Paulo, Brazil.
RP Fernande, A (corresponding author), Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Zantut-Wittmann, Denise Engelbrecht/ABE-5858-2020
OI Zantut-Wittmann, Denise Engelbrecht/0000-0002-7434-5701
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo Research
   Fundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Sao Paulo State Health Department (SES-SP)
FX Brazilian National Research Council (CNPq); The Sao Paulo Research
   Fundation (FAPESP); Sao Paulo State Health Department (SES-SP)
CR Babatunde OO, 2014, J BONE MINER METAB, V32, P305, DOI 10.1007/s00774-013-0497-y
   Choi E, 2016, PLOS ONE, V27
   Clark MK, 2006, FERTIL STERIL, V86, P1466, DOI 10.1016/j.fertnstert.2006.05.024
   Clark MK, 2004, FERTIL STERIL, V82, P1580, DOI 10.1016/j.fertnstert.2004.04.064
   Compston JE, 2001, PHYSIOL REV, V81, P419
   Dvornyk V, 2003, ANN HUM GENET, V67, P216, DOI 10.1046/j.1469-1809.2003.00037.x
   Fisberg RM, 2009, ARQ BRAS ENDOCRINOL, V53, P617, DOI 10.1590/S0004-27302009000500014
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Gai L, 2011, CONTRACEPTION, V83, P218, DOI 10.1016/j.contraception.2010.07.027
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Grimes DA, 2010, FERTIL STERIL, V93, P1731, DOI 10.1016/j.fertnstert.2009.12.054
   Hallstrom H, 2006, OSTEOPOROSIS INT, V17, P1055, DOI 10.1007/s00198-006-0109-y
   Harel Z, 2010, J PEDIATR ADOL GYNEC, V23, P209, DOI 10.1016/j.jpag.2009.11.004
   HOLICK MF, 1995, AM J CLIN NUTR, V61, p638S, DOI 10.1093/ajcn/61.3.638S
   Ishida Y, 2002, OSTEOPOROSIS INT, V13, P601, DOI 10.1007/s001980200080
   Kaunitz AM, 2008, CONTRACEPTION, V77, P67, DOI 10.1016/j.contraception.2007.10.005
   Kaunitz AM, 2006, CONTRACEPTION, V74, P90, DOI 10.1016/j.contraception.2006.03.010
   Kyvernitakis I, 2016, OSTEOPOROSIS INT, V28, P291
   Meier C, 2010, J CLIN ENDOCR METAB, V95, P4909, DOI 10.1210/jc.2010-0032
   Nejar KA, 2007, REV SAUDE PUBL, V41, P1061
   Ott SM, 2001, J CLIN ENDOCR METAB, V86, P179, DOI 10.1210/jc.86.1.179
   Quintino-Moro A, EVALUATION THYROID H
   Rahman M, 2010, OBSTET GYNECOL, V115, P35, DOI 10.1097/AOG.0b013e3181c4e864
   Shaarawy M, 2006, CONTRACEPTION, V74, P297, DOI 10.1016/j.contraception.2006.04.003
   Tang OS, 1999, CONTRACEPTION, V59, P25, DOI 10.1016/S0010-7824(98)00144-9
   World Health Organization, 2015, MED EL CRIT CONTR US
NR 26
TC 0
Z9 0
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD DEC
PY 2019
VL 147
IS 3
BP 319
EP 325
DI 10.1002/ijgo.12958
EA SEP 2019
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA JI7KQ
UT WOS:000487361500001
PM 31479152
DA 2020-12-01
ER

PT J
AU Archer, DF
   Merkatz, RB
   Bahamondes, L
   Westhoff, CL
   Darney, P
   Apter, D
   Jensen, JT
   Brache, V
   Nelson, AL
   Banks, E
   Bartfai, G
   Portman, DJ
   Plagianos, M
   Dart, C
   Kumar, N
   Creasy, GW
   Sitruk-Ware, R
   Blithe, DL
AF Archer, David F.
   Merkatz, Ruth B.
   Bahamondes, Luis
   Westhoff, Carolyn L.
   Darney, Philip
   Apter, Dan
   Jensen, Jeffrey T.
   Brache, Vivian
   Nelson, Anita L.
   Banks, Erika
   Bartfai, Gyorgy
   Portman, David J.
   Plagianos, Modena
   Dart, Clint
   Kumar, Narender
   Creasy, George W.
   Sitruk-Ware, Regine
   Blithe, Diana L.
TI Efficacy of the 1-year (13-cycle) segesterone acetate and
   ethinylestradiol contraceptive vaginal system: results of two
   multicentre, open-label, single-arm, phase 3 trials
SO LANCET GLOBAL HEALTH
LA English
DT Article
ID UNITED-STATES; PEARL INDEXES; NESTORONE(R); PREDICTORS; PROGESTIN;
   FAILURE; TRENDS
AB Background A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive vaginal system and return to menses or pregnancy after use.
   Methods In two identically designed, multicentre, open-label, single-arm, phase 3 trials (one at 15 US academic and community sites and one at 12 US and international academic and community sites), participants followed a 21-days-in, 7-days-out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycles. Participants were healthy, sexually active, non-pregnant, non-sterilised women aged 18-40 years. Women were cautioned that any removals during the 21 days of cyclic use should not exceed 2 h, and used daily paper diaries to record vaginal system use. Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index for women aged 35 years and younger, excluding adjunctive contraception cycles, as the primary efficacy outcome measure. We also did intention-to-treat Kaplan-Meier life table analyses and followed up women who did not use hormonal contraceptives or desired pregnancy after study completion for 6 months for return to menses or pregnancy. The trials are registered with ClinicalTrials.gov, numbers NCT00455156 and NCT00263341.
   Findings Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites, and between Nov 1, 2006, and July 2, 2009, at the 12 US and international sites we enrolled 2278 women. Our overall efficacy analysis included 2265 participants (1130 in the US study and 1135 in the international study) and 1303 (57.5%) participants completed up to 13 cycles. The Pearl Index for the primary efficacy group was 2.98 (95% CI 2.13-4.06) per 100 woman-years, and was well within the range indicative of efficacy for a contraceptive under a woman's control. The Kaplan-Meier analysis revealed the contraceptive vaginal system was 97.5% effective, which provided further evidence of efficacy. Pregnancy occurrence was similar across cycles. All 290 follow-up participants reported return to menses or became pregnant (24 [63%] of 38 women who desired pregnancy) within 6 months.
   Interpretation The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contraceptive for 13 consecutive cycles of use. This new product adds to the contraceptive method mix and the 1-year duration of use means that women do not need to return to the clinic or pharmacy for refills every few months. Copyright (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Archer, David F.] Eastern Virginia Med Sch, Clin Res Ctr, Norfolk, VA 23501 USA.
   [Merkatz, Ruth B.; Plagianos, Modena; Kumar, Narender; Creasy, George W.; Sitruk-Ware, Regine] Populat Council, Ctr Biomed Res, New York, NY 10065 USA.
   [Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP, Brazil.
   [Westhoff, Carolyn L.] Columbia Univ, Irving Med Ctr, New York, NY USA.
   [Darney, Philip] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth, San Francisco, CA USA.
   [Apter, Dan] VL Medi Clin Res Ctr, Helsinki, Finland.
   [Jensen, Jeffrey T.] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA.
   [Brache, Vivian] Profamilia, Biomed Res Dept, Santo Domingo, Dominican Rep.
   [Nelson, Anita L.] Essential Access Hlth, Res Div, Los Angeles, CA USA.
   [Banks, Erika] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, New York, NY USA.
   [Bartfai, Gyorgy] Univ Szeged, Dept Obstet & Gynaecol, Szeged, Hungary.
   [Portman, David J.] Columbus Ctr Womens Hlth Res, Columbus, OH USA.
   [Portman, David J.] Sermonix Pharmaceut, Columbus, OH USA.
   [Dart, Clint] Hlth Decis, Durham, NC USA.
   [Blithe, Diana L.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Contracept Res Branch, NIH, Bethesda, MD USA.
RP Merkatz, RB (corresponding author), Populat Council, Ctr Biomed Res, New York, NY 10065 USA.
EM rmerkatz@popcouncil.org
RI Jensen, Jeffrey T/C-7421-2014
OI Jensen, Jeffrey T/0000-0002-4733-1224; Sitruk-Ware,
   Regine/0000-0001-5183-9875
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development of the National Institutes of Health (NICHD); US Agency for
   International Development (USAID)United States Agency for International
   Development (USAID); WHOWorld Health Organization; TherapeuticsMD (Boca
   Raton, FL, USA); NICHDUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [HHSN27500403372]; USAIDUnited States Agency for International
   Development (USAID) [GPO-A-00-04-00019-00]; WHO Department of
   Reproductive Health and Research; TherapeuticsMD
FX We thank The Eunice Kennedy Shriver National Institute of Child Health
   and Human Development of the National Institutes of Health (NICHD), the
   US Agency for International Development (USAID), and WHO for funding the
   phase 3 studies. We also acknowledge all participating study
   investigators (appendix p 1) and coordinators at the 27 clinical sites
   for conduct of the two phase 3 clinical trials and the over 2200 women
   participants from eight countries. We further acknowledge the medical
   writing assistance of Kathleen Ohleth (Precise Publications; Bedminster.
   NJ, USA) supported by TherapeuticsMD (Boca Raton, FL, USA). The NICHD
   (contract no HHSN27500403372) funded and conducted the US study and
   USAID (grant no GPO-A-00-04-00019-00) funded the international study,
   which was conducted by the Population Council. WHO Department of
   Reproductive Health and Research funded two international study sites.
   Medical writing support for manuscript submission and resubmission was
   supported by TherapeuticsMD. The authors acknowledge the major
   contribution of Daniel R Mishell Jr (deceased), from the Department of
   Obstetrics and Gynecology, University of Southern California, Keck
   School of Medicine (Los Angeles, CA, USA) who invented the concept of
   the vaginal system to deliver contraceptive steroids, did many of the
   clinical studies for the segesterone acetate and ethinylestradiol
   contraceptive vaginal system, and was a principle investigator for the
   300 B phase 3 study analysed in this Article while a member of the
   International Committee for Contraceptive Research (ICCR) of the
   Population Council. The authors also gratefully acknowledge the
   contribution of Horacio B Croxatto, from the University of Chile
   (Santiago, Chile), who established the clinical centre in Chile,
   participated in all pivotal clinical studies for this ring, and provided
   guidance for the full development of this new contraceptive while a
   member of the ICCR.
CR Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1
   [Anonymous], 2010, PRESCRIBING INFORM
   [Anonymous], 2010, PRESCRIBING INFORM
   Barnett C, 2017, EUR J CONTRACEP REPR, V22, P17, DOI 10.1080/13625187.2016.1241991
   Brache V, 2000, CONTRACEPTION, V61, P199, DOI 10.1016/S0010-7824(00)00092-5
   Brache V, 2013, CONTRACEPTION, V87, P264, DOI 10.1016/j.contraception.2012.08.037
   CHOWDHURY V, 1980, CONTRACEPTION, V22, P241, DOI 10.1016/S0010-7824(80)80003-5
   Creasy G, 2014, EUR J CONTRACEP REPR, V19, pS85
   DIAZ S, 1995, CONTRACEPTION, V51, P33, DOI 10.1016/0010-7824(94)00006-I
   Gemzell-Danielsson K, 2019, CONTRACEPTION, V99, P323, DOI 10.1016/j.contraception.2019.02.001
   Gerlinger C, 2014, CONTRACEPTION, V90, P142, DOI 10.1016/j.contraception.2014.03.018
   HAUKKAMAA M, 1992, CONTRACEPTION, V45, P49, DOI 10.1016/0010-7824(92)90140-O
   Kavanaugh ML, 2018, CONTRACEPTION, V97, P14, DOI 10.1016/j.contraception.2017.10.003
   Kazerooni R, 2015, ANN PHARMACOTHER, V49, P1284, DOI 10.1177/1060028015607825
   Kemet S, 2018, CONTRACEPTION, V97, P313, DOI 10.1016/j.contraception.2017.12.014
   Kroll R, 2010, CONTRACEPTION, V81, P41, DOI 10.1016/j.contraception.2009.07.003
   Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7
   Kumar N, 2017, ENDOCRINOLOGY, V158, P170, DOI 10.1210/en.2016-1426
   Abascal PL, 2016, EUR J CONTRACEP REPR, V21, P88, DOI 10.3109/13625187.2015.1059416
   MISHELL DR, 1970, FERTIL STERIL, V21, P99
   Polis CB, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0561-0
   Portman DJ, 2014, CONTRACEPTION, V89, P299, DOI 10.1016/j.contraception.2014.01.013
   Rocca CH, 2012, PERSPECT SEX REPRO H, V44, P150, DOI 10.1363/4415012
   Starbird E, 2016, GLOB HEALTH-SCI PRAC, V4, P191, DOI 10.9745/GHSP-D-15-00374
   Stifani BM, 2018, CONTRACEPTION, V97, P415, DOI 10.1016/j.contraception.2017.12.011
   Trussell J, 1999, FAM PLANN PERSPECT, V31, P64, DOI 10.2307/2991641
   Trussell J, 2013, CONTRACEPTION, V88, P604, DOI 10.1016/j.contraception.2013.04.001
   Westhoff CL, 2012, CONTRACEPTION, V85, P465, DOI 10.1016/j.contraception.2011.09.019
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Yang Genyan, 2012, Open J Prev Med, V2, P499, DOI 10.4236/ojpm.2012.24069
NR 30
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD AUG
PY 2019
VL 7
IS 8
BP E1054
EP E1064
DI 10.1016/S2214-109X(19)30265-7
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA IH9JV
UT WOS:000474823700029
PM 31231065
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Peloggia, A
AF Bahamondes, Luis
   Peloggia, Alessandra
TI Modern contraceptives in sub-Saharan African countries
SO LANCET GLOBAL HEALTH
LA English
DT Editorial Material
C1 [Bahamondes, Luis; Peloggia, Alessandra] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, BR-13084971 Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
CR Ackerson K, 2017, MIDWIFERY, V54, P35, DOI 10.1016/j.midw.2017.07.021
   Ahmed S, 2019, LANCET GLOB HEALTH, V7, pE904, DOI 10.1016/S2214-109X(19)30200-1
   Brown W, 2014, STUD FAMILY PLANN, V45, P73, DOI 10.1111/j.1728-4465.2014.00377.x
   Cleland J, 2006, LANCET, V368, P1810, DOI 10.1016/S0140-6736(06)69480-4
   Mbizvo MT, 2014, BEST PRACT RES CL OB, V28, P931, DOI 10.1016/j.bpobgyn.2014.04.014
   Obwoya JG, 2018, INT J POPUL RES, V2018, P1
   Osotimehin B, 2015, GLOBAL HEALTH ACTION, V8, DOI 10.3402/gha.v8.29978
   Tsui AO, 2017, POPUL DEV REV, V43, P166, DOI 10.1111/padr.12051
   WHO, 2018, FAM PLANN CONTR
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD JUL
PY 2019
VL 7
IS 7
BP E819
EP E820
DI 10.1016/S2214-109X(19)30199-8
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA IC5GT
UT WOS:000470996500007
PM 31109882
OA DOAJ Gold
DA 2020-12-01
ER

PT J
AU Rebelo, RC
   Pignaton, E
   Bahamondes, MV
   Costallat, LTL
   Appenzeller, S
   Bahamondes, L
   Fernandes, A
AF Rebelo, Rafaella C.
   Pignaton, Estephania
   Valeria Bahamondes, M.
   Costallat, Lilian T. L.
   Appenzeller, Simone
   Bahamondes, Luis
   Fernandes, Arlete
TI Disease activity and thromboembolic events in women with systemic lupus
   erythematosus with and without anti-phospholipid syndrome: users of the
   52-mg levonorgestrel-releasing intrauterine system
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Systemic lupus erythematosus; Antiphospholipid syndrome;
   Levonorgestrel-releasing intrauterine system; Arterial and venous
   thrombotic events
ID PROGESTIN-ONLY CONTRACEPTION; ARTERIAL THROMBOSIS; ACTIVITY INDEX;
   RISK-FACTORS; CLASSIFICATION; POPULATION; PREVALENCE; MANAGEMENT;
   CRITERIA
AB Purpose The disease status and thromboembolic events in women with systemic lupus erythematosus (SLE), with and without anti-phospholipid syndrome (APS), were evaluated before and after placement of the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS).
   Methods A retrospective cohort study, with review of medical records of SLE women, who received an LNG-IUS placement between January 2007 and December 2016, carried out at the University of Campinas Medical School, Brazil. The outcomes included the disease activity (SLEDAI-2K) and damage index scores (SLICC/ACR-DI) presented for each year of device use, as well as venous/arterial thrombotic events, insertion up to a median of 5 years. The author's used chi(2), Fisher's exact and the Mann-Whitney tests for analysis and generalized estimating equations for score comparison.
   Results The study evaluated 46 women with SLE, 18 with and 28 without APS; the mean age (+/- standard deviation [SD]) was 31.8 (SD +/- 8.3) years old. The length of follow-up after LNG-IUS placement was 5.6 (SD +/- 2.7) and 4.1 (SD +/- 2.3) years for the groups with and without APS, respectively. Comparison of the groups found that the SLEDAI and SLICC mean scores were low for both at baseline, without variations through the follow-up. After LNG-IUS placement, two women presented three thrombotic arterial events, and one of them died from causes unrelated to LNG-IUS use.
   Conclusions Our results, although restricted, provide information to policymakers and health professionals that the use of a 52 mg LNG-IUS over a 5-year median did not increase disease activity or damage index scores among women with SLE, with and without APS.
C1 [Rebelo, Rafaella C.; Valeria Bahamondes, M.; Bahamondes, Luis; Fernandes, Arlete] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Family Planning Clin, Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
   [Pignaton, Estephania; Costallat, Lilian T. L.; Appenzeller, Simone] Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Med, Rheumatol Div, Rua Alexander Fleming,101 Cidade Univ, BR-13083881 Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Family Planning Clin, Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Appenzeller, Simone/B-9150-2012; Appenzeller, Simone/O-1947-2018;
   Fernandes, Arlete/I-7561-2018
OI Appenzeller, Simone/0000-0001-5075-4474; Fernandes,
   Arlete/0000-0001-5872-0017
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo Foundation
   for the Support of Research (Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo-FAPESP)
FX The original study was funded by the Brazilian National Research Council
   (CNPq) and the Sao Paulo Foundation for the Support of Research
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESP). The
   sponsors played no role in the study design, in the collection, analysis
   or interpretation of data, in writing the report or in the decision to
   submit the article for publication. The authors claim they do not have a
   financial relationship with the organizations that sponsored the
   research. They claim that they have had full control of all primary data
   and agree to allow the Journal to review their data if requested.
CR Andreoli L, 2017, ANN RHEUM DIS, V76, P476, DOI 10.1136/annrheumdis-2016-209770
   Blanco-Molina MA, 2012, THROMB RES, V129, pE257, DOI 10.1016/j.thromres.2012.02.042
   BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606
   Brito MB, 2018, J OBSTET GYNAECOL, V19, P1
   Choojitarom K, 2008, CLIN RHEUMATOL, V27, P345, DOI 10.1007/s10067-007-0721-z
   Conard J, 2004, CONTRACEPTION, V70, P437, DOI 10.1016/j.contraception.2004.07.009
   Franco JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110242
   Garcia D, 2018, NEW ENGL J MED, V378, P2010, DOI 10.1056/NEJMra1705454
   Gould T, 2006, SCAND J RHEUMATOL, V35, P29, DOI 10.1080/03009740510026913
   Griffiths B, 2005, BEST PRACT RES CL RH, V19, P685, DOI 10.1016/j.berh.2005.03.010
   Hinojosa-Azaola A, 2016, J RHEUMATOL, V43, P576, DOI 10.3899/jrheum.150506
   Kaiser R, 2014, ARTHRITIS RHEUMATOL, V66, P1882, DOI 10.1002/art.38520
   Kuhl H, 1996, MATURITAS, V24, P1, DOI 10.1016/0378-5122(96)00994-2
   Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840
   Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890
   Mantha S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4944
   Matyja-Bednarczyk A, 2014, THROMB RES, V133, P173, DOI 10.1016/j.thromres.2013.11.012
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Mok CC, 2013, MEDICINE, V92, P217, DOI 10.1097/MD.0b013e31829cae47
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   Ossandon A, 2002, CLIN EXP RHEUMATOL, V20, P709
   Petri M, 2005, NEW ENGL J MED, V353, P2550, DOI 10.1056/NEJMoa051135
   Pons-Estel GJ, 2017, J AUTOIMMUN, V76, P10, DOI 10.1016/j.jaut.2016.10.004
   Rengasamy P, 2017, ANTI-CANCER AGENT ME, V17, P1211, DOI 10.2174/1871520616666161206150421
   Romero-Diaz J, 2011, ARTHRIT CARE RES, V63, pS37, DOI 10.1002/acr.20572
   Sanchez-Guerrero J, 2005, NEW ENGL J MED, V353, P2539, DOI 10.1056/NEJMoa050817
   Seeber B, 2012, CONTRACEPTION, V86, P345, DOI 10.1016/j.contraception.2012.01.015
   TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101
   Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014
   Urbanus RT, 2009, LANCET NEUROL, V8, P998, DOI 10.1016/S1474-4422(09)70239-X
   VIANNA JL, 1992, ANN RHEUM DIS, V51, P160, DOI 10.1136/ard.51.2.160
   Vlieg AVH, 2010, ARTERIOSCL THROM VAS, V30, P2297, DOI 10.1161/ATVBAHA.110.211482
   WILLIAMSON RA, 1981, OBSTET GYNECOL, V58, P247
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Hlth Org, 1998, CONTRACEPTION, V57, P315
NR 35
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD JUN
PY 2019
VL 299
IS 6
BP 1597
EP 1605
DI 10.1007/s00404-019-05131-x
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA HZ3NG
UT WOS:000468754900011
PM 30941559
DA 2020-12-01
ER

PT J
AU Gomez-Elias, MD
   May, M
   Munuce, MJ
   Bahamondes, L
   Cuasnicu, PS
   Cohen, DJ
AF Gomez-Elias, Matias D.
   May, Maria
   Munuce, Maria Jose
   Bahamondes, Luis
   Cuasnicu, Patricia S.
   Cohen, Debora J.
TI A single post-ovulatory dose of ulipristal acetate impairs
   post-fertilization events in mice
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE emergency contraception; ulipristal acetate; implantation; embryo
   transport; decidualization
ID PROGESTERONE-RECEPTOR MODULATOR; EMERGENCY CONTRACEPTION; IN-VITRO;
   GENE-EXPRESSION; ANTIPROGESTIN CDB-2914; LEVONORGESTREL; EMBRYO;
   MIFEPRISTONE; OVULATION; FOLLICULOGENESIS
AB Ulipristal acetate (UPA) is a selective progesterone receptor modulator used for emergency contraception that has proven to be highly effective in preventing pregnancy when taken up to 120 h after unprotected sexual intercourse. Even though it may act mainly by delaying or inhibiting ovulation, additional effects of UPA on post-fertilization events cannot be excluded. Therefore, the aim of this study was to determine whether a single post-ovulatory dose of UPA could prevent pregnancy using the mouse as a pre-clinical model. Mated females received a single dose of UPA (40 mg/kg) on Day E1.5 or E2.5 (E0.5: copulatory plug detection) and post-fertilization events were evaluated. Our studies revealed that UPA administration produced a significant decrease in the number of conceptuses compared to control. Moreover, UPA-treated females exhibited a lower number of early implantation sites on Day E5.5, despite normal in vivo embryo development and transport to the uterus at E3.5. Administration of UPA produced histological and functional alterations in the uterine horns, i.e., a dyssynchronous growth between endometrial glands and stroma, with non-physiological combination of both fractions compared to controls, and a completely impaired ability to respond to an artificial decidualization stimulus. Altogether, our results show that the administration of a single post-ovulatory dose of UPA impairs mouse pregnancy probably due to an effect on embryo-uterine interaction, supporting additional effects of the drug on post-fertilization events. Although these studies cannot be performed with human samples, our results with the mouse model provide new insights into the mechanism of action of UPA as an emergency contraception method.
C1 [Gomez-Elias, Matias D.; Cuasnicu, Patricia S.; Cohen, Debora J.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
   [May, Maria] Univ Buenos Aires, Fac Farm & Bioquim, Inst Invest Farmacol ININFA UBA CONICET, Buenos Aires, DF, Argentina.
   [Munuce, Maria Jose] Natl Univ Rosario, Sch Biochem & Pharmaceut Sci, Lab Reprod Med, Biochem Chem Area, Rosario, Santa Fe, Argentina.
   [Bahamondes, Luis] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, UNICAMP, Campinas, SP, Brazil.
RP Cohen, DJ (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt IBYME, Vuelta Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
EM dcohen@ibyme.conicet.gov.ar
OI Cohen, Debora Juana/0000-0002-0903-216X; Bahamondes,
   Luis/0000-0002-7356-8428
FU University of Rosario [BIO 486 (1480/2016)]; Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2015/20504-9]; National Agency of Scientific and Technological
   Promotion (ANPCyT), ArgentinaANPCyT [PICT 2015-0471, PICT 2016-1057]
FX This study was partially supported by grants BIO 486 (1480/2016) from
   the University of Rosario to M.J.M., 2015/20504-9 from the Sao Paulo
   Research Foundation (FAPESP) to L.B., PICT 2015-0471 to P.S.C. and PICT
   2016-1057 to D.J.C. from the National Agency of Scientific and
   Technological Promotion (ANPCyT), Argentina.
CR Berger C, 2015, HUM REPROD, V30, P800, DOI 10.1093/humrep/dev030
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   Brache V, 2013, CONTRACEPTION, V88, P611, DOI 10.1016/j.contraception.2013.05.010
   Carson DD, 2000, DEV BIOL, V223, P217, DOI 10.1006/dbio.2000.9767
   De Milliano I, 2017, EUR J OBSTET GYN R B, V214, P56, DOI 10.1016/j.ejogrb.2017.04.042
   Deb K, 2006, METH MOLEC MED, V121, P9
   ERBACH GT, 1994, BIOL REPROD, V50, P1027, DOI 10.1095/biolreprod50.5.1027
   Fine P, 2010, OBSTET GYNECOL, V115, P257, DOI 10.1097/AOG.0b013e3181c8e2aa
   Gemzell-Danielsson K, 2014, GYNECOL ENDOCRINOL, V30, P685, DOI 10.3109/09513590.2014.950648
   Glasier A, 2014, GYNECOL ENDOCRINOL, V30, P688, DOI 10.3109/09513590.2014.950645
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Gomez-Elias MD, 2016, HUM REPROD, V31, P53, DOI 10.1093/humrep/dev287
   Guidobaldi HA, 2017, HUM REPROD, V32, P1560, DOI 10.1093/humrep/dex232
   Hild SA, 2000, HUM REPROD, V15, P822, DOI 10.1093/humrep/15.4.822
   Munuce MJ, 2013, EUR J CONTRACEP REPR, V18, P355, DOI 10.3109/13625187.2013.813930
   Ko JKY, 2014, ANDROLOGY-US, V2, P868, DOI 10.1111/j.2047-2927.2014.00261.x
   Li HWR, 2014, HUM REPROD, V29, P2156, DOI 10.1093/humrep/deu210
   Li HWR, 2017, HUM REPROD, V32, P2414, DOI 10.1093/humrep/dex328
   Lira-Albarran S, 2018, MOL CELL ENDOCRINOL, V476, P70, DOI 10.1016/j.mce.2018.04.010
   Lira-Albarran S, 2017, MOL CELL ENDOCRINOL, V447, P1, DOI 10.1016/j.mce.2017.02.024
   Lira-Albarran S, 2017, MOL CELL ENDOCRINOL, V439, P337, DOI 10.1016/j.mce.2016.09.020
   Lyons RA, 2006, HUM REPROD UPDATE, V12, P363, DOI 10.1093/humupd/dml012
   Mozzanega B, 2013, TRENDS PHARMACOL SCI, V34, P195, DOI 10.1016/j.tips.2013.02.003
   Muller AL, 2003, CONTRACEPTION, V67, P415, DOI 10.1016/S0010-7824(03)00021-0
   Munuce MJ, 2012, EUR J CONTRACEP REPR, V17, P428, DOI 10.3109/13625187.2012.725877
   Nagy A., 2003, MANIPULATING MOUSE E
   Nallasamy S, 2013, REPROD SCI, V20, P371, DOI 10.1177/1933719112459239
   NAU H, 1986, ENVIRON HEALTH PERSP, V70, P113, DOI 10.2307/3430348
   Nogales FF, 2018, INT J GYNECOL PATHOL, V37, P575, DOI 10.1097/PGP.0000000000000450
   Palanisamy GS, 2006, MOL ENDOCRINOL, V20, P2784, DOI 10.1210/me.2006-0093
   Passaro MD, 2003, HUM REPROD, V18, P1820, DOI 10.1093/humrep/deg342
   Patel B, 2015, HUM REPROD UPDATE, V21, P155, DOI 10.1093/humupd/dmu056
   Ramathal CY, 2010, SEMIN REPROD MED, V28, P17, DOI 10.1055/s-0029-1242989
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reel JR, 1998, CONTRACEPTION, V58, P129, DOI 10.1016/S0010-7824(98)00067-5
   Rosato E, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00315
   Stratton P, 2000, HUM REPROD, V15, P1092, DOI 10.1093/humrep/15.5.1092
   Stratton P, 2010, FERTIL STERIL, V93, P2035, DOI 10.1016/j.fertnstert.2008.12.057
   Whitaker LHR, 2017, HUM REPROD, V32, P531, DOI 10.1093/humrep/dew359
   Williams ARW, 2012, INT J GYNECOL PATHOL, V31, P556, DOI 10.1097/PGP.0b013e318251035b
   Zhao WH, 2015, CLIN EXP PHARMACOL P, V42, P171, DOI 10.1111/1440-1681.12337
   Zumoffen C, 2017, CONTRACEPTION, V95, P586, DOI 10.1016/j.contraception.2017.02.019
NR 42
TC 1
Z9 1
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460-2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD MAY
PY 2019
VL 25
IS 5
BP 257
EP 264
DI 10.1093/molehr/gaz013
PG 8
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA JI0BL
UT WOS:000493132800002
PM 30824928
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Carreiro, AV
   Fernandes, A
   Bahamondes, L
AF Ferreira, Jessica Mayra
   Carreiro, Andrea Vieira
   Fernandes, Arlete
   Bahamondes, Luis
TI Sexual Function and Quality of Life in a Cohort of Brazilian Users of
   Two Kind of Intrauterine Contraceptives
SO REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA
LA English
DT Article
DE contraception; quality of life; sexuality
ID IMPACT; WOMEN; DEVICE; SYSTEM
AB Objective To compare sexual function and quality of life (QOL) among intrauterine contraceptive (copper-intrauterine device [Cu-IUD] or the 52-mg 20 mu g/day levonorgestrel-releasing intrauterine system [LNG-IUS]) users.
   Methods This was part of a cross-sectional study. Women aged between 18 and 49 years old, in a heterosexual relationship, reporting sexual intercourse in the previous 4 weeks, using Cu-IUD (Group 1) or LNG-IUS (Group 2) responded to a questionnaire with sociodemographic information, to the Female Sexual Function Index (FSFI), to the World Health Organization QOL Questionnaire Abbreviated Version (WHOQOL-BREF), and to a questionnaire about the contraceptive method used. The Student t-test, the Pearson chi(2) test or the Fisher exact test, and the Mann-Whitney test were used for the analysis. For the adjusted comparison, we have used the analysis of covariance (ANCOVA). A multiple regression analyzing factors related to FSFI <= 26.55 was done. Significance was established at p < 0.05.
   Results A total of 347 women in Group 1 (mean age of 32.3 +/- 7.5 years old) and of 298 in Group 2 (mean age of 32.7 +/- 6.4 years old) completed the questionnaires. Most women had >= 8 years of schooling, were in a monogamous relationship, and had had <= 2 pregnancies. A total of 122 Cu-IUD and of 87 LNG-IUS users scored <= 26.55 on the FSFI. Significant lower scores in physical, environmental, and overall QOL domains in the WHOQOL-BREF questionnaire were found in Group 1. More women using the Cu-IUD were not satisfied with the method.
   Conclusion We did not find significant differences in sexual function; there was a lower score in some domains of QOL among women who used the Cu-IUD. It was not possible to ensure that those differences were related to the contraceptive method.
C1 [Ferreira, Jessica Mayra; Carreiro, Andrea Vieira; Fernandes, Arlete; Bahamondes, Luis] Univ Estadual Campinas, Dept Gynecol & Obstet, Rua Dr Ruy Vicente 1047,Cidade Univ Zeferino Vaz, BR-13083970 Campinas, SP, Brazil.
RP Ferreira, JM (corresponding author), Univ Estadual Campinas, Dept Gynecol & Obstet, Rua Dr Ruy Vicente 1047,Cidade Univ Zeferino Vaz, BR-13083970 Campinas, SP, Brazil.
EM jessicamayraf@gmail.com
RI Ferreira, Jessica/I-3350-2018
OI Ferreira, Jessica/0000-0003-2153-0353
CR Bastianelli C, 2011, CONTRACEPTION, V84, P402, DOI 10.1016/j.contraception.2011.01.020
   Boozalis A, 2016, OBSTET GYNECOL, V127, P563, DOI 10.1097/AOG.0000000000001286
   Brown A, 2010, BEST PRACT RES CL OB, V24, P617, DOI 10.1016/j.bpobgyn.2010.04.005
   Carreiro AV, 2016, INT J GYNECOL OBSTET, V134, P260, DOI 10.1016/j.ijgo.2016.01.024
   Cristobal I, 2016, CONTRACEPTION, V93, P367, DOI 10.1016/j.contraception.2015.12.014
   Enzlin P, 2012, J SEX MED, V9, P1065, DOI 10.1111/j.1743-6109.2011.02266.x
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Higgins JA, 2016, OBSTET GYNECOL, V128, P1143, DOI 10.1097/AOG.0000000000001655
   Kahramanoglu I, 2017, ARCH GYNECOL OBSTET, V295, P907, DOI 10.1007/s00404-017-4299-7
   Koseoglu SB, 2016, J CLIN DIAGN RES, V10, pQC21, DOI 10.7860/JCDR/2016/21714.8730
   Li RHW, 2004, CONTRACEPTION, V70, P474, DOI 10.1016/j.contraception.2004.06.010
   Neri M, 2018, GYNECOL ENDOCRINOL, V34, P532, DOI 10.1080/09513590.2017.1416465
   Sakinci M, 2016, TAIWAN J OBSTET GYNE, V55, P460, DOI 10.1016/j.tjog.2016.04.001
   Wellings K, 2007, CONTRACEPTION, V76, P208, DOI 10.1016/j.contraception.2007.05.085
   Wiegel M, 2005, J SEX MARITAL THER, V31, P1, DOI 10.1080/00926230590475206
NR 15
TC 2
Z9 2
U1 0
U2 1
PU FEDERACAO BRASILEIRA SOC GINECOLOGIA & OBSTETRICIA-FEBRASGO
PI RIO DE JANEIRO RJ
PA AV DAS AMERICAS, 8445, SALA 711-BARRA DA TIJUCA, RIO DE JANEIRO RJ,
   22793-081, BRAZIL
SN 0100-7203
EI 1806-9339
J9 REV BRAS GINECOL OBS
JI Rev. Bras. Ginecol. Obstet.
PD APR
PY 2019
VL 41
IS 4
BP 236
EP 241
DI 10.1055/s-0039-1683370
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA HW7SL
UT WOS:000466889900005
PM 30912090
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Collins, M
   Palmqvist, H
   Pasquino, N
   Bahamondes, L
   Brotto, LA
AF Mayra Ferreira, Jessica
   Collins, Marisa
   Palmqvist, Helena
   Pasquino, Nicole
   Bahamondes, Luis
   Brotto, Lori A.
TI Analysis of 16 years of calls and emails to the Options for Sexual
   Health "Sex Sense" information and referral service
SO CANADIAN JOURNAL OF HUMAN SEXUALITY
LA English
DT Article
DE Reproduction; reproductive health; sexual health; sexuality
ID TRANSMITTED INFECTIONS; WOMEN; ADOLESCENT; PREGNANCY; PREVALENCE;
   EDUCATION; PARENTS; ONLINE; MEN
AB Sex Sense, a service provided by Options for Sexual Health in Canada, offers a telephone and online information service in which people can confidentially ask questions concerning sexual health. To analyze data over 16 years of the Sex Sense services (2000-2016) and to identify primary client concerns according to gender, age, and region and how the frequency of these concerns may have changed over time we analyzed the database where all data were stored. Descriptive analyses and Pearson's Chi-Square tests were performed. Among our sample, more women contacted the service, and most clients were aged 17-29. Contraception was the main reason for contact; however, the proportion of contacts about this decreased over the years. When genders were compared, women were more concerned about contraception, emergency contraceptive pills, and pregnancy, while men asked about sexually transmitted infections, general sexual health, and pleasure. Contraception was the main reason for contact among all age groups except for people over 40 years, who asked more about sexually transmitted infections. Some reasons differed with the region from where people were situated, and this may relate to services available in those regions that might eliminate the need to contact Sex Sense. These findings revealed some of the main concerns about sexual and reproductive health among the Sex Sense service users. Furthermore, analyses showed that concerns differed by gender, age, and region. The findings are important for informing health care professionals and policy makers, government leaders, and stakeholders on the provision of sexual information and services.
C1 [Mayra Ferreira, Jessica; Bahamondes, Luis] Univ Estadual Campinas, Fac Ciencias Med, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Collins, Marisa; Palmqvist, Helena; Pasquino, Nicole] Opt Sexual Hlth, Vancouver, BC, Canada.
   [Brotto, Lori A.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada.
RP Ferreira, JM (corresponding author), Univ Estadual Campinas, Fac Ciencias Med, Obstet & Gynaecol, 1047 Dr Ruy Vicente de Mello St, BR-13083970 Campinas, SP, Brazil.
EM jessicamayraf@gmail.com
RI Ferreira, Jessica/I-3350-2018
OI Ferreira, Jessica/0000-0003-2153-0353
FU CAPES, Coordenacao de Aperfeicoamento de Pessoal de Nivel superiorCAPES
   [88881.133631/2016-01]
FX The lead author was supported by CAPES, Coordenacao de Aperfeicoamento
   de Pessoal de Nivel superior (Grant #88881.133631/2016-01). We wish to
   express thanks to Executive Director for Options for Sexual Health,
   Michelle Fortin, for supporting this project.
CR Black A, 2009, J OBSTET GYNAECOL CA, V31, P627, DOI 10.1016/S1701-2163(16)34242-6
   Brown A, 2010, BEST PRACT RES CL OB, V24, P617, DOI 10.1016/j.bpobgyn.2010.04.005
   Brown S, 2012, J FAM PLAN REPROD H, V38, P44, DOI 10.1136/jfprhc-2011-100119
   Bryant-Comstock K, 2016, J PEDIATR ADOL GYNEC, V29, P22, DOI 10.1016/j.jpag.2015.05.008
   Charlton BM, 2011, J ADOLESCENT HEALTH, V49, P505, DOI 10.1016/j.jadohealth.2011.03.013
   Cheng T, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-015-2627-z
   Choudhri Y, 2018, Can Commun Dis Rep, V44, P43, DOI 10.14745/ccdr.v44i02a02
   Clare C., 2016, INT J ADOLESCENT MED, V30, DOI [10. 1515/ijamh-2016-0098, DOI 10.1515/IJAMH-2016-0098.MEDLINE:27743510]
   Curtis KM, 2017, NEW ENGL J MED, V376, P461, DOI 10.1056/NEJMcp1608736
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Guilamo-Ramos V, 2015, PREV SCI, V16, P53, DOI 10.1007/s11121-014-0469-z
   Hathaway M, 2014, CLIN OBSTET GYNECOL, V57, P718, DOI 10.1097/GRF.0000000000000071
   Johnson BK, 2013, J GERONTOL NURS, V39, P53, DOI 10.3928/00989134-20130918-01
   Khurana A, 2015, CONTRACEPTION, V91, P157, DOI 10.1016/j.contraception.2014.09.012
   Kirby D, 2002, J SEX RES, V39, P51, DOI 10.1080/00224490209552120
   Kumar MM, 2013, PAED CHILD HEALT-CAN, V18, P74
   Lesnewski R, 2006, AM FAM PHYSICIAN, V74, P105
   Lopez LM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012249
   Magee JC, 2012, HEALTH EDUC BEHAV, V39, P276, DOI 10.1177/1090198111401384
   MATICKATYNDALE E, 2000, CANADIAN J HUMAN SEX, V9, P41
   Nair MKC, 2012, INDIAN J PEDIATR, V79, pS60, DOI 10.1007/s12098-011-0436-7
   O'Neil-Callahan M, 2013, OBSTET GYNECOL, V122, P1083, DOI 10.1097/AOG.0b013e3182a91f45
   Options for Sexual Health, 2017, OPT
   Oulman E, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0663-4
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Romero-Estudillo E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-745
   ROTERMANN M, 2012, HLTH REPORTS, V23, P1
   Satterwhite CL, 2013, SEX TRANSM DIS, V40, P187, DOI 10.1097/OLQ.0b013e318286bb53
   Shoveller J, 2009, SEX TRANSM INFECT, V85, P397, DOI 10.1136/sti.2008.035568
   Waldenstrom U, 2016, UPSALA J MED SCI, V121, P235, DOI 10.1080/03009734.2016.1201553
   Whitfield C, 2013, J CLIN NURS, V22, P3259, DOI 10.1111/jocn.12192
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 32
TC 0
Z9 0
U1 0
U2 1
PU UNIV TORONTO PRESS INC
PI TORONTO
PA JOURNALS DIVISION, 5201 DUFFERIN ST, DOWNSVIEW, TORONTO, ON M3H 5T8,
   CANADA
SN 1188-4517
EI 2291-7063
J9 CAN J HUM SEX
JI Can. J. Hum. Sex.
PD APR 1
PY 2019
VL 28
IS 1
BP 38
EP 45
DI 10.3138/cjhs.2018-0008
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA HS4BP
UT WOS:000463807000005
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Monteiro, I
   Fernandes, A
   Gaffield, ME
AF Bahamondes, Luis
   Monteiro, Ilza
   Fernandes, Arlete
   Gaffield, Mary E.
TI Follow-up visits to check strings after intrauterine contraceptive
   placement cannot predict or prevent future expulsion
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Intrauterine contraceptives; expulsion; strings check
ID DEVICE; DISCONTINUATION; PARITY; WOMEN; AGE
AB Objectives: In some settings women are advised to return to the clinic after intrauterine contraceptive (IUC) placement, for a follow-up visit to check the strings and identify any expulsions. Our objective was to evaluate whether the number of follow-up visits to check the strings at the external cervical os after IUC placement predicts or prevents future expulsions.Methods: This was a retrospective study conducted at the University of Campinas Medical School, Brazil. We reviewed the medical records of all women who used an IUC between January 1980 and December 2017, to identify women who had experienced IUC expulsion (N=1974). We excluded women whose IUC was expelled more than once (n=331) or after 10 years of use (n=31). We fitted a generalised linear model of the time between IUC placement and expulsion, adjusting for several variables at expulsion. Significance was established at p<.05.Results: Most expulsions (843/1612; 52.3%) occurred within the first 6 months after IUC placement and 691/1612 (42.9%) were within the first three months after placement. The adjusted model showed that the number of visits, the woman's age, and complaints of pain and bleeding during use were not significantly associated with and had no influence on expulsion.Conclusions: Our results indicate that after IUC insertion more than one follow-up visit within the first four to six months after placement is not necessary, as additional visits to check for IUC strings do not appear to reduce or predict future expulsion.
C1 [Bahamondes, Luis; Monteiro, Ilza; Fernandes, Arlete] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Family Planning Clin, Campinas, SP, Brazil.
   [Gaffield, Mary E.] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
RI monteiro, ilza m u/F-4871-2014; Fernandes, Arlete/I-7561-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Fernandes,
   Arlete/0000-0001-5872-0017
FU Fundacao de Apoioa Pesquisa do Estado de Sao Paulo [FAPESP]Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9];
   Brazilian National Research Council [CNPq]National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de
   Apoioa Pesquisa do Estado de Sao Paulo [FAPESP; grant no. 2015/20504-9]
   and from the Brazilian National Research Council [CNPq; grant no.
   573747/2008-3].
CR [Anonymous], 2016, SKYL LEV REL INTR SY
   [Anonymous], 2015, LIL LEV REL INTR SYS
   [Anonymous], 2014, MIR LEV REL INTR SYS
   [Anonymous], 2013, PARAGARD T 380A INTR
   Aoun J, 2014, OBSTET GYNECOL, V123, P585, DOI 10.1097/AOG.0000000000000144
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Bernard A, 2018, BMJ SEX REPROD HEAL, V44, P32, DOI 10.1136/bmjsrh-2017-101791
   Curtis KM, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6504a1
   D'Alton M, 2018, OBSTET GYNECOL, V132, P3, DOI 10.1097/AOG.0000000000002697
   Davies A, 2014, J FAM PLAN REPROD H, V40, P122, DOI 10.1136/jfprhc-2013-100585
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   Diedrich JT, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.001
   Diedrich JT, 2017, AM J OBSTET GYNECOL, V216, P364, DOI 10.1016/j.ajog.2016.12.024
   Draper IB, 2012, J FAM PLAN REPROD H, V38, P15, DOI 10.1136/jfprhc-2011-0098
   Faundes D, 2000, CONTRACEPTION, V62, P165, DOI 10.1016/S0010-7824(00)00167-0
   Gerkowicz SA, 2019, AM J OBSTET GYNECOL, V220, DOI 10.1016/j.ajog.2018.11.122
   Hubacher D, 1999, INT FAM PLAN PERSPEC, V25, P21, DOI 10.2307/2991898
   Kaislasuo J, 2015, HUM REPROD, V30, P1580, DOI 10.1093/humrep/dev102
   Kathpalia S K, 2017, Med J Armed Forces India, V73, P85, DOI 10.1016/j.mjafi.2015.05.004
   LUUKKAINEN T, 1983, AM J OBSTET GYNECOL, V147, P885, DOI 10.1016/0002-9378(83)90240-5
   Madden T, 2014, OBSTET GYNECOL, V124, P718, DOI 10.1097/AOG.0000000000000475
   Melo J, 2017, INT J GYNECOL OBSTET, V137, P309, DOI 10.1002/ijgo.12130
   National Institute for Health and Clinical Excellence, 2005, LONG ACT REV CONTR C
   Neuteboom K, 2003, CONTRACEPTION, V68, P101, DOI 10.1016/S0010-7824(03)00111-2
   Rivera R, 2002, CONTRACEPTION, V65, P385, DOI 10.1016/S0010-7824(02)00304-9
   Rivera R, 1999, CONTRACEPTION, V60, P155, DOI 10.1016/S0010-7824(99)00077-3
   Simonatto P, 2016, J OBSTET GYNAECOL RE, V42, P554, DOI 10.1111/jog.12939
   Steenland MW, 2013, CONTRACEPTION, V87, P625, DOI 10.1016/j.contraception.2012.09.018
   Teal SB, 2019, OBSTET GYNECOL, V133, P63, DOI 10.1097/AOG.0000000000003034
   United Nations Department of Economic and Social Affairs Population Division, FAM PLANN
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Zapata LB, 2010, CONTRACEPTION, V82, P41, DOI 10.1016/j.contraception.2010.02.011
   ZHANG J, 1992, CONTRACEPTION, V46, P427, DOI 10.1016/0010-7824(92)90146-K
NR 33
TC 1
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD MAR 4
PY 2019
VL 24
IS 2
BP 97
EP 101
DI 10.1080/13625187.2019.1586872
PG 5
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA HX1OI
UT WOS:000467162200002
PM 30870042
DA 2020-12-01
ER

PT J
AU Quintino-Moro, A
   Zantut-Wittmann, DE
   dos Santos, PDS
   Melhado-Kimura, V
   da Silva, CA
   Bahamondes, L
   Fernandes, A
AF Quintino-Moro, Alessandra
   Zantut-Wittmann, Denise Engelbrecht
   Silva dos Santos, Priscilla de Nazare
   Melhado-Kimura, Vaneska
   da Silva, Conceicao Aparecida
   Bahamondes, Luis
   Fernandes, Arlete
TI Thyroid function during the first year of use of the injectable
   contraceptive depot medroxyprogesterone acetate
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Contraception; thyroid function; depot medroxyprogesterone acetate; body
   weight; body composition; deiodinases
ID WEIGHT-GAIN; INSULIN-RESISTANCE; METABOLIC SYNDROME; EXERCISE;
   TRIIODOTHYRONINE; PARAMETERS; OBESITY; FAT
AB Purpose: The aim of the study was to evaluate thyroid function profile as a possible factor influencing weight and body composition variation in new users of depot medroxyprogesterone acetate (DMPA).Materials and methods: A prospective, non-randomised, comparative study was conducted at the University of Campinas, Brazil. Women aged 18-40years with a body mass index (BMI) less than 30kg/m(2), normal oral glucose tolerance test, no known diseases, and using no medication, who opted to use DMPA were paired by age (1year) and BMI (1kg/m(2)) with women initiating copper intrauterine device (IUD) use. The main outcome measures were thyroid function profile, weight, and body composition, as measured by dual-energy X-ray absorptiometry. We used repeated measures ANOVA to perform comparisons between times and groups.Results: We evaluated 28 DMPA users and 24 IUD users who completed the 12-month follow-up. We observed that FT4 levels were higher at 12months (compared to baseline) in the DMPA group (p<.0001) and that FT4/FT3 ratio had increased in both groups. Additionally, at 12months, total body mass had increased around 2kg and lean mass increased in the DMPA group compared to the IUD group; there was also an increase in weight, BMI, total body mass, and fat mass when compared to baseline.Conclusions: No changes in thyroid function occurred that could explain the weight increase observed in DMPA users.
C1 [Quintino-Moro, Alessandra; Silva dos Santos, Priscilla de Nazare; Melhado-Kimura, Vaneska; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Med Sch UNICAMP, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP, Brazil.
   [Zantut-Wittmann, Denise Engelbrecht; da Silva, Conceicao Aparecida] Univ Estadual Campinas, Med Sch UNICAMP, Dept Internal Med, Div Endocrinol, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Zantut-Wittmann, Denise Engelbrecht/ABE-5858-2020; Fernandes,
   Arlete/I-7561-2018
OI Zantut-Wittmann, Denise Engelbrecht/0000-0002-7434-5701; Bahamondes,
   Luis/0000-0002-7356-8428; Fernandes, Arlete/0000-0001-5872-0017
FU Brazilian National Research Council (CNPq), BrazilNational Council for
   Scientific and Technological Development (CNPq); Sao Paulo Foundation
   for the Support of Research (Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo - FAPESP), Brazil; Sao Paulo State Health Department (SES-SP),
   Brazil [2009/53293-0]
FX This work was supported by the Brazilian National Research Council
   (CNPq), the Sao Paulo Foundation for the Support of Research (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP), and by the Sao
   Paulo State Health Department (SES-SP) under Grant [PPSUS/2009
   #2009/53293-0], Brazil.
CR ABEP - Brazilian Association of Research Companies, 2009, BRAZ EC CLASS CRIT
   Africander DJ, 2014, J STEROID BIOCHEM, V143, P404, DOI 10.1016/j.jsbmb.2014.05.007
   AMATAYAKUL K, 1980, CONTRACEPTION, V22, P605, DOI 10.1016/0010-7824(80)90087-6
   Aras S, 2015, BALK MED J, V32, P414, DOI 10.5152/balkanmedj.2015.151218
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38
   Bjergved L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093515
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   Cursino K, 2016, EUR J CONTRACEP REPR, V21, P22, DOI 10.3109/13625187.2015.1059415
   Dal'Ava N, 2014, CONTRACEPTION, V90, P182, DOI 10.1016/j.contraception.2014.03.011
   Espey E, 2000, CONTRACEPTION, V62, P55, DOI 10.1016/S0010-7824(00)00144-X
   Feldt-Rasmussen U, 2007, THYROID, V17, P413, DOI 10.1089/thy.2007.0032
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Fraser I S, 1981, Med J Aust, V1, P3
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Haider S, 2007, CLIN OBSTET GYNECOL, V50, P898, DOI 10.1097/GRF.0b013e318159c20a
   Irving BA, 2008, MED SCI SPORT EXER, V40, P1863, DOI 10.1249/MSS.0b013e3181801d40
   KAUNITZ AM, 1994, AM J OBSTET GYNECOL, V170, P1543, DOI 10.1016/S0002-9378(12)91813-X
   Kitahara CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034979
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   LOPEZ LM, 2016, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD008815.PUB4
   Marzullo P, 2010, J CLIN ENDOCR METAB, V95, P3965, DOI 10.1210/jc.2009-2798
   Melhado-Kimura V, 2018, CONTRACEPTION, V98, P144, DOI 10.1016/j.contraception.2018.04.003
   Nault AM, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.876
   Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200
   O'Leary VB, 2006, J APPL PHYSIOL, V100, P1584, DOI 10.1152/japplphysiol.01336.2005
   Ortega E, 2007, AM J CLIN NUTR, V85, P440
   Pantoja M, 2010, CONTRACEPTION, V81, P107, DOI 10.1016/j.contraception.2009.07.008
   Refetoff S, 2015, THYROID PHYSL DIS
   Reinehr T, 2010, MOL CELL ENDOCRINOL, V316, P165, DOI 10.1016/j.mce.2009.06.005
   Roef GL, 2014, THYROID, V24, P223, DOI 10.1089/thy.2013.0314
   Sasson M, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-017-0208-0
   Schindler AE, 2003, MATURITAS, V46, pS7, DOI 10.1016/j.maturitas.2003.09.014
   Strich D, 2016, EUR J ENDOCRINOL, V175, P49, DOI 10.1530/EJE-16-0007
   Toombs RJ, 2012, OBESITY, V20, P30, DOI 10.1038/oby.2011.211
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   World Health Organization, 2015, MED EL CRIT CONTR US
   Yu TT, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0916-z
NR 38
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD MAR 4
PY 2019
VL 24
IS 2
BP 102
EP 108
DI 10.1080/13625187.2018.1559284
PG 7
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA HX1OI
UT WOS:000467162200003
PM 30721635
DA 2020-12-01
ER

PT J
AU Bahamondes, L
AF Bahamondes, L.
TI Long term social consequences of adolescent pregnancy
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Editorial Material
C1 [Bahamondes, L.] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
CR BRAZIL, 2019, BJOG, V126, P360
   Fall CHD, 2015, LANCET GLOB HEALTH, V3, pE366, DOI 10.1016/S2214-109X(15)00038-8
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
   Taylor JL, 2009, J FAM ISSUES, V30, P484, DOI 10.1177/0192513X08329601
NR 4
TC 2
Z9 2
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
PD FEB
PY 2019
VL 126
IS 3
BP 368
EP 368
DI 10.1111/1471-0528.15488
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA HH2LE
UT WOS:000455549300018
PM 30291658
OA Bronze
DA 2020-12-01
ER

PT J
AU Peloggia, A
   Ali, M
   Nanda, K
   Bahamondes, L
AF Peloggia, Alessandra
   Ali, Moazzam
   Nanda, Kavita
   Bahamondes, Luis
TI Zika virus exposure in pregnancy and its association with newborn visual
   anomalies and hearing loss
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Review
DE Hearing loss; Microcephaly; Neonates; Ophthalmologic disorder;
   Pregnancy; Zika virus
ID WEST-NILE VIRUS; INFANTS; INFECTION; OUTBREAK; STATES; BRAZIL
AB Exposure to Zika virus (ZIKV) in pregnancy leads to a spectrum of congenital effects in the newborn. Recent studies have begun to evaluate the impact of ZIKV during pregnancy. Among 39 relevant studies, nine were related specifically to clinical studies of ophthalmologic disorders and one was related to hearing loss impairment; most of these studies were case reports and case series reports. Importantly, congenital toxoplasmosis was ruled out in all studies. The data show that, in addition to microcephaly, ZIKV exposure in pregnancy may result in subtle ocular impairments in the newborn. The most common anomalies are macular pigment mottling and/or chorioretinal atrophy, and optic nerve disorders. Sensorineural hearing loss has also been noted in 5.8% of infants with microcephaly. The effects of ZIKV infection during pregnancy are potentially devastating to the fetus and newborn. Although microcephaly is an important signal, the current information emphasizes the importance of ocular and auditory screenings, otherwise sight and hearing anomalies may be underestimated. Healthcare providers should fully understand the spectrum of anomalies related to ZIKV exposure in pregnancy in order to counsel pregnant women living in high-risk areas, in addition to those wanting to become pregnant.
C1 [Peloggia, Alessandra; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Ali, Moazzam] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.
   [Nanda, Kavita] Contracept Technol Innovat Dept, Durham, NC USA.
RP Peloggia, A (corresponding author), 169 Batista Scavone, BR-12327130 Jacarei, SP, Brazil.
EM apeloggia@hotmail.com
FU Fundacao de Apoio a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)
FX Fundacao de Apoio a Pesquisa do Estado de Sao Paulo
CR Aleman TS, 2017, JAMA OPHTHALMOL, V135, P1069, DOI 10.1001/jamaophthalmol.2017.3292
   Alpert SG, 2003, AM J OPHTHALMOL, V136, P733, DOI 10.1016/S0002-9394(03)00452-5
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P609
   [Anonymous], 2015, RAP RISK ASS ZIK VIR
   Bahamondes L, 2017, HUM REPROD, V32, P88, DOI 10.1093/humrep/dew310
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Calvet G, 2016, LANCET INFECT DIS, V16, P866
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Centers for Disease Control and Prevention, AB ZIK
   Dasti JI, 2016, ASIAN PAC J TROP MED, V9, P601, DOI 10.1016/j.apjtm.2016.05.010
   de Miranda HA, 2016, OPHTHALMOLOGY, V123, P1788, DOI 10.1016/j.ophtha.2016.05.001
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Epelboin S, 2017, HUM REPROD UPDATE, V23, P629, DOI 10.1093/humupd/dmx024
   Fernandez MP, 2017, JAMA OPHTHALMOL, V135, P1163, DOI 10.1001/jamaophthalmol.2017.3595
   Freitas BD, 2016, JAMA OPHTHALMOL, V134, P529, DOI 10.1001/jamaophthalmol.2016.0267
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203
   Leal MC, 2016, MMWR-MORBID MORTAL W, V65, P917, DOI 10.15585/mmwr.mm6534e3
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Marquezan MC, 2018, SURV OPHTHALMOL, V63, P166, DOI 10.1016/j.survophthal.2017.06.001
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Ministerio da Saude, 2016, B EP 3 MON CAS DENG
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   SMITHBURN KC, 1952, J IMMUNOL, V69, P223
   Suthar MS, 2013, NAT REV MICROBIOL, V11, P115, DOI 10.1038/nrmicro2950
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tsai TF, 2006, PEDIATRICS, V117, P936, DOI 10.1542/peds.2005-2729
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P1420, DOI 10.1001/jamaophthalmol.2016.4283
   Ventura CV, 2016, JAMA OPHTHALMOL, V134, P912, DOI 10.1001/jamaophthalmol.2016.1784
   Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0
   Ventura CV, 2016, LANCET, V387, P228, DOI 10.1016/S0140-6736(16)00006-4
   WHO, UNM NEED FAM PLANN
   WHO, MICR GUILL BARR SYND
   World Health Organization (WHO), EP AL NEUR SYNDR CON
NR 39
TC 8
Z9 8
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD DEC
PY 2018
VL 143
IS 3
BP 277
EP 281
DI 10.1002/ijgo.12663
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA GZ9MN
UT WOS:000449823700004
PM 30191558
OA Other Gold
DA 2020-12-01
ER

PT J
AU Carvalho, N
   Margatho, D
   Cursino, K
   Benetti-Pinto, CL
   Bahamondes, L
AF Carvalho, Nelsilene
   Margatho, Deborah
   Cursino, Kleber
   Benetti-Pinto, Cristina L.
   Bahamondes, Luis
TI Control of endometriosis-associated pain with etonogestrel-releasing
   contraceptive implant and 52-mg levonorgestrel-releasing intrauterine
   system: randomized clinical trial
SO FERTILITY AND STERILITY
LA English
DT Article
DE Endometriosis; etonogestrel-releasing contraceptive implant;
   levonorgestrel-releasing intrauterine system; pelvic pain
ID CHRONIC PELVIC PAIN; HEALTH PROFILE EHP-30; MANAGEMENT; ANALOG; LIFE
AB Objective: To assess the efficacy of an etonogestrel (ENG)-releasing contraceptive implant or the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) in the control of endometriosis-associated pelvic pain.
   Design: Noninferiority randomized clinical trial in which women with endometriosis were assigned to use an ENG implant (experimental treatment) or an LNG-IUS (active comparator). Monthly follow-up visits were conducted up to 6 months.
   Setting: University teaching hospital.
   Patient(s): One hundred three women, with endometriosis-associated chronic pelvic pain, dysmenorrhea, or both for more than 6 months. In cases of deep endometriosis, vaginal ultrasonography and magnetic resonance imaging were used as additional diagnostic tools.
   Intervention(s): The ENG implant or the LNG-IUS were inserted within the first 5 days of the menstrual cycle.
   Main Outcome Measure(s): Daily scores of noncyclic pelvic pain and dysmenorrhea were evaluated using a daily visual analogue scale. Health-related quality of life was evaluated using the Endometriosis Health Profile-30 questionnaire at baseline and up to 6 months. Bleeding patterns were assessed daily from a menstrual calendar.
   Result(s): Both contraceptives improved significantly the mean visual analogue scale endometriosis-associated pelvic pain and dysmenorrhea, without significant differences between treatment group profiles. Health-related quality of life improved significantly in all domains of the core and modular segments of the Endometriosis Health Profile-30 questionnaire, with no difference between both treatment groups. The most common bleeding patterns at 180 days of follow-up were amenorrhea and infrequent bleeding and infrequent bleeding and spotting among ENG implant and LNG-IUS users, respectively.
   Conclusion(s): In this noninferiority study both contraceptives improved significantly pelvic pain, dysmenorrhea, and health-related quality of life in endometriosis. (C) 2018 by American Society for Reproductive Medicine.
C1 [Carvalho, Nelsilene; Margatho, Deborah; Cursino, Kleber; Benetti-Pinto, Cristina L.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
EM bahamond@caism.unicamp.br
RI Benetti-Pinto, Cristina Laguna/AAX-3512-2020
OI Benetti-Pinto, Cristina Laguna/0000-0001-6198-5593; Bahamondes,
   Luis/0000-0002-7356-8428
FU Sao Paulo Research Council [2015/20504-9, 2015/10021]; Brazilian
   National Research CouncilNational Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]; Merck, the Netherlands
   [37228]; International Contraceptive Access Foundation, Turku, Finland
FX This study received partial financial support from Sao Paulo Research
   Council awards 2015/20504-9 and 2015/10021 and from Brazilian National
   Research Council grant 573747/2008-3. Merck, the Netherlands also
   provided funds for the study under unrestricted grant 37228. The
   LNG-IUSs used in this study were donated by the International
   Contraceptive Access Foundation, Turku, Finland under an unrestricted
   grant. The donors did not have any participation in the elaboration of
   the protocol, conducting the study, analyzing the data, or writing the
   manuscript.
CR Bahamondes MV, 2015, HUM REPROD, V30, P1861, DOI 10.1093/humrep/dev137
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   Bourdel N, 2015, HUM REPROD UPDATE, V21, P136, DOI 10.1093/humupd/dmu046
   Brown J, 2015, JAMA-J AM MED ASSOC, V313, P296, DOI 10.1001/jama.2014.17119
   Canis M, 1997, FERTIL STERIL, V67, P817
   Casper RF, 2017, FERTIL STERIL, V107, P521, DOI 10.1016/j.fertnstert.2017.01.008
   Chen YJ, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.02.008
   Gerlinger C, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-138
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   Jenkinson C, 2008, QUAL LIFE RES, V17, P1147, DOI 10.1007/s11136-008-9403-9
   Johnson NP, 2013, HUM REPROD, V28, P1552, DOI 10.1093/humrep/det050
   Khong SY, 2010, FERTIL STERIL, V94, P1928, DOI 10.1016/j.fertnstert.2010.01.047
   Kim MK, 2018, REPROD SCI, V25, P39, DOI 10.1177/1933719117718274
   Koninckx PR, 2012, FERTIL STERIL, V98, P564, DOI 10.1016/j.fertnstert.2012.07.1061
   Mansour D, 2011, CONTRACEPTION, V83, P202, DOI 10.1016/j.contraception.2010.08.001
   Nnoaham KE, 2011, FERTIL STERIL, V96, P366, DOI 10.1016/j.fertnstert.2011.05.090
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   REDWINE DB, 1991, FERTIL STERIL, V56, P628
   SAS Institute, 2012, SAS SYST WIND REL 9
   Tekin YB, 2011, FERTIL STERIL, V95, P492, DOI 10.1016/j.fertnstert.2010.08.042
   van Aken MAW, 2017, FERTIL STERIL, V108, P679, DOI 10.1016/j.fertnstert.2017.07.016
   Vercellini P, 1999, FERTIL STERIL, V72, P505, DOI 10.1016/S0015-0282(99)00291-5
   Vincent K, 2010, FERTIL STERIL, V93, P62, DOI 10.1016/j.fertnstert.2008.09.056
   Walch K, 2009, CONTRACEPTION, V79, P29, DOI 10.1016/j.contraception.2008.07.017
   WOODFORDE JM, 1972, J PSYCHOSOM RES, V16, P173, DOI 10.1016/0022-3999(72)90041-4
   World Health Organization, 2015, MED EL CRIT CONTR US
   Yisa SB, 2005, J FAM PLAN REPROD H, V31, P67, DOI 10.1783/0000000052972799
   Zito G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/191967
NR 28
TC 14
Z9 14
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD NOV
PY 2018
VL 110
IS 6
BP 1129
EP 1136
DI 10.1016/j.fertnstert.2018.07.003
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA GZ1DI
UT WOS:000449105600027
PM 30396557
OA Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Brache, V
   Ali, M
   Habib, N
AF Bahamondes, Luis
   Brache, Vivian
   Ali, Moazzam
   Habib, Ndema
CA WHO Study Grp Contraceptive
TI A multicenter randomized clinical trial of etonogestrel and
   levonorgestrel contraceptive implants with nonrandomized copper
   intrauterine device controls: effect on weight variations up to 3 years
   after placement
SO CONTRACEPTION
LA English
DT Article
DE Weight variation; Body mass index; Etonogestrel implant; Levonorgestrel
   implant; Copper intrauterine device
ID ACTING REVERSIBLE CONTRACEPTION; ROD ETONOGESTREL; BODY-COMPOSITION;
   WOMEN; IMPLANON(R); SAFETY; USERS; EFFICACY; COHORT; IUD
AB Objectives: To evaluate weight changes in women randomized to either the etonogestrel (ENG)- or the levonorgestrel (LNG)-releasing contraceptive implants and to compare with users of the TCu380A intrauterine device (IUD).
   Study design: A multicenter randomized trial with 1:1 allocation ratio of the ENG and the LNG implants with nonrandomized, age-matched control group of women choosing TCu380A IUD. The primary objective was to assess contraceptive efficacy and method continuation rates and, secondarily, the incidence of common complaints and side effects (including weight changes) associated with use of the three contraceptives. All women were enrolled in nine centers at seven countries. Weight change was evaluated from time at device (s) placement. Confounders were sociodemographic, baseline weight and body mass index, center and time from insertion. We used a linear mixed-effects regression modeling with random intercept and slope. Weight was compared between the two implants groups and between the implants and the IUD groups through linear mixed multivariable regression model.
   Results: A total of 995, 997 and 971 users in the ENG implant, LNG implant and IUD groups, respectively, were included. At 36 months of use, ENG and LNG implant users had similar significant mean weight increase of 3.0 kg [95% confidence interval (CI) 2.5-3.5] and 2.9 kg (95% CI 2.4-3.4), respectively (p<.0001), while IUD users had an increase of 1.1 kg (95% CI 0.5-1.7) (p=.0003). On adding the group-time interaction term to the stratified baseline weight models, implant users gained 0.759 kg (standard error [SE] .11) and 0.787 kg (SE .22) more weight than their IUD-user counterparts per year since placement if their baseline weight was in the category 51-69 kg (p<.0001) or >= 70 kg (p=.0005), respectively.
   Conclusions: ENG and LNG implant as well as IUD users had a small but significant weight increase with little clinical significance during the 3 years of follow-up, and it was slightly higher among implant than IUD users weighing >50 kg.
   Implications: These findings must be useful for clinicians to counsel implant users which could improve method continuation. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynecol, Family Planning Clin, Fac Med Sci, Campinas, SP, Brazil.
   [Brache, Vivian] Profamilia, Biomed Res Dept, Santo Domingo, Dominican Rep.
   [Ali, Moazzam; Habib, Ndema] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynecol, Family Planning Clin, Fac Med Sci, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP),
   Department of Reproductive Health and Research (RHR), World Healt
FX United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP),
   Department of Reproductive Health and Research (RHR), World Health
   Organization (WHO) funded this study including provision of subdermal
   implants and intrauterine device.
CR Ali M, 2016, HUM REPROD, V31, P2491, DOI 10.1093/humrep/dew222
   [Anonymous], 2017, R LANG ENV STAT COMP
   Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Blumenthal PD, 2008, EUR J CONTRACEP REPR, V13, P29, DOI 10.1080/13625180801960012
   Brache V, 2002, CONTRACEPTION, V65, P63, DOI 10.1016/S0010-7824(01)00289-X
   COLDITZ GA, 1990, AM J CLIN NUTR, V51, P1100
   Coombe J, 2016, SEX HEALTH, V13, P404, DOI 10.1071/SH15189
   Croxatto HB, 1999, HUM REPROD, V14, P976, DOI 10.1093/humrep/14.4.976
   Darney P, 2009, FERTIL STERIL, V91, P1646, DOI 10.1016/j.fertnstert.2008.02.140
   Gallo MF, 2016, OBSTET GYNECOL, V127, P573, DOI 10.1097/AOG.0000000000001289
   Hassan DF, 2003, CONTRACEPTION, V68, P27, DOI 10.1016/S0010-7824(03)00079-9
   Lakha F, 2006, CONTRACEPTION, V74, P287, DOI 10.1016/j.contraception.2006.05.072
   Lopez LM, 2016, COCHRANE DB SYST REV, V8
   Meirik O, 2013, CONTRACEPTION, V87, P113, DOI 10.1016/j.contraception.2012.08.044
   Modesto W, 2015, ARCH GYNECOL OBSTET, V292, P1387, DOI 10.1007/s00404-015-3784-0
   Modesto W, 2015, EUR J CONTRACEP REPR, V20, P57, DOI 10.3109/13625187.2014.951433
   Nault AM, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.876
   SAS Institute, 2012, SAS SYST WIND REL 9
   dos Santos PDS, 2017, CONTRACEPTION, V95, P382, DOI 10.1016/j.contraception.2016.12.006
   Sivin I, 1998, CONTRACEPTION, V58, P275, DOI 10.1016/S0010-7824(98)00112-7
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   Wigginton B, 2016, J FAM PLAN REPROD H, V42, P256, DOI 10.1136/jfprhc-2015-101184
   WILLIAMSON DF, 1993, ANN INTERN MED, V119, P646, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00004
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization Reproductive Health and Research, 2000, MED EL CRIT CONTR US
NR 26
TC 6
Z9 8
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2018
VL 98
IS 3
BP 181
EP 187
DI 10.1016/j.contraception.2018.05.009
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA GU3HZ
UT WOS:000445168500003
PM 29777663
DA 2020-12-01
ER

PT J
AU Juliato, CRT
   Stahlschmidt, P
   Fernandes, A
   Monteiro, I
   Bahamondes, L
AF Juliato, Cassia R. T.
   Stahlschmidt, Paulo
   Fernandes, Arlete
   Monteiro, Ilza
   Bahamondes, Luis
TI A case series on the use of levonorgestrel 52 mg intrauterine system
   after OF organ transplant
SO CONTRACEPTION
LA English
DT Article
DE Clinical performance; Levonorgestrel-releasing intrauterine system;
   Organ transplantation; Contraception
ID DEVICE; CONTRACEPTION; WOMEN
AB Objective: To assess the clinical performance (pregnancy and occurrence of pelvic infection) of the levonorgestrel 52-mg intrauterine system (LNG IUS) in solid organ transplant recipients.
   Study design: We performed a retrospective chart review of all patients seen in the Family Planning Clinic at the University of Campinas Department of Obstetrics and Gynecology from 2007 to 2017 to identify women with solid organ transplantation using immunosuppression who received an LNG IUS. Our routine clinical practice for such patients is to perform initial follow-up 40-60 days after placement and then every 12 months. We analyzed women's sociodemographic characteristics, duration of use of the LNG IUS, continuation and discontinuation reasons, and complications.
   Results: Of the 23 women evaluated, 21 had kidney transplantation and 2 had liver transplantation. One woman received an LNG IUS prior to solid organ implantation (1.7 years, renal transplant). The 22 other women received the LNG IUS a median of 6.3 years (interquartile [IQ25-75] range 1.7-15 years). Seventeen (74%) women primarily used the LNG IUS for contraception; the other 6 desired the LNG IUS for contraception and heavy menstrual bleeding (HMB) treatment. We observed no cases of pregnancy or pelvic infection. Over the median follow-up time of 49.3 months (IQ(25-75) 15-80 months), 7 women used the same IUS for more than 60 months and 8 women received a second IUS.
   Conclusions: Due to the fact that no pregnancies or pelvic infections were observed in this case series, we concluded that the LNG IUS is an option for transplanted women for contraception and for HMB treatment. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Juliato, Cassia R. T.; Stahlschmidt, Paulo; Fernandes, Arlete; Monteiro, Ilza; Bahamondes, Luis] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
RP Juliato, CRT (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
EM cassia.raquel@gmail.com
RI Juliato, Cassia R T/D-4447-2012; monteiro, ilza m u/F-4871-2014
OI Juliato, Cassia R T/0000-0003-3197-1195; monteiro, ilza m
   u/0000-0002-9536-0564
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de Apoio
   a Pesquisa do Estado de Sao Paulo (FAPESP) award no. 2015/20504-9 and
   from the National Research Council (CNPq) grant no. 573747/2008-3. Since
   2007, the LNG IUSs used at our clinic have been donated by the
   International Contraceptive Access Foundation, Turku, Finland, under an
   unrestricted grant.
CR Bahamondes L, 2018, CONTRACEPTION, V97, P205, DOI 10.1016/j.contraception.2017.10.007
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Estes CM, 2007, SEMIN PERINATOL, V31, P372, DOI 10.1053/j.semperi.2007.09.007
   Guazzelli CAF, 2008, TRANSPLANTATION, V86, P669, DOI 10.1097/TP.0b013e3181817e7d
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Kim CR, 2016, CONTRACEPTION, V94, P534, DOI 10.1016/j.contraception.2016.06.021
   LAIFER SA, 1990, OBSTET GYNECOL, V76, P1083
   McNicholas C, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.01.036
   Moraes LG, 2016, EUR J CONTRACEP REPR, V21, P318, DOI 10.1080/13625187.2016.1193139
   Paulen ME, 2010, CONTRACEPTION, V82, P102, DOI 10.1016/j.contraception.2010.02.007
   Rowe P, 2016, CONTRACEPTION, V93, P498, DOI 10.1016/j.contraception.2016.02.024
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2015, MED EL CRIT CONTR US
   ZERNER J, 1981, J REPROD MED, V26, P99
NR 14
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2018
VL 98
IS 3
BP 252
EP 254
DI 10.1016/j.contraception.2018.04.017
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA GU3HZ
UT WOS:000445168500017
PM 29746814
DA 2020-12-01
ER

PT J
AU Melhado-Kimura, V
   Batista, GA
   de Souza, AL
   dos Santos, PDS
   Alegre, SM
   Pavin, EJ
   Bahamondes, L
   Fernandes, A
AF Melhado-Kimura, Vaneska
   Batista, Gisele Almeida
   de Souza, Aglecio Luiz
   Silva dos Santos, Priscilla de Nazare
   Alegre, Sarah Monte
   Pavin, Elizabeth Joao
   Bahamondes, Luis
   Fernandes, Arlete
TI Hyperinsulinemic-euglycemic clamp over the first year of use of
   depot-medroxyprogesterone acetate as a contraceptive
SO CONTRACEPTION
LA English
DT Article
DE Insulin resistance; Hyperinsulinemic-euglycemic clamp;
   Depot-medroxyprogesterone acetate; Contraception
ID ORAL-CONTRACEPTIVES; WEIGHT-GAIN; CARBOHYDRATE-METABOLISM;
   PHYSICAL-ACTIVITY; DIETARY-INTAKE; INSULIN; GLUCOSE; RESISTANCE;
   MECHANISM; PROVERA
AB Objective: The literature lacks data on the use of the gold-standard hyperinsulinemic-euglycemic clamp (HEC) technique for the evaluation of insulin resistance (IR) in depot-medroxyprogesterone acetate (DMPA) users. This study assessed carbohydrate metabolism in non-obese users of DMPA using the HEC technique.
   Study Design: A prospective, non-randomized, comparative study conducted at the Family Planning Clinic/Metabolic Unit, University of Campinas, Brazil. Forty-eight women aged 18-39 years underwent HEC: 30 initiating use of DMPA and 18 initiating use of a copper intrauterine device (IUD). Data from 15 women in each group, who completed the follow-up and underwent HEC at12 months, were compared using repeated measures ANOVA. All women were advised to perform aerobic physical exercise for 150 min/week; body composition and total energy intake were evaluated. Main outcome measures were IR defined by M-value <4 mg/kg/min, and blood levels of insulin. Additional outcomes were total cholesterol, HDL-cholesterol, triglycerides, LDLcholesterol, adipokines and free fatty acids.
   Results: At 12 months, two women in the DMPA group and none in the IUD group had developed IR. The groups were similar in in M-values and in blood levels of insulin, total cholesterol, HDL-cholesterol, LDL-cholesterol, adipokines or free fatty acids. Triglyceride levels increased in the DMPA group when compared to the IUD group, 80.0 (SD 47.8) versus 61.8 (SD 35.8) mg/dL respectively, (p=.033); and increased the total daily energy intake, 1828.3 (SD 518.9) versus 1300.8 (SD 403.4) kilocalories/24hs, respectively in the same groups, (p=.041). All the DMPA users showing higher insulin sensitivity at 12 months reported performing physical activity regularly.
   Conclusions: Changes occurred in carbohydrate metabolism in DMPA users in the first year of use of the method. It is possible that the regular aerobic exercise may exert a beneficial and protective effect against the factors that trigger these changes.
   Implications statement: Carbohydrate metabolism undergoes adverse changes in few young non-obese women during the first year of DMPA use and regular aerobic exercise may exert a beneficial and protective effect against these changes. (C) 2018 Published by Elsevier Inc.
C1 [Melhado-Kimura, Vaneska; Silva dos Santos, Priscilla de Nazare; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
   [Batista, Gisele Almeida; de Souza, Aglecio Luiz; Alegre, Sarah Monte; Pavin, Elizabeth Joao] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Dept Clin Med, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI DE SOUZA, AGLECIO/Q-4056-2016
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo Foundation
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP); Sao
   Paulo State Health Department (SES-SP) under grant PPSUS/2009, Brazil
   [2009/53293-0]
FX The original study was funded by the Brazilian National Research Council
   (CNPq), the Sao Paulo Foundation for the Support of Research (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP) and by the Sao
   Paulo State Health Department (SES-SP) under grant PPSUS/2009
   #2009/53293-0, Brazil. The sponsors played no role in the study design,
   in the collection, analysis or interpretation of data, in writing the
   report, or in the decision to submit the article for publication.
CR ABEP-Brazilian Association of Research Companies, BRAZ EC CLASS CRIT
   AMATAYAKUL K, 1979, J STEROID BIOCHEM, V11, P475, DOI 10.1016/0022-4731(79)90070-0
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Berenson AB, 2011, OBSTET GYNECOL, V117, P41, DOI 10.1097/AOG.0b013e318202ac23
   BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286
   Bonny Andrea E, 2004, J Pediatr Adolesc Gynecol, V17, P109, DOI 10.1016/j.jpag.2004.01.006
   Bonny AE, 2015, CONTRACEPTION, V92, P298, DOI 10.1016/j.contraception.2015.05.014
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   FAHMY K, 1991, CONTRACEPTION, V44, P419, DOI 10.1016/0010-7824(91)90032-B
   Fisberg RM, 2009, ARQ BRAS ENDOCRINOL, V53, P617, DOI 10.1590/S0004-27302009000500014
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Fraser I S, 1981, Med J Aust, V1, P3
   Fraser I S, 1982, Clin Reprod Fertil, V1, P67
   Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243
   HAZZARD WR, 1969, NEW ENGL J MED, V280, P471, DOI 10.1056/NEJM196902272800904
   Kim C, 2001, ARCH INTERN MED, V161, P1766, DOI 10.1001/archinte.161.14.1766
   Lange HLH, 2015, J PEDIATR ADOL GYNEC, V28, P139, DOI 10.1016/j.jpag.2014.04.004
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   Lopez LM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006133.pub5
   LOPEZ LM, 2016, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD008815.PUB4
   Melhado-Kimura V, 2015, EUR J CONTRACEP REPR, V20, P110, DOI 10.3109/13625187.2014.961599
   NASH HA, 1975, CONTRACEPTION, V12, P377, DOI 10.1016/0010-7824(75)90074-8
   Pantoja M, 2010, CONTRACEPTION, V81, P107, DOI 10.1016/j.contraception.2009.07.008
   PEREZPALACIOS G, 1981, J STEROID BIOCHEM, V15, P125, DOI 10.1016/0022-4731(81)90266-1
   Segall-Gutierrez P, 2012, CONTRACEPTION, V85, P36, DOI 10.1016/j.contraception.2011.04.016
   dos Santos PDS, 2017, J REPROD MED, V62, P526
   SPELLACY WN, 1970, FERTIL STERIL, V21, P457
   VERMEULEN A, 1974, DIABETOLOGIA, V10, P253
   Warburton DER, 2010, INT J BEHAV NUTR PHY, V7, DOI 10.1186/1479-5868-7-39
   World Health Organization, 2010, GLOB REC PHYS ACT HL
NR 30
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD AUG
PY 2018
VL 98
IS 2
BP 144
EP 150
DI 10.1016/j.contraception.2018.04.003
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA GO7PB
UT WOS:000440262500013
PM 29665358
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Fernandes, A
   Bahamondes, MV
   Juliato, CT
   Ali, M
   Monteiro, I
AF Bahamondes, Luis
   Fernandes, Arlete
   Valeria Bahamondes, M.
   Juliato, Cassia T.
   Ali, Moazzam
   Monteiro, Ilza
TI Pregnancy outcomes associated with extended use of the 52-mg 20 mu g/day
   levonorgestrel-releasing intrauterine system beyond 60 months: A chart
   review of 776 women in Brazil
SO CONTRACEPTION
LA English
DT Review
DE Levonorgestrel-releasing intrauterine system; Extended use; Clinical
   performance; Mirena
ID CLINICAL-PRACTICE; PROLONGED USE; DEVICE; RECOMMENDATIONS; PROVISION;
   EFFICACY; SAFETY; HEALTH
AB Objective: To assess the contraceptive performance of the 52-mg 20 mu g/day levonorgestrel-releasing intrauterine system (LNG-IUS, Mirena; Bayer Oy, Turku, Finland) among women who maintain the same device without changes after 60 months.
   Study design: This is a chart review study in which we assessed the charts of 766 women who continue the same LNG-IUS for contraception beyond 60 months. The women were evaluated at the Family Planning clinic, University of Campinas Medical School, Campinas, SP, Brazil, from November 1990 to March 2011. We obtained sociodemographic data, duration of use, continuation and discontinuation rates and reasons, bleeding pattern at the recorded last visit. The statistical analysis was performed using Kaplan Meier analysis.
   Results: A total of 776 charts were identified of women who used the LNG-IUS beyond 60 months. The mean age (+/- S.E.M.) at LNG-IUS placement was 32.0 +/- 0.2 years (ranged 15 to 44 years; median was 32 years). The distribution of number of pregnancies was 0-1 (45%); 2-4 (54.1%) and >= 5 (0.9%). The median length of the LNG-IUS' use was 73 months after placement (ranged 61-184 months). Zero pregnancies were reported and the main reasons for discontinuation were expiration of approved effective lifespan, menopause and planning pregnancy. The cumulative women-years (W-Y) of exposure were 967 and 1403 up to seven and 15 years, respectively. The main bleeding pattern reported by the women was amenorrhea.
   Conclusions: The 52-mg 20 mu g/day LNG-IUD (Mirena) showed continue contraceptive efficacy beyond 5 years of use with no pregnancies detected over 967 and 1403 W-Y up to seven and 15 years after placement.
   Implications statement: The 52-mg 20 mu g/day LNG-IUD presented a very high contraceptive efficacy beyond the first 5 years of lifetime labeled. Increasing data support that efficacy beyond 5 years of use, and new data suggested efficacy as long as 15 years. Healthcare professionals, policy makers and stakeholders could take advantage of the present information to decide to maintain the same device at least up to seven years. Furthermore, amenorrhea could be a good indicator of contraceptive effect. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Bahamondes, Luis; Fernandes, Arlete; Valeria Bahamondes, M.; Juliato, Cassia T.; Monteiro, Ilza] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
   [Ali, Moazzam] WHO, Dept Reprod Hlth & Res, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Juliato, Cassia R T/D-4447-2012; Fernandes, Arlete/I-7561-2018;
   monteiro, ilza m u/F-4871-2014
OI Juliato, Cassia R T/0000-0003-3197-1195; Fernandes,
   Arlete/0000-0001-5872-0017; monteiro, ilza m u/0000-0002-9536-0564
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR [Anonymous], 2011, SAS SYST WIND
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Creinin MD, 2014, CONTRACEPTION, V90, P104, DOI 10.1016/j.contraception.2014.04.002
   Crosignani PG, 2008, HUM REPROD UPDATE, V14, P197, DOI 10.1093/humupd/dmn003
   Diaz J., 1992, Advances in Contraception, V8, P275, DOI 10.1007/BF02042585
   DIAZ J, 1982, CONTRACEPTION, V26, P221, DOI 10.1016/0010-7824(82)90071-3
   Eisenberg DL, 2015, CONTRACEPTION, V92, P10, DOI 10.1016/j.contraception.2015.04.006
   Ferreira JM, 2017, J FAM PLAN REPROD H, V43, P181, DOI 10.1136/jfprhc-2016-101569
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   McNicholas C, 2015, OBSTET GYNECOL, V125, P599, DOI 10.1097/AOG.0000000000000690
   NILSSON CG, 1986, FERTIL STERIL, V45, P805
   R Development Core Team R, 2012, LANG ENV STAT COMP
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   Rowe P, 2016, CONTRACEPTION, V93, P498, DOI 10.1016/j.contraception.2016.02.024
   SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706
   Seeber B, 2012, CONTRACEPTION, V86, P345, DOI 10.1016/j.contraception.2012.01.015
   SIVIN I, 1994, FERTIL STERIL, V61, P70
   United Nations Department of Economic and Social Affairs Population Division, 2015, STESASERA349 UN DEP
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wu JP, 2014, CONTRACEPTION, V89, P495, DOI 10.1016/j.contraception.2014.02.011
NR 21
TC 14
Z9 14
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD MAR
PY 2018
VL 97
IS 3
BP 205
EP 209
DI 10.1016/j.contraception.2017.10.007
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FZ5US
UT WOS:000427662400003
PM 29055780
DA 2020-12-01
ER

PT J
AU Silva, P
   Qadir, S
   Fernandes, A
   Bahamondes, L
   Peipert, JF
AF Silva, P.
   Qadir, S.
   Fernandes, A.
   Bahamondes, L.
   Peipert, J. F.
TI Dietary intake and eating behavior in depot medroxyprogesterone acetate
   users: a systematic review
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Review
DE Dietary intake; Eating behavior; Body weight; Female; Depot
   medroxyprogesterone acetate; Contraception
ID WEIGHT-GAIN; BODY-COMPOSITION; CONTRACEPTIVE FAILURE; ADULTS; BIAS
AB Because of weight gain, women often discontinue hormonal contraception, especially depot medroxyprogesterone acetate (DMPA). Our objective was to conduct a systematic review of studies describing dietary intake or eating behavior in DMPA users to understand whether the use of DMPA is associated with changes in dietary habits and behaviors leading to weight gain. We searched the PubMed, POPLINE, CENTRAL Cochrane, Web of Science, and EMBASE databases for reports published in English between 1980 and 2017 examining dietary intake or eating behavior in healthy women in reproductive age and adolescents using DMPA (150 mg/mL). Of the 749 publications screened, we excluded 742 due to duplicates (96), not addressing the key research question (638), not reporting dietary intake data (4), and not evaluating the relationship of body weight and dietary or eating behaviors (4). We identified seven relevant studies, including one randomized placebo-controlled trial, one non-randomized paired clinical trial, and five cohort studies. The randomized trial found no association and the other reports were inconsistent. Findings varied from no change in dietary intake or eating behavior with DMPA use to increased appetite in the first six months of DMPA use. Few studies report dietary intake and eating behavior in DMPA users and the available data are insufficient to conclude whether DMPA use is associated with changes in dietary habits or behavior leading to weight gain.
C1 [Silva, P.; Fernandes, A.; Bahamondes, L.] Univ Estadual Campinas, Fac Ciencias Med, Dept Tocoginecol, Campinas, SP, Brazil.
   [Silva, P.; Qadir, S.] Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO USA.
   [Peipert, J. F.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Ciencias Med, Dept Tocoginecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Peipert, Jeffrey F./ABC-1981-2020
FU CAPES (Coordination for the Improvement of Higher Education Personnel)
   foundation, Ministerio da Educacao do BrazilCAPES
   [99999.003163/2015-2016]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2009/53293-0, 2015/20504-9]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The authors gratefully acknowledge the financial support of CAPES
   (Coordination for the Improvement of Higher Education Personnel)
   foundation, Ministerio da Educacao do Brazil (#99999.003163/2015-2016)
   to P.S. This study received partial financial support from Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; #2009/53293-0,
   #2015/20504-9) and from Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq; #573747/2008-3). The authors thank Deborah J. Frank
   for her valuable comments and manuscript review.
CR Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Bonny Andrea E, 2004, J Pediatr Adolesc Gynecol, V17, P109, DOI 10.1016/j.jpag.2004.01.006
   Bonny AE, 2015, CONTRACEPTION, V92, P298, DOI 10.1016/j.contraception.2015.05.014
   Bonny AE, 2014, CONTRACEPTION, V89, P357, DOI 10.1016/j.contraception.2014.01.017
   Daniels Kimberly, 2015, Natl Health Stat Report, P1
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Golder S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001026
   Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2
   Haider S, 2007, CLIN OBSTET GYNECOL, V50, P898, DOI 10.1097/GRF.0b013e318159c20a
   Helmerhorst FM, 2014, EUR J CONTRACEP REPR, V19, P71, DOI 10.3109/13625187.2013.871251
   Heyward VH, 1998, INT J SPORT NUTR, V8, P285, DOI 10.1123/ijsn.8.3.285
   Jacobstein R, 2014, BEST PRACT RES CL OB, V28, P795, DOI 10.1016/j.bpobgyn.2014.05.003
   Lange HLH, 2015, J PEDIATR ADOL GYNEC, V28, P139, DOI 10.1016/j.jpag.2014.04.004
   Le YCL, 2010, J WOMENS HEALTH, V19, P1987, DOI 10.1089/jwh.2009.1776
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   Lewis SC, 2004, J NEUROL NEUROSUR PS, V75, P181, DOI 10.1136/jnnp.2003.025833
   Lopez LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008815.pub3
   Melhado-Kimura V, 2015, EUR J CONTRACEP REPR, V20, P110, DOI 10.3109/13625187.2014.961599
   Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI [10.14306/renhyd.20.2.223, 10.1186/2046-4053-4-1]
   Mosher William D, 2004, Adv Data, P1
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Pelkman CL, 2001, AM J CLIN NUTR, V73, P19
   dos Santos PDS, 2017, J REPROD MED, V62, P526
   dos Santos PDS, 2014, EUR J CONTRACEP REPR, V19, P432, DOI 10.3109/13625187.2014.936934
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   Trussell J, 2004, CONTRACEPTION, V70, P89, DOI 10.1016/j.contraception.2004.03.009
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   WHO (World Health Organization), 2002, GLOB REC PHYS ACT HL
   World Health Organization, 2003, DIET NUTR PREV CHRON, V916
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2018
VL 51
IS 6
AR e7575
DI 10.1590/1414-431X20187575
PG 6
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA GD6ZV
UT WOS:000430659100001
PM 29694506
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Margatho, D
   Carvalho, NM
   Eloy, L
   Bahamondes, L
AF Margatho, Deborah
   Carvalho, Nelsilene Mota
   Eloy, Larissa
   Bahamondes, Luis
TI Assessment of biomarkers in women with endometriosis-associated pain
   using the ENG contraceptive implant or the 52 mg LNG-IUS: a
   non-inferiority randomised clinical trial
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Biomarkers; CA-125; CD23; endometrial nerve fibres; endometriosis;
   etonogestrel implant; levonorgestrel-releasing intrauterine system
ID INTRAUTERINE SYSTEM; NERVE-FIBERS; EUTOPIC ENDOMETRIUM; LEUPROLIDE
   ACETATE; SERUM CA-125; PELVIC PAIN; DIAGNOSIS; CLASSIFICATION;
   DYSMENORRHEA; CONSENSUS
AB Objective: The aim of the study was to assess the serum levels of the following biomarkers in women with endometriosis-associated pelvic pain before and after six months of using the etonogestrel (ENG) contraceptive implant or the 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS): cancer antigen (CA)-125, cluster of differentiation (CD) 23 and endometrial nerve fibre density.
   Methods: The study was conducted at the Department of Obstetrics and Gynaecology, University of Campinas Medical School, Brazil. A total of 103 women with endometriosis-associated pain diagnosed by surgery, transvaginal ultrasound and/or magnetic resonance imaging were included. Endometrial nerve fibre density and serum levels of CA-125 and soluble CD23 were assessed before and after six months of using the allocated method and were correlated to 10 cm visual analogue scale (VAS) scores for non-cyclical pelvic pain and dysmenorrhoea.
   Results: Both contraceptive methods significantly reduced concentrations of serum soluble CD23 and endometrial nerve fibre density (p < .001); however, CA-125 was significantly reduced only among users of the ENG implant (p < .05). No correlation was observed between reduction of biomarkers and improvement of VAS pain and dysmenorrhoea scores. No differences were observed between the ENG implant and the LNG-IUS.
   Conclusion: Both progestin-only contraceptives significantly reduced two out of the three biomarkers evaluated. These two biomarkers could, therefore, be used as surrogate markers to follow up medical treatment of endometriosis-associated pain.
C1 [Margatho, Deborah; Carvalho, Nelsilene Mota; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
   [Eloy, Larissa] Univ Estadual Campinas, Dept Pathol, Med Sch, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9,
   2015/10021]; National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de Apoio
   a Pesquisa do Estado de Sao Paulo (FAPESP), awards 2015/20504-9 and
   2015/10021 and from the National Research Council (CNPq), [grant
   573747/2008-3]. Funds for the study were also provided by Merck, in
   addition to the ENG implants.
CR Ahn SH, 2017, FERTIL STERIL, V107, P523, DOI 10.1016/j.fertnstert.2017.01.009
   Al-Jefout M, 2009, HUM REPROD, V24, P3019, DOI 10.1093/humrep/dep275
   Zevallos HBV, 2015, ARCH GYNECOL OBSTET, V291, P85, DOI 10.1007/s00404-014-3379-1
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   Canis M, 1997, FERTIL STERIL, V67, P817
   Carvalho N, 2018, FERTIL STERIL, V110, P1129, DOI 10.1016/j.fertnstert.2018.07.003
   Department of Reproductive Health World Health Organization, 2015, MED EL CRIT CONTR US
   Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
   Ellett L, 2015, HUM REPROD, V30, P2808, DOI 10.1093/humrep/dev259
   Fassbender A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/130854
   Fraser IS, 2013, CONTRACEPTION, V87, P273, DOI 10.1016/j.contraception.2012.08.039
   Gerlinger C, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-138
   Gordts S, 2017, FERTIL STERIL, V108, P872, DOI 10.1016/j.fertnstert.2017.08.036
   Guerriero S, 2016, ULTRASOUND OBST GYN, V48, P318, DOI 10.1002/uog.15955
   Gupta D, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012165
   Haas D, 2013, ACTA OBSTET GYN SCAN, V92, P3, DOI 10.1111/aogs.12026
   Hirsch M, 2016, BJOG-INT J OBSTET GY, V123, P1761, DOI 10.1111/1471-0528.14055
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   Johnson NP, 2017, HUM REPROD, V32, P315, DOI 10.1093/humrep/dew293
   Koninckx PR, 2012, FERTIL STERIL, V98, P564, DOI 10.1016/j.fertnstert.2012.07.1061
   MASAHASHI T, 1988, OBSTET GYNECOL, V72, P328
   Matalliotakis IM, 2000, OBSTET GYNECOL, V95, P810, DOI 10.1016/S0029-7844(99)00635-3
   Maximo MM, 2015, FERTIL STERIL, V104, P1182, DOI 10.1016/j.fertnstert.2015.07.1165
   Mol BWJ, 1998, FERTIL STERIL, V70, P1101, DOI 10.1016/S0015-0282(98)00355-0
   Newman TA, 2013, HUM REPROD, V28, P2502, DOI 10.1093/humrep/det274
   NILOFF JM, 1984, OBSTET GYNECOL, V64, P703
   Nisenblat V, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012281
   Odukoya OA, 1996, HUM REPROD, V11, P2018
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Pfeifer S, 2014, FERTIL STERIL, V101, P927, DOI 10.1016/j.fertnstert.2014.02.012
   Silva ACJSRE, 2007, INT J GYNECOL OBSTET, V96, P206, DOI 10.1016/j.ijgo.2006.11.016
   Silva ACJDRE, 2006, FERTIL STERIL, V86, P742, DOI 10.1016/j.fertnstert.2006.02.082
   Strowitzki T, 2010, HUM REPROD, V25, P633, DOI 10.1093/humrep/dep469
   Tarjanne S, 2015, ACTA OBSTET GYN SCAN, V94, P693, DOI 10.1111/aogs.12652
   Tokushige N, 2007, FERTIL STERIL, V88, P795, DOI 10.1016/j.fertnstert.2006.12.078
   Tokushige N, 2009, FERTIL STERIL, V92, P1234, DOI 10.1016/j.fertnstert.2008.07.1774
   Vercellini P, 1999, FERTIL STERIL, V72, P505, DOI 10.1016/S0015-0282(99)00291-5
   Walch K, 2009, CONTRACEPTION, V79, P29, DOI 10.1016/j.contraception.2008.07.017
   Yucel N, 2018, AUST NZ J OBSTET GYN, V58, P560, DOI 10.1111/ajo.12773
NR 39
TC 1
Z9 1
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PY 2018
VL 23
IS 5
BP 344
EP 350
DI 10.1080/13625187.2018.1531117
PG 7
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA HD9BI
UT WOS:000452854900005
PM 30372645
DA 2020-12-01
ER

PT J
AU Monteiro, I
   Guazzelli, CF
   Bahamondes, L
AF Monteiro, Ilza
   Guazzelli, Cristina Falbo
   Bahamondes, Luis
TI Advances in contraceptive vaginal rings: what does the future hold?
SO EXPERT OPINION ON PHARMACOTHERAPY
LA English
DT Review
DE Contraceptive vaginal ring; menstrual disturbances; etonogestrel;
   segesterone
ID BLEEDING PATTERNS; NORETHINDRONE ACETATE; CLINICAL-PERFORMANCE;
   ORAL-CONTRACEPTIVES; DOSAGE COMBINATIONS; ENDOCRINE PROFILES; EXTENDED
   REGIMENS; ETHINYL ESTRADIOL; DELIVERY-SYSTEMS; OVARIAN-FUNCTION
AB Introduction: Contraceptive vaginal rings (CVRs) are good contraceptive options because they do not require skilled providers, are self-administered, and show a higher stability of drug diffusion.Area covered: This article provides a review of the developments made with CVRs over the past number of years, while giving focus to the latest CVRs that have gone through clinical development. The author of the article also provides an expert perspective on the future of these useful therapeutic options.Expert opinion: Pharmacokinetic studies have shown that segesterone, an absorbable progestin that is used alone or in combination with ethinyl estradiol (EE) or E-2,E- is the CVR of choice at this present time. Indeed, segesterone has demonstrated safety and efficacy as a CVR and is also an appropriate option for lactating women, as they are not absorbed orally. However, good cycle control is important for improved CVR adherence. CVRs that allow the combination of more than one drug may unravel another multi-purpose use when combined with microbicides and could provide combined protection to women who wish to protect themselves from pregnancy and sexually transmitted infection.
C1 [Monteiro, Ilza; Bahamondes, Luis] Fed Univ, Sch Med, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
   [Guazzelli, Cristina Falbo] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Family Planning Clin, Sao Paulo, Brazil.
RP Monteiro, I (corresponding author), Fed Univ, Sch Med, Dept Obstet & Gynecol, Family Planning Clin, BR-13084971 Campinas, SP, Brazil.
EM ilza@unicamp.br
RI monteiro, ilza m u/F-4871-2014; Guazzelli, Cristina/B-3949-2015
OI monteiro, ilza m u/0000-0002-9536-0564; Bahamondes,
   Luis/0000-0002-7356-8428; Guazzelli, Cristina/0000-0002-6985-0818
CR ADAMS MR, 1987, FERTIL STERIL, V47, P1010
   AHREN T, 1981, CONTRACEPTION, V24, P451, DOI 10.1016/0010-7824(81)90009-3
   Alan Guttmacher Institute, 2017, ADD INV CONTR MAT NE
   Algorta J, 2017, EUR J CONTRACEP REPR, V22, P429, DOI 10.1080/13625187.2017.1413179
   ALVAREZSANCHEZ F, 1992, CONTRACEPTION, V46, P387, DOI 10.1016/0010-7824(92)90101-X
   APTER D, 1990, CONTRACEPTION, V42, P285, DOI 10.1016/0010-7824(90)90016-O
   BALLAGH SA, 1994, CONTRACEPTION, V50, P517, DOI 10.1016/0010-7824(94)90011-6
   BALLAGH SA, 1994, CONTRACEPTION, V50, P535, DOI 10.1016/0010-7824(94)90012-4
   Barreiros FA, 2007, CONTRACEPTION, V75, P204, DOI 10.1016/j.contraception.2006.10.009
   Barreiros FA, 2011, CONTRACEPTION, V84, P155, DOI 10.1016/j.contraception.2010.11.002
   Benson LS, 2015, OBSTET GYN CLIN N AM, V42, P669, DOI 10.1016/j.ogc.2015.07.009
   Brache V, 2001, CONTRACEPTION, V63, P257, DOI 10.1016/S0010-7824(01)00199-8
   Brache V, 2000, STEROIDS, V65, P687, DOI 10.1016/S0039-128X(00)00175-6
   Brache V, 2013, CONTRACEPTION, V87, P264, DOI 10.1016/j.contraception.2012.08.037
   Brache V, 2012, CONTRACEPTION, V85, P480, DOI 10.1016/j.contraception.2011.10.003
   Brache V, 2010, CONTRACEPTION, V82, P418, DOI 10.1016/j.contraception.2010.04.012
   Devlin B, 2013, ANTIVIR RES, V100, pS3, DOI 10.1016/j.antiviral.2013.09.025
   DIAZ S, 1985, CONTRACEPTION, V32, P603, DOI 10.1016/S0010-7824(85)80005-6
   Dieben TOM, 2002, OBSTET GYNECOL, V100, P585, DOI 10.1016/S0029-7844(02)02124-5
   Dinger J, 2013, OBSTET GYNECOL, V122, P800, DOI 10.1097/AOG.0b013e3182a5ec6b
   Dragoman M, 2013, CONTRACEPTION, V87, P432, DOI 10.1016/j.contraception.2012.12.001
   Edelman A, 2014, COCHRANE DB SYST REV, V29
   Guazzelli CAF, 2009, CONTRACEPTION, V80, P430, DOI 10.1016/j.contraception.2009.05.004
   Fraser IS, 2005, CONTRACEPTION, V72, P40, DOI 10.1016/j.contraception.2004.12.015
   Gallegos AJ, 1980, RES FRONTIERS FERTIL, P230
   Hathaway M, 2014, CLIN OBSTET GYNECOL, V57, P718, DOI 10.1097/GRF.0000000000000071
   Hoffman AS, 2008, J CONTROL RELEASE, V132, P153, DOI 10.1016/j.jconrel.2008.08.012
   JACKANICZ TM, 1981, CONTRACEPTION, V24, P323, DOI 10.1016/0010-7824(81)90002-0
   Johansson EDB, 2004, AM J OBSTET GYNECOL, V190, pS54, DOI 10.1016/j.ajog.2004.01.056
   Kavanaugh ML, 2015, OBSTET GYNECOL, V126, P917, DOI 10.1097/AOG.0000000000001094
   KIRKMAN RJ, 1992, BR J FAM PLANN, V18, P12
   KOETSAWANG S, 1990, CONTRACEPTION, V41, P9, DOI 10.1016/0010-7824(90)90122-C
   Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7
   Larner JM, 2000, HUM REPROD, V15, P1100, DOI 10.1093/humrep/15.5.1100
   LAURIKKAROUTTI M, 1990, CONTRACEPTION, V42, P111, DOI 10.1016/0010-7824(90)90095-D
   Lidegaard O, 2012, BMJ-BRIT MED J, V344, P2990
   LOBO RA, 1994, AM J OBSTET GYNECOL, V170, P1499, DOI 10.1016/S0002-9378(94)05011-8
   Lopez-Picado A, 2017, EUR J CONTRACEP REPR, V22, P131, DOI 10.1080/13625187.2017.1287351
   Malcolm RK, 2012, INT J WOMENS HEALTH, V4, P595, DOI 10.2147/IJWH.S36282
   Massai R, 2000, STEROIDS, V65, P703, DOI 10.1016/S0039-128X(00)00125-2
   Merkatz RB, 2014, CONTRACEPTION, V90, P514, DOI 10.1016/j.contraception.2014.05.015
   Miller L, 2005, OBSTET GYNECOL, V106, P473, DOI 10.1097/01.AOG.0000175144.08035.74
   MISHELL DR, 1978, AM J OBSTET GYNECOL, V130, P55, DOI 10.1016/0002-9378(78)90438-6
   MISHELL DR, 1970, FERTIL STERIL, V21, P99
   Nguyen BT, 2014, EXPERT OPIN DRUG SAF, V13, P1423, DOI 10.1517/14740338.2014.948842
   Oddsson K, 2005, HUM REPROD, V20, P557, DOI 10.1093/humrep/deh604
   OLSSON SE, 1990, CONTRACEPTION, V42, P563, DOI 10.1016/0010-7824(90)90083-8
   POULTER NR, 1995, LANCET, V346, P1575
   RamaRao S, 2013, CONTRACEPTION, V88, P591, DOI 10.1016/j.contraception.2013.05.004
   Rohan LC, 2014, CURR TOP MICROBIOL, V383, P27, DOI 10.1007/82_2013_357
   Roumen FJME, 2001, HUM REPROD, V16, P469, DOI 10.1093/humrep/16.3.469
   Saxena BB, 2009, AIDS, V23, P917, DOI 10.1097/QAD.0b013e32832af57c
   Schurmans C, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1680-y
   Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x
   Shapiro S, 2010, J FAM PLAN REPROD H, V36, P33, DOI 10.1783/147118910790291037
   Sitruk-Ware R, 2006, HUM REPROD UPDATE, V12, P169, DOI 10.1093/humupd/dmi046
   Sivin I, 2005, CONTRACEPTION, V71, P122, DOI 10.1016/j.contraception.2004.08.010
   SIVIN I, 1981, CONTRACEPTION, V24, P359, DOI 10.1016/0010-7824(81)90004-4
   Sivin I, 1997, CONTRACEPTION, V55, P225, DOI 10.1016/S0010-7824(97)00008-5
   SIVIN I, 1981, CONTRACEPTION, V24, P341, DOI 10.1016/0010-7824(81)90003-2
   Stifani BM, 2018, CONTRACEPTION, V97, P415, DOI 10.1016/j.contraception.2017.12.011
   Sulak PJ, 2008, OBSTET GYNECOL, V112, P563, DOI 10.1097/AOG.0b013e3181842071
   Thurman AR, 2013, INT J WOMENS HEALTH, V5, P695, DOI 10.2147/IJWH.S34030
   Timmer CJ, 2000, CLIN PHARMACOKINET, V39, P233, DOI 10.2165/00003088-200039030-00005
   TOIVONEN J, 1978, CONTRACEPTION, V18, P201, DOI 10.1016/S0010-7824(78)80014-6
   VICTOR A, 1984, UPSALA J MED SCI, V89, P179, DOI 10.3109/03009738409178478
   Weisberg E, 1999, CONTRACEPTION, V59, P311, DOI 10.1016/S0010-7824(99)00035-9
   Weisberg E, 1997, CONTRACEPTION, V56, P233, DOI 10.1016/S0010-7824(97)00133-9
   Weisberg E, 2005, CONTRACEPTION, V72, P46, DOI 10.1016/j.contraception.2004.12.014
   Weisberg E, 1999, CONTRACEPTION, V59, P305, DOI 10.1016/S0010-7824(99)00036-0
   Woolfson AD, 1999, J CONTROL RELEASE, V61, P319, DOI 10.1016/S0168-3659(99)00148-0
NR 71
TC 3
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1465-6566
EI 1744-7666
J9 EXPERT OPIN PHARMACO
JI Expert Opin. Pharmacother.
PY 2018
VL 19
IS 15
BP 1685
EP 1691
DI 10.1080/14656566.2018.1519549
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA GY9YI
UT WOS:000449009600007
PM 30286682
DA 2020-12-01
ER

PT J
AU Cursino, K
   de Lima, GA
   dos Santos, PDS
   Pavin, EJ
   Bahamondes, L
   Fernandes, A
AF Cursino, Kleber
   de Lima, Gabriel Araujo
   Silva dos Santos, Priscilla de Nazare
   Pavin, Elizabeth Joao
   Bahamondes, Luis
   Fernandes, Arlete
TI Subclinical cardiovascular disease parameters after one year in new
   users of depot medroxyprogesterone acetate compared to copper-IUD
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Contraception; depot-medroxyprogesterone acetate; lipid metabolism;
   cardiovascular disease
ID CORONARY-HEART-DISEASE; LONG-TERM USERS; ENDOTHELIAL FUNCTION; WOMEN;
   PREVENTION; PROVERA; CARBOHYDRATE; GUIDELINES; MORTALITY; UPDATE
AB Purpose: To evaluate markers of cardiovascular disease in women with normal insulin sensitivity who had recently initiated use of depot medroxyprogesterone acetate (DMPA) as a contraceptive.
   Materials and methods: A prospective, non-randomised, comparative study. Data of 30 women of 18-40 years of age, with normal hyperinsulinaemic-euglycaemic clamp at baseline and body mass index (BMI) < 30, who opted to use DMPA or a copper intrauterine device (IUD) as a contraceptive, were analysed. Serum samples were collected for evaluation of the lipid and hepatic profile, C-reactive protein, TNF-alpha, interleukin-6, leptin/adiponectin ratio and free fatty acids; body composition was evaluated using DXA, blood pressure and carotid intima-media thickness were measured. Evaluations were performed at baseline and 12 months later. The groups were compared using repeated measures analysis of variance (ANOVA). Significance level was 5%.
   Results: The mean age of the women in the DMPA and IUD group was 28.76.5 and 28.3 +/- 5.8 years, respectively; the BMI was 23.0 +/- 3.4 and 24.3 +/- 2.7 kg/m(2), respectively, in the same groups. At 12 months, triglyceride levels were higher in the DMPA group compared to the IUD group and there was an increase in apolipoprotein B-100 in relation to baseline in DMPA group; there were no other difference between the groups.
   Conclusions: No clinical cardiovascular effect was found but deterioration in CV markers was observed in the first year of use of DMPA.
C1 [Cursino, Kleber; de Lima, Gabriel Araujo; Silva dos Santos, Priscilla de Nazare; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Med Sch, Family Planning Clin, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Pavin, Elizabeth Joao] Univ Estadual Campinas, Dept Clin Med, Med Sch, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Sao Paulo Foundation
   for the Support of Research (Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo - FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Sao Paulo State Health Department (SES-SP) [FAPESP
   PPSUS2009/53293-0]
FX This work was supported by the Brazilian National Research Council
   (CNPq), the Sao Paulo Foundation for the Support of Research (Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP) and by the Sao
   Paulo State Health Department (SES-SP) [FAPESP PPSUS2009/53293-0].
CR Alkema L, 2013, LANCET, V381, P1642, DOI 10.1016/S0140-6736(12)62204-1
   AMATAYAKUL K, 1979, J STEROID BIOCHEM, V11, P475, DOI 10.1016/0022-4731(79)90070-0
   Bakry S, 2008, ARCH GYNECOL OBSTET, V278, P1, DOI 10.1007/s00404-007-0497-z
   CRONA N, 1983, EUR J OBSTET GYN R B, V16, P97, DOI 10.1016/0028-2243(83)90106-5
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   Dilshad H, 2016, AM J MED SCI, V352, P487, DOI 10.1016/j.amjms.2016.08.007
   ENK L, 1992, HORM METAB RES, V24, P85, DOI 10.1055/s-2007-1003262
   FAHRAEUS L, 1986, FERTIL STERIL, V45, P503
   Garcia M, 2016, CIRC RES, V118, P1273, DOI 10.1161/CIRCRESAHA.116.307547
   GARZAFLORES J, 1991, CONTRACEPTION, V44, P61, DOI 10.1016/0010-7824(91)90106-P
   Graff-Iversen S, 2002, CONTRACEPTION, V66, P7, DOI 10.1016/S0010-7824(02)00311-6
   HELLMAN L, 1976, J CLIN ENDOCR METAB, V42, P912, DOI 10.1210/jcem-42-5-912
   Jellinger PS, 2017, ENDOCR PRACT, V23, P1, DOI 10.4158/EP171764.APPGL
   Kaunitz AM, 1996, INT J FERTIL MENOP S, V41, P69
   Klempfner R, 2016, CIRC-CARDIOVASC QUAL, V9, P100, DOI 10.1161/CIRCOUTCOMES.115.002104
   KONGSAYREEPONG R, 1993, CONTRACEPTION, V47, P177
   Leon-Acuna A, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0380-y
   LIEW DFM, 1985, CONTRACEPTION, V31, P51, DOI 10.1016/0010-7824(85)90074-5
   Lizarelli PM, 2009, CONTRACEPTION, V79, P35, DOI 10.1016/j.contraception.2008.07.024
   Mosca L, 2011, J AM COLL CARDIOL, V57, P1404, DOI 10.1016/j.jacc.2011.02.005
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/CIR.0000000000000152, 10.1161/01.cir.0000441139.02102.80]
   NASH HA, 1975, CONTRACEPTION, V12, P377, DOI 10.1016/0010-7824(75)90074-8
   Segall-Gutierrez P, 2012, CONTRACEPTION, V85, P36, DOI 10.1016/j.contraception.2011.04.016
   Sitruk-Ware R, 2004, MATURITAS, V47, P277, DOI 10.1016/j.maturitas.2004.01.001
   Sorensen MB, 2002, CIRCULATION, V106, P1646, DOI 10.1161/01.CIR.0000030940.73167.4E
   VIRUTAMASEN P, 1986, INT J GYNECOL OBSTET, V24, P291, DOI 10.1016/0020-7292(86)90086-X
   Walldius G, 2004, J INTERN MED, V255, P188, DOI 10.1046/j.1365-2796.2003.01276.x
   Wilmot KA, 2015, CIRCULATION, V132, P997, DOI 10.1161/CIRCULATIONAHA.115.015293
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Hlth Org, 1998, CONTRACEPTION, V57, P315
NR 30
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PY 2018
VL 23
IS 3
BP 201
EP 206
DI 10.1080/13625187.2018.1455087
PG 6
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA GI7FO
UT WOS:000434668100005
PM 29671344
DA 2020-12-01
ER

PT J
AU Ali, M
   Bahamondes, L
   Landoulsi, SB
AF Ali, Moazzam
   Bahamondes, Luis
   Landoulsi, Sihem Bent
TI Extended Effectiveness of the Etonogestrel-Releasing Contraceptive
   Implant and the 20 mu g Levonorgestrel-Releasing Intrauterine System for
   2 Years Beyond U.S. Food and Drug Administration Product Labeling
SO GLOBAL HEALTH-SCIENCE AND PRACTICE
LA English
DT Editorial Material
ID WOMEN; DEVICES
C1 [Ali, Moazzam; Landoulsi, Sihem Bent] WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.
   [Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Fac Med Sci, Family Planning Clin, Sao Paulo, Brazil.
RP Ali, M (corresponding author), WHO, Dept Reprod Hlth & Res, Geneva, Switzerland.
EM alimoa@who.int
FU UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP); World
   Health Organization (WHO)World Health Organization
FX This work was funded by the UNDP-UNFPA-UNICEF-WHO-World Bank Special
   Programme of Research, Development and Research Training in Human
   Reproduction (HRP), a cosponsored program executed by the World Health
   Organization (WHO).
CR Ali M, 2016, HUM REPROD, V31, P2491, DOI 10.1093/humrep/dew222
   [Anonymous], 2013, MIR PACK INS
   Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   Bayer Inc, 2017, PROD MON MIR MISS ON
   Bryant AG, 2012, J PEDIATR ADOL GYNEC, V25, P347, DOI 10.1016/j.jpag.2012.05.016
   Cleland K, 2011, NEW ENGL J MED, V364, DOI 10.1056/NEJMp1104373
   Cravioto MD, 2014, CONTRACEPTION, V90, P147, DOI 10.1016/j.contraception.2014.04.001
   Crosignani PG, 2008, HUM REPROD UPDATE, V14, P197, DOI 10.1093/humupd/dmn003
   Croxatto HB, 2002, CONTRACEPTION, V65, P21, DOI 10.1016/S0010-7824(01)00294-3
   DIAZ J, 1993, CONTRACEPTION, V47, P169, DOI 10.1016/0010-7824(93)90089-P
   DIAZ S, 1991, CONTRACEPTION, V44, P393, DOI 10.1016/0010-7824(91)90030-J
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024
   Huber J, 1998, CONTRACEPTION, V58, p85S, DOI 10.1016/S0010-7824(98)00120-6
   Kiriwat O, 1998, Eur J Contracept Reprod Health Care, V3, P85
   Krajewski CM, 2013, TRANSPLANTATION, V95, P1183, DOI 10.1097/TP.0b013e31827c64de
   Lahteenmaki P, 2000, STEROIDS, V65, P693, DOI 10.1016/S0039-128X(00)00176-8
   McNicholas C, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.01.036
   Merck & Co. Inc, IMPL PRESCR INF
   NILSSON CG, 1986, FERTIL STERIL, V45, P805
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   Rowe P, 2016, CONTRACEPTION, V93, P498, DOI 10.1016/j.contraception.2016.02.024
   Seeber B, 2012, CONTRACEPTION, V86, P345, DOI 10.1016/j.contraception.2012.01.015
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   Trussell J, 2011, CONTRACEPTIVE TECHNO
   Trussell J, 2013, CONTRACEPTION, V87, P154, DOI 10.1016/j.contraception.2012.07.016
   WHO, 2014, ENS HUM RIGHTS PROV
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Zheng S R, 1999, Eur J Contracept Reprod Health Care, V4, P85
NR 29
TC 10
Z9 10
U1 0
U2 2
PU US AGENCY INT DEVELOPMENT-USAID
PI BALTIMORE
PA US AGENCY INT DEVELOPMENT-USAID, BALTIMORE, MD 00000 USA
SN 2169-575X
J9 GLOB HEALTH-SCI PRAC
JI Glob. Health
PD DEC 28
PY 2017
VL 5
IS 4
BP 534
EP 539
DI 10.9745/GHSP-D-17-00296
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA FU6HW
UT WOS:000423953500002
PM 29263025
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Carvalho, NM
   Chou, V
   Modesto, W
   Margatho, D
   Garcia, EAL
   Bahamondes, L
AF Carvalho, Nelsilene M.
   Chou, Victoria
   Modesto, Waleska
   Margatho, Deborah
   Garcia, Elaine A. L.
   Bahamondes, Luis
TI Relationship between user satisfaction with the levonorgestrel-releasing
   intrauterine system and bleeding patterns
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE bleeding pattern; levonorgestrel-releasing intrauterine system;
   satisfaction
ID PATIENT SATISFACTION; MENSTRUAL DISORDERS; LNG-IUS; DISCONTINUATION;
   ACCEPTABILITY; EXPERIENCE; HEALTH; WOMEN
AB AimSatisfaction with a contraceptive method constitutes an important factor in its acceptance and long-term use. The objective of this study was to assess the relationship between user satisfaction with the 20-g/day levonorgestrel-releasing intrauterine system (LNG-IUS) and the bleeding patterns reported at two different time-points during follow-up.
   MethodsA total of 251 LNG-IUS users aged 18-45 years were invited to answer a questionnaire on their return to the clinic for a routine follow-up visit and again 1 year later. Data were collected face-to-face.
   ResultsTwenty women discontinued prematurely; therefore, the analysis was performed on 231 women. Most users were either highly satisfied (66.6% and 66.2% at the first and second interviews, respectively) or satisfied (26.4% and 26.4% at the first and second interviews, respectively) with the LNG-IUS. Satisfaction was related to amenorrhea (P < 0.001) and duration of use (P < 0.001). Prolonged bleeding and spotting were the main causes of dissatisfaction with the device.
   ConclusionMost LNG-IUS users in this sample were satisfied with the device. The only two factors associated with satisfaction were amenorrhea and duration of use, while prolonged bleeding and spotting were the main causes of dissatisfaction. These findings could be useful for health-care professionals and policy-makers when developing information material for women. The study provides insight into the profile of satisfied LNG-IUS users; however, this information is not suitable for counseling women who are considering using an LNG-IUS.
C1 [Carvalho, Nelsilene M.; Chou, Victoria; Modesto, Waleska; Margatho, Deborah; Garcia, Elaine A. L.; Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Dept Obstet & Gynaecol, Family Planning Clin,Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Obstet & Gynaecol, Family Planning Clin,Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@unicamp.br
OI Bahamondes, Luis/0000-0002-7356-8428
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9]; International
   Contraceptive Access Foundation, Turku, Finland
FX Partial financial support was received from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (2015/20504-9). Since 2006, all LNG-IUS
   have been donated by the International Contraceptive Access Foundation,
   Turku, Finland as an unrestricted grant.
CR Backman T, 2002, OBSTET GYNECOL, V99, P608, DOI 10.1016/S0029-7844(01)01764-1
   Bahamondes L, 2017, HUM REPROD, V32, P88, DOI 10.1093/humrep/dew310
   Bahamondes L, 2015, INT J WOMENS HEALTH, V7, P717, DOI 10.2147/IJWH.S84173
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   BAVEJA R, 1989, Contraception, V39, P37
   Concin H, 2009, CURR OPIN OBSTET GYN, V21, pS1, DOI 10.1097/01.gco.0000361658.98177.59
   DARCANGUES C, 1989, CONTRACEPTION, V40, P531
   de Jonge ET, 2007, CONTRACEPTION, V76, P91, DOI 10.1016/j.contraception.2007.04.003
   Dickerson LM, 2013, FAM MED, V45, P701
   Dubuisson JB, 2002, CONTRACEPTION, V66, P121, DOI 10.1016/S0010-7824(02)00329-3
   Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x
   Glick P, 2009, SOC SCI MED, V68, P368, DOI 10.1016/j.socscimed.2008.09.053
   Guttinger A, 2007, CONTRACEPTION, V75, pS93, DOI 10.1016/j.contraception.2007.01.015
   Haugen MM, 1996, J REPROD MED, V41, P849
   Heath CB, 1996, J REP MED, V41, P849
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Kaunitz AM, 2012, DRUGS, V72, P193, DOI 10.2165/11598960-000000000-00000
   Luukkainen T, 2000, STEROIDS, V65, P699, DOI 10.1016/S0039-128X(00)00177-X
   Makuch MY, 2012, INT J GYNECOL OBSTET, V117, P5, DOI 10.1016/j.ijgo.2011.11.018
   Makuch MY, 2011, CONTRACEPTION, V84, P622, DOI 10.1016/j.contraception.2011.03.010
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   Mosher William D, 2010, Vital Health Stat 23, P1
   Nascimento Roberta, 2002, Drugs R D, V3, P387, DOI 10.2165/00126839-200203060-00003
   Orbo A, 2014, BJOG-INT J OBSTET GY, V121, P477, DOI 10.1111/1471-0528.12499
   Pakarinen P, 2001, SEMIN REPROD MED, V19, P365, DOI 10.1055/s-2001-18644
   Radesic B, 2004, AUST NZ J OBSTET GYN, V44, P247, DOI 10.1111/j.1479-828X.2004.00206.x
   Rivera R, 1999, CONTRACEPTION, V60, P155, DOI 10.1016/S0010-7824(99)00077-3
   Robinson R, 2008, J OBSTET GYNAECOL, V28, P728, DOI 10.1080/01443610802462605
   Romer T, 2009, EUR J CONTRACEP REPR, V14, P391, DOI 10.3109/13625180903203154
   SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X
NR 30
TC 3
Z9 4
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD NOV
PY 2017
VL 43
IS 11
BP 1732
EP 1737
DI 10.1111/jog.13441
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FL6AF
UT WOS:000414326900009
PM 28833891
DA 2020-12-01
ER

PT J
AU dos Santos, PDS
   Bahamondes, MV
   Modesto, WO
   Bahamondes, L
   Fernandes, AMD
AF Silva dos Santos, Priscilla de Nazare
   Bahamondes, M. Valeria
   Modesto, Waleska Oliveira
   Bahamondes, Luis
   dos Santos Fernandes, Arlete Maria
TI Dietary Intake and Body Composition in New Users of the Injectable
   Contraceptive Depot-Medroxyprogesterone Acetate During the First Year of
   Use
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE body composition; contraception; dietary intake; medroxyprogesterone
   acetate
ID LATER WEIGHT-GAIN; WOMEN; CARBOHYDRATE; METABOLISM; PROGESTIN; INCREASE;
   GLUCOSE; ADULTS; IUD
AB OBJECTIVE: To evaluate dietary intake and body composition in new users of the injectable contraceptive depot-medroxyprogesterone acetate (DMPA).
   STUDY DESIGN: A non-randomized clinical trial. Healthy women (28 DMPA users and 24 copper intrauterine device [IUD] users) were paired for age (1 year) and body mass index (BMI) (kg/m(2)) (1). Weight, lifestyle habits, and dietary intake recorded using a 3-day food recall form were evaluated at three-monthly intervals during the first year of use of the method. Body composition was assessed at baseline and at 12 months by dual-energy x-ray absorptiometry.
   RESULTS: Mean age was 29.6 and 28.6 years in DMPA and IUD users, respectively, while BMI was 23.9 and 24.5 kg/m(2), respectively. An increase of approximately 12% was found in calorie intake (kilocalories/24 h) and in all the macronutrients of the diet in the DMPA group from the third month onwards. There was increase in total lean mass (p<0.046) in the DMPA group and no statistically significant difference in body weight be tween the groups. No association was found between dietary intake and weight gain.
   CONCLUSION: When initiating use, new DMPA users should be counseled regarding possible changes in dietary intake.
C1 [Silva dos Santos, Priscilla de Nazare; Bahamondes, M. Valeria; Modesto, Waleska Oliveira; Bahamondes, Luis; dos Santos Fernandes, Arlete Maria] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, Campinas, SP, Brazil.
RP Fernandes, AMD (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
FU Brazilian Ministry of Health; National Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Sao Paulo Foundation for the Support
   of ResearchFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Sao Paulo State Health Department through a research project
   on behalf of the Brazilian National Health System (PPSUS)
   [2009/53293-0]; Coordination for the Improvement of Higher Education
   PersonnelCAPES
FX Supported by the Brazilian Ministry of Health, the National Council for
   Scientific and Technological Development (CNPq), the Sao Paulo
   Foundation for the Support of Research, and the Sao Paulo State Health
   Department through a research project on behalf of the Brazilian
   National Health System (PPSUS/2009), grant #2009/53293-0. The authors
   gratefully acknowledge the financial support of the Coordination for the
   Improvement of Higher Education Personnel through a grant conceded to
   Dr. de Nazare Silva dos Santos.
CR AMATAYAKUL K, 1980, CONTRACEPTION, V22, P605, DOI 10.1016/0010-7824(80)90087-6
   Amatayakul K, 1979, SINGAPORE J OBSTET G, V9, P57
   Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Bakry S, 2008, ARCH GYNECOL OBSTET, V278, P1, DOI 10.1007/s00404-007-0497-z
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Berenson AB, 2011, OBSTET GYNECOL, V117, P41, DOI 10.1097/AOG.0b013e318202ac23
   Bonny AE, 2014, CONTRACEPTION, V89, P357, DOI 10.1016/j.contraception.2014.01.017
   Bonny AE, 2011, OBSTET GYNECOL, V117, P793, DOI 10.1097/AOG.0b013e31820f387c
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   FAHMY K, 1991, CONTRACEPTION, V44, P419, DOI 10.1016/0010-7824(91)90032-B
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Fraser I S, 1981, Med J Aust, V1, P3
   Friendly M, 1995, SAS SYSTEM STAT GRAP
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   LIEW DFM, 1985, CONTRACEPTION, V31, P51, DOI 10.1016/0010-7824(85)90074-5
   MAINWARING R, 1995, CONTRACEPTION, V51, P149, DOI 10.1016/0010-7824(95)00011-X
   Maltoni M, 2001, ANN ONCOL, V12, P289, DOI 10.1023/A:1011156811739
   Melhado-Kimura V, 2015, EUR J CONTRACEP REPR, V20, P110, DOI 10.3109/13625187.2014.961599
   Modesto W, 2014, EUR J CONTRACEP REPR, V19, P244, DOI 10.3109/13625187.2014.924098
   PARIANI S, 1991, STUD FAMILY PLANN, V22, P384, DOI 10.2307/1966452
   Pelkman C, 2002, J REPROD MED, V47, P791
   Pelkman CL, 2001, AM J CLIN NUTR, V73, P19
   dos Santos PDS, 2014, EUR J CONTRACEP REPR, V19, P432, DOI 10.3109/13625187.2014.936934
   Taneepanichskul S, 1998, CONTRACEPTION, V58, P149, DOI 10.1016/S0010-7824(98)00085-7
   THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   Wanyonyi Sikolia Z, 2011, Contraception, V84, pe17, DOI 10.1016/j.contraception.2011.05.022
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
   WHO, 2011, GLOB STAT REP NONC D
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 32
TC 2
Z9 2
U1 0
U2 6
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
EI 1943-3565
J9 J REPROD MED
JI J. Reprod. Med.
PD SEP-OCT
PY 2017
VL 62
IS 9-10
BP 526
EP 533
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FJ9XD
UT WOS:000413133900012
DA 2020-12-01
ER

PT J
AU Guidobaldi, HA
   Cubilla, M
   Moreno, A
   Molino, MV
   Bahamondes, L
   Giojalas, LC
AF Guidobaldi, H. A.
   Cubilla, M.
   Moreno, A.
   Molino, M. V.
   Bahamondes, L.
   Giojalas, L. C.
TI Sperm chemorepulsion, a supplementary mechanism to regulate
   fertilization
SO HUMAN REPRODUCTION
LA English
DT Article
DE sperm repulsion; sperm chemoattraction; contraception; fertilization;
   ulipistral acetate; mifepristone; levonorgestrel; zinc; progesterone
ID ULIPRISTAL ACETATE; ACROSOME REACTION; HUMAN-SPERMATOZOA; RECEPTOR
   MODULATORS; UTERINE FIBROIDS; MAMMALIAN EGGS; CUMULUS CELLS; ZINC
   SPARKS; PROGESTERONE; POLYSPERMY
AB STUDY QUESTION: Are human spermatozoa able of chemorepulsive behaviour?
   SUMMARY ANSWER: Capacitated human spermatozoa are able to be chemorepelled by synthetic Progesterone Receptor Ligands (sPRL, known as contraceptives) and zinc (a cation released by the oocyte upon fertilization).
   WHAT IS KNOWN ALREADY: Moving cells can be oriented towards or against a molecular gradient, processes called chemoattraction and chemorepulsion, respectively, which have been described in unicellular organisms such as amoebas and bacteria, to organismic cells such macrophages and developmental cells. In the case of spermatozoa, chemoattraction may help the finding of an oocyte and has been widely studied in various invertebrate and mammalian species; however, chemorepulsion has not yet been verified in spermatozoa.
   STUDY DESIGN, SIZE, DURATION: This is an in vitro study involving human, rabbit and mouse spermatozoa which were used to perform 3-30 experiments per treatment.
   PARTICIPANTS/MATERIALS, SETTING, METHODS: Human sperm samples were obtained by masturbation from healthy donors who gave written consent. Only those samples exhibiting normal semen parameters according to current WHO criteria were included in the study. Rabbit spermatozoa were obtained by artificial vagina whereas mice spermatozoa were obtained from epididymis. The sperm selection assay (SSA), originally designed to evaluate sperm chemoattraction towards progesterone (P), and a video-microscopy and computer motion analysis system were used to test sperm chemorepulsion. Additional kinetic parameters were also determined by video-microscopy and computer motion analysis. In some experiments, the level of induced acrosome-reacted spermatozoa was determined. Rabbit mating manipulation was achieved to perform the sperm-oocyte co-incubation assay.
   MAIN RESULTS AND THE ROLE OF CHANCE: Sperm accumulation in the well containing 100 pg/ml of sPRL was lower than the culture medium negative control (P < 0.05). The percentage of sperm persistence against the well containing 100 pg/ml ulipristal acetate (UPA) (P = 0.001), and the percentage of sperm showing a repulsive pattern of movement (a linear trajectory followed by a transitional one after turning against the UPA), were higher than the culture medium negative control (P = 0.049). Sperm accumulation was diminished when spermatozoa where exposed to a homogeneous distribution of 100 pg/ml sPRL combined with a chemotactic gradient of progesterone (P), with respect to the culture medium negative control (P < 0.05). These results were reverted when non-capacitated spermatozoa were used to perform the same experimental settings. The accumulation of spermatozoa against 100 pg/ml sPRL was lower than the culture medium negative control also in rabbits and mice (P < 0.05). The relative number of rabbit spermatozoa arriving to the vicinity of the oocyte was diminished under the presence of 100 pg/ml UPA (P = 0.004). Sperm accumulation in the well containing zinc was decreased compared to the culture medium negative control (P < 0.05). A homogeneous distribution of zinc combined with a gradient of 10 pM P, was lower than the culture medium negative control (P = 0.016). The results were quite reproducible with two different methodologies (accumulation assay and video-microscopy combined with computer motion analysis), in three mammalian species.
   LIMITATIONS REASONS FOR CAUTION: The experiments were performed in vitro. Even though a quite complete characterization of sperm chemorepulsion was provided, the molecular mechanism that governs sperm repulsion is currently under investigation.
   WIDER IMPLICATIONS OF THE FINDINGS: Since the chemorepelled spermatozoa are those physiologically ready to fertilize the oocyte, these findings may have both biological and clinical implications, preventing either polyspermy under natural conditions or fertilization under pharmacological treatment with sPRL.
C1 [Guidobaldi, H. A.; Cubilla, M.; Moreno, A.; Molino, M. V.; Giojalas, L. C.] UNC, FCEFyN, Ctr Biol Celular & Mol, Av Velez Sarsfield 1611,X5016GCA, Cordoba, Argentina.
   [Guidobaldi, H. A.; Cubilla, M.; Moreno, A.; Giojalas, L. C.] UNC, CONICET, FCEFyN, Inst Invest Biol & Tecnol, Cordoba, Argentina.
   [Bahamondes, L.] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Family Planning Clin, Campinas, SP, Brazil.
RP Giojalas, LC (corresponding author), UNC, FCEFyN, Ctr Biol Celular & Mol, Av Velez Sarsfield 1611,X5016GCA, Cordoba, Argentina.
EM lgiojalas@unc.edu.ar
RI Guidobaldi, Hector Alejandro/K-6724-2017
OI Guidobaldi, Hector Alejandro/0000-0002-5033-2981; Moreno,
   Ayelen/0000-0001-6810-6475; Giojalas, Laura/0000-0002-1036-1251;
   Bahamondes, Luis/0000-0002-7356-8428
FU Universidad Nacional de Cordoba (Argentina) PCC-UNC
FX Universidad Nacional de Cordoba (Argentina) PCC-UNC-2013.
CR Guidobaldi HA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003040
   Beltran C, 2014, DEV BIOL, V394, P15, DOI 10.1016/j.ydbio.2014.07.017
   Bianchi E, 2014, NATURE, V508, P483, DOI 10.1038/nature13203
   Blengini CS, 2011, ASIAN J ANDROL, V13, P769, DOI 10.1038/aja.2011.27
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Brito KS, 2005, CONTRACEPTION, V72, P225, DOI 10.1016/j.contraception.2005.04.005
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Chenouard N, 2014, NAT METHODS, V11, P281, DOI 10.1038/nmeth.2808
   Cooper TG, 2010, WHO LAB MAN EX PROC
   Di Rienzo JA, 2002, J AGRIC BIOL ENVIR S, V7, P129, DOI 10.1198/10857110260141193
   Di Rienzo JA, 2011, INFOSTAT
   Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165
   Saavedra MD, 2014, REPRODUCTION, V147, P369, DOI 10.1530/REP-13-0454
   Donnez J, 2012, NEW ENGL J MED, V366, P421, DOI 10.1056/NEJMoa1103180
   Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893
   Eisenbach M., 2004, CHEMOTAXIS
   Ernesto JI, 2015, J CELL BIOL, V210, P1213, DOI 10.1083/jcb.201412041
   Teves ME, 2010, FERTIL STERIL, V93, P2450, DOI 10.1016/j.fertnstert.2009.09.012
   Fabro G, 2002, BIOL REPROD, V67, P1565, DOI 10.1095/biolreprod.102.006395
   Gardner AJ, 2006, REPROD FERT DEVELOP, V18, P53, DOI 10.1071/RD05122
   Gatica LV, 2013, MOL HUM REPROD, V19, P559, DOI 10.1093/molehr/gat037
   Giojalas LC, 2015, FLAGELLAR MECH SPERM, P272, DOI [10.2174/9781681081281115010012, DOI 10.2174/9781681081281115010012]
   Gomez-Elias MD, 2016, HUM REPROD, V31, P53, DOI 10.1093/humrep/dev287
   Guidobaldi HA, 2017, MOL REPROD DEV, V84, P310, DOI 10.1002/mrd.22782
   HUNTER RHF, 1993, MOL REPROD DEV, V35, P324, DOI 10.1002/mrd.1080350315
   Huttenlocher A, 2008, TRENDS CELL BIOL, V18, P298, DOI 10.1016/j.tcb.2008.04.001
   Jaiswal BS, 1998, FEBS LETT, V427, P309, DOI 10.1016/S0014-5793(98)00455-4
   Kim AM, 2011, ACS CHEM BIOL, V6, P716, DOI 10.1021/cb200084y
   Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6
   Masuda T, 2005, NEUROSCI RES, V51, P337, DOI 10.1016/j.neures.2005.01.007
   Michailov Y, 2014, DEV BIOL, V396, P246, DOI 10.1016/j.ydbio.2014.10.009
   Miller MR, 2016, SCIENCE, V352, P555, DOI 10.1126/science.aad6887
   MORTIMER D, 1988, GAMETE RES, V20, P313, DOI 10.1002/mrd.1120200307
   Mortimer ST, 1996, HUM REPROD, V11, P1049
   Nallasamy S, 2013, REPROD SCI, V20, P371, DOI 10.1177/1933719112459239
   Que EL, 2017, INTEGR BIOL-UK, V9, P135, DOI 10.1039/c6ib00212a
   Unates DR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091181
   Reig G, 2014, DEVELOPMENT, V141, P1999, DOI 10.1242/dev.101451
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023
   SUGARMAN B, 1988, J GEN MICROBIOL, V134, P1623
   Teves ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008211
   Teves ME, 2006, FERTIL STERIL, V86, P745, DOI 10.1016/j.fertnstert.2006.02.080
   Thomas P, 2008, FRONT NEUROENDOCRIN, V29, P292, DOI 10.1016/j.yfrne.2008.01.001
   TSO WW, 1979, CONTRACEPTION, V19, P207, DOI 10.1016/0010-7824(79)90014-3
   VANDERHYDEN BC, 1995, BIOL REPROD, V53, P1243, DOI 10.1095/biolreprod53.6.1243
   WAKELING AE, 1991, CANCER RES, V51, P3867
   Williams ARW, 2012, INT J GYNECOL PATHOL, V31, P556, DOI 10.1097/PGP.0b013e318251035b
   Yamashita Y, 2003, BIOL REPROD, V68, P1193, DOI 10.1095/biolreprod.102.010934
   Zumoffen C, 2017, CONTRACEPTI IN PRESS, DOI [10.1016/j.contraception.2017.02.019, DOI 10.1016/J.CONTRACEPTION.2017.02.019]
NR 51
TC 11
Z9 11
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2017
VL 32
IS 8
BP 1560
EP 1573
DI 10.1093/humrep/dex232
PG 14
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA FB2PK
UT WOS:000405985500005
PM 28854585
OA Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Fernandes, A
   Monteiro, I
AF Bahamondes, Luis
   Fernandes, Arlete
   Monteiro, Ilza
TI Barriers to Implementing and Consolidating a Family Planning Program
   that would meet Brazilian Needs
SO REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA
LA English
DT Editorial Material
ID NO-COST; PROVISION
C1 [Bahamondes, Luis; Fernandes, Arlete; Monteiro, Ilza] Univ Estadual Campinas, Dept Obstet & Gynecol, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9]
FX This editorial was supported in part by Fundacao de Apoio a Pesquisa do
   Estado de Sao Paulo (FAPESP) (grant # 2015/20504-9).
CR *AM COLL OBST GYN, 2007, OBSTET GYNECOL, V110, P1493, DOI DOI 10.1097/01.AOG.0000291575.93944.1A
   Amaral G, 2007, HEALTH SERV RES, V42, P1960, DOI 10.1111/j.1475-6773.2007.00702.x
   American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, 2009, Obstet Gynecol, V114, P1434, DOI 10.1097/AOG.0b013e3181c6f965
   [Anonymous], 2012, RED REV DAT LAB DEL
   [Anonymous], 2008, NAT DEM HLTH CHILDR
   Bahamondes L, 2017, HUM REPROD, V32, P88, DOI 10.1093/humrep/dew310
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Curtis Siân L., 2012, Rev. bras. estud. popul., V29, P191, DOI 10.1590/S0102-30982012000100012
   Ferreira JM, 2017, J FAM PLAN REPROD H
   Guttmacher Institute, 2012, FACTS AB LAT AM CAR
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Oringanje C, 2009, COCHRANE DB SYST REV
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Potter JE, 2010, POPUL DEV REV, V36, P283, DOI 10.1111/j.1728-4457.2010.00330.x
   Rocha RCL, 2010, J PEDIATR ADOL GYNEC, V23, P142, DOI 10.1016/j.jpag.2009.08.011
   Santelli J, 2003, PERSPECT SEX REPRO H, V35, P94, DOI 10.1363/3509403
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
   Trussell J, 2011, CONTRACEPTIVE TECHNO
   Vlassoff M, 2009, INT PERSPECT SEX R H, V35, P114, DOI [10.1363/3511409, 10.1363/ipsrh.35.114.09]
   WHO, 2012, BORN TOO SOON GLOB A
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2011, UNS AB GLOB REG EST
NR 22
TC 0
Z9 0
U1 0
U2 0
PU FEDERACAO BRASILEIRA SOC GINECOLOGIA & OBSTETRICIA-FEBRASGO
PI RIO DE JANEIRO RJ
PA AV DAS AMERICAS, 8445, SALA 711-BARRA DA TIJUCA, RIO DE JANEIRO RJ,
   22793-081, BRAZIL
SN 0100-7203
EI 1806-9339
J9 REV BRAS GINECOL OBS
JI Rev. Bras. Ginecol. Obstet.
PD AUG
PY 2017
VL 39
IS 8
BP 373
EP 375
DI 10.1055/s-0037-1604423
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FO2VZ
UT WOS:000416655700001
PM 28772333
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Monteiro, I
   Fernandes, A
   Bahamondes, MV
   Pitoli, A
   Bahamondes, L
AF Ferreira, Jessica M.
   Monteiro, Ilza
   Fernandes, Arlete
   Bahamondes, Maria V.
   Pitoli, Ana
   Bahamondes, Luis
TI Estimated disability-adjusted life years averted by free-of-charge
   provision of the levonorgestrel-releasing intrauterine system over a
   9-year period in Brazil
SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
ID NO-COST; UNINTENDED PREGNANCY
AB Background The objective was to analyse the contribution of the provision at no cost to users of the 20 mu g/day levonorgestrel-releasing intrauterine system (LNG-IUS) towards disability-adjusted life years (DALY) averted over a 9-year period.
   Methods We analysed data from 15 030 new users of the LNG-IUS who had the device inserted at 26 Brazilian teaching hospitals between January 2007 and December 2015. The devices came from the International Contraceptive Access Foundation (ICA), a not-for-profit foundation that donates the devices to developing countries for use by low-income women who desire long-term contraception and who freely choose to use this device. Estimation of the DALY averted included live births averted, maternal morbidity and mortality, child mortality and unsafe abortions averted.
   Results A total of 15 030 women chose the LNG-IUS as a contraceptive method during the study period. Over the 9 years of evaluation, the estimated cumulative contribution of the Brazilian program in terms of DALY averted consisted of 486 live births, 14 cases of combined maternal mortality and morbidity, 143 cases of child mortality and 410 unsafe abortions.
   Conclusions Provision of the LNG-IUS at no cost to low-income Brazilian women reduced unwanted pregnancies and probably averted maternal mortality and morbidity, child mortality and unsafe abortions. Family planning programs, policymakers and stakeholders based in low-resource settings could take advantage of the information that the provision of this contraceptive at no cost, or at affordable cost to a publicly-insured population, is an effective policy to help promote women's health.
C1 [Ferreira, Jessica M.; Monteiro, Ilza; Fernandes, Arlete; Bahamondes, Maria V.; Pitoli, Ana; Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018; monteiro, ilza m u/F-4871-2014; Ferreira,
   Jessica/I-3350-2018
OI Fernandes, Arlete/0000-0001-5872-0017; monteiro, ilza m
   u/0000-0002-9536-0564; Ferreira, Jessica/0000-0003-2153-0353
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504/9];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008/3]; International
   Contraceptive Access Foundation, Turku, Finland
FX This study received partial financial support from the Fundacao de Apoio
   a Pesquisa do Estado de Sao Paulo (FAPESP) award # 2015/20504/9 and from
   the National Research Council (CNPq), grant # 573747/2008/3. The
   LNG/IUSs were donated by the International Contraceptive Access
   Foundation, Turku, Finland under an unrestricted grant.
CR Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Birgisson NE, 2015, J WOMENS HEALTH, V24, P349, DOI 10.1089/jwh.2015.5191
   Comissao Nacional de Incorporacao de Tecnologias no SUS (CONITEC), 2015, SIST INTR LIB LEV 52
   Diedrich JT, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.001
   Eisenberg D, 2013, J ADOLESCENT HEALTH, V52, pS59, DOI 10.1016/j.jadohealth.2013.01.012
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Rocca CH, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.009
   Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
   Secura GM, 2014, OBSTET GYNECOL, V123, P771, DOI 10.1097/AOG.0000000000000184
   Trussell J, 2007, CONTRACEPTIVE TECHNO, P747
   Yazdkhasti M, 2015, IRAN J PUBLIC HEALTH, V44, P12
NR 15
TC 3
Z9 3
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1471-1893
EI 2045-2098
J9 J FAM PLAN REPROD H
JI J. Fam. Plan. Reprod. Health Care
PD JUL
PY 2017
VL 43
IS 3
BP 181
EP 185
DI 10.1136/jfprhc-2016-101569
PG 5
WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical
SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences
GA FP8SF
UT WOS:000417915700002
PM 28330857
OA Bronze
DA 2020-12-01
ER

PT J
AU Melhado-Kimura, V
   Bizzacchi, JMA
   Quaino, SKP
   Montalvao, S
   Bahamondes, L
   Fernandes, A
AF Melhado-Kimura, Vaneska
   Annichino Bizzacchi, Joyce Maria
   Picoli Quaino, Susan Kelly
   Montalvao, Silmara
   Bahamondes, Luis
   Fernandes, Arlete
TI Effect of the injectable contraceptive depot-medroxyprogesterone acetate
   on coagulation parameters in new users
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE blood coagulation tests; contraception; depot-medroxyprogesterone;
   hypercoagulability; venous thrombosis
ID PROGESTIN-ONLY CONTRACEPTION; VENOUS THROMBOEMBOLISM; D-DIMER;
   ORAL-CONTRACEPTIVES; THROMBIN GENERATION; DIAGNOSIS; RISK
AB Aim: The aim of this study was to assess the effects of the injectable depot-medroxyprogesterone acetate (DMPA) contraceptive on selected blood coagulation parameters in young, healthy new users.
   Methods: The prospective study included 39 healthy women aged 20-39 years, with a body mass index (BMI; kg/m(2)) < 30, who were never users of DMPA, and who opted to use DMPA (21 women) or a copper intrauterine device (IUD; 18 women). The women in the two groups were matched for age (+/- 1 year) and BMI (+/- 1). Blood samples were obtained from all participants at baseline and at 6 and 12 months. Activated partial thromboplastin time, D-dimer, protein C, antithrombin, protein S, and thrombin generation test (lag time, endogenous thrombin potential, time to peak, and velocity index of thrombin generation) were analyzed. Repeated-measures analysis of variance was used to compare the groups.
   Results: There were no significant differences between the groups at baseline with respect to any of the parameters evaluated; however, in the DMPA group, D-dimer levels were lower and the time to peak thrombin generation was longer than in the IUD group at 12 months of evaluation.
   Conclusion: Lower D-dimer and longer time to peak thrombin generation in new users of DMPA suggest a positive profile against hypercoagulability.
C1 [Melhado-Kimura, Vaneska; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Rua Alexander Fleming 101,Cidade Univ, BR-13083881 Campinas, SP, Brazil.
   [Annichino Bizzacchi, Joyce Maria; Picoli Quaino, Susan Kelly; Montalvao, Silmara] Univ Estadual Campinas, Sch Med Sci, Blood Ctr, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Rua Alexander Fleming 101,Cidade Univ, BR-13083881 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Fernandes, Arlete/I-7561-2018; De Lima Montalvao, Silmara/F-2853-2019
OI Fernandes, Arlete/0000-0001-5872-0017; De Lima Montalvao,
   Silmara/0000-0002-8920-3765
FU Sao Paulo State Foundation for the Support of Research (FAPESP)Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/14827-9];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2015/20504-9]
FX The authors are grateful for the financial support of the Sao Paulo
   State Foundation for the Support of Research (FAPESP) under award
   #2011/14827-9. This study also received partial financial support from
   FAPESP award #2015/20504-9. The funding sources did not play a role in
   the study design, in the collection, analysis and interpretation of
   data, in the writing of the report, or in the decision to submit the
   article for publication.
CR Adam SS, 2009, BLOOD, V113, P2878, DOI 10.1182/blood-2008-06-165845
   Anita K, 2014, ORVOSI HETILAP, V155, P851, DOI 10.1556/OH.2014.29899
   [Anonymous], 1967, J R Coll Gen Pract, V13, P267
   Bates SM, 2012, SEMIN THROMB HEMOST, V38, P673, DOI 10.1055/s-0032-1326782
   Bergendal A, 2014, OBSTET GYNECOL, V124, P600, DOI 10.1097/AOG.0000000000000411
   Cosmi B, 2010, THROMB RES, V125, pS62, DOI 10.1016/S0049-3848(10)70016-5
   Cursino K, 2016, EUR J CONTRACEP REPR, V21, P22, DOI 10.3109/13625187.2015.1059415
   Fraser IS, 1983, LONG ACTING STEROID, P1
   Goldstein J, 2007, FERTIL STERIL, V87, P1267, DOI 10.1016/j.fertnstert.2006.11.040
   Hemker HC, 2006, THROMB HAEMOSTASIS, V96, P553, DOI 10.1160/TH06-07-0408
   Lance MD, 2015, THROMB J, V13, DOI 10.1186/1477-9560-13-1
   Lewis MA, 1996, CONTRACEPTION, V54, P5, DOI 10.1016/0010-7824(96)00112-6
   Liang YD, 2013, THROMB J, V11, DOI 10.1186/1477-9560-11-12
   Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890
   Mantha S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4944
   POULTER NR, 1995, LANCET, V346, P1575
   Rott H, 2013, MINERVA MED, V104, P161
   SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082
   Tepper NK, 2016, CONTRACEPTION, V94, P678, DOI 10.1016/j.contraception.2016.04.014
   van Veen JJ, 2008, BRIT J HAEMATOL, V142, P889, DOI 10.1111/j.1365-2141.2008.07267.x
   VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651
   Vlieg AVH, 2010, ARTERIOSCL THROM VAS, V30, P2297, DOI 10.1161/ATVBAHA.110.211482
   Wilbur J, 2012, AM FAM PHYSICIAN, V86, P913
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Hlth Org, 1998, CONTRACEPTION, V57, P315
NR 25
TC 3
Z9 3
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD JUN
PY 2017
VL 43
IS 6
BP 1054
EP 1060
DI 10.1111/jog.13306
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FA1XG
UT WOS:000405234300014
PM 28503774
DA 2020-12-01
ER

PT J
AU Zumoffen, C
   Gomez-Elias, MD
   Caille, AM
   Bahamondes, L
   Cuasnicu, PS
   Cohen, DJ
   Munuce, MJ
AF Zumoffen, Carlos
   Gomez-Elias, Matias D.
   Caille, Adriana M.
   Bahamondes, Luis
   Cuasnicu, Patricia S.
   Cohen, Debora J.
   Jose Munuce, Maria
TI Study of the effect of ulipristal acetate on human sperm ability to
   interact with tubal tissue and cumulus-oocyte-complexes
SO CONTRACEPTION
LA English
DT Article
DE Ulipristal acetate; Emergency contraception; Human spermatozoa;
   Progesterone; Fertilization
ID HUMAN FALLOPIAN-TUBE; PROGESTERONE-RECEPTOR; FERTILIZATION; SPERMATOZOA;
   ANTAGONISTS; ACTIVATION; CATSPER
AB Objective: Ulispristal acetate (UPA) is a selective progesterone receptor modulator widely used for emergency contraception (EC). The described main mechanism of action is by inhibiting or delaying ovulation; however, the postovulatory effects of the drug are still on debate. Therefore, the aim of this study was to determine whether UPA could interfere with human sperm fertilizing ability.
   Study design: Human motile spermatozoa were incubated under capacitating conditions with or without UPA, and then used to inseminate human tubal explants, mouse cumulus-oocyte complexes and zona-free hamster eggs. The ability of UPA to interact with human sperm progesterone (P)-binding sites was investigated by incubating the cells with fluorescent-labeled P and analyzing them by fluorescence microscopy.
   Results: UPA did not affect the ability of human sperm to bind to human tubal tissue explants surface or to penetrate the mouse cumulus mass and the zona-free hamster eggs. In addition, concentrations of UPA much higher than those present in the plasma of EC pill users were required to bind to human sperm P-binding sites.
   Conclusions: Our study supports a lack of an agonist or antagonist action of UPA on different functional parameters associated with the fertilizing ability of human sperm. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Zumoffen, Carlos; Caille, Adriana M.; Jose Munuce, Maria] Natl Univ Rosario, Lab Reprod Med, Sch Biochem & Pharmaceut Sci, Suipacha 531, RA-2000 Rosario, Santa Fe, Argentina.
   [Gomez-Elias, Matias D.; Cuasnicu, Patricia S.; Cohen, Debora J.] Consejo Nacl Invest Cient & Tecn, IBYME, Vuelta Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.
   [Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Family Planning Clin,Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Munuce, MJ (corresponding author), Natl Univ Rosario, Lab Reprod Med, Sch Biochem & Pharmaceut Sci, Suipacha 531, RA-2000 Rosario, Santa Fe, Argentina.
EM slorenzo939@hotmail.com
FU University of Rosario [BIO 314]; Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2015/20504-9]; National Agency of Scientific; National
   Agency of Scientific and Technological Promotion (ANPCyT),
   ArgentinaANPCyT [PICT 2011-061, PIP 2012-905]
FX This study was supported by a grant of the University of Rosario (BIO
   314) to MJM, a grant (2015/20504-9) from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) award # 2015/20504-9 to LB, and
   partially supported by the National Agency of Scientific and partially
   supported by the National Agency of Scientific and Technological
   Promotion (ANPCyT), Argentina grants PICT 2011-061 to DJC and PIP
   2012-905 to PSC.
CR Alasmari W, 2013, J BIOL CHEM, V288, P6248, DOI 10.1074/jbc.M112.439356
   BALDI E, 1995, TRENDS ENDOCRIN MET, V6, P198, DOI 10.1016/1043-2760(95)00083-T
   Baldi E, 2009, MOL CELL ENDOCRINOL, V308, P39, DOI 10.1016/j.mce.2009.02.006
   Battistone MA, 2014, MOL HUM REPROD, V20, P1054, DOI 10.1093/molehr/gau073
   Berger C, 2015, HUM REPROD, V30, P800, DOI 10.1093/humrep/dev030
   BIGGERS J. D., 1971, Methods in mammalian embryology, P86
   BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655
   BLACKMORE PF, 1991, BIOCHEM BIOPH RES CO, V181, P331, DOI 10.1016/S0006-291X(05)81422-6
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   CALVO L, 1989, FERTIL STERIL, V52, P1048
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Ernesto JI, 2015, J CELL BIOL, V210, P1213, DOI 10.1083/jcb.201412041
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Gomez-Elias MD, 2016, HUM REPROD, V31, P53, DOI 10.1093/humrep/dev287
   Guidobaldi HA, 2012, REPRODUCTION, V143, P587, DOI 10.1530/REP-11-0478
   Hennet ML, 2012, INT J DEV BIOL, V56, P819, DOI 10.1387/ijdb.120133cc
   Munuce MJ, 2013, EUR J CONTRACEP REPR, V18, P355, DOI 10.3109/13625187.2013.813930
   Leonhardt SA, 2002, EXP BIOL MED, V227, P969
   Li HWR, 2014, HUM REPROD, V29, P2156, DOI 10.1093/humrep/deu210
   Li Hw Raymond, 2010, F1000 Med Rep, V2, P58, DOI 10.3410/M2-58
   Munuce MJ, 2012, EUR J CONTRACEP REPR, V17, P428, DOI 10.3109/13625187.2012.725877
   Quintero I, 2005, INT J ANDROL, V28, P137, DOI 10.1111/j.1365-2605.2005.00525.x
   Rosato E, 2016, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00315
   Wanggren K, 2008, HUM REPROD, V23, P2359, DOI 10.1093/humrep/den260
   WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301
   World Health Organization, 2010, WHO LAB MAN EX PROC
   Yanagimachi R., 1994, Zygote, V2, P371
NR 28
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2017
VL 95
IS 6
BP 586
EP 591
DI 10.1016/j.contraception.2017.02.019
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EZ8AO
UT WOS:000404947000010
PM 28238840
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Monteiro, I
AF Bahamondes, Luis
   Monteiro, Ilza
TI Comments on manuscript: vaginal misoprostol prior to intrauterine device
   insertion in women delivered only by elective cesarean section: a
   randomized double-blind clinical trial
SO CONTRACEPTION
LA English
DT Letter
ID CONTRACEPTIVES
C1 [Bahamondes, Luis; Monteiro, Ilza] Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Med Sch, Dept Obstet & Gynecol, Family Planning Clin, Campinas, SP, Brazil.
EM drluisbahamondes@hotmail.com
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
CR Abdellah M.S., 2017, CONTRACEPTION
   Bahamondes L, 2014, J FAM PLAN REPROD H, V40, P54, DOI 10.1136/jfprhc-2013-100636
   Bahamondes MV, 2015, HUM REPROD, V30, P1861, DOI 10.1093/humrep/dev137
   Gemzell-Danielsson K, 2013, HUM REPROD UPDATE, V19, P419, DOI 10.1093/humupd/dmt022
NR 4
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD APR
PY 2017
VL 95
IS 4
BP 434
EP 435
DI 10.1016/j.contraception.2017.01.012
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA ES0ZG
UT WOS:000399257100017
PM 28189667
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Ali, M
   Monteiro, I
   Fernandes, A
AF Bahamondes, Luis
   Ali, Moazzam
   Monteiro, Ilza
   Fernandes, Arlete
TI Stagnant contraceptive sales after the Zika epidemic in Brazil
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Brazil; contraceptive use; long-acting reversible contraception; Zika
   virus epidemic
AB Objectives: Our aim was to assess national hormonal and non-hormonal contraceptive sales in Brazil after the Zika virus outbreak.
   Methods: Pharmaceutical companies based in Brazil provided data on monthly sales from September 2016 to June 2017. Data from both the public and private sectors were obtained about sales of registered, available modern contraceptive methods: combined oral contraceptive pill; progestin-only pill; vaginal and transdermal contraceptives; injectable contraceptives; long-acting reversible contraceptive (LARC) methods, including the copper-releasing intrauterine device, the levonorgestrel-releasing intrauterine system and the etonogestrel-releasing subdermal implant; and emergency contraceptive pills.
   Results: Seventy-eight percent of sales comprised pills, patches and vaginal rings (11.1-13.8 million cycles/units per month), followed by emergency contraceptive pills (1.8-2.6 million pills), injectables (1.2-1.4 million ampoules) and LARC methods (6500-17,000 devices).
   Conclusions: The data showed much higher sales of short-acting methods compared with more effective LARC methods. The public sector needs to strengthen its focus on ensuring better access to LARC methods through a systematic approach ensuring regular supply, improved professional skills and better demand generation to couples wishing to avoid or delay pregnancy. In Zika virus-affected areas, many women of reproductive age may want to delay or postpone pregnancy by using an effective LARC method. The public sector should review its policies on LARC, as the need for these methods especially in Zika virus endemic areas may increase. A clear emphasis on quality in services, access and use is warranted.
C1 [Bahamondes, Luis; Monteiro, Ilza; Fernandes, Arlete] Univ Estadual Campinas, Family Planning Clin, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
   [Ali, Moazzam] World Hlth Org, Dept Reprod Hlth & Res, Geneva, Switzerland.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Family Planning Clin, Dept Obstet & Gynaecol, Med Sch, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Fernandes, Arlete/I-7561-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Fernandes,
   Arlete/0000-0001-5872-0017
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo, Brazil
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2015/20504-9]
FX The study was supported by Fundacao de Apoio a Pesquisa do Estado de Sao
   Paulo, Brazil (FAPESP) award # 2015/20504-9 and from a large anonymous
   donor. The funding sources did not play a role in the study design, in
   the collection, analysis and interpretation of data, in the writing of
   the report, or in the decision to submit the article for publication.
   This report contains the collective views of an international group of
   experts and does not necessarily represent the decisions or the stated
   policy of the WHO.
CR Ali M, 2017, EUR J CONTRACEP REPR, V22, P102, DOI 10.1080/13625187.2017.1288902
   Bahamondes L, 2017, HUM REPROD, V32, P88, DOI 10.1093/humrep/dew310
   Brazilian Ministry of Health, 2016, PREV COMB DENG CHIK
   Coelho AVC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081714
   Centers for Disease Control and Prevention, 2016, WOM THEIR PARTN TRYI
   Centers for Disease Control and Prevention, 2017, CDC AN DAT US TERR F
   Garcia-Subirats I, 2014, INT J EQUITY HEALTH, V13, DOI 10.1186/1475-9276-13-10
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   World Health Organization, 2016, ZIK SIT REP 15 SEPT
   World Health Organization Fifth Meeting of the Emergency Committee under the International Health Regulations, 2005, 5 M EM COMM INT HLTH
NR 10
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PY 2017
VL 22
IS 5
BP 381
EP 383
DI 10.1080/13625187.2017.1397623
PG 3
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA FP7LF
UT WOS:000417815100010
PM 29166843
OA Other Gold
DA 2020-12-01
ER

PT J
AU Bahamondes, L
AF Bahamondes, L.
TI Advantages of self-administration of injectable contraceptives
SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
LA English
DT Editorial Material
C1 [Bahamondes, L.] Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynaecol, Med Sch, Campinas, SP, Brazil.
CR Keith B, 2014, CONTRACEPTION, V89, P344, DOI 10.1016/j.contraception.2014.03.003
   Ruminjo JK, 2005, CONTRACEPTION, V72, P138, DOI 10.1016/j.contraception.2005.04.001
   Santelli J, 2003, PERSPECT SEX REPRO H, V35, P94, DOI 10.1363/3509403
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
NR 4
TC 0
Z9 0
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1470-0328
EI 1471-0528
J9 BJOG-INT J OBSTET GY
JI BJOG
PD JAN
PY 2017
VL 124
IS 2
SI SI
BP 209
EP 209
DI 10.1111/1471-0528.14301
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EO0HI
UT WOS:000396378500006
PM 27699960
OA Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Ali, M
   Monteiro, I
   Fernandes, A
AF Bahamondes, Luis
   Ali, Moazzam
   Monteiro, Ilza
   Fernandes, Arlete
TI Contraceptive sales in the setting of the Zika virus epidemic
SO HUMAN REPRODUCTION
LA English
DT Article
DE Zika virus; contraception; long-acting contraceptive methods; Brazil;
   unintended pregnancies
ID SEXUAL TRANSMISSION; UNITED-STATES; NO-COST; PROVISION
AB STUDY QUESTION: Has there been any influence of the Zika virus (ZIKV) outbreak on the sales of contraceptive methods in Brazil?
   SUMMARY ANSWER: Contraceptive sales in the 24 months of evaluation showed little variation and no significant change has been observed since the ZIKV outbreak.
   WHAT IS KNOWN ALREADY: Transmission of ZIKV is primarily by Aedes aegypti mosquitoes; however, sexual transmission has also been described. The association of several birth defects and the ZIKV infection during pregnancy has been established, and it was estimated in Bahia, Brazil that the infection rate could range from 10% to 80%. The World Health Organisation (WHO) declared the cluster of microcephaly cases and other neurological disorders a health emergency on 1 February 2016. The Brazilian government also made recommendations for women who were planning to become pregnant and who reside in ZIKV-affected areas to reconsider or postpone pregnancy.
   STUDY DESIGN, SIZE, DURATION: The objective of this study was to assess the sales of contraceptive methods in Brazil, tracking it from before and through the ZIKV outbreak. We obtained information from all pharmaceutical companies based in Brazil and from the manufacturers of long-acting reversible contraceptives (LARCs), including the copper-intrauterine device (IUD), the levonorgestrel-releasing intrauterine system (LNG-IUS) and implants, about contraceptives sales in the public and private sectors between September 2014 and August 2016.
   PARTICIPANTS/MATERIALS, SETTING, METHODS: We analyzed the data for: (i) oral contraceptives, i.e. combined oral contraceptives (COC) and progestin-only pills (POP), and vaginal and transdermal contraceptives, (ii) injectable contraceptives, i.e. once-a-month and depot-medroxyprogesterone acetate, (iii) LARCs and (iv) emergency contraceptive (EC) pills.
   MAIN RESULTS AND THE ROLE OF CHANCE: Monthly sales of COC, POP, patches and vaginal rings represent the major sales segment of the market, i.e. 12.7-13.8 million cycles/units per month (90%). The second largest group of sales was injectables, representing 0.81.5 million ampoules per month (9.5%). Following this, are LARC methods with sales of 37 000-41 000 devices per month (0.5%). It is important to note that although the peak months of sales were different for each group of contraceptives, there were no significant differences overall between the months of observation. The EC pill sales were between 1.0 million and 1.3 million of pills per month.
   LIMITATIONS, REASONS FOR CAUTION: Although the use of contraceptive methods was already high and no change was noted, the ZIKV outbreak may have changed the pregnancy intentions of Brazilian women. Consequently, the number of women planning pregnancy may be lower than that recorded. The contraceptive sales figures did not include condoms. Since condoms might not only prevent pregnancies, but also sexual transmission of ZIKV, this lack of information is a limitation.
   WIDER IMPLICATIONS OF THE FINDINGS: The results from this assessment showed that the sales of contraceptives presented little variation during the ZIKV outbreak in Brazil. Furthermore, it is possible that access to LARC methods was limited. Although we did not investigate the reason for low LARC uptake, we suspect that it is due to lack of availability of LARC in the public sector, the high cost of the methods and the incomplete insurance coverage on contraception for women. Projections estimate millions of additional cases of ZIKV transmission. Thus, a coordinated response is needed to ensure access to a wide range of contraceptive methods for women during the ZIKV outbreak. In conclusion, this assessment of contraceptive sales in Brazil identifies challenges in contraceptive access, especially for LARC methods, and represents an alternative source of data to help us understand the trends in demand for contraception in ZIKV-affected areas.
C1 [Bahamondes, Luis; Monteiro, Ilza; Fernandes, Arlete] Univ Estadual Campinas, UNICAMP, Sch Med, Family Planning Clin,Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
   [Ali, Moazzam] WHO, Dept Reprod Hlth & Res, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, UNICAMP, Sch Med, Family Planning Clin,Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Fernandes, Arlete/I-7561-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Fernandes,
   Arlete/0000-0001-5872-0017
FU Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2015/20504-9]
FX The Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP) award #
   2015/20504-9 and from an anonymous donor. The funding sources did not
   play a role in the study design, in the collection, analysis and
   interpretation of data, in the writing of the report, or in the decision
   to submit the article for publication. This report contains the
   collective views of an international group of experts, and does not
   necessarily represent the decisions or the stated policy of the World
   Health Organisation.
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Armstrong P, 2016, MMWR-MORBID MORTAL W, V65, P286, DOI 10.15585/mmwr.mm6511e1
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Brasil P., 2016, N ENGL J ME IN PRESS
   Brooks JT, 2016, MMWR-MORBID MORTAL W, V65, P745, DOI 10.15585/mmwr.mm6529e2
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Daniels K., 2015, NATL HLTH STAT REPOR
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Rocha RCL, 2010, J PEDIATR ADOL GYNEC, V23, P142, DOI 10.1016/j.jpag.2009.08.011
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
   Trussell J, 2011, CONTRACEPTIVE TECHNO
NR 20
TC 17
Z9 19
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD JAN
PY 2017
VL 32
IS 1
BP 88
EP 93
DI 10.1093/humrep/dew310
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA EL7QH
UT WOS:000394815100011
PM 27932442
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU Ali, M
   Akin, A
   Bahamondes, L
   Brache, V
   Habib, N
   Landoulsi, S
   Hubacher, D
AF Ali, Moazzam
   Akin, Ayse
   Bahamondes, Luis
   Brache, Vivian
   Habib, Ndema
   Landoulsi, Sihem
   Hubacher, David
CA WHO Study Grp Subdermal Contracept
TI Extended use up to 5 years of the etonogestrel-releasing subdermal
   contraceptive implant: comparison to levonorgestrel-releasing subdermal
   implant
SO HUMAN REPRODUCTION
LA English
DT Article
DE subdermal contraceptive implants; etonogestrel; levonorgestrel; extended
   use; intrauterine device
ID INTRAUTERINE-DEVICE; TRIAL
AB Is it possible to extend the use of the 3-year one-rod etonogestrel (ENG)-releasing subdermal contraceptive implant to 5 years?
   The extended use of the one-rod ENG-releasing subdermal contraceptive implant showed 100% efficacy in years 4 and 5.
   The initial regulated trials on the ENG-releasing subdermal contraceptive implant conducted in the 1990 s were designed to measure cumulative 3-year efficacy. The ENG-implant has both well established safety and efficacy for up to 3 years. Pharmacokinetic data on ENG show high levels at 3 years and some previous clinical research confirms efficacy beyond the current approved duration of 3 years. Today, many women, because the labeled duration has been reached, have the ENG implant removed at 3 years, increasing costs, inconvenience and risks.
   For the first 3 years, this study was an open-label, multi-centre randomized trial comparing the 3-year ENG implant to the 5-year levonorgestrel (LNG)-releasing implant. After 3 years, a subset of 390 ENG participants, consented to extended use. We compared efficacy, side effects and removal procedures of both implants. We used Kaplan-Meier (K-M) analysis. We included an observational cohort of copper intrauterine device (IUD) users as non-users of hormonal contraceptive method for comparative purposes.
   The study took place in family planning clinics in seven countries worldwide. Women were enlisted after an eligibility check and informed consent, and 1328 women were enrolled: 390, 522 and 416 in the ENG-implant, LNG-implant and IUD groups, respectively.
   Over 200 women used the ENG implant for at least 5 years. No pregnancies occurred during the additional 2 years of follow up in the ENG or LNG implant group. The overall 5-year K-M cumulative pregnancy rates for ENG- and LNG- implants were 0.6 per 100 women-years (W-Y) [95% confidence interval (CI): 0.2-1.8] and 0.8 per 100 W-Y [95% CI: 0.2-2.3], respectively. Complaints of bleeding changes were similar; however, ENG-users were more likely than LNG-users to experience heavy bleeding (p < 0.05). The median duration of the implant removal procedure was 64 seconds shorter for the one-rod ENG-implant (inter-quartile range (IQR) = 30.5, 117.5) compared to the two-rod LNG product (IQR = 77.0, 180.0). The 2-year rate for pregnancy in the IUD group compared with the two implant groups combined was 4.1 per 100 W-Y [95% CI: 2.5-6.5].
   Few women were a parts per thousand currency sign19 years old or nulligravida. Although there was no weight limit for enrolment in the study, the number of women a parts per thousand yen70 kg were few.
   The results from this study corroborate previous evidence showing high contraceptive efficacy through 4 years for the ENG-implant. Data through 5 years are a novel contribution and further proof of the product's capability to provide safe and effective contraception that rivals the current 5-year LNG-subdermal implant. The findings provide valuable information for policy makers, family planning programmers and clinicians that the ENG-releasing subdermal implant is still highly effective up to 5 years after insertion. Compared to previous efforts, our study population was geographically diverse and our study had the highest number of participants completing at least 5 years of use.
   The trial was registered as ISRCTN33378571.
   The contraceptive devices and funds for conduct of the study were provided by the United Nations Development Programme/United Nations Population Fund/World Health Organization (WHO)/UNICEF/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR), WHO. This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the WHO. All stated authors have no conflict of interest, except Dr Hubacher who reported grants from United States Agency for International Development, during the conduct of the study; other from Advisory Boards (Teva, Bayer, OCON), outside the submitted work.
C1 [Ali, Moazzam; Habib, Ndema; Landoulsi, Sihem] WHO, UNFPA, UNICEF, UNDP,World Bank Special Programme Res Dev & Res T, Geneva, Switzerland.
   [Akin, Ayse] Baskent Univ, Fac Med, Ankara, Turkey.
   [Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Fac Med Sci, Family Planning Clin, Campinas, SP, Brazil.
   [Brache, Vivian] PROFAMILIA, Santo Domingo, Dominican Rep.
   [Hubacher, David] FHI 360, Durham, NC USA.
RP Ali, M (corresponding author), WHO, UNFPA, UNICEF, UNDP,World Bank Special Programme Res Dev & Res T, Geneva, Switzerland.
EM alimoa@who.int
FU United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP);
   Department of Reproductive Health and Research (RHR); World Health
   Organization (WHO)World Health Organization; US Agency for International
   DevelopmentUnited States Agency for International Development (USAID)
   [GPO-A-00-08-00001-00]
FX United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP),
   Department of Reproductive Health and Research (RHR), World Health
   Organization (WHO) funded this study including provision of subdermal
   implants and IUDs. This report contains the collective views of an
   international group of experts, and does not necessarily represent the
   decisions or the stated policy of the World Health Organization. FHI 360
   participation in this project was funded by the US Agency for
   International Development (GPO-A-00-08-00001-00, Program Research for
   Strengthening Services (PROGRESS)). The views expressed in this
   publication do not necessarily reflect those of FHI 360, or the United
   States Agency for International Development.
CR Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   DIAZ S, 1991, CONTRACEPTION, V44, P393, DOI 10.1016/0010-7824(91)90030-J
   Huber J, 1998, CONTRACEPTION, V58, p85S, DOI 10.1016/S0010-7824(98)00120-6
   Kiriwat O, 1998, Eur J Contracept Reprod Health Care, V3, P85
   McNicholas C, 2015, OBSTET GYNECOL, V125, P599, DOI 10.1097/AOG.0000000000000690
   Weisberg E, 2014, EUR J CONTRACEP REPR, V19, P5, DOI 10.3109/13625187.2013.853034
   Wenzl R, 1998, CONTRACEPTION, V58, P283, DOI 10.1016/S0010-7824(98)00110-3
   World Health Organization, 2000, REPR HLTH RES
   Zheng S R, 1999, Eur J Contracept Reprod Health Care, V4, P85
NR 9
TC 28
Z9 28
U1 2
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD NOV
PY 2016
VL 31
IS 11
BP 2491
EP 2498
DI 10.1093/humrep/dew222
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA ED1GY
UT WOS:000388594300013
PM 27671673
OA Green Published, Other Gold
DA 2020-12-01
ER

PT J
AU dos Santos, PDS
   de Souza, AL
   Batista, GA
   Melhado-Kimura, V
   de Lima, GA
   Bahamondes, L
   Fernandes, A
AF Silva dos Santos, Priscilla de Nazare
   de Souza, Aglecio Luiz
   Batista, Gisele Almeida
   Melhado-Kimura, Vaneska
   de Lima, Gabriel Araujo
   Bahamondes, Luis
   Fernandes, Arlete
TI Binge eating and biochemical markers of appetite in new users of the
   contraceptive depot medroxyprogesterone acetate
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Depot medroxyprogesterone acetate; Contraception; NPY; Appetite; Eating
   disorder
ID WEIGHT-GAIN; INSULIN-RESISTANCE; NEUROPEPTIDE-Y; BODY-WEIGHT;
   FOOD-INTAKE; WOMEN; PROGESTIN; BEHAVIOR; LEPTIN; ADULTS
AB Weight gain has been cited by women as one of the main reasons for discontinuation of the contraceptive depot medroxyprogesterone acetate (DMPA). This study aimed to evaluate binge eating and the biochemical markers of appetite in new DMPA users.
   In this prospective non randomized study with adult healthy women, twenty-eight users of DMPA and twenty-five users of a copper intrauterine device (IUD) were paired for age (+/- 1 year) and body mass index (BMI) (+/- 1 kg/m(2)). We evaluated binge eating using the Binge Eating Scale (BES), the serum levels of neuropeptide Y, leptin and adiponectin, and the BMI at baseline and after 12 months in both groups. For statistical analysis was used ANOVA for to compare the means of the repeated measurements.
   Mean age was 29.6 and 28.6 years and BMI was 23.9 and 24.5 kg/m(2) for the DMPA and IUD groups, respectively. After 12 months, the frequency of the scores of binge eating remained low in both groups. There were no significant differences between the groups at 12 months with respect to BMI, levels of NPY, leptin, adiponectin, and BES scores.
   Healthy adult women did not present with central stimulation of appetite or binge eating disorder in their first year after starting use of DMPA. This study reinforces the use of the contraceptive DPMA and the need for guidance related to living a healthy lifestyle for women who attribute the increase of body weight to the use of the method.
C1 [Silva dos Santos, Priscilla de Nazare; Melhado-Kimura, Vaneska; de Lima, Gabriel Araujo; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, Dept Obstet & Gynecol, Human Reprod Unit, Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
   [de Souza, Aglecio Luiz; Batista, Gisele Almeida] Univ Estadual Campinas, Sch Med Sci, Dept Clin Med, Metab Unit, Rua Alexander Fleming,101,Cidade Univ, BR-13083881 Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynecol, Human Reprod Unit, Caixa Postal 6181, BR-13083970 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI DE SOUZA, AGLECIO/Q-4056-2016; Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/14827-9]; CAPES (Coordination for the
   Improvement of Higher Education Personnel) through a Grant conceded to
   PNSS; Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); Secretaria de Estado da Saude de Sao Paulo
   (SES-SP), Brazil [PPSUS/2009, 2009/53293-0]
FX Sao Paulo Research Foundation (FAPESP), Grant #2011/14827-9 and CAPES
   (Coordination for the Improvement of Higher Education Personnel) through
   a Grant conceded to PNSS. The original study was funded by the Brazilian
   National Research Council (CNPq) and by the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP), Secretaria de Estado da Saude
   de Sao Paulo (SES-SP) Grant PPSUS/2009, #2009/53293-0, Brazil. The
   authors claim they have not a financial relationship with the
   organization that sponsored the research. We claim that we have had full
   control of all primary data and that we agree to allow the Journal to
   review their data if requested.
CR ABEP, 2009, BRAZ ASS RES CO BRAZ
   AMATAYAKUL K, 1980, CONTRACEPTION, V22, P605, DOI 10.1016/0010-7824(80)90087-6
   American Psychiatric Association, 2013, FEED EAT DIS DIAGN S
   Bakry S, 2008, ARCH GYNECOL OBSTET, V278, P1, DOI 10.1007/s00404-007-0497-z
   Beck B, 2006, PHILOS T R SOC LON B
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Bonny Andrea E, 2004, J Pediatr Adolesc Gynecol, V17, P109, DOI 10.1016/j.jpag.2004.01.006
   Bonny AE, 2015, CONTRACEPTION, V92, P298, DOI 10.1016/j.contraception.2015.05.014
   BUFFENSTEIN R, 1995, PHYSIOL BEHAV, V58, P1067, DOI 10.1016/0031-9384(95)02003-9
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   Cursino K, 2016, EUR J CONTRACEP REPR, V21, P22, DOI 10.3109/13625187.2015.1059415
   Dos Santos P, J REPROD ME IN PRESS
   Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0
   Ford ES, 2005, OBES RES, V13, P608, DOI 10.1038/oby.2005.65
   Fraser I S, 1981, Med J Aust, V1, P3
   Freitas Silvia, 2001, Revista Brasileira de Psiquiatria, V23, P215
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   GORMALLY J, 1982, ADDICT BEHAV, V7, P47, DOI 10.1016/0306-4603(82)90024-7
   Hirschberg AL, 2012, MATURITAS, V71, P248, DOI 10.1016/j.maturitas.2011.12.016
   Kaunitz AM, 1996, INT J FERTIL MENOP S, V41, P69
   Kokot F, 1999, MINER ELECTROL METAB, V25, P303, DOI 10.1159/000057464
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   MAINWARING R, 1995, CONTRACEPTION, V51, P149, DOI 10.1016/0010-7824(95)00011-X
   Pelkman CL, 2001, AM J CLIN NUTR, V73, P19
   Schinner S, 2005, DIABETIC MED, V22, P674, DOI 10.1111/j.1464-5491.2005.01566.x
   Taneepanichskul S, 1999, CONTRACEPTION, V59, P301, DOI 10.1016/S0010-7824(99)00037-2
   TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   Wanyonyi Sikolia Z, 2011, Contraception, V84, pe17, DOI 10.1016/j.contraception.2011.05.022
   Weigle DS, 2005, AM J CLIN NUTR, V82, P41
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
NR 31
TC 1
Z9 1
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD NOV
PY 2016
VL 294
IS 6
BP 1331
EP 1336
DI 10.1007/s00404-016-4192-9
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA EA4TB
UT WOS:000386606600031
PM 27604241
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Bottura, BF
   Goncalves, MP
   Monteiro, I
   Bahamondes, L
AF Ferreira, Jessica M.
   Bottura, Bruna F.
   Goncalves, Mayara P.
   Monteiro, Ilza
   Bahamondes, Luis
TI Comparison of two strategies for the administration of injectable depot
   medroxyprogesterone acetate: among women who returned to a family
   planning clinic at three- or six-month intervals
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Depot-medroxyprogesterone acetate; continuation rate; strategies;
   service provision
ID REVERSIBLE CONTRACEPTION; ACCEPTABILITY; DMPA; CONTINUATION; PROVISION;
   EFFICACY; SAFETY; SELF
AB Objectives: The aim of this study was to compare the clinical performance of depot medroxyprogesterone acetate (DMPA) in women who received injections every 3 months at the Family Planning Clinic, and those who received every other injection at a health care facility near their place of residence, only returning to the clinic every 6 months.
   Materials and methods: The medical charts of DMPA users from 2 January 1980 through 31 December 2012 were evaluated for this study. Two cohorts of women were created and compared: those who regularly received DMPA injections every 3 months (3-month group) at the clinic and those who received alternating 3-month injections at a health care facility near their residence house, returning to the clinic every 6 months for an injection (6-month group). In addition, effectiveness rates, reasons for discontinuation, and continuation rates were evaluated.
   Results: Overall, 2637 women received all injections at 3-month intervals at the clinic, and 1190 women received every other injection at a health care facility near their residence. The women in the 3-month group had higher pregnancy rates and higher discontinuation rates (with the exception of discontinuation due to the loss of libido).
   Conclusion: The women who received alternating injections near their homes were more likely to continue using DMPA as a contraception method and presented lower pregnancy and discontinuation rates (for the majority of reasons), when compared to those women who returned to the clinic every 3 months.
C1 Univ Estadual Campinas, UNICAMP, Family Planning Clin, Dept Obstet & Gynaecol,Sch Med Sci, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Ferreira, Jessica/I-3350-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Ferreira,
   Jessica/0000-0003-2153-0353
FU National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the National Research
   Council (CNPq) [grant #573747/2008-3].
CR Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Beasley A, 2014, CONTRACEPTION, V89, P352, DOI 10.1016/j.contraception.2014.01.026
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Bonny AE, 2015, CONTRACEPTION, V92, P298, DOI 10.1016/j.contraception.2015.05.014
   CASTLE WM, 1978, S AFR MED J, V53, P842
   Fathizadeh Nahid, 2011, Iran J Nurs Midwifery Res, V16, P304
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Hubacher D, 1999, CONTRACEPTION, V60, P345, DOI 10.1016/S0010-7824(99)00104-3
   Jacobstein R, 2014, BEST PRACT RES CL OB, V28, P795, DOI 10.1016/j.bpobgyn.2014.05.003
   Jain J, 2004, CONTRACEPTION, V70, P269, DOI 10.1016/j.contraception.2004.06.011
   Malarcher S, 2011, CONTRACEPTION, V83, P495, DOI 10.1016/j.contraception.2010.08.013
   Modesto W, 2015, J WOMENS HEALTH, V24, P636, DOI 10.1089/jwh.2014.5077
   O'Neil-Callahan M, 2013, OBSTET GYNECOL, V122, P1083, DOI 10.1097/AOG.0b013e3182a91f45
   Picardo C, 2010, CONTRACEPTION, V82, P160, DOI 10.1016/j.contraception.2010.01.013
   Prabhakaran S, 2012, CONTRACEPTION, V85, P453, DOI 10.1016/j.contraception.2011.09.015
   Ruminjo JK, 2005, CONTRACEPTION, V72, P138, DOI 10.1016/j.contraception.2005.04.001
   Susheela S, 2010, STUD FAMILY PLANN, V41, P241
   Trussell J, 2011, CONTRACEPTIVE TECHNO, P4
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
NR 21
TC 1
Z9 1
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD OCT
PY 2016
VL 21
IS 5
BP 408
EP 411
DI 10.1080/13625187.2016.1217326
PG 4
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA DX5FV
UT WOS:000384406100012
PM 27530899
DA 2020-12-01
ER

PT J
AU Ragazini, CS
   Bahamondes, MV
   Prandini, TRR
   Brito, MB
   Amaral, E
   Bahamondes, L
   Duarte, G
   Quintana, SM
   Ferriani, RA
   Vieira, CS
AF Ragazini, Conrado S.
   Bahamondes, Maria Valeria
   Rocha Prandini, Tatiana R.
   Brito, Milena Bastos
   Amaral, Eliana
   Bahamondes, Luis
   Duarte, Geraldo
   Quintana, Silvana Maria
   Ferriani, Rui Alberto
   Vieira, Carolina Sales
TI Bleeding patterns of HIV-infected women using an etonogestrel-releasing
   contraceptive implant and efavirenz-based or lopinavir/ritonavir-based
   antiretroviral therapy
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Bleeding pattern; contraceptive; etonogestrel; HIV
ID ADOLESCENTS; TRIAL; RATES
AB Objectives: The use of progestogen-only contraceptives may cause a change in bleeding pattern, which is a common cause of discontinuation of these methods. Co-administration with some antiretroviral therapies (ART) changes the bioavailability of the etonogestrel (ENG)-releasing contraceptive implant, possibly affecting the bleeding pattern. Bleeding patterns were evaluated in HIV-positive users of the ENG implant co-administered with two common ART regimens.Methods: Forty-five HIV-positive women who wished to use an ENG implant were included in this study: 15 had received zidovudine/lamivudine (AZT/3TC) + lopinavir/ritonavir (LPV/r) for 3 months (LPV/r-based ART group), 15 had received AZT/3TC+efavirenz (EFV) for 3 months (EFV-based ART group), and 15 had not received ART (non-ART group). Bleeding patterns were evaluated at 3 and 6 months after implant placement using a standard bleeding calendar.Results: Amenorrhoea and infrequent bleeding rates were higher in the LPV/r-based ART group (50% and 36%, respectively) than in the other groups (non-ART group, 36% and 29%, respectively; EFV-based ART group, 7% and 14.5%, respectively; p=0.01). The EFV-based ART group more frequently had regular bleeding (71.5%) compared with the other groups (LPV/r-based ART group, 7%; non-ART group, 21%; p=0.01). The proportions of women with frequent and prolonged bleeding were similar (p>0.05) in the three groups.Conclusions: The co-administration of EFV-based or LPV/r-based ART with the ENG implant affected the expected bleeding patterns during use of the implant, although unfavourable bleeding (frequent and prolonged) was not associated with the medications under evaluation.
C1 [Ragazini, Conrado S.; Rocha Prandini, Tatiana R.; Duarte, Geraldo; Quintana, Silvana Maria; Ferriani, Rui Alberto; Vieira, Carolina Sales] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Gynecol & Obstet, Sao Paulo, Brazil.
   [Bahamondes, Maria Valeria; Amaral, Eliana; Bahamondes, Luis] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Sao Paulo, Brazil.
   [Brito, Milena Bastos] Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil.
RP Vieira, CS (corresponding author), Univ Sao Paulo, Dept Ginecol & Obstet, Fac Med Ribeirao Preto, Ave Bandeirantes 3900,Campus Univ, BR-14049900 Ribeirao Preto, SP, Brazil.
EM carol.sales@uol.com.br
RI Vieira, Carolina Sales/N-6855-2015; Duarte, Geraldo/J-7906-2012; BRITO,
   MILENA B/K-9457-2018
OI Vieira, Carolina Sales/0000-0003-2933-5755; BRITO, MILENA
   B/0000-0002-2397-4145
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/53147-3];
   Brazilian Council of Science and Technology [479795/2010-0]
FX The study was co-funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) (grant no. 2009/53147-3) and the Brazilian Council of
   Science and Technology (grant no. 479795/2010-0).
CR Brandao KDAG, 2015, REV BRAS GINECOL OBS, V37, P486, DOI 10.1590/SO100-720320150005347
   Bahamondes L, 2015, HUM REPROD, V30, P2527, DOI 10.1093/humrep/dev221
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   Darney P, 2009, FERTIL STERIL, V91, P1646, DOI 10.1016/j.fertnstert.2008.02.140
   Elgalib A, 2011, HIV MED, V12, P118, DOI 10.1111/j.1468-1293.2010.00878.x
   Fiore S, 2008, HUM REPROD, V23, P2140, DOI 10.1093/humrep/den232
   Hickey M, 2012, REV ENDOCR METAB DIS, V13, P301, DOI 10.1007/s11154-012-9227-3
   Jeffreys LA, 2012, CONTRACEPTION, V85, P381, DOI 10.1016/j.contraception.2011.09.012
   Kenny J, 2012, HIV MED, V13, P304, DOI 10.1111/j.1468-1293.2011.00967.x
   Koenig LJ, 2007, AM J OBSTET GYNECOL, V197, pS123, DOI 10.1016/j.ajog.2007.03.004
   Loutfy MR, 2012, HIV MED, V13, P107, DOI 10.1111/j.1468-1293.2011.00946.x
   Mansour D, 2008, EUR J CONTRACEP REPR, V13, P13, DOI 10.1080/13625180801959931
   Mansour D, 2011, CONTRACEPTION, V83, P202, DOI 10.1016/j.contraception.2010.08.001
   Ministerio da Saude [Ministry of Health], PROT CLIN DIR TER MA
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   O'Neil-Callahan M, 2013, OBSTET GYNECOL, V122, P1083, DOI 10.1097/AOG.0b013e3182a91f45
   Patel RC, 2015, LANCET HIV, V2, pE474, DOI 10.1016/S2352-3018(15)00184-8
   Rodriguez G, 1976, Estud Poblac, V1, P90
   Schwartz SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036039
   Secura GM, 2014, NEW ENGL J MED, V371, P1316, DOI 10.1056/NEJMoa1400506
   Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x
   Shulman LP, 2011, AM J OBSTET GYNEC S4, V205, P9
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Tsui AO, 2010, EPIDEMIOL REV, V32, P152, DOI 10.1093/epirev/mxq012
   Vieira CS, 2014, JAIDS-J ACQ IMM DEF, V66, P378, DOI 10.1097/QAI.0000000000000189
   WHO, 2012, GLOB MON FRAM STRAT
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2013, CONS GUID US ANT DRU
   World Health Organization, 2015, MED EL CRIT CONTR US
   World Health Organization, 2009, MED EL CRIT CONTR US
NR 30
TC 2
Z9 2
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD AUG
PY 2016
VL 21
IS 4
BP 285
EP 289
DI 10.1080/13625187.2016.1177718
PG 5
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA DT3DP
UT WOS:000381361100004
PM 27227739
DA 2020-12-01
ER

PT J
AU Moraes, LG
   Marchi, NM
   Pitoli, AC
   Hidalgo, MM
   Silveira, C
   Modesto, W
   Bahamondes, L
AF Moraes, Leticia G.
   Marchi, Nadia M.
   Pitoli, Ana C.
   Hidalgo, Maria M.
   Silveira, Carolina
   Modesto, Waleska
   Bahamondes, Luis
TI Assessment of the quality of cervical mucus among users of the
   levonorgestrel-releasing intrauterine system at different times of use
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Cervical mucus; levonorgestrel-releasing intrauterine system; ovulation
ID OVARIAN-FUNCTION; CONTRACEPTIVE METHODS; SATISFACTION; ENDOMETRIUM;
   DEVICE; IUD; EXPERIENCE; GLYCODELIN
AB Background and objectives: The quality of cervical mucus (CM) among the levonorgestrel-releasing intrauterine system (LNG-IUS) users is controversial. The objectives were to assess CM compared to the levels of oestradiol (E-2) and the frequency of cycles with luteal activity among users of the LNG-IUS.Materials and methods: In total, 224 LNG-IUS users for between two months and five years were recruited at a Brazilian family planning clinic. For the cross-sectional part of the study, we enrolled 175 LNG-IUS users at 2, 6 12, 24, 36, 48, and 60 months after insertion (25 women in each group), and we performed one evaluation. For the prospective part of the study, we enrolled 49 LNG-IUS users at the same lengths of use after insertion (7 women in each group), and we evaluated these women once a week for five consecutive weeks. (.)Results: Mean ( SEM) CM scores of all evaluations among women with single and weekly evaluations were between 3.30.9 and 8.5 +/- 0.3, respectively independently of the length of use of the LNG-IUS. Mean E-2 values ranged from 45.5 +/- 6.8 to 472.5 +/- 34.7pg/ml and the maximum ovarian follicle diameter on the days of evaluation varied from 14.0 +/- 1.3 to 31.2 +/- 0.4mm.Conclusions: The mean CM score of all evaluations, independent of the length of use of the LNG-IUS and normal levels of serum E-2, was below 10 was according to the WHO is inadequate for sperm penetration.
C1 [Moraes, Leticia G.; Marchi, Nadia M.; Pitoli, Ana C.; Hidalgo, Maria M.; Silveira, Carolina; Modesto, Waleska; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Family Planning Clin, Sch Med, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynaecol, Family Planning Clin, Sch Med, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]; International
   Contraceptive Access (ICA) Foundation, Turku, Finland
FX This study received partial financial support from the National Research
   Council (CNPq), grant #573747/2008-3. The LNG-IUS was donated by the
   International Contraceptive Access (ICA) Foundation, Turku, Finland
   under unrestricted grant.
CR Backman T, 2002, OBSTET GYNECOL, V99, P608, DOI 10.1016/S0029-7844(01)01764-1
   Bahamondes L, 2003, J REPROD MED, V48, P637
   Bahamondes L, 2015, HUM REPROD UPDATE, V21, P640, DOI 10.1093/humupd/dmv023
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   BARBOSA I, 1995, ADV CONTRACEPT, V11, P85, DOI 10.1007/BF01987274
   BARBOSA I, 1990, CONTRACEPTION, V42, P51, DOI 10.1016/0010-7824(90)90092-A
   do Nascimento JAA, 2007, HUM REPROD, V22, P2190, DOI 10.1093/humrep/dem119
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Inki P, 2002, ULTRASOUND OBST GYN, V20, P381, DOI 10.1046/j.1469-0705.2002.00805.x
   Lewis RA, 2010, CONTRACEPTION, V82, P491, DOI 10.1016/j.contraception.2010.06.006
   LUUKKAINEN T, 1986, CONTRACEPTION, V33, P139, DOI 10.1016/0010-7824(86)90080-6
   Mandelin E, 1997, HUM REPROD, V12, P2671, DOI 10.1093/humrep/12.12.2671
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   MOGHISSI KS, 1971, FERTIL STERIL, V22, P424
   Natavio MF, 2013, CONTRACEPTION, V87, P426, DOI 10.1016/j.contraception.2012.09.034
   NILSSON CG, 1984, FERTIL STERIL, V41, P52
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   NILSSON CG, 1986, FERTIL STERIL, V45, P805
   Robinson R, 2008, J OBSTET GYNAECOL, V28, P728, DOI 10.1080/01443610802462605
   Romer T, 2009, EUR J CONTRACEP REPR, V14, P391, DOI 10.3109/13625180903203154
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organisation (WHO), 2010, WHO LAB MAN EX HUM S
   XIAO BL, 1990, CONTRACEPTION, V41, P353, DOI 10.1016/0010-7824(90)90035-T
NR 23
TC 10
Z9 10
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD AUG
PY 2016
VL 21
IS 4
BP 318
EP 322
DI 10.1080/13625187.2016.1193139
PG 5
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA DT3DP
UT WOS:000381361100009
PM 27269613
DA 2020-12-01
ER

PT J
AU Simonatto, P
   Bahamondes, MV
   Fernandes, A
   Silveira, C
   Bahamondes, L
AF Simonatto, Paula
   Bahamondes, Maria Valeria
   Fernandes, Arlete
   Silveira, Carolina
   Bahamondes, Luis
TI Comparison of two cohorts of women who expulsed either a
   copper-intrauterine device or a levonorgestrel-releasing intrauterine
   system
SO JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
LA English
DT Article
DE copper IUD; expulsion; Intrauterine device; levonorgestrel-releasing
   intrauterine system
ID T-SHAPED IUDS; NULLIPAROUS WOMEN; RISK-FACTORS; PERFORMANCE;
   CONTRACEPTION; FAILURE; TRIAL
AB AimTo assess if there is a difference in the characteristics of the women who expelled a copper-intrauterine device (TCu-IUD) or the levonorgestrel-releasing intrauterine system (LNG-IUS) and the frequency of expulsions over different periods of observation.
   MethodsWe retrospectively analyzed 19697 medical charts of women consulting between January 1980 and December 2013 who requested a TCu-IUD or a LNG-IUS.
   ResultsThe medical records of 17644 Cu-IUD and 2053 LNG-IUS users returning to the clinic for a follow-up visit after insertion of an IUC were reviewed. Of these, 1532 Cu-IUD and 254 LNG-IUS parous users were found to have expelled the IUC for a first time. The mean age at insertion ( standard deviation) was 26.3 +/- 6.6 years (range 16-49) for Cu-IUD users and 31.7 +/- 7.6 years (range 18-48) for LNG-IUS users (P < 0.001). A total of 263 (13.4%) and 12 (4.3%) of the Cu-IUD and the LNG-IUS users were 19 years old, and 49.1% and 54.1% of the expulsions among the Cu-IUD and LNG-IUS users, respectively, were reported in the first six months after placement. A regression model showed that the variables significantly associated with an expulsion of either a Cu-IUD or LNG-IUS were age < 25 years, less than two deliveries and using a Cu-IUD.
   ConclusionOur findings showed that the characteristics associated with IUC expulsion were age under 25 years, having had less than two deliveries and being users of Cu-IUD.
C1 Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynaecol, Sch Med Sci,UNICAMP, Campinas, SP, Brazil.
   Univ Estadual Campinas, Natl Inst Hormones & Womens Hlth, UNICAMP, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/12 810-4];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573 747/2008-3]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant #2012/12 810-4
   and from the National Research Council (CNPq), grant #573 747/2008-3.
CR ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0
   Aoun J, 2014, OBSTET GYNECOL, V123, P585, DOI 10.1097/AOG.0000000000000144
   Bahamondes L, 1995, HUM REPROD, V10, P2917, DOI 10.1093/oxfordjournals.humrep.a135819
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Behringer Tiffany, 2011, Contraception, V84, pe5, DOI 10.1016/j.contraception.2011.05.010
   Berenson AB, 2013, OBSTET GYNECOL, V121, P951, DOI 10.1097/AOG.0b013e31828b63a0
   Brigid Fitzgerald Reading, GROWTH WORLD CONTRAC
   Deans EI, 2009, CONTRACEPTION, V79, P418, DOI 10.1016/j.contraception.2008.12.009
   DIAZ J, 1993, CONTRACEPTION, V48, P23, DOI 10.1016/0010-7824(93)90062-C
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   Faundes D, 1998, CONTRACEPTION, V57, P413, DOI 10.1016/S0010-7824(98)00049-3
   Faundes D, 2000, CONTRACEPTION, V62, P165, DOI 10.1016/S0010-7824(00)00167-0
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Hubacher D, 2007, CONTRACEPTION, V75, pS8, DOI 10.1016/j.contraception.2006.12.005
   Kaunitz AM, 2010, OBSTET GYNECOL, V116, P625, DOI 10.1097/AOG.0b013e3181ec622b
   Madden T, 2014, OBSTET GYNECOL, V124, P718, DOI 10.1097/AOG.0000000000000475
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   Morales-Rosello J, 2005, CONTRACEPTION, V72, P430, DOI 10.1016/j.contraception.2005.06.064
   National Institute for Health and Care Excellence (NICE), LONG ACT REV CONTR U
   Okusanya BO, 2014, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD001777.PUB4
   Petta CA, 1996, J BIOSOC SCI, V28, P241, DOI 10.1017/S0021932000022276
   SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X
   Thonneau P, 2001, CONTRACEPTION, V64, P33, DOI 10.1016/S0010-7824(01)00215-3
   Thonneau P, 2006, HUM REPROD, V21, P2612, DOI 10.1093/humrep/del208
   United Nations, 2014, WORLD CONTR US 2014
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Youm J, 2014, INT J GYNECOL OBSTET, V126, P165, DOI 10.1016/j.ijgo.2014.02.017
   ZHANG J, 1993, CONTRACEPTION, V48, P13, DOI 10.1016/0010-7824(93)90061-B
NR 29
TC 3
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1341-8076
EI 1447-0756
J9 J OBSTET GYNAECOL RE
JI J. Obstet. Gynaecol. Res.
PD MAY
PY 2016
VL 42
IS 5
BP 554
EP 559
DI 10.1111/jog.12939
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DK5NL
UT WOS:000374966500010
PM 26817571
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Monteiro, I
   Castro, S
   Villarroel, M
   Silveira, C
   Bahamondes, L
AF Ferreira, Jessica Mayra
   Monteiro, Ilza
   Castro, Sara
   Villarroel, Marina
   Silveira, Carolina
   Bahamondes, Luis
TI The Use of Long Acting Reversible Contraceptives and the Relationship
   between Discontinuation Rates due to Menopause and to Female and Male
   Sterilizations
SO REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA
LA English
DT Article
DE long acting reversible contraceptives; sterilization; menopause; copper
   IUD; LNG-IUS
ID TUBAL-STERILIZATION; WOMEN; REASONS; REGRET; RISK; AGE
AB Introduction Women require effective contraception until they reach menopause. The long acting reversible contraceptives (LARC) and the depot-medroxyprogesterone acetate (DMPA, Depo-Provera (R) , Pfizer, Puurs, Belgium) are great options and can replace possible sterilizations.
   Purpose To assess the relationship between the use of LARCs and DMPA and terminations ascribed to menopause and sterilizations in a Brazilian clinic.
   Methods We reviewed the records of women between 12 and 50 years of age attending the clinic that chose to use a LARC method or DMPA. Cumulative termination rates due to sterilization or because the woman had reached menopause were computed using single decrement life-table analysis over 32 years. We also examined all records of surgical sterilization at our hospital between the years 1980-2012.
   Results Three hundred thirty-two women had continuously used the same contraceptive until menopause, and 555 women had discontinued the method because they or their partners underwent sterilization. From year 20 to year 30 of use, levonorgestrel intrauterine-releasing system (LNG-IUS -Mirena (R), Bayer Oy, Turku, Finland; available since 1980), copper intrauterine device (IUD-available since 1980) and DMPA users showed a trend of cumulative higher discontinuation rates due to menopause when compared with the discontinuation rates due to sterilization. Over the study period, a steep decline in the use of sterilization occurred.
   Conclusion Over the past 15 years of research we have observed a trend: women usually preferred to continue using LARC methods or DMPA until menopause rather than decide for sterilization, be it their own, or their partners'. The annual number of sterilizations dropped in the same period. The use of LARC methods and DMPA until menopause is an important option to avoid sterilization, which requires a surgical procedure with potential complications.
C1 [Ferreira, Jessica Mayra; Monteiro, Ilza; Silveira, Carolina; Bahamondes, Luis] Univ Estadual Campinas Unicamp, Dept Obstet & Gynecol, Fac Ciencias Med, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
   [Castro, Sara; Villarroel, Marina] Univ Estadual Campinas Unicamp, Family Planning Clin, Womens Hosp CAISM, Fac Ciencias Med, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas Unicamp, Dept Obstet & Gynecol, Fac Ciencias Med, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Ferreira, Jessica/I-3350-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Ferreira,
   Jessica/0000-0003-2153-0353
FU State of Sao Paulo's Foundation [2012/12810-4]; Brazilian National
   Council for Research and Development (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The State of Sao Paulo's Foundation for Research Support (Fapesp), under
   grant #2012/12810-4, and the Brazilian National Council for Research and
   Development (CNPq), under grant #573747/2008-3 gave financial support
   for this study. Since 2001, all of the TCu380A IUDs have been donated by
   Injeflex, Sao Paulo, Brazil, and since 2006, all of the LNG-IUS have
   been donated by the International Contraceptive Access Foundation (ICA),
   Turku, Finland. Both donations were as unrestricted grants.
CR Adams CE, 2009, UROL CLIN N AM, V36, P331, DOI 10.1016/j.ucl.2009.05.009
   Allen RH, 2013, CAN MED ASSOC J, V185, P565, DOI 10.1503/cmaj.121280
   Anguzu Ronald, 2014, BMC Res Notes, V7, P153, DOI 10.1186/1756-0500-7-153
   Astrup K, 2004, ACTA OBSTET GYN SCAN, V83, P197, DOI 10.1111/j.0001-6349.2004.00401.x
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Bahamondes L, 2014, INT J WOMENS HEALTH, V6, P221, DOI 10.2147/IJWH.S46811
   BC Cancer Agency. BC Cancer Foundation, 2010, OV CANC RES REQ PRAC
   Black A, 2009, J OBSTET GYNAECOL CA, V31, P627, DOI 10.1016/S1701-2163(16)34242-6
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Chen ZE, 2008, CONTRACEPTION, V78, P309, DOI 10.1016/j.contraception.2008.05.010
   Creinin MD, 2014, OBSTET GYNECOL, V124, P596, DOI 10.1097/AOG.0000000000000422
   Curtis KM, 2006, CONTRACEPTION, V73, P205, DOI 10.1016/j.contraception.2005.08.006
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Hardy E, 1996, CONTRACEPTION, V54, P159, DOI 10.1016/S0010-7824(96)00171-0
   Huijgens ANJ, 2014, EUR J OBSTET GYN R B, V175, P82, DOI 10.1016/j.ejogrb.2014.01.026
   Inki P, 2007, CONTRACEPTION, V75, pS161, DOI 10.1016/j.contraception.2006.12.016
   Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79
   Lader D, 2009, 41 OFF NAT STAT
   Le HH, 2014, INT J WOMENS HEALTH, V6, P663, DOI 10.2147/IJWH.S61543
   Malacova E, 2014, FERTIL STERIL, V101, P728, DOI 10.1016/j.fertnstert.2013.11.127
   Mattinson A, 2003, J FAM PLAN REPROD H, V29, P136, DOI 10.1783/147118903101197809
   Mosher William D, 2010, Vital Health Stat 23, P1
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Reade CJ, 2014, J OBSTET GYNAECOL CA, V36, P133, DOI 10.1016/S1701-2163(15)30659-9
   White K, 2014, CONTRACEPTION, V89, P550, DOI 10.1016/j.contraception.2013.11.019
   White K, 2013, WOMEN HEALTH ISS, V23, pE257, DOI 10.1016/j.whi.2013.05.001
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 27
TC 3
Z9 3
U1 0
U2 1
PU FEDERACAO BRASILEIRA SOC GINECOLOGIA & OBSTETRICIA-FEBRASGO
PI RIO DE JANEIRO RJ
PA AV DAS AMERICAS, 8445, SALA 711-BARRA DA TIJUCA, RIO DE JANEIRO RJ,
   22793-081, BRAZIL
SN 0100-7203
EI 1806-9339
J9 REV BRAS GINECOL OBS
JI Rev. Bras. Ginecol. Obstet.
PD MAY
PY 2016
VL 38
IS 5
BP 210
EP 217
DI 10.1055/s-0036-1583758
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA FG4PJ
UT WOS:000410246000002
PM 27187927
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Dal Ava, N
   Stein, C
   Bahamondes, L
   Monteiro, I
AF Dal Ava, N.
   Stein, C.
   Bahamondes, L.
   Monteiro, I.
TI BODY COMPOSITION USING DUAL-ENERGY X-RAY ABSORPTIOMETRY IN WOMEN OF
   REPRODUCTIVE AGE
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Meeting Abstract
CT WCO-IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and
   Musculoskeletal Diseases
CY APR 14-17, 2016
CL Malaga, SPAIN
SP WCO, IOF, ESCEO
C1 [Dal Ava, N.; Stein, C.; Bahamondes, L.; Monteiro, I.] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, SP, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
EI 1433-2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD APR
PY 2016
VL 27
SU 1
MA P998
BP S534
EP S535
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA DM6NH
UT WOS:000376469103110
DA 2020-12-01
ER

PT J
AU Festin, MPR
   Bahamondes, L
   Nguyen, TMH
   Habib, N
   Thamkhantho, M
   Singh, K
   Gosavi, A
   Bartfai, G
   Bito, T
   Bahamondes, MV
   Kapp, N
AF Festin, Mario P. R.
   Bahamondes, Luis
   Thi My Huong Nguyen
   Habib, Ndema
   Thamkhantho, Manopchai
   Singh, Kuldip
   Gosavi, Arundhati
   Bartfai, Gyorgy
   Bito, Tamas
   Valeria Bahamondes, M.
   Kapp, Nathalie
TI A prospective, open-label, single arm, multicentre study to evaluate
   efficacy, safety and acceptability of pericoital oral contraception
   using levonorgestrel 1.5 mg
SO HUMAN REPRODUCTION
LA English
DT Article
DE oral levonorgestrel; contraception; pericoital; effectiveness; anaemia
ID EMERGENCY CONTRACEPTION; MIFEPRISTONE; MECHANISM
AB Will the use of levonorgestrel (LNG) 1.5 mg taken at each day of coitus by women who have relatively infrequent sex be an efficacious, safe and acceptable contraceptive method?
   Typical use of LNG 1.5 mg taken pericoitally, before or within 24 h of sexual intercourse, provides contraceptive efficacy of up to 11.0 pregnancies per 100 women-years (W-Y) in the primary evaluable population and 7.1 pregnancies per 100 W-Y in the evaluable population.
   LNG 1.5 mg is an effective emergency contraception following unprotected intercourse. Some users take it repeatedly, as their means of regular contraception.
   This was a prospective, open-label, single-arm, multicentre Phase III trial study with women who have infrequent coitus (on up to 6 days a month). Each woman had a follow-up visit at 2.5, 4.5 and 6.5 months after admission or until pregnancy occurs if sooner, or she decided to interrupt participation. The study was conducted between 10 January 2012 and 15 November 2014.
   A total of 330 healthy fertile women aged 18-45 years at risk of pregnancy who reported sexual intercourse on up to 6 days a month, were recruited from four university centres located in Bangkok, Thailand; Campinas, Brazil; Singapore and Szeged, Hungary to use LNG 1.5 mg pericoitally (24 h before or after coitus) as their primary method of contraception. The participants were instructed to take one tablet every day she had sex, without taking more than one tablet in any 24-h period, and to maintain a paper diary for recording date and time for every coital act and ingestion of the study tablet, use of other contraceptive methods and vaginal bleeding patterns. Anaemia was assessed by haemoglobin evaluation. Pregnancy tests were performed monthly and pregnancies occurring during product use were assessed by ultrasound. At the 2.5-month and final visit at 6.5 months, acceptability questions were administered.
   There were 321 women included in the evaluable population (which includes all eligible women enrolled), with 141.9 woman-years (W-Y) of observation and with a rate (95% confidence interval [CI]) of 7.1 (3.8; 13.1) pregnancies per 100 W-Y of typical use (which reflects use of the study drug as main contraceptive method, but also includes possible use of other contraceptives from admission to end of study) and 7.5 (4.0; 13.9) pregnancies per 100 W-Y of sole use. In the primary evaluable population (which includes only eligible enrolled women < 35 years old), the rate was 10.3 (5.4; 19.9) pregnancies per 100 W-Y of typical use, and 11.0 (5.7; 13.1) pregnancies per 100 W-Y of sole use. There were three reported severe adverse events and 102 other mild adverse events (most common were headache, nausea, abdominal and pelvic pain), with high recovery rate. The vaginal bleeding patterns showed a slight decrease in volume of bleeding and the number of bleeding-free days increased over time. There was only one case of severe anaemia, found at the final visit (0.4%). The method was considered acceptable, as over 90% of participants would choose to use it in the future or would recommend it to others.
   This was a single-arm study with small sample size, without a control group, designed as a proof of concept study to explore the feasibility of this type of contraception.
   A larger clinical study evaluating pericoital contraception with LNG is feasible and our data show that this method would be acceptable to many women.
   This study received partial financial support from the UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), Department of Reproductive Health and Research (RHR) and the World Health Organization. Gynuity and the Bill and Melinda Gates Foundation (BMGF) provided financial support for project monitoring. HRA Pharma donated the LNG product. N.K. was the initial project manager when she was with WHO/HRP and was employed by HRA Pharma, which distributes LNG for emergency contraception. The other authors declare no conflicts of interest.
   This study was registered on ANZCTR, Trial ID ACTRN12611001037998.
   4 October 2011.
   10 January 2012.
C1 [Festin, Mario P. R.; Thi My Huong Nguyen; Habib, Ndema] WHO, Dept Reprod Hlth & Res, CH-1221 Geneva, Switzerland.
   [Bahamondes, Luis; Valeria Bahamondes, M.] Univ Estadual Campinas, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Thamkhantho, Manopchai] Mahidol Univ, Siriraj Hosp, Dept Obstet & Gynaecol, Bangkok 10700, Thailand.
   [Singh, Kuldip; Gosavi, Arundhati] Natl Univ Singapore Hosp, Dept Obstet & Gynaecol, Lower Kent Ridge Rd, Singapore 117548, Singapore.
   [Bartfai, Gyorgy; Bito, Tamas] Univ Szeged, Albert Szent Gyorgyi Med Ctr, Dept Obstet & Gynaecol, Szeged, Hungary.
RP Festin, MPR (corresponding author), WHO, HRP, CH-1221 Geneva, Switzerland.
EM festinma@who.int
FU UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme on Research,
   Development and Research Training in Human Reproduction (HRP); Gynuity;
   HRP
FX This study received partial financial support from the
   UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme on Research,
   Development and Research Training in Human Reproduction (HRP) and from
   Gynuity and the Bill and Melinda Gates Foundation (BMGF) for support for
   the monitoring of the project. Funding to pay the Open Access
   publication charges for this article was provided by HRP.
CR Arowojolu A O, 2000, Afr J Reprod Health, V4, P56, DOI 10.2307/3583243
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   BHATTACHARJEE S K, 1987, Contraception, V36, P275
   Committee on Health Care for Underserved Women, 2012, Obstet Gynecol, V120, P1250, DOI http://10.1097/AOG.0b013e318277c960
   Croxatto HB, 2004, CONTRACEPTION, V70, P442, DOI 10.1016/j.contraception.2004.05.007
   Croxatto HB, 2001, CONTRACEPTION, V63, P111, DOI 10.1016/S0010-7824(01)00184-6
   Dada OA, 2010, CONTRACEPTION, V82, P373, DOI 10.1016/j.contraception.2010.06.004
   DARCANGUES C, 1989, CONTRACEPTION, V40, P531
   Gemzell-Danielsson K, 2004, HUM REPROD UPDATE, V10, P341, DOI 10.1093/humupd/dmh027
   Gemzell-Danielsson K, 2010, CONTRACEPTION, V82, P404, DOI 10.1016/j.contraception.2010.05.004
   Gilliam ML, 2009, J PEDIATR ADOL GYNEC, V22, P97, DOI 10.1016/j.jpag.2008.05.008
   Halpern V, 2014, COCHRANE DB SYST REV, V9
   HE CH, 1991, INT J GYNECOL OBSTET, V36, P43
   Lerkiatbundit S, 2000, J CLIN PHARM THER, V25, P185
   Marions L, 2004, CONTRACEPTION, V69, P373, DOI 10.1016/j.contraception.2003.11.018
   Marions L, 2002, OBSTET GYNECOL, V100, P65, DOI 10.1016/S0029-7844(02)02006-9
   Okewole IA, 2007, CONTRACEPTION, V75, P372, DOI 10.1016/j.contraception.2007.01.019
   Piaggio G, 2011, CONTRACEPTION, V84, P35, DOI 10.1016/j.contraception.2010.11.010
   Reece M, 2010, J SEX MED, V7, P291, DOI 10.1111/j.1743-6109.2010.02009.x
   Taylor DJ, 2014, CONTRACEPTION, V89, P215, DOI 10.1016/j.contraception.2013.11.013
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Trussell J, 2009, BEST PRACT RES CL OB, V23, P199, DOI 10.1016/j.bpobgyn.2008.11.008
   von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3
   von Hertzen H, 2000, CONTRACEPTION, V61, P303, DOI 10.1016/S0010-7824(00)00116-5
NR 24
TC 6
Z9 6
U1 0
U2 14
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD MAR
PY 2016
VL 31
IS 3
BP 530
EP 540
DI 10.1093/humrep/dev341
PG 11
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DG9QN
UT WOS:000372419000006
PM 26830816
OA Green Published, Green Accepted, Other Gold
DA 2020-12-01
ER

PT J
AU Marin-Cantu, V
   Lira-Plascencia, J
   Bahamondes, L
   Arreaga-Quan, I
AF Marin-Cantu, Victor
   Lira-Plascencia, Josefina
   Bahamondes, Luis
   Arreaga-Quan, Ingrid
TI Attitudes and knowledge of HCPs from 4 Latin American countries
   regarding intrauterine contraception for parous and nulligravidas women
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Meeting Abstract
C1 [Marin-Cantu, Victor] Hosp Cent Sur Alta Especialidad, Pemex, Mexico.
   [Lira-Plascencia, Josefina] Hosp Angeles Pedregal, Mexico City, DF, Mexico.
   [Bahamondes, Luis] Univ Estadual Campinas, CEMICAMP, Campinas, SP, Brazil.
   [Arreaga-Quan, Ingrid] Instuto Guatemalteco Seguridad Social, Campinas, SP, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0951-3590
EI 1473-0766
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD FEB 26
PY 2016
VL 32
SU 1
BP 68
EP 68
PG 1
WC Endocrinology & Metabolism; Obstetrics & Gynecology
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA DG6FZ
UT WOS:000372180000144
DA 2020-12-01
ER

PT J
AU Cursino, K
   Sider, M
   Pavin, EJ
   dos Santos, PDS
   Bahamondes, L
   Zantut-Wittmann, DE
   Fernandes, A
AF Cursino, Kleber
   Sider, Marina
   Pavin, Elizabeth Joao
   Silva dos Santos, Priscilla de Nazare
   Bahamondes, Luis
   Zantut-Wittmann, Denise Engelbrecht
   Fernandes, Arlete
TI Insulin resistance parameters in users of the injectable contraceptive
   depot medroxyprogesterone acetate during one year of use
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Contraception; Depot medroxyprogesterone acetate; HOMA index; Insulin
   resistance
ID HOMEOSTASIS MODEL ASSESSMENT; GLUCOSE CLAMP TECHNIQUE; CARBOHYDRATE;
   TOLERANCE; PROVERA; WEIGHT
AB Objectives The aim of the study was to assess insulin resistance parameters using successive homeostasis model assessment (HOMA) and clinical evaluations in healthy new users of depot medroxyprogesterone acetate (DMPA).
   Methods A prospective 12-month study was carried out to compare 31 DMPA users with 25 copper intrauterine device (Cu-IUD; TCu380A) users, matched for age (+/- 1 year) and body mass index (BMI; 1 kg/m(2)). Participants met the following criteria: age 18 to 40 years, BMI < 30 kg/m(2), fasting glucose < 5.5 mmol/l, 2-h glucose after a 75 g oral glucose load < 140 mg/dl. BMI, waist circumference, fasting glucose, fasting insulin and HOMA of insulin resistance (HOMA-IR) were evaluated at baseline and after 6 and 12 months of contraceptive use. Insulin resistance was defined as a HOMA-IR value > 2.7.
   Results The DMPA group showed significant increases in BMI, waist circumference, fasting insulin and HOMA-IR throughout the observation period in relation to baseline. Significant increases in BMI and waist circumference were observed in the DMPA group at 12 months compared with the Cu-IUD group. Five DMPA users had abnormal HOMA-IR values, three of whom had gained > 5 kg in weight at 12 months.
   Conclusions HOMA-IR represents a useful tool to indicate changes in carbohydrate metabolism in non-obese DMPA users, especially when accompanied by measurement of clinical parameters such as BMI and waist circumference.
C1 [Cursino, Kleber; Sider, Marina; Silva dos Santos, Priscilla de Nazare; Bahamondes, Luis; Fernandes, Arlete] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Pavin, Elizabeth Joao; Zantut-Wittmann, Denise Engelbrecht] Univ Estadual Campinas, UNICAMP, Fac Med Sci, Div Endocrinol,Dept Clin Med, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Caixa Postal 6181, BR-13083971 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Fernandes, Arlete/I-7561-2018; Zantut-Wittmann, Denise
   Engelbrecht/ABE-5858-2020
OI Fernandes, Arlete/0000-0001-5872-0017; Zantut-Wittmann, Denise
   Engelbrecht/0000-0002-7434-5701
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP), Secretaria de Estado da Saude
   de Sao Paulo (SES-SP), Brazil [2009/53293-0, PPSUS/2009]
FX This study was funded by the Brazilian National Research Council (CNPq)
   and by the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP), Secretaria de Estado da Saude de Sao Paulo (SES-SP) grant
   PPSUS/2009, #2009/53293-0, Brazil.
CR ABEP, 2009, BRAZ EC CLASS CRIT 2
   AMATAYAKUL K, 1980, CONTRACEPTION, V21, P283, DOI 10.1016/0010-7824(80)90007-4
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57
   Chang AM, 2006, J CLIN ENDOCR METAB, V91, P629, DOI 10.1210/jc.2005-1803
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   FAHMY K, 1991, CONTRACEPTION, V44, P419, DOI 10.1016/0010-7824(91)90032-B
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Fraser I S, 1981, Med J Aust, V1, P3
   Geloneze B, 2009, ARQ BRAS ENDOCRINOL, V53, P281, DOI 10.1590/S0004-27302009000200020
   GERSHBERG H, 1969, OBSTET GYNECOL, V33, P383
   Hanley AJG, 2002, DIABETES CARE, V25, P1177, DOI 10.2337/diacare.25.7.1177
   Katsuki A, 2001, DIABETES CARE, V24, P362, DOI 10.2337/diacare.24.2.362
   LIEW DFM, 1985, CONTRACEPTION, V31, P51, DOI 10.1016/0010-7824(85)90074-5
   Lopez LM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006133.pub5
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   NASH HA, 1975, CONTRACEPTION, V12, P377, DOI 10.1016/0010-7824(75)90074-8
   Tam CS, 2012, DIABETES CARE, V35, P1605, DOI 10.2337/dc11-2339
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organisation, 2011, GLOB REC PHYS ACT HL
NR 22
TC 4
Z9 4
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD JAN 2
PY 2016
VL 21
IS 1
BP 22
EP 29
DI 10.3109/13625187.2015.1059415
PG 8
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA DA2CC
UT WOS:000367601900004
PM 26140543
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Marin, V
   Ciarmatori, S
   Silva, AL
   Acuna, JM
   Makuch, MY
AF Bahamondes, Luis
   Marin, Victor
   Ciarmatori, Silvia
   Silva-Filho, Agnaldo L.
   Acuna, Juan Manuel
   Makuch, Maria Y.
TI Knowledge of Latin American Obstetricians and Gynecologists regarding
   Heavy Menstrual Bleeding
SO OBSTETRICS AND GYNECOLOGY INTERNATIONAL
LA English
DT Article
ID INTRAUTERINE SYSTEM; ESTRADIOL VALERATE; DOUBLE-BLIND; MENORRHAGIA;
   ATTITUDES; TRIAL; CARE
AB Background. Heavy menstrual bleeding (HMB) is a common gynecological complaint affecting quality of life. Objectives. To assess knowledge on diagnosis and treatments of HMB of Latin American (LA) obstetricians and gynecologists (OBGYNs). Methods. A survey was conducted during a scientific meeting, organized to provide updated information on topics of reproductive medicine to OBGYNs from 12 LA countries who were invited to respond to a multiple-choice questionnaire. Results. Of the 210 OBGYNs participating in the survey, from 169 (80.4%) to 203 (96.7%) answered the questions. Most respondents (80%) gave accurate answers regarding the amount of blood loss which defines HMB, underreported the proportion of women who consulted due to HMB, and were aware that the use of combined oral contraceptives (COCs) with ethynyl estradiol is not an adequate treatment in women with HMB. Female OBGYNs and those who worked in the private sector were more prone to report a higher possibility of improvement of HMB with a COC that contained estradiol valerate and dienogest or with a levonorgestrel-releasing intrauterine system. Conclusions. In general, the respondents were aware of the importance of HMB in gynecological practice and of the new medical treatments and underreported the proportion of women who consulted due to HMB.
C1 [Bahamondes, Luis; Makuch, Maria Y.] Univ Estadual Campinas, Dept Obstet & Gynecol, Med Sch UNICAMP, Campinas, SP, Brazil.
   [Marin, Victor] Bayer HealthCare, Mexico City, DF, Mexico.
   [Ciarmatori, Silvia] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [Silva-Filho, Agnaldo L.] Univ Fed Minas Gerais, Belo Horizonte, MG, Brazil.
   [Acuna, Juan Manuel] Florida Int Univ, Coll Med, Miami, FL 33199 USA.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynecol, Med Sch UNICAMP, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
OI Acuna, Juan/0000-0002-0212-5558
CR Ahrendt HJ, 2009, CONTRACEPTION, V80, P436, DOI 10.1016/j.contraception.2009.03.018
   ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x
   [Anonymous], 2007, HEAVY MENSTRUAL BLEE
   Bahamondes L, 2015, INT J WOMENS HEALTH, V7, P717, DOI 10.2147/IJWH.S84173
   Bahamondes L, 2015, INT J WOMENS HEALTH, V7, P485, DOI 10.2147/IJWH.S78874
   Bahamondes Luis, 2015, F1000Prime Rep, V7, P33, DOI 10.12703/P7-33
   Bradley LD, 2016, AM J OBSTET GYNECOL, V214, P31, DOI 10.1016/j.ajog.2015.07.044
   Cohen B J, 1980, Obstet Gynecol Surv, V35, P597
   COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x
   FAIRHURST E, 1977, P NUTR SOC, V36, pA98
   Farquhar C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000154.pub2
   Fraser IS, 2011, HUM REPROD, V26, P2698, DOI 10.1093/humrep/der224
   Fraser IS, 2011, EUR J CONTRACEP REPR, V16, P258, DOI 10.3109/13625187.2011.591456
   FRASER IS, 1991, AUST NZ J OBSTET GYN, V31, P66, DOI 10.1111/j.1479-828X.1991.tb02769.x
   Gupta JK, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19880
   HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455
   Heliovaara-Peippo S, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.08.041
   Herman MC, 2016, WOMENS HEALTH, V12, P15, DOI 10.2217/whe.15.90
   Hoaglin DC, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-17
   Karlsson TS, 2014, ACTA OBSTET GYN SCAN, V93, P52, DOI 10.1111/aogs.12292
   Kaunitz AM, 2012, CONTRACEPTION, V86, P452, DOI 10.1016/j.contraception.2012.07.018
   Kaunitz AM, 2010, OBSTET GYNECOL, V116, P625, DOI 10.1097/AOG.0b013e3181ec622b
   Knol HM, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.05.059
   Lukes AS, 2010, OBSTET GYNECOL, V116, P865, DOI 10.1097/AOG.0b013e3181f20177
   Marjoribanks J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003855.pub3
   Matteson KA, 2013, OBSTET GYNECOL, V121, P632, DOI 10.1097/AOG.0b013e3182839e0e
   Montalti CS, 2015, INT J CLIN PRACT, V69, P1526, DOI 10.1111/ijcp.12711
   Munro MG, 2011, INT J GYNECOL OBSTET, V113, P3, DOI 10.1016/j.ijgo.2010.11.011
   Nicholson WK, 2001, AM J OBSTET GYNECOL, V184, P523, DOI 10.1067/mob.2001.111795
   Ragni MV, 2016, HAEMOPHILIA, V22, P397, DOI 10.1111/hae.12898
   RYBO G, 1966, ACTA OBSTET GYN SCAN, VS 45, P3
NR 31
TC 1
Z9 1
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-9589
EI 1687-9597
J9 OBSTET GYNECOL INT
JI Obstet. Gynecol. Int.
PY 2016
VL 2016
AR 6870679
DI 10.1155/2016/6870679
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA DV1PE
UT WOS:000382692400001
PM 27648073
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Gomez-Elias, MD
   Munuce, MJ
   Bahamondes, L
   Cuasnicu, PS
   Cohen, DJ
AF Gomez-Elias, Matias D.
   Munuce, Maria J.
   Bahamondes, Luis
   Cuasnicu, Patricia S.
   Cohen, Debora J.
TI In vitro and in vivo effects of ulipristal acetate on fertilization and
   early embryo development in mice
SO HUMAN REPRODUCTION
LA English
DT Article
DE emergency contraception; ulipristal acetate; sperm; fertilization;
   embryo development
ID PROGESTERONE-RECEPTOR MODULATORS; HUMAN-SPERM; EMERGENCY CONTRACEPTION;
   ACROSOME REACTION; HUMAN SPERMATOZOA; MOUSE EMBRYOS; CA2+ CHANNEL;
   LEVONORGESTREL; MIFEPRISTONE; OVULATION
AB STUDY QUESTION: Does ulipristal acetate (UPA), a selective progesterone receptor modulator used for emergency contraception (EC), interfere with fertilization or early embryo development in vitro and in vivo?
   SUMMARY ANSWER: At doses similar to those used for EC, UPA does not affect mouse gamete transport, fertilization or embryo development.
   WHAT IS KNOWN ALREADY: UPA acts as an emergency contraceptive mainly by inhibiting or delaying ovulation. However, there is little information regarding its effects on post-ovulatory events preceding implantation.
   STUDY DESIGN, SIZE, DURATION: This was an in vitro and in vivo experimental study involving the use of mouse gametes and embryos from at least three animals in each set of experiments.
   PARTICIPANTS/MATERIALS, SETTING, METHODS: For in vitro fertilization experiments, mouse epididymal spermatozoa capacitated in the presence of different concentrations of UPA (0-1000 ng/ml) were used to inseminate cumulus-intact or cumulus-free eggs in the presence or absence of UPA during gamete co-incubation, and the percentage of fertilized eggs was determined. For in vivo fertilization experiments, superovulated females caged with proven fertile males were injected with UPA (40 mg/kg) or vehicle just before or just after mating and the percentage of fertilized eggs recovered from the ampulla was determined. To investigate the effect of UPA on embryo development, zygotes were recovered from mated females, cultured in the presence of UPA (1000 ng/ml) for 4 days and the progression of embryo development was monitored daily.
   MAIN RESULTS AND THE ROLE OF CHANCE: In vitro studies revealed that the presence of UPA during capacitation and/or gamete co-incubation does not affect fertilization. Whereas the in vivo administration of UPA at the same time as hCG injection produced a decrease in the number of eggs ovulated compared with controls (vehicle injected animals, P < 0.05), no effects on fertilization were observed when UPA was administered shortly before or after mating. No differences were observed in either the percentage of cleaved embryos or the cleavage speed when UPA was present during in vitro embryo culture.
   LIMITATIONS, REASONS FOR CAUTION: Considering the ethical and technical limitations inherent to the use of human gametes for fertilization studies, the mouse model was used as an approach for exploring the potential effects of UPA on in vivo sperm transport and fertilization. Nevertheless, the extrapolation of these results to humans requires further investigation.
   WIDER IMPLICATIONS OF THE FINDINGS: This study presents new evidence on the lack of effect of UPA on gamete interaction and embryo development, providing new insights into the mechanism of action of UPA as an emergency contraceptive method with potential clinical implications. These new findings could contribute to increase the acceptability and proper use of UPA as an emergency contraceptive method.
C1 [Gomez-Elias, Matias D.; Cuasnicu, Patricia S.; Cohen, Debora J.] Inst Biol & Med Expt IBYME CONICET, Vuelta de Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
   [Munuce, Maria J.] Natl Univ Rosario, Sch Biochem & Pharmaceut Sci, Lab Reprod Studies, Rosario, Santa Fe, Argentina.
   [Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Sch Med, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
RP Cohen, DJ (corresponding author), Inst Biol & Med Expt IBYME CONICET, Vuelta de Obligado 2490,C1428ADN, Buenos Aires, DF, Argentina.
EM dcohen@ibyme.conicet.gov.ar
FU National Agency of Scientific and Technological Promotion (ANPCyT),
   ArgentinaANPCyT [PICT 2011-061, PICT 2011-2023]
FX This study was partially supported by the National Agency of Scientific
   and Technological Promotion (ANPCyT), Argentina, grants PICT 2011-061 to
   D.J.C. and PICT 2011-2023 to P.S.C.
CR Attardi BJ, 2004, J STEROID BIOCHEM, V88, P277, DOI 10.1016/j.jsbmb.2003.12.004
   Baldi E, 2009, MOL CELL ENDOCRINOL, V308, P39, DOI 10.1016/j.mce.2009.02.006
   Benagiano G, 2014, EXPERT OPIN PHARMACO, V15, P1403, DOI 10.1517/14656566.2014.914494
   Berger C, 2015, HUM REPROD, V30, P800, DOI 10.1093/humrep/dev030
   BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376
   BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   Brache V, 2013, CONTRACEPTION, V88, P611, DOI 10.1016/j.contraception.2013.05.010
   Busso D, 2007, BIOL REPROD, V76, P701, DOI 10.1095/biolreprod.106.056770
   Caligioni C.S., 2009, CURR PROTOC NEUROSCI
   Chabbert-Buffet N, 2005, HUM REPROD UPDATE, V11, P293, DOI 10.1093/humupd/dmi002
   Cheng L, 2012, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001324.PUB4.
   Chung JJ, 2014, CELL, V157, P808, DOI 10.1016/j.cell.2014.02.056
   Contreras HR, 2001, INT J ANDROL, V24, P246, DOI 10.1046/j.1365-2605.2001.00294.x
   Croxatto Horacio B, 2002, Reprod Biomed Online, V4, P160
   Curia CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071995
   Da Ros VG, 2008, DEV BIOL, V320, P12, DOI 10.1016/j.ydbio.2008.03.015
   ERBACH GT, 1994, BIOL REPROD, V50, P1027, DOI 10.1095/biolreprod50.5.1027
   FRASER LR, 1975, BIOL REPROD, V13, P513, DOI 10.1095/biolreprod13.5.513
   Gemzell-Danielsson K, 2013, CONTRACEPTION, V88, P585, DOI 10.1016/j.contraception.2013.08.007
   Gemzell-Danielsson K, 2010, INT J WOMENS HEALTH, V2, P53
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Holt WV, 2010, MOL REPROD DEV, V77, P934, DOI 10.1002/mrd.21234
   Munuce MJ, 2013, EUR J CONTRACEP REPR, V18, P355, DOI 10.3109/13625187.2013.813930
   Ko JKY, 2014, ANDROLOGY-US, V2, P868, DOI 10.1111/j.2047-2927.2014.00261.x
   Li HWR, 2014, HUM REPROD, V29, P2156, DOI 10.1093/humrep/deu210
   LIBERSKY EA, 1995, BIOL REPROD, V53, P483, DOI 10.1095/biolreprod53.3.483
   Lishko PV, 2011, NATURE, V471, P387, DOI 10.1038/nature09767
   Mulac-Jericevic B, 2004, REPRODUCTION, V128, P139, DOI 10.1530/rep.1.00189
   Munuce MJ, 2012, EUR J CONTRACEP REPR, V17, P428, DOI 10.3109/13625187.2012.725877
   Munuce MJ, 2005, CONTRACEPTION, V72, P71, DOI 10.1016/j.contraception.2004.12.003
   Nallasamy S, 2013, REPROD SCI, V20, P371, DOI 10.1177/1933719112459239
   Nishimura H, 2004, J BIOL CHEM, V279, P34957, DOI 10.1074/jbc.M314249200
   Niswender GD, 2000, PHYSIOL REV, V80, P1, DOI 10.1152/physrev.2000.80.1.1
   Palanisamy GS, 2006, MOL ENDOCRINOL, V20, P2784, DOI 10.1210/me.2006-0093
   Reel JR, 1998, CONTRACEPTION, V58, P129, DOI 10.1016/S0010-7824(98)00067-5
   Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027
   ROBLERO LS, 1987, CONTRACEPTION, V36, P549, DOI 10.1016/0010-7824(87)90007-2
   Sagare-Patil V, 2012, INT J ANDROL, V35, P633, DOI 10.1111/j.1365-2605.2012.01291.x
   Smith JF, 2013, P NATL ACAD SCI USA, V110, P6823, DOI 10.1073/pnas.1216588110
   Snow SE, 2011, ANN PHARMACOTHER, V45, P780, DOI 10.1345/aph.1P704
   Strunker T, 2011, NATURE, V471, P382, DOI 10.1038/nature09769
   Suarez SS, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P113
   Teves ME, 2006, FERTIL STERIL, V86, P745, DOI 10.1016/j.fertnstert.2006.02.080
   UHLER ML, 1992, FERTIL STERIL, V58, P1191
   Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819
   Wu JT, 2005, REPROD FERT DEVELOP, V17, P733, DOI 10.1071/RD05074
   Wu JT, 2006, ANIM REPROD SCI, V93, P34, DOI 10.1016/j.anireprosci.2005.06.007
   Yanagimachi R., 1994, P189
   YANG YQ, 1990, CONTRACEPTION, V41, P551, DOI 10.1016/0010-7824(90)90063-2
NR 51
TC 9
Z9 9
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD JAN
PY 2016
VL 31
IS 1
BP 53
EP 59
DI 10.1093/humrep/dev287
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA DF2CY
UT WOS:000371148900008
PM 26582845
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Modesto, W
   DalAva, N
   Monteiro, I
   Bahamondes, L
AF Modesto, Waleska
   DalAva, Natalia
   Monteiro, Ilza
   Bahamondes, Luis
TI Body composition and bone mineral density in users of the
   etonogestrel-releasing contraceptive implant
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Etonogestrel-releasing implant; Bone mineral density; Body composition
ID RATES
AB There is scarce information about bone mineral density (BMD) and body composition (BC) among users of the etonogestrel (ENG)-releasing implant.
   To evaluate BC and BMD in ENG-releasing implant users as compared to copper intrauterine device (Cu-IUD)-users.
   A prospective study was conducted on 75 users of both contraceptive methods. BMD was evaluated at femoral neck (FN) and lumbar spine (LS) (L1-L4) and BC at baseline and at 12 months after insertion.
   The mean (+/- SD) age was 30.4 +/- A 6.8 and 29.8 +/- A 8.4 years and body mass index (kg/m(2)) was 24.9 +/- A 4.1 and 24.6 +/- A 3.5 in ENG-releasing implant- and Cu-IUD-users, respectively. ENG-releasing implant users did not show significant differences on BMD at the LS and FN at 12 months of use. Furthermore, ENG-implant users had an increase in body weight at 12 months (p < 0.001) and an increase of 2 % in the percentage of body fat, when compared with Cu-IUD users. There was a significant increase in lean mass in ENG-implant users at 12 months (p = 0.020).
   No significant changes of BMD were seen after the first year of use among the ENG-releasing implant-users, albeit an increase of weight and fat mass was seen when compared to Cu-IUD users.
C1 [Modesto, Waleska; DalAva, Natalia; Monteiro, Ilza; Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Human Reprod Unit, Dept Obstet & Gynaecol,Sch Med Sci, BR-13084971 Campinas, SP, Brazil.
   [Modesto, Waleska; DalAva, Natalia; Monteiro, Ilza; Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Modesto, W (corresponding author), Univ Estadual Campinas, UNICAMP, Human Reprod Unit, Dept Obstet & Gynaecol,Sch Med Sci, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM waleskamodesto@yahoo.com.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/01554-4];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/12432-0]
FX W.M. received grants from the Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Grants# 2011/01554-4 and this study received
   financial support from the FAPESP Grants# 2012/12432-0.
CR Agrawal A, 2005, J FAM PLAN REPROD H, V31, P310, DOI 10.1783/147118905774480581
   Bahamondes L, 2006, HUM REPROD, V21, P466, DOI 10.1093/humrep/dei358
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Beerthuizen R, 2000, HUM REPROD, V15, P118, DOI 10.1093/humrep/15.1.118
   Cundy T, 1998, OBSTET GYNECOL, V92, P569, DOI 10.1016/S0029-7844(98)00270-1
   De Laet C, 2005, OSTEOPOROSIS INT, V16, P1330, DOI 10.1007/s00198-005-1863-y
   Freeman S, 2010, J AM ACAD NURSE PRAC, V22, P81, DOI 10.1111/j.1745-7599.2009.00473.x
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   Hohmann H, 2007, CLIN OBSTET GYNECOL, V50, P907, DOI 10.1097/GRF.0b013e318159c2f6
   Lakha F, 2006, CONTRACEPTION, V74, P287, DOI 10.1016/j.contraception.2006.05.072
   Mansour D, 2011, CONTRACEPTION, V83, P202, DOI 10.1016/j.contraception.2010.08.001
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   Monteiro-Dantas Cecilia, 2007, Reprod Health, V4, P11, DOI 10.1186/1742-4755-4-11
   Nault AM, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.876
   Peterson HB, 2005, NEW ENGL J MED, V353, P2169, DOI 10.1056/NEJMcp044148
   Pongsatha S, 2010, INT J GYNECOL OBSTET, V109, P223, DOI 10.1016/j.ijgo.2010.01.018
   Scholes D, 2004, CONTRACEPTION, V69, P99, DOI 10.1016/j.contraception.2003.10.005
   Smith A, 2002, J FAM PLAN REPROD H, V28, P193, DOI 10.1783/147118902101196540
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   WHO, 2005, Wkly Epidemiol Rec, V80, P302
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wong RC, 2009, CONTRACEPTION, V80, P452, DOI 10.1016/j.contraception.2009.03.021
NR 22
TC 18
Z9 19
U1 0
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
EI 1432-0711
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD DEC
PY 2015
VL 292
IS 6
BP 1387
EP 1391
DI 10.1007/s00404-015-3784-0
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA CT7SZ
UT WOS:000363016100033
PM 26088190
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Brache, V
   Meirik, O
   Ali, M
   Habib, N
   Landoulsi, S
AF Bahamondes, Luis
   Brache, Vivian
   Meirik, Olav
   Ali, Moazzam
   Habib, Ndema
   Landoulsi, Sihem
CA WHO Study Grp Contraceptive Implan
TI A 3-year multicentre randomized controlled trial of etonogestrel- and
   levonorgestrel-releasing contraceptive implants, with non-randomized
   matched copper-intrauterine device controls
SO HUMAN REPRODUCTION
LA English
DT Article
DE contraception; implants; implanon; Jadelle; etonogestrel;
   levonorgestrel; TCu380A IUD; randomized clinical trial
ID BLEEDING PATTERN; EFFICACY; WOMEN
AB STUDY QUESTION: Is there any difference in the clinical performance of the 3-year one-rod etonogestrel (ENG)-and the 5-year two-rod levonorgestrel (LNG)-releasing contraceptive implants during 3 years of insertion, and between implant and intrauterine device (IUD) contraception, in particular complaints possibly related to hormonal contraceptives?
   SUMMARY ANSWER: The cumulative contraceptive effectiveness after 3 years and method continuation through 2.5 years were not significantly different between ENG and LNG implants, but both outcomes were significantly worse in the non-randomized age-matched group of IUD users than in the combined implant group.
   WHAT IS KNOWN ALREADY: ENG- and LNG-releasing implants are safe and highly efficacious contraceptives with pregnancy rates reported to be 0.0-0.5 per 100 women-years (W-Y). No head-to-head comparative study of the two implants has been undertaken, and little information is available on comparisons of complaints of side effects of implant and copper IUD users.
   STUDY DESIGN, SIZE, DURATION: This was an open parallel group RCT with 1:1 allocation ratio of the ENG and the LNG implants with non-randomized control group of women choosing TCu380A IUD to address lack of reliable data on common side effects typically attributed to the use of progestogen-only contraceptives. After device(s) placement, follow-ups were at 2 weeks, 3 and 6 months, and semi-annually thereafter for 3 years or until pregnancy, removal or expulsion of the implant/IUD occurred.
   PARTICIPANTS, SETTING, METHODS: The study took place in family planning clinics in Brazil, Chile, Dominican Republic, Hungary, Thailand, Turkey and Zimbabwe. Women seeking long-term contraception were enlisted after an eligibility check and informed consent, and 2982 women were enrolled: 1003, 1005 and 974 in the ENG-implant, LNG-implant and IUD groups, respectively; 995, 997 and 971, respectively, were included in the per protocol analysis reported here.
   MAIN RESULTS AND THE ROLE OF CHANCE: ENG and LNG implants each had the same 3-year cumulative pregnancy rate of 0.4 per 100 W-Y [95% confidence interval (CI) 0.1-1.4]. A weight of >= 70 kg at admission was unrelated to pregnancy. Method continuation rates for ENG and LNG implants at 2.5 years were 69.8 (95% CI 66.8-72.6) and 71.8 per 100W-Y(68.8-74.5), and at 3 years 12.1 (95% CI 5.2-22.0) and 52.0 per 100 W-Y (95% CI 41.8-61.2), respectively. Bleeding disturbances, the most frequent reason for method discontinuation, were significantly more common in the ENG group [16.7 (95% CI 14.4-19.3)] than in the LNG group [12.5 (95% CI 10.5-14.9)] (P 0.019). The 3-year cumulative loss to follow-up was lower in the ENG-than in the LNG-implant group, 8.1 (95% CI 6.4-10.2) and 14.4 per 100 W-Y (95% CI 12.1-17.1), respectively. The median duration of implant removal was 50 s shorter among women with ENG than among women with LNG implant (P, 0.0001). In the observational comparison between IUD and implant users, the 3-year relative risk for pregnancy in IUD group compared with the combined implant group was 5.7 per 100W-Y (95% CI 4.4-7.3) (P = 0.0003). The 3-year expulsion rate of the IUD was 17.8 per 100 W-Y (95% CI 14.5-21.9), while the discontinuation rate for bleeding disturbances was 8.5 (95% CI 6.7-10.9). Frequency of complaints of headache and dizziness was not significantly different between implant and IUD users (P = 0.16 and 0.77, respectively), acne and bleeding irregularities were more frequent among implant users (P, 0.0001), while heavy bleeding and lower abdominal pain occurred more often among IUD than implant users (P < 0.0001).
   LIMITATIONS, REASONS FOR CAUTION: Few women were = 19 years old or nulligravida, the proportion of implant users >= 70 kg was <20% and <8% were obese.
   WIDER IMPLICATIONS OF THE FINDINGS: Findings of the study can inform policy makers and clinicians about choice of implant, but also about TCu380A IUD in relation to implants.
C1 [Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Family Planning Clin, Campinas, SP, Brazil.
   [Brache, Vivian] PROFAMILIA, Santo Domingo, Dominican Rep.
   [Meirik, Olav; Ali, Moazzam; Habib, Ndema; Landoulsi, Sihem] WHO, World Bank Special Programme Res Dev & Res Traini, UNFPA, UNICEF,UNDP, CH-1211 Geneva, Switzerland.
   [Meirik, Olav] ICMER, Santiago, Chile.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI villarroel, claudio/F-2713-2010; DILBAZ, BERNA/AAC-5818-2019
OI villarroel, claudio/0000-0001-5184-9715; Habib,
   Ndema/0000-0003-4882-1687; Beksac, M.Sinan/0000-0001-6362-787X
FU United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research;
   Development and Research Training in Human Reproduction (HRP),
   Department of Reproductive Health and Research (RHR); World Health
   Organisation (WHO)World Health Organization; US Agency for International
   DevelopmentUnited States Agency for International Development (USAID)
   [GPO-A-00-08-00001-00]
FX United Nations Development Programme/United Nations Population
   Fund/UNICEF/WHO/UNICEF/World Bank Special Programme of Research,
   Development and Research Training in Human Reproduction (HRP),
   Department of Reproductive Health and Research (RHR), and World Health
   Organisation (WHO) funded this study including provision of implants and
   IUDs. This report contains the collective views of an international
   group of experts and does not necessarily represent the decisions or the
   stated policy of the WHO. Family Health International (FHI) 360
   participation in this project was funded by the US Agency for
   International Development [GPO-A-00-08-00001-00, Program Research for
   Strengthening Services (PROGRESS)]. The views expressed in this
   publication do not necessarily reflect those of FHI 360 or USAID.
CR Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Brache V, 2002, CONTRACEPTION, V65, P63, DOI 10.1016/S0010-7824(01)00289-X
   DAVIES GC, 1993, CONTRACEPTION, V47, P251, DOI 10.1016/0010-7824(93)90042-6
   FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M
   Funk S, 2005, CONTRACEPTION, V71, P319, DOI 10.1016/j.contraception.2004.11.007
   Glasier A, 2002, CONTRACEPTION, V65, P29, DOI 10.1016/S0010-7824(01)00284-0
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   Hubacher D, 2013, OBSTET GYNECOL, V121, P1091, DOI 10.1097/AOG.0b013e31828ac03a
   Kiriwat O, 1998, Eur J Contracept Reprod Health Care, V3, P85
   Meirik O, 2003, HUM REPROD UPDATE, V9, P49, DOI 10.1093/humupd/dmg004
   Meirik O, 2007, CONTRACEPTION, V75, pS41, DOI 10.1016/j.contraception.2006.12.017
   Meirik O, 2013, CONTRACEPTION, V87, P113, DOI 10.1016/j.contraception.2012.08.044
   O'Brien PA, 2008, CONTRACEPTION, V77, P318, DOI 10.1016/j.contraception.2007.12.011
   Power J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001326.pub2
   R Development Core Team, 2012, R LANG ENV STAT COMP
   SAS Institute, 2011, SAS SYST WIND REL 9
   Sivin I, 1998, CONTRACEPTION, V58, P275, DOI 10.1016/S0010-7824(98)00112-7
   Sivin I, 2010, EUR J CONTRACEP REPR, V15, P96, DOI 10.3109/13625180903519885
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization Reproductive Health and Research, 2000, MED EL CRIT CONTR US
   Zheng SR, 1999, CONTRACEPTION, V60, P1, DOI 10.1016/S0010-7824(99)00053-0
NR 21
TC 39
Z9 39
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD NOV
PY 2015
VL 30
IS 11
BP 2527
EP 2538
DI 10.1093/humrep/dev221
PG 12
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CT8GQ
UT WOS:000363053400011
PM 26409014
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bahamondes, MV
   Shulman, LP
AF Bahamondes, Luis
   Bahamondes, M. Valeria
   Shulman, Lee P.
TI Non-contraceptive benefits of hormonal and intrauterine reversible
   contraceptive methods
SO HUMAN REPRODUCTION UPDATE
LA English
DT Article
DE non-contraceptive benefits; levonorgestrel-releasing intrauterine
   system; oral contraceptives; depot medroxyprogesterone acetate; copper
   intrauterine device
ID DEPOT MEDROXYPROGESTERONE ACETATE; SICKLE-CELL-DISEASE; CHRONIC PELVIC
   PAIN; QUALITY-OF-LIFE; SYSTEM LNG-IUS; OVARIAN-CANCER; ENDOMETRIAL
   CANCER; ORAL-CONTRACEPTIVES; RISK-FACTORS; DEVICE USE
AB BACKGROUND: Most contraceptive methods present benefits beyond contraception; however, despite a large body of evidence, many healthcare professionals (HCPs), users and potential users are unaware of those benefits. This review evaluates the evidence for non-contraceptive benefits of hormonal and non-hormonal contraceptive methods.
   METHODS: We searched the medical publications in PubMed, POPLINE, CENTRAL, EMBASE and LILACS for relevant articles, on non-contraceptive benefits of the use of hormonal and intrauterine reversible contraceptive methods, which were published in English between 1980 and July 2014. Articles were identified using the following search terms: 'contraceptive methods', 'benefits', 'cancer', 'anaemia', 'heavy menstrual bleeding (HMB)', 'endometrial hyperplasia', 'endometriosis' and 'leiomyoma'.
   RESULTS: We identified, through the literature search, evidence that some combined oral contraceptives have benefits in controlling HMB and anaemia, reducing the rate of endometrial, ovarian and colorectal cancer and ectopic pregnancy as well as alleviating symptoms of premenstrual dysphoric disorder. Furthermore, the use of the levonorgestrel-releasing intrauterine system also controls HMB and anaemia and endometrial hyperplasia and cancer, reduces rates of endometrial polyps in users of tamoxifen and alleviates pain associated with endometriosis and adenomyosis. Depot medroxyprogesterone acetate controls crises of pain associated with sickle cell disease and endometriosis. Users of the etono-gestrel-releasing contraceptive implant have the benefits of a reduction of pain associated with endometriosis, and users of the copper intrauterine device have reduced rates of endometrial and cervical cancer.
   CONCLUSIONS: Despite the high contraceptive effectiveness of many hormonal and intrauterine reversible contraceptive methods, many HCPs, users and potential users are concerned mainly about side effects and safety of both hormonal and non-hormonal contraceptive methods, and there is scarce information about the many benefits that these methods offer beyond contraception.
C1 [Bahamondes, Luis; Bahamondes, M. Valeria] Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   [Shulman, Lee P.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the National Research
   Council (CNPq) under grant #573747/2008-3.
CR Abou-Setta AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005072
   ACOG (American Congress of Obstetricians and Gynecologists), 2006, OBSTET GYNECOL, V107, P1453, DOI DOI 10.1097/00006250-200606000-00055.PUBMED:16738183
   Ahrendt HJ, 2009, CONTRACEPTION, V80, P436, DOI 10.1016/j.contraception.2009.03.018
   ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x
   Arnes M, 2014, ANTICANCER RES, V34, P2319
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Bahamondes MV, 2010, HUM REPROD, V25, P1158, DOI 10.1093/humrep/deq043
   Beining RM, 2008, ANN EPIDEMIOL, V18, P492, DOI 10.1016/j.annepidem.2007.11.011
   Benshushan A, 2002, EUR J OBSTET GYN R B, V105, P166
   Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1
   Bitzer J, 2013, EUR J CONTRACEP REPR, V18, P143, DOI 10.3109/13625187.2013.792637
   Booth C, 2010, INT J INFECT DIS, V14, pE2, DOI 10.1016/j.ijid.2009.03.010
   Bosetti C, 2009, HUM REPROD UPDATE, V15, P489, DOI 10.1093/humupd/dmp017
   Bragheto AM, 2007, CONTRACEPTION, V76, P195, DOI 10.1016/j.contraception.2007.05.091
   Burkman R, 2004, AM J OBSTET GYNECOL, V190, pS5, DOI 10.1016/j.ajog.2004.01.061
   Burkman RT, 2001, AM J OBSTET GYNECOL, V185, pS4, DOI 10.1067/mob.2001.117416
   CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032
   CASTELLSAGUE X, 1993, INT J CANCER, V54, P911, DOI 10.1002/ijc.2910540607
   Castellsague X, 2011, LANCET ONCOL, V12, P1023, DOI 10.1016/S1470-2045(11)70223-6
   Chan SSC, 2007, BJOG-INT J OBSTET GY, V114, P1510, DOI 10.1111/j.1471-0528.2007.01545.x
   CHANG MC, 1978, AM J OBSTET GYNECOL, V132, P217, DOI 10.1016/0002-9378(78)90928-6
   Cheewadhanaraks S, 2012, GYNECOL OBSTET INVES, V74, P151, DOI 10.1159/000337713
   Chin J, 2009, COCHRANE DB SYST REV, V4
   Cho S, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.10.798
   Coffee AL, 2006, AM J OBSTET GYNECOL, V195, P1311, DOI 10.1016/j.ajog.2006.05.012
   Crosignani PG, 2006, HUM REPROD, V21, P248, DOI 10.1093/humrep/dei290
   de Abood M, 1997, CONTRACEPTION, V56, P313, DOI 10.1016/S0010-7824(97)00156-X
   DONNEZ J, 1985, FERTIL STERIL, V43, P554
   Dossus L, 2010, INT J CANCER, V127, P442, DOI 10.1002/ijc.25050
   Eissa AA, 2015, J FAM PLAN REPROD H, V41, P96, DOI 10.1136/jfprhc-2013-100763
   Farquhar C, 2009, COCHRANE DB SYST REV, V4
   Fedele L, 1997, FERTIL STERIL, V68, P426, DOI 10.1016/S0015-0282(97)00245-8
   Fong YF, 1999, CONTRACEPTION, V60, P173, DOI 10.1016/S0010-7824(99)00075-X
   Fraser IS, 2011, EUR J CONTRACEP REPR, V16, P258, DOI 10.3109/13625187.2011.591456
   FRASER IS, 1991, AUST NZ J OBSTET GYN, V31, P66, DOI 10.1111/j.1479-828X.1991.tb02769.x
   Furlong LA, 2002, J REPROD MED, V47, P881
   Gadducci A, 2013, ANN ONCOL, V24, P47, DOI 10.1093/annonc/mdt311
   Gallos ID, 2013, HUM REPROD, V28, P2966, DOI 10.1093/humrep/det320
   Gallos ID, 2013, OBSTET GYNECOL, V121, P1165, DOI 10.1097/AOG.0b013e31828cb563
   Gallos ID, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.037
   Gardner FJE, 2000, LANCET, V356, P1711, DOI 10.1016/S0140-6736(00)03204-9
   Gardner FJE, 2009, GYNECOL ONCOL, V114, P452, DOI 10.1016/j.ygyno.2009.06.014
   Gierisch JM, 2013, CANCER EPIDEM BIOMAR, V22, P1931, DOI 10.1158/1055-9965.EPI-13-0298
   Grigorieva V, 2003, FERTIL STERIL, V79, P1194, DOI 10.1016/S0015-0282(03)00175-4
   Guleria K, 2004, J OBSTET GYNAECOL RE, V30, P181, DOI 10.1111/j.1447-0756.2004.00182.x
   Gupta J, 2013, NEW ENGL J MED, V368, P128, DOI 10.1056/NEJMoa1204724
   Haberal A, 2006, ULTRASOUND OBST GYN, V27, P316, DOI 10.1002/uog.2664
   Haddad LB, 2012, CONTRACEPTION, V85, P527, DOI 10.1016/j.contraception.2011.10.008
   Hale GE, 2010, OBSTET GYNECOL, V115, P249, DOI 10.1097/AOG.0b013e3181ca4b3a
   Hannaford PC, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c927
   Hassell KL, 2010, AM J PREV MED, V38, pS512, DOI 10.1016/j.amepre.2009.12.022
   Havrilesky LJ, 2013, OBSTET GYNECOL, V122, P139, DOI 10.1097/AOG.0b013e318291c235
   Heliovaara-Peippo S, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.08.041
   Hill DA, 1997, INT J CANCER, V70, P278, DOI 10.1002/(SICI)1097-0215(19970127)70:3<278::AID-IJC5>3.3.CO;2-1
   Hoaglin DC, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-17
   Horst KE, 2014, OBSTET GYNECOL, V123, p183S, DOI 10.1097/01.AOG.0000447203.28173.5c
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   Imperato F, 2002, Minerva Ginecol, V54, P271
   Iodice S, 2010, EUR J CANCER, V46, P2275, DOI 10.1016/j.ejca.2010.04.018
   ISAACS WA, 1972, LANCET, V1, P570
   ISAACS WA, 1967, NATURE, V215, P1139, DOI 10.1038/2151139a0
   Jensen JT, 2011, OBSTET GYNECOL, V117, P777, DOI 10.1097/AOG.0b013e3182118ac3
   Joffe H, 2003, AM J OBSTET GYNECOL, V189, P1523, DOI 10.1016/S0002-9378(03)00927-X
   Johnson NP, 2013, HUM REPROD, V28, P1552, DOI 10.1093/humrep/det050
   Kadir RA, 2007, CONTRACEPTION, V75, pS123, DOI 10.1016/j.contraception.2007.01.005
   Kaunitz AM, 2007, CONTRACEPTION, V75, pS130, DOI 10.1016/j.contraception.2007.01.012
   Kaunitz AM, 2012, CONTRACEPTION, V86, P452, DOI 10.1016/j.contraception.2012.07.018
   Kaunitz AM, 2010, OBSTET GYNECOL, V116, P625, DOI 10.1097/AOG.0b013e3181ec622b
   Kaunitz AM, 2009, OBSTET GYNECOL, V113, P1104, DOI 10.1097/AOG.0b013e3181a1d3ce
   Kingman CEC, 2004, BJOG-INT J OBSTET GY, V111, P1425, DOI 10.1111/j.1471-0528.2004.00305.x
   KIRTON KT, 1974, CONTRACEPTION, V10, P39, DOI 10.1016/0010-7824(74)90130-9
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   Lu KH, 2013, FAM CANCER, V12, P273, DOI 10.1007/s10689-013-9664-5
   Lukes AS, 2008, FERTIL STERIL, V90, P673, DOI 10.1016/j.fertnstert.2007.07.1315
   Luukkainen T, 2001, SEMIN REPROD MED, V19, P355, DOI 10.1055/s-2001-18643
   Manchikanti A, 2007, COCHRANE DB SYST REV, V2
   Marjoribanks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003855.pub2
   Mercorio F, 2003, CONTRACEPTION, V67, P277, DOI 10.1016/S0010-7824(02)00522-X
   Middleton LJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3929
   Moorman PG, 2013, J CLIN ONCOL, V31, P4188, DOI 10.1200/JCO.2013.48.9021
   MUNKER R, 2000, CONT HEMATOL, P1
   Newcomb PA, 2008, ADV EXP MED BIOL, V617, P259, DOI 10.1007/978-0-387-69080-3_24
   NILSSON CG, 1981, LANCET, V1, P577
   Gomes MKO, 2007, FERTIL STERIL, V87, P1231, DOI 10.1016/j.fertnstert.2006.11.044
   PARAZZINI F, 1994, BRIT J CANCER, V70, P672, DOI 10.1038/bjc.1994.369
   Parslov M, 2000, AM J OBSTET GYNECOL, V182, P23, DOI 10.1016/S0002-9378(00)70486-8
   Pearlstein TB, 2005, CONTRACEPTION, V72, P414, DOI 10.1016/j.contraception.2005.08.021
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Peuranpaa P, 2014, ACTA OBSTET GYN SCAN, V93, P654, DOI 10.1111/aogs.12394
   PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303
   Reade CJ, 2014, J OBSTET GYNAECOL CA, V36, P133, DOI 10.1016/S1701-2163(15)30659-9
   Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X
   RISCH HA, 1983, AM J EPIDEMIOL, V117, P128, DOI 10.1093/oxfordjournals.aje.a113523
   Rodriguez GC, 1998, J SOC GYNECOL INVEST, V5, P271, DOI 10.1016/S1071-5576(98)00017-3
   Rodriguez GC, 2013, CANCER PREV RES, V6, P1283, DOI 10.1158/1940-6207.CAPR-12-0426
   Silva ACJDRE, 2006, FERTIL STERIL, V86, P742, DOI 10.1016/j.fertnstert.2006.02.082
   Rosenblatt KA, 1996, CONTRACEPTION, V54, P329, DOI 10.1016/S0010-7824(96)00199-0
   Schaedel ZE, 2005, AM J OBSTET GYNECOL, V193, P1361, DOI 10.1016/j.ajog.2005.05.002
   Schildkraut JM, 2002, JNCI-J NATL CANCER I, V94, P32
   Schlaff WD, 2006, FERTIL STERIL, V85, P314, DOI 10.1016/j.fertnstert.2005.07.1315
   SHU XO, 1991, INT J CANCER, V49, P38, DOI 10.1002/ijc.2910490108
   Shulman LP, 2011, AM J OBSTET GYNECOL, V205, pS9, DOI 10.1016/j.ajog.2011.06.057
   Shulman LP, 2010, CANCER TREAT RES, V156, P69, DOI 10.1007/978-1-4419-6518-9_6
   Shulman LP, 2013, CONTRACEPTIVE TECHNO, P69
   Soini T, 2014, OBSTET GYNECOL, V124, P292, DOI 10.1097/AOG.0000000000000356
   Soliman PT, 2005, OBSTET GYNECOL, V105, P575, DOI 10.1097/01.AOG.0000154151.14516.f7
   Soysal S, 2005, GYNECOL OBSTET INVES, V59, P29, DOI 10.1159/000080932
   Sturgeon SR, 1997, INT J EPIDEMIOL, V26, P496, DOI 10.1093/ije/26.3.496
   Szarewski A, 2010, J FAM PLAN REPROD H, V36, P231, DOI 10.1783/147118910793048665
   Tanmahasamut P, 2012, OBSTET GYNECOL, V119, P519, DOI 10.1097/AOG.0b013e31824264c3
   Tekin YB, 2011, FERTIL STERIL, V95, P492, DOI 10.1016/j.fertnstert.2010.08.042
   Bahamondes MV, 2012, CONTRACEPTION, V86, P244, DOI 10.1016/j.contraception.2011.12.005
   Varma R, 2008, EUR J OBSTET GYN R B, V139, P169, DOI 10.1016/j.ejogrb.2008.02.022
   Vercellini P, 1996, AM J OBSTET GYNECOL, V175, P396, DOI 10.1016/S0002-9378(96)70152-7
   Vercellini P, 2003, FERTIL STERIL, V80, P305, DOI 10.1016/S0015-0282(03)00608-3
   Vilos GA, 2009, J MINIM INVAS GYN, V16, P480, DOI 10.1016/j.jmig.2009.04.018
   Walch K, 2009, CONTRACEPTION, V79, P29, DOI 10.1016/j.contraception.2008.07.017
   WEISS NS, 1980, NEW ENGL J MED, V302, P551, DOI 10.1056/NEJM198003063021004
   Wilailak S, 2012, BJOG-INT J OBSTET GY, V119, P672, DOI 10.1111/j.1471-0528.2012.03298.x
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wong AWY, 2013, OBSTET GYNECOL, V121, P943, DOI 10.1097/AOG.0b013e31828bf80c
   Xiao BL, 2003, FERTIL STERIL, V79, P963, DOI 10.1016/S0015-0282(02)04913-0
   Xu L, 2014, INT J WOMENS HEALTH, V6, P547, DOI 10.2147/IJWH.S57470
   Yonkers KA, 2005, OBSTET GYNECOL, V106, P492, DOI 10.1097/01.AOG.0000175834.77215.2e
   Zorbas KA, 2015, ARCH GYNECOL OBSTET, V292, P37, DOI 10.1007/s00404-015-3641-1
NR 125
TC 45
Z9 53
U1 0
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1355-4786
EI 1460-2369
J9 HUM REPROD UPDATE
JI Hum. Reprod. Update
PD SEP-OCT
PY 2015
VL 21
IS 5
BP 640
EP 651
DI 10.1093/humupd/dmv023
PG 12
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CV5SK
UT WOS:000364331200007
PM 26037216
OA Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   Espejo-Arce, X
   Bahamondes, L
AF Bahamondes, M. Valeria
   Espejo-Arce, Ximena
   Bahamondes, Luis
TI Effect of vaginal administration of misoprostol before intrauterine
   contraceptive insertion following previous insertion failure: a double
   blind RCT
SO HUMAN REPRODUCTION
LA English
DT Article
DE misoprostol; insertion failure; intrauterine contraceptives; copper
   intrauterine device; levonorgestrel-releasing intrauterine system
ID NULLIPAROUS WOMEN; DEVICE INSERTION
AB STUDY QUESTION: Is pretreatment with misoprostol useful in insertion of intrauterine contraceptives (IUCs) after insertion failure at the first attempt?
   summary answer: Pretreatment with intravaginal administration of 200 mcg of misoprostol after IUC insertion failure 10 and 4 h before the second attempt of IUC placement was significantly better than placebo at facilitating the insertion of an IUC.
   what is known already: One of the reasons for low use of IUCs is the concept that insertion is difficult. Misoprostol was used in several randomized clinical trials (RCT) before IUC insertion to facilitate the insertion. In general, the results showed no significant differences when compared with placebo. However, most previous studies have been carried out among unselected women whereas the present study is among women with previous insertion failure.
   study design, size, duration: This was a double blind RCT conducted between February 2013 and October 2014. Participants were 104 women who requested an insertion of an IUC and the insertion failed at the first attempt. After insertion failure, the women received a sealed envelope with misoprostol or placebo. The randomization system (1: 1) in one block size was computer-generated.
   participants/materials, setting, methods: The study was conducted at a tertiary care centre. The women were instructed to insert vaginally one tablet of misoprostol 200 mg (Prostokos, Hebron, Cariacica, PE, Brazil) or placebo 10 and 4 h before the woman returned to the clinic for a new insertion attempt. The outcomes were successful IUC insertion and the use of a cervical dilator immediately prior to the insertion procedure.
   main results and the role of chance: A total of 2639 women requested the insertion of an IUC during the study period. The IUC was inserted at the first attempt in 2535 women (96%) and 104 women in whom we were unable to insert the device were eligible to participate in the RCT. Four women declined and 100 women were randomized (55 for the misoprostol group and 45 for the placebo group). From the 100 participating women, the levonorgestrel-releasing intrauterine system (LNG-IUS) was chosen by 55 and 37 women and the TCu380A intrauterine device (Cu-IUD) was chosen by none and 8 women in the misoprostol and placebo group, respectively. Seven and three women allocated to misoprostol and placebo, respectively, never returned to the clinic after randomization. We placed the IUC in 42 (87.5%) out of the 48 women and in 26 (61.9%) out of the 42 women randomized to misoprostol and placebo, respectively (P = 0.0066). Regarding the Evaluable Population the relative risk (RR) of successful insertions was 1.41 (95% confidence interval (CI) for absolute difference (8.2, 43.0), P = 0.0066); in the Intent-to-Treat Population the RR (95% CI) was 1.32 (0.3, 36.9). Multiple regression analysis showed that the significant variables associated with the insertion failure were the number of Caesarean section >= 1 (P = 0.020) and the use of placebo (P = 0.026). Dilators were used in 21 (43.7%) out of the 48 and 21 (50%) out of the 42 women randomized to misoprostol and placebo, respectively (P = 0.804).
   limitations, reasons for caution: The limitations were that the majority of the women chose the LNG-IUS, and consequently the data for the Cu-IUD were limited, and there was a small number of nulligravidas.
   wider implications of the findings: The results show that IUC insertion difficulties and failures are not common. Pretreatment with intravaginal misoprostol facilitated IUC insertion after failure of insertion at the first attempt, and insertion failure was associated with number of Caesarean sections.
C1 [Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Family Planning Clin,Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, UNICAMP, Sch Med Sci, Family Planning Clin,Dept Obstet & Gynaecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/10085-0];
   Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant #2012/10085-0
   and from the Brazilian National Research Council (CNPq), grant
   #573747/2008-3.
CR Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Bahamondes L, 2014, J FAM PLAN REPROD H, V40, P54, DOI 10.1136/jfprhc-2013-100636
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Berenson AB, 2013, OBSTET GYNECOL, V121, P951, DOI 10.1097/AOG.0b013e31828b63a0
   Crosignani PG, 2008, HUM REPROD UPDATE, V14, P197, DOI 10.1093/humupd/dmn003
   Dijkhuizen K, 2011, HUM REPROD, V26, P323, DOI 10.1093/humrep/deq348
   Edelman AB, 2011, CONTRACEPTION, V84, P234, DOI 10.1016/j.contraception.2011.01.016
   Espey E, 2014, AM J OBSTET GYNECOL, V210, DOI 10.1016/j.ajog.2013.11.018
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Gemzell-Danielsson K, 2013, HUM REPROD UPDATE, V19, P419, DOI 10.1093/humupd/dmt022
   Heikinheimo O, 2010, CONTRACEPTION, V81, P481, DOI 10.1016/j.contraception.2010.01.020
   Ibrahim ZM, 2013, EUR J CONTRACEP REPR, V18, P300, DOI 10.3109/13625187.2013.800855
   Lathrop E, 2013, CONTRACEPTION, V88, P725, DOI 10.1016/j.contraception.2013.07.011
   Li YT, 2005, INT J GYNECOL OBSTET, V89, P67, DOI 10.1016/j.ijgo.2005.01.036
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   Ofili-Yebovi D, 2008, ULTRASOUND OBST GYN, V31, P72, DOI 10.1002/uog.5200
   Saav I, 2007, HUM REPROD, V22, P2647, DOI 10.1093/humrep/dem244
   Scavuzzi A, 2013, HUM REPROD, V28, P2118, DOI 10.1093/humrep/det240
   Schaefer E, 2010, CONTRACEPTION, V82, P188, DOI 10.1016/j.contraception.2010.04.043
   Ward K, 2011, CONTRACEPTION, V84, P594, DOI 10.1016/j.contraception.2011.03.011
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 21
TC 16
Z9 16
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2015
VL 30
IS 8
BP 1861
EP 1866
DI 10.1093/humrep/dev137
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA CP2YG
UT WOS:000359743300014
PM 26040478
OA Bronze
DA 2020-12-01
ER

PT J
AU Modesto, W
   Bahamondes, MV
   Bahamondes, L
AF Modesto, Waleska
   Bahamondes, M. Valeria
   Bahamondes, Luis
TI Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the
   Injectable Contraceptive Depot Medroxyprogesterone Acetate
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID MINERAL DENSITY; ORAL-CONTRACEPTIVES; HORMONAL CONTRACEPTION; WOMEN;
   FRACTURE; HEALTH
AB Background: Bone mineral density (BMD) loss among depot medroxyprogesterone acetate (DMPA) users is a controversial issue. Aspects under debate include whether the number of years of use has any effect on continuous BMD loss, whether this loss will stabilise over the years of use or if it will progress to low bone mass, osteoporosis and an increased fracture risk. The aim of this study was to compare the difference in osteoporosis and low bone mass between DMPA and copper intrauterine device (Cu-IUD) users. Methods: This was a cross-sectional study that evaluated BMD at the lumbar spine and femoral neck in 47 long-term DMPA users and 41 Cu-IUD users as control group. BMD was measured by dual-energy X-ray absorptiometry. The participants were 27 to 57 years of age, had used either DMPA or a Cu-IUD uninterruptedly for at least ten years, had initiated use of the method prior to 40 years of age and had follicle stimulating hormone values <40mIU/mL. Results: Findings showed that 68.1% and 36.6% of the DMPA and Cu-IUD users, respectively, had low bone mass and 29.8% and 2.4% of DMPA and Cu-IUD users, respectively, had osteoporosis. BMD decreased as the number of years of DMPA use increased. Conclusion: Long-term DMPA use was associated with low bone mass and osteoporosis in women who had used the method for 10 years or more. DMPA users with longer time of use showed a greater bone mass loss.
C1 Univ Estadual Campinas, Dept Obstet & Gynaecol, Sch Med Sci, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Univ Estadual Campinas, Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Modesto, W (corresponding author), Univ Estadual Campinas, Dept Womens Hlth, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM waleskamodesto@yahoo.com.br
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/01554-4,
   2013/03590-3]
FX The study was partially funded (grant 573747/2008-3) by the Brazilian
   National Research Council (CNPq). W. M. and V. M. C. received a grant
   from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   grants 2011/01554-4 and 2013/03590-3, respectively.
CR American College of Obstetricians and Gynecologists Committee on Gynecologic Practice, 2008, Obstet Gynecol, V112, P727, DOI 10.1097/AOG.0b013e318188d1ec
   Beksinska ME, 2005, CONTRACEPTION, V71, P170, DOI 10.1016/j.contraception.2004.09.003
   Berenson AB, 2004, OBSTET GYNECOL, V103, P899, DOI 10.1097/01.AOG.0000117082.49490.d5
   Berenson AB, 2008, OBSTET GYNECOL, V112, P788, DOI 10.1097/AOG.0b013e3181875b78
   Clark MK, 2004, FERTIL STERIL, V82, P1580, DOI 10.1016/j.fertnstert.2004.04.064
   Cromer BA, 2008, FERTIL STERIL, V90, P2060, DOI 10.1016/j.fertnstert.2007.10.070
   CUNDY T, 1994, BRIT MED J, V308, P247, DOI 10.1136/bmj.308.6923.247
   Cundy T, 1998, OBSTET GYNECOL, V92, P569, DOI 10.1016/S0029-7844(98)00270-1
   Cundy T, 2002, AM J OBSTET GYNECOL, V186, P978, DOI 10.1067/mob.2002.122420
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   Food and Drugs Administration (FDA), 2004, PFIZ UPD INF DEP PRO
   Gbolade B, 1998, BRIT J OBSTET GYNAEC, V105, P790, DOI 10.1111/j.1471-0528.1998.tb10211.x
   Kaunitz AM, 2011, CONTRACEPTION, V84, P212, DOI 10.1016/j.contraception.2011.01.009
   Lanza LL, 2013, OBSTET GYNECOL, V121, P593, DOI 10.1097/AOG.0b013e318283d1a1
   Lappe JM, 2001, OSTEOPOROSIS INT, V12, P35, DOI 10.1007/s001980170155
   Lopez LM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006033.pub4
   Medicines and Healthcare Products Regulatory Agency (MHRA), UPD GUID US DEP PROV
   Renner RM, 2010, WOMENS HEALTH, V6, P339, DOI [10.2217/whe.10.17, 10.2217/WHE.10.17]
   Scholes D, 2004, CONTRACEPTION, V69, P99, DOI 10.1016/j.contraception.2003.10.005
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648-200209000-00015
   Schonau E, 2004, PEDIATR NEPHROL, V19, P825, DOI 10.1007/s00467-004-1465-5
   Tang OS, 1999, CONTRACEPTION, V59, P25, DOI 10.1016/S0010-7824(98)00144-9
   Tang OS, 2000, CONTRACEPTION, V62, P161, DOI 10.1016/S0010-7824(00)00168-2
   The UK National Institute for Health and Care Excellence (NICE), RES REC 2005
   Vestergaard P, 2008, CONTRACEPTION, V78, P459, DOI 10.1016/j.contraception.2008.07.014
   Viola AS, 2011, CONTRACEPTION, V84, P122, DOI 10.1016/j.contraception.2011.06.012
   Watson KC, 2006, WOMEN HEALTH ISS, V16, P346, DOI 10.1016/j.whi.2006.09.003
   *WHO, 2005, WKLY EPIDEMIOL REC, V80, P302
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wooltorton E, 2005, CAN MED ASSOC J, V172, P746, DOI 10.1503/cmaj.050158
   World Health Organization, 2004, SUMM M BRUSS BELG MA
   Zeman S, 2013, Ceska Gynekol, V78, P116
NR 32
TC 12
Z9 12
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD AUG 1
PY 2015
VL 24
IS 8
BP 636
EP 640
DI 10.1089/jwh.2014.5077
PG 5
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
   Medicine; Obstetrics & Gynecology; Women's Studies
GA CP1FL
UT WOS:000359621600004
PM 26098552
DA 2020-12-01
ER

PT J
AU Melhado-Kimura, V
   Alegre, SM
   Pavin, EJ
   dos Santos, PDS
   Bahamondes, L
   Fernandes, A
AF Melhado-Kimura, Vaneska
   Alegre, Sarah Monte
   Pavin, Elizabeth Joao
   Silva dos Santos, Priscilla de Nazare
   Bahamondes, Luis
   Fernandes, Arlete
TI High prevalence of insulin resistance assessed by the glucose clamp
   technique in hormonal and non-hormonal contraceptive users
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Contraceptive methods; Insulin resistance; Prevalence; Euglycemic clamp;
   Combined hormonal contraceptives
ID ORAL-CONTRACEPTIVES; ETHINYL ESTRADIOL; SENSITIVITY; METABOLISM; WOMEN;
   CARBOHYDRATE; TOLERANCE; SECRETION; DISEASE; ACETATE
AB Objective To assess the prevalence of insulin resistance (IR) and associated factors in contraceptive users.
   Methods A total of 47 women 18 to 40 years of age with a body mass index (kg/m(2)) < 30, fasting glucose levels < 100 mg/dl and 2-hour glucose level < 140 mg/dl after a 75-g oral glucose load were submitted to a hyperinsulinemic-euglycemic clamp. The women were distributed in tertiles regarding M-values. The analysed variables were use of combined hormonal/non-hormonal contraception, duration of use, body composition, lipid profile, glucose levels and blood pressure.
   Results IR was detected in 19% of the participants. The women with low M-values presented significantly higher body fat mass, waist-to-hip ratio, fasting insulin, HOMA-IR and were nulligravida, showed > 1 year of contraceptive use and higher triglyceride levels. IR was more frequent among combined oral contraceptive users, however no association was observed after regression analysis.
   Conclusions The prevalence of IR was high among healthy women attending a family planning clinic independent of the contraceptive method used with possible long-term negative consequences regarding their metabolic and cardiovascular health. Although an association between hormonal contraception and IR could not be found this needs further research. Family planning professionals should be proactive counselling healthy women about the importance of healthy habits.
C1 [Melhado-Kimura, Vaneska; Silva dos Santos, Priscilla de Nazare; Bahamondes, Luis; Fernandes, Arlete] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Alegre, Sarah Monte; Pavin, Elizabeth Joao] Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Med, Campinas, SP, Brazil.
RP Fernandes, A (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM arlete@fcm.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Ministry of Health, the National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); Sao Paulo State Health Department (SES-SP) through
   Research for the National Health Service Initiative, PPSUS, Brazil
   [2009/53293-0]
FX This study received financial support from the Ministry of Health, the
   National Council for Scientific and Technological Development (CNPq) and
   from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP).
   In addition, the Sao Paulo State Health Department (SES-SP) provided
   funding through the Research for the National Health Service Initiative,
   PPSUS/2009, Brazil, under award #2009/53293-0. The authors gratefully
   acknowledge Aglecio Luiz de Souza, Gisele Almeida Batista, Conceicao
   Aparecida da Silva by clinical tests and Cleide Moreira Silva for
   statistical analysis.
CR ABEP-Brazilian Association of Research Companies, BRAZ EC CLASS CRIT
   Aydin K, 2013, CONTRACEPTION, V87, P358, DOI 10.1016/j.contraception.2012.07.005
   Balkau B, 2008, DIABETES, V57, P2613, DOI 10.2337/db07-1605
   BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45
   Cagnacci A, 2009, CONTRACEPTION, V79, P111, DOI 10.1016/j.contraception.2008.09.002
   Carstens MT, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-8
   de Rooij SR, 2009, EUR J ENDOCRINOL, V161, P223, DOI 10.1530/EJE-09-0058
   DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214
   Ebbert JO, 2013, NUTRIENTS, V5, P498, DOI 10.3390/nu5020498
   GODSLAND IF, 1992, J CLIN ENDOCR METAB, V74, P64, DOI 10.1210/jc.74.1.64
   GOLAY A, 1986, J CLIN ENDOCR METAB, V62, P1081, DOI 10.1210/jcem-62-6-1081
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715
   Hills SA, 2004, DIABETOLOGIA, V47, P566, DOI 10.1007/s00125-004-1335-5
   HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169
   Hu FB, 2003, J WOMEN HEALTH GEN-B, V12, P163, DOI 10.1089/154099903321576565
   IBGE. [Brazilian Institute of Geography and Statistics], 2010 CENS TOT FERT R
   KASDORF G, 1988, J CLIN ENDOCR METAB, V66, P846, DOI 10.1210/jcem-66-4-846
   KRITZSILVERSTEIN D, 1994, AM J EPIDEMIOL, V140, P375, DOI 10.1093/oxfordjournals.aje.a117260
   Lopez LM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006133.pub5
   Mastorakos G, 2006, FERTIL STERIL, V85, P420, DOI 10.1016/j.fertnstert.2005.07.1306
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   MCGUIRE EAH, 1976, J APPL PHYSIOL, V41, P565
   Pataky Z, 2013, DIABETES METAB, V39, P330, DOI 10.1016/j.diabet.2013.05.008
   PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9
   Reaven G, 2012, ARTERIOSCL THROM VAS, V32, P1754, DOI 10.1161/ATVBAHA.111.241885
   REAVEN GM, 1967, J CLIN INVEST, V46, P1756, DOI 10.1172/JCI105666
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   SCHEEN AJ, 1993, FERTIL STERIL, V59, P797
   Sitruk-Ware R, 2013, BEST PRACT RES CL EN, V27, P13, DOI 10.1016/j.beem.2012.09.004
   Tuzcu A, 2009, PITUITARY, V12, P330, DOI 10.1007/s11102-009-0183-1
   World Health Organisation, 2011, GLOB REC PHYS ACT HL
NR 32
TC 4
Z9 4
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD APR
PY 2015
VL 20
IS 2
BP 110
EP 118
DI 10.3109/13625187.2014.961599
PG 9
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA CD9DS
UT WOS:000351398300005
PM 25328007
DA 2020-12-01
ER

PT J
AU Modesto, W
   dos Santos, PDS
   Correia, VM
   Borges, L
   Bahamondes, L
AF Modesto, Waleska
   Silva dos Santos, Priscila de Nazare
   Correia, Vinicius Machado
   Borges, Luiza
   Bahamondes, Luis
TI Weight variation in users of depot-medroxyprogesterone acetate, the
   levonorgestrel-releasing intrauterine system and a copper intrauterine
   device for up to ten years of use
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Weight; Levonorgestrel-releasing intrauterine system;
   Depot-medroxyprogesterone acetate; Copper IUD
ID WOMEN; INCREASE; OBESITY; IUD
AB Background and objective Data on record regarding weight variation in depot-medroxyprogesterone acetate (DMPA) and levonorgestrel-releasing intrauterine system (LNG-IUS) users are controversial. To date, no studies have yet evaluated weight variation in DMPA and LNG-IUS users in up to ten years of use compared to non-hormonal contraceptive users.
   Materials and methods A retrospective study analysed weight variations in 2138 women using uninterruptedly DMPA (150 mg intramuscularly, three-monthly; n = 714), the LNGIUS (n = 701) or a copper-intrauterine device (Cu-IUD; n = 723).
   Results At the end of the first year of use, there was a mean weight increase of 1.3 kg, 0.7 kg and 0.2 kg among the DMPA-, LNG-IUS-and Cu-IUD users, respectively, compared to weight at baseline (p < 0.0001). After ten years of use, the mean weight had risen by 6.6 kg, 4.0 and 4.9 kg among the DMPA-, LNG-IUS-and Cu-IUD users, respectively. DMPA-users had gained more weight than LNG-IUS-(p = 0.0197) and than Cu-IUD users (p = 0.0294), with the latter two groups not differing significantly from each other in this respect (p = 0.5532).
   Conclusion Users of hormonal and non-hormonal contraceptive methods gained a signifi cant amount of weight over the years. DMPA users gained more weight over the treatment period of up to ten years than women fitted with either a LNG-IUS or a Cu-IUD.
C1 Univ Estadual Campinas, UNICAMP, Sch Med Sci, Human Reprod Unit,Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3];
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/01554-4,
   2013/03590-3]
FX The study was partially funded [grant 573747/2008-3] by the Brazilian
   National Research Council (CNPq). W.M. and V.M.C. each received a grant
   from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [grants # 2011/01554-4 and 2013/03590-3, respectively].
CR Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Baldaszti E, 2003, CONTRACEPTION, V67, P87, DOI 10.1016/S0010-7824(02)00482-1
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Caballero B, 2007, EPIDEMIOL REV, V29, P1, DOI 10.1093/epirev/mxm012
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   Dal'Ava N, 2012, CONTRACEPTION, V86, P350, DOI 10.1016/j.contraception.2012.01.017
   Hassan DF, 2003, CONTRACEPTION, V68, P27, DOI 10.1016/S0010-7824(03)00079-9
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   Lopez LM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008815.pub3
   May AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050712
   Ministerio da Saude.Secretaria de Vigilancia em Saude, 2012, EST INF SAUD G
   Modesto W, 2014, EUR J CONTRACEP REPR, V19, P244, DOI 10.3109/13625187.2014.924098
   Nault AM, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.876
   Pantoja M, 2010, CONTRACEPTION, V81, P107, DOI 10.1016/j.contraception.2009.07.008
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Pelkman C, 2002, J REPROD MED, V47, P791
   Rennie KL, 2005, OBES REV, V6, P11, DOI 10.1111/j.1467-789X.2005.00164.x
   SAID S, 1986, CONTRACEPTION, V34, P223, DOI 10.1016/0010-7824(86)90004-1
   Sheng J, 2009, CONTRACEPTION, V79, P189, DOI 10.1016/j.contraception.2008.11.004
   Suhonen S, 2004, CONTRACEPTION, V69, P407, DOI 10.1016/j.contraception.2003.11.008
   Vickery Z, 2013, CONTRACEPTION, V88, P503, DOI 10.1016/j.contraception.2013.03.004
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Yela Daniela Angerame, 2006, Rev. Assoc. Med. Bras., V52, P32, DOI 10.1590/S0104-42302006000100019
NR 23
TC 14
Z9 16
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD FEB
PY 2015
VL 20
IS 1
BP 57
EP 63
DI 10.3109/13625187.2014.951433
PG 7
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA CA5HG
UT WOS:000348938900007
PM 25160484
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Lira-Plascencia, J
   Martin, R
   Marin, V
   Makuch, MY
AF Bahamondes, Luis
   Lira-Plascencia, Josefina
   Martin, Ricardo
   Marin, Victor
   Makuch, Maria Y.
TI Knowledge and attitudes of Latin American gynecologists regarding
   unplanned pregnancy and use of combined oral contraceptives
SO INTERNATIONAL JOURNAL OF WOMENS HEALTH
LA English
DT Article
DE contraception; unintended pregnancy; benefits of oral contraceptives
ID UNINTENDED PREGNANCY; HORMONAL CONTRACEPTIVES; FAILURE RATES; PREVENTION
AB Background: Unintended pregnancy is a public health problem and unmet medical need worldwide. It is estimated that in the year 2012, almost 213 million pregnancies occurred, and the global pregnancy rate decreased only slightly from 2008 to 2012. It was also estimated that 85 million pregnancies (40% of all pregnancies) were unintended and that 38% ended in an unintended birth.
   Objectives: To assess knowledge and attitudes of Latin American (LA) obstetricians and gynecologists (OBGYNs) regarding unintended pregnancies and aspects of combined oral contraceptive (COC) use.
   Methods: A survey was conducted during a scientific meeting about contraception in 2014, in which OBGYNs from 12 LA countries who provide attention in contraception were invited to respond to a multiple-choice questionnaire to assess their knowledge and attitudes regarding unplanned pregnancy and some aspects regarding COC use.
   Results: A total of 210 OBGYNs participated in the study. Their knowledge regarding COC failure was low. The participants reported they believed that their patients habitually forgot to take a pill and that their patients did not know what to do in these situations. They were aware of the benefits of COC use; however, they were less prone to prescribe COCs for the purpose of protecting against ovarian and endometrial cancer, and one-quarter of them had doubts about the association between COC use and cancer risk.
   Conclusion: The interviewed LA OBGYNs showed some flaws in terms of knowledge of COC failure rates and the non-contraceptive benefits and risks of COCs. To adequately counsel their patients regarding COC intake, OBGYNs must be updated regarding all aspects of COC use.
C1 [Bahamondes, Luis; Makuch, Maria Y.] Univ Campinas UNICACAMP, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Lira-Plascencia, Josefina] Inst Nacl Perinatol, Mexico City, DF, Mexico.
   [Martin, Ricardo] Hosp Univ, Fdn Santa Fe Bogota, Bogota, Colombia.
   [Marin, Victor] Hosp Cent, Petroleos Mexicanos, Mexico City, DF, Mexico.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
CR Amaral G, 2007, HEALTH SERV RES, V42, P1960, DOI 10.1111/j.1475-6773.2007.00702.x
   [Anonymous], 1995, Contraception, V52, P77
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Blumenthal PD, 2008, OBSTET GYNECOL, V112, P670, DOI 10.1097/AOG.0b013e31818425b7
   Emmerich J, 2014, J THROMB HAEMOST, V12, P1388, DOI 10.1111/jth.12661
   Finer LB, 2006, PERSPECT SEX REPRO H, V38, P90, DOI 10.1363/3809006
   Finer LB, 2014, AM J PUBLIC HEALTH, V104, pS43, DOI 10.2105/AJPH.2013.301416
   Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640
   Gallo MF, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003987.pub5
   Gaudet LM, 2004, CONTRACEPTION, V69, P31, DOI 10.1016/j.contraception.2003.07.003
   Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x
   Grimbizis GF, 2010, BEST PRACT RES CL OB, V24, P29, DOI 10.1016/j.bpobgyn.2009.08.010
   Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522
   Horst KE, 2014, OBSTET GYNECOL, V123, p183S, DOI 10.1097/01.AOG.0000447203.28173.5c
   Jensen JT, 2010, EXPERT OPIN PHARMACO, V11, P1147, DOI 10.1517/14656561003724713
   JONES EF, 1992, FAM PLANN PERSPECT, V24, P12, DOI 10.2307/2135719
   Makuch MY, 2013, INT J WOMENS HEALTH, V5, P795, DOI 10.2147/IJWH.S52086
   Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]
   Rapkin AJ, 2008, J REPROD MED, V53, P729
   Reading BF, 2012, GROWTH WORLD CONTRAC
   Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x
   Shulman LP, 2011, AM J OBSTET GYNECOL, V205, pS9, DOI 10.1016/j.ajog.2011.06.057
   Trussell J, 2008, CONTRACEPTION, V77, P1, DOI 10.1016/j.contraception.2007.09.001
   Urrutia RP, 2013, OBSTET GYNECOL, V122, P380, DOI 10.1097/AOG.0b013e3182994c43
   *WHO DEP REPR HLTH, 2004, SEL PRACT REC CONTR, P42331
   WHO Department of Reproductive Health, 2010, MED EL CRIT CONTR US
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization Guttmacher Institute, 2007, FACTS IND AB WORLDW
NR 29
TC 4
Z9 4
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1411
J9 INT J WOMENS HEALTH
JI Int. J. Womens Health
PY 2015
VL 7
BP 485
EP 491
DI 10.2147/IJWH.S78874
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA V18KR
UT WOS:000214750800050
PM 25999766
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Makuch, MY
   Monteiro, I
   Marin, V
   Lynen, R
AF Bahamondes, Luis
   Makuch, Maria Y.
   Monteiro, Ilza
   Marin, Victor
   Lynen, Richard
TI Knowledge and attitudes of Latin American obstetricians and
   gynecologists regarding intrauterine contraceptives
SO INTERNATIONAL JOURNAL OF WOMENS HEALTH
LA English
DT Article
DE contraception; Latin America; intrauterine contraceptives; health care
   professionals; knowledge; myths; attitudes
ID UNINTENDED PREGNANCY; WOMENS KNOWLEDGE; DISCONTINUATION; SATISFACTION;
   ADOLESCENT; PROVISION; DEVICES; SYSTEM; HEALTH
AB Background: Intrauterine contraceptives (IUCs), including the copper intrauterine device and the levonorgestrel-releasing intrauterine system (LNG-IUS), are among the reversible contraceptive methods with high effectiveness. However, use is low in many settings, including some Latin American countries, mainly due to the influences of myths, fears, and negative attitudes, not only of users and potential users, but also of different cadres of health care professionals. The purpose of this study was to assess the knowledge and attitudes of a group of Latin American obstetricians and gynecologists regarding IUCs.
   Methods: A survey was conducted during a scientific meeting organized in Chile in 2014 to present and discuss updated information about contraception. Obstetricians and gynecologists from 12 Latin American countries, who reported that they provide daily contraception services in both the public and private sectors, participated in the meeting. Participants who agreed to take part in the survey responded to a multiple-choice questionnaire on issues regarding knowledge, use, and attitudes about IUCs.
   Results: Of the 210 obstetricians and gynecologists participating in the meeting, the respondents to each question varied from 168 (80.0%) to 205 (97.6%). Almost 50% recognized that the failure rate of combined oral contraceptives, patches, and vaginal rings is 8%-10%. Furthermore, 10% of the participants did not recognize the high contraceptive effectiveness of long-acting reversible contraceptive methods. Additionally, almost 80% of the respondents answered that they did not offer IUCs to nulligravidas and almost 10% did not offer IUCs to adolescents, albeit almost 90% of the respondents reported that nulligravidas are candidates for an LNG-IUS.
   Conclusion: Some deficiencies and contradictions in terms of knowledge and attitudes were identified from the answers of the Latin American obstetricians and gynecologists who participated in the survey. The knowledge and attitudes of health care professionals about IUCs are important in order to provide adequate counseling and to expand the use of IUCs.
C1 [Bahamondes, Luis; Makuch, Maria Y.; Monteiro, Ilza] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, Brazil.
   [Marin, Victor] Hosp Cent Petroleos Mexicanos, Dept Obstet & Gynaecol, Mexico City, DF, Mexico.
   [Lynen, Richard] Bayer HealthCare, Newark, NJ USA.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynaecol, Caixa Postal 6181, BR-13084971 Campinas, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
CR Amaral G, 2007, HEALTH SERV RES, V42, P1960, DOI 10.1111/j.1475-6773.2007.00702.x
   Aoun J, 2014, OBSTET GYNECOL, V123, P585, DOI 10.1097/AOG.0000000000000144
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 2015, INT J WOMENS HEALTH, V7, P485, DOI 10.2147/IJWH.S78874
   Bahamondes L, 2014, HUM REPROD, V29, P2163, DOI 10.1093/humrep/deu191
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group The American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P983
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Finer LB, 2014, AM J PUBLIC HEALTH, V104, pS43, DOI 10.2105/AJPH.2013.301416
   Friedman JO, 2015, J PEDIATR ADOL GYNEC, V28, P38, DOI 10.1016/j.jpag.2014.02.015
   Gipson JD, 2008, STUD FAMILY PLANN, V39, P18, DOI 10.1111/j.1728-4465.2008.00148.x
   Grimes D.A., 2001, COCHRANE DB SYST REV, V1
   Hameed W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104633
   Harper CC, 2008, OBSTET GYNECOL, V111, P1359, DOI 10.1097/AOG.0b013e318173fd83
   Heliovaara-Peippo S, 2013, AM J OBSTET GYNECOL, V209, DOI 10.1016/j.ajog.2013.08.041
   Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438
   Kaunitz AM, 2010, OBSTET GYNECOL, V116, P625, DOI 10.1097/AOG.0b013e3181ec622b
   Madden T, 2010, CONTRACEPTION, V81, P112, DOI 10.1016/j.contraception.2009.08.002
   Modesto W, 2014, HUM REPROD, V29, P1393, DOI 10.1093/humrep/deu089
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Population Reference Bureau, 2014, WORLD POP DAT SHEET
   Reading BF, GROWTH WORLD CONTRAC
   Sedgh G, 2014, STUD FAMILY PLANN, V45, P301, DOI 10.1111/j.1728-4465.2014.00393.x
   Stanwood NL, 2006, OBSTET GYNECOL, V108, P1417, DOI 10.1097/01.AOG.0000245447.56585.a0
   Trussell J, 2012, CONTRACEPTION, V85, P611, DOI 10.1016/j.contraception.2012.02.009
   Tyler CP, 2012, OBSTET GYNECOL, V119, P762, DOI 10.1097/AOG.0b013e31824aca39
   Bahamondes MV, 2012, CONTRACEPTION, V86, P244, DOI 10.1016/j.contraception.2011.12.005
   Whitaker AK, 2008, CONTRACEPTION, V78, P211, DOI 10.1016/j.contraception.2008.04.119
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2010, MED EL CRIT CONTR US
   Wu JP, 2014, CONTRACEPTION, V89, P495, DOI 10.1016/j.contraception.2014.02.011
NR 31
TC 7
Z9 7
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1411
J9 INT J WOMENS HEALTH
JI Int. J. Womens Health
PY 2015
VL 7
BP 717
EP 722
DI 10.2147/IJWH.S84173
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA V18KR
UT WOS:000214750800076
PM 26213479
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bottura, BF
   Bahamondes, MV
   Goncalves, MP
   Correia, VM
   Espejo-Arce, X
   Sousa, MH
   Monteiro, I
   Fernandes, A
AF Bahamondes, Luis
   Bottura, Bruna F.
   Valeria Bahamondes, M.
   Goncalves, Mayara P.
   Correia, Vinicius M.
   Espejo-Arce, Ximena
   Sousa, Maria H.
   Monteiro, Ilza
   Fernandes, Arlete
TI Estimated disability-adjusted life years averted by long-term provision
   of long acting contraceptive methods in a Brazilian clinic
SO HUMAN REPRODUCTION
LA English
DT Article
DE contraceptive methods; long-acting reversible contraceptives (LARCs);
   effectiveness; disability-adjusted life years; Brazil
ID UNITED-STATES; REVERSIBLE CONTRACEPTIVES; UNINTENDED PREGNANCY;
   EXPERIENCE; HEALTH; WOMEN; OPINION; DEVICES; BURDEN; IUD
AB STUDY QUESTION: What is the contribution of the provision, at no cost for users, of long acting reversible contraceptive methods (LARC; copper intrauterine device [IUD], the levonorgestrel-releasing intrauterine system [LNG-IUS], contraceptive implants and depot-medroxyprogesterone [DMPA] injection) towards the disability-adjusted life years (DALY) averted through a Brazilian university-based clinic established over 30 years ago.
   SUMMARY ANSWER: Over the last 10 years of evaluation, provision of LARC methods and DMPA by the clinic are estimated to have contributed to DALY averted by between 37 and 60 maternal deaths, 315-424 child mortalities, 634-853 combined maternal morbidity and mortality and child mortality, and 1056-1412 unsafe abortions averted.
   WHAT IS KNOWN ALREADY: LARC methods are associated with a high contraceptive effectiveness when compared with contraceptive methods which need frequent attention; perhaps because LARC methods are independent of individual or couple compliance. However, in general previous studies have evaluated contraceptive methods during clinical studies over a short period of time, or not more than 10 years. Furthermore, information regarding the estimation of the DALY averted is scarce.
   STUDY DESIGN, SIZE AND DURATION: We reviewed 50 004 medical charts from women who consulted for the first time looking for a contraceptive method over the period from 2 January 1980 through 31 December 2012.
   PARTICIPANTS/MATERIALS, SETTING, METHODS: Women who consulted at the Department of Obstetrics and Gynaecology, University of Campinas, Brazil were new users and users switching contraceptive, including the copper IUD (n = 13 826), the LNG-IUS (n = 1525), implants (n = 277) and DMPA (n = 9387). Estimation of the DALY averted included maternal morbidity and mortality, child mortality and unsafe abortions averted.
   MAIN RESULTS AND THE ROLE OF CHANCE: We obtained 29 416 contraceptive segments of use including 25 009 contraceptive segments of use from 20 821 new users or switchers to any LARC method or DMPA with at least 1 year of follow-up. The mean (+/- SD) age of the women at first consultation ranged from 25.3 +/- 5.7 (range 12- 47) years in the 1980s, to 31.9 +/- 7.4 (range 16-50) years in 2010-2011. The most common contraceptive chosen at the first consultation was copper IUD (48.3, 74.5 and 64.7% in the 1980s, 1990s and 2000s, respectively). For an evaluation over 20 years, the cumulative pregnancy rates (SEM) were 0.4 (0.2), 2.8 (2.1), 4.0 (0.4) and 1.3 (0.4) for the LNG-IUS, the implants, copper IUD and DMPA, respectively and cumulative continuation rates (SEM) were 15.1 (3.7), 3.9 (1.4), 14.1 (0.6) and 7.3 (1.7) for the LNG-IUS, implants, copper IUD and DMPA, respectively (P < 0.001). Over the last 10 years of evaluation, the estimation of the contribution of the clinic through the provision of LARC methods and DMPA to DALY averted was 37-60 maternal deaths; between 315 and 424 child mortalities; combined maternal morbidity and mortality and child mortality of between 634 and 853, and 1056-1412 unsafe abortions averted.
   LIMITATIONS, REASONS FOR CAUTION: The main limitations are the number of women who never returned to the clinic (overall 14% among the four methods under evaluation); consequently the pregnancy rate could be different. Other limitations include the analysis of two kinds of copper IUD and two kinds of contraceptive implants as the same IUD or implant, and the low number of users of implants. In addition, the DALY calculation relies on a number of estimates, which may vary in different parts of the world.
   WIDER IMPLICATIONS OF THE FINDINGS: LARC methods and DMPA are highly effective and women who were well-counselled used these methods for a long time. The benefit of averting maternal morbidity and mortality, child mortality, and unsafe abortions is an example to health policy makers to implement more family planning programmes and to offer contraceptive methods, mainly LARC and DMPA, at no cost or at affordable cost for the underprivileged population.
   STUDY FUNDING/COMPETING INTEREST(S): This study received partial financial support from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant # 2012/12810-4 and from the National Research Council (CNPq), grant # 573747/ 2008- 3. B. F. B., M.P.G., and V.M.C. were fellows from the scientific initiation programme from FAPESP. Since the year 2001, all the TCu380A IUD were donated by Injeflex, Sao Paulo, Brazil, and from the year 2006 all the LNG-IUS were donated by the International Contraceptive Access Foundation (ICA), Turku, Finland. Both donations are as unrestricted grants. The authors declare that there are no conflicts of interest associated with this study.
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
   Univ Campinas UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Fernandes, Arlete/I-7561-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Fernandes,
   Arlete/0000-0001-5872-0017
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/12810-4];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant # 2012/12810-4
   and from the National Research Council (CNPq), grant # 573747/2008-3.
CR [Anonymous], 2008, PREV CONTR US SEL CO
   [Anonymous], 2013, AB STAT ENGL WAL 201
   Aoun J, 2014, OBSTET GYNECOL, V123, P585, DOI 10.1097/AOG.0000000000000144
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Blumenthal PD, 2013, CONTRACEPTION, V87, P170, DOI 10.1016/j.contraception.2012.10.002
   Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6
   Diaz J., 1992, Advances in Contraception, V8, P275, DOI 10.1007/BF02042585
   DIAZ J, 1992, Advances in Contraception, V8, P67, DOI 10.1007/BF01849351
   do Amaral MCE, 2005, CONTRACEPTION, V72, P157, DOI 10.1016/j.contraception.2005.02.013
   Eisenberg D, 2013, J ADOLESCENT HEALTH, V52, pS59, DOI 10.1016/j.jadohealth.2013.01.012
   Espey E, 2011, OBSTET GYNECOL, V117, P705, DOI 10.1097/AOG.0b013e31820ce2f0
   Etienne CF, 2013, REV PANAM SALUD PUBL, V34, P375
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Finer LB, 2012, FERTIL STERIL, V98, P893, DOI 10.1016/j.fertnstert.2012.06.027
   Mendes ADG, 2012, CAD SAUDE PUBLICA, V28, P955, DOI 10.1590/S0102-311X2012000500014
   Jones J, 2012, NATL HLTH STAT REPOR
   Jones RK, 2014, PERSPECT SEX REPRO H, V46, P3, DOI 10.1363/46e0414
   Makuch MY, 2012, INT J GYNECOL OBSTET, V117, P5, DOI 10.1016/j.ijgo.2011.11.018
   Makuch MY, 2011, CONTRACEPTION, V84, P622, DOI 10.1016/j.contraception.2011.03.010
   Mavranezouli I, 2008, HUM REPROD, V23, P1338, DOI 10.1093/humrep/den091
   Meirik O, 2001, OBSTET GYNECOL, V97, P539, DOI 10.1016/S0029-7844(00)01220-5
   Nascimento Roberta, 2002, Drugs R D, V3, P387, DOI 10.2165/00126839-200203060-00003
   Office for National Statistics, 2009, 41 OFF NAT STAT
   Okie S, 2006, NEW ENGL J MED, V354, P1977, DOI 10.1056/NEJMp068069
   Organisation World Health, 2003, INTR METH ASS ENV BU
   SIVIN I, 1994, FERTIL STERIL, V61, P70
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   Sivin I, 2000, CONTRACEPTION, V61, P187, DOI 10.1016/S0010-7824(00)00095-0
   SIVIN I, 1993, CONTRACEPTION, V47, P37
   Sivin I, 2007, CONTRACEPTION, V75, pS70, DOI 10.1016/j.contraception.2007.01.016
   Stover J, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S4
   Trussell J, 2013, CONTRACEPTION, V87, P154, DOI 10.1016/j.contraception.2012.07.016
   Tsui AO, 2010, EPIDEMIOL REV, V32, P152, DOI 10.1093/epirev/mxq012
   United Nations Department of Economic and Social Affairs Population Division, 2012, WORLD CONTR US 2012
   Wellings K, 2007, CONTRACEPTION, V76, P208, DOI 10.1016/j.contraception.2007.05.085
   Wilson EK, 2013, J ADOLESCENT HEALTH, V52, P278, DOI 10.1016/j.jadohealth.2012.05.004
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2008, GLOB BURD DIS 2004 U
   World Health Organization, 2010, MED EL CRIT CONTR US
   World Health Organization UNICEF UNFPA World Bank, 2012, TRENDS MAT MORT 1990
   Xu X, 2012, CONTRACEPTION, V85, P155, DOI 10.1016/j.contraception.2011.06.007
NR 42
TC 20
Z9 20
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD OCT
PY 2014
VL 29
IS 10
BP 2163
EP 2170
DI 10.1093/humrep/deu191
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA AR2LO
UT WOS:000343418500010
PM 25085802
OA Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Makuch, MY
AF Bahamondes, Luis
   Makuch, Maria Y.
TI Infertility care and the introduction of new reproductive technologies
   in poor resource settings
SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
LA English
DT Review
DE Infertility; Assisted reproductive technologies; Low cost; Inequity
ID MINIMAL OVARIAN STIMULATION; IN-VITRO FERTILIZATION; ELECTIVE SINGLE;
   FERTILITY AWARENESS; CLOMIPHENE CITRATE; ACCESS; SERVICES; FEMALE;
   HEALTH; IVF
AB Background: The overall prevalence of infertility was estimated to be 3.5-16.7% in developing countries and 6.9-9.3% in developed countries. Furthermore, according to reports from some regions of sub-Saharan Africa, the prevalence rate is 30-40%. The consequences of infertility and how it affects the lives of women in poor-resource settings, particularly in developing countries, has become an important issue to be discussed in reproductive health. In some societies, the inability to fulfill the desire to have children makes life difficult for the infertile couple. In many regions, infertility is considered a tragedy that affects not only the infertile couple or woman, but the entire family.
   Methods: This is a position paper which encompasses a review of the needs of low-income infertile couples, mainly those living in developing countries, regarding access to infertility care, including ART and initiatives to provide ART at low or affordable cost. Information was gathered from the databases MEDLINE, CENTRAL, POPLINE, EMBASE, LILACS, and ICTRP with the key words: infertility, low income, assisted reproductive technologies, affordable cost, low cost.
   Results: There are few initiatives geared toward implementing ART procedures at low cost or at least at affordable cost in low-income populations. Nevertheless, from recent studies, possibilities have emerged for new low-cost initiatives that can help millions of couples to achieve the desire of having a biological child.
   Conclusions: It is necessary for healthcare professionals and policymakers to take into account these new initiatives in order to implement ART in resource-constrained settings.
C1 [Bahamondes, Luis; Makuch, Maria Y.] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
CR Aleyamma TK, 2011, HUM REPROD, V26, P3312, DOI 10.1093/humrep/der323
   Allersma T, 2013, COCHRANE DB SYST REV, V8
   Amato P, 2013, FERTIL STERIL, V100, P645, DOI 10.1016/j.fertnstert.2013.02.051
   Araoye Margaret O, 2003, West Afr J Med, V22, P190
   Baird DT, 2010, HUM REPROD UPDATE, V16, P590, DOI 10.1093/humupd/dmq023
   Blackwell RE, 2001, FERTIL STERIL, V75, P749, DOI 10.1016/S0015-0282(01)01673-9
   Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046
   Brkovich AM, 1998, J PSYCHOSOM OBST GYN, V19, P218, DOI 10.3109/01674829809025700
   Chai J, 2014, HONG KONG MED J, V20, P102, DOI 10.12809/hkmj134065
   Daar A. S., 2002, CURRENT PRACTICES CO
   DANIELS KR, 1992, AUST NZ J OBSTET GYN, V32, P51
   DANILUK JC, 1988, FERTIL STERIL, V49, P982
   Dhont N, 2011, HUM REPROD, V26, P623, DOI 10.1093/humrep/deq373
   Dyer SJ, 2007, J PSYCHOSOM OBST GYN, V28, P69, DOI 10.1080/01674820701409959
   Dyer SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/humrep/17.6.1663
   ELSTEIN M, 1975, BRIT MED J, V3, P296, DOI 10.1136/bmj.3.5978.296
   Ercan CM, 2014, EUR J OBSTET GYN R B, V175, P163, DOI 10.1016/j.ejogrb.2014.01.008
   European Society for Human Reproduction (ESHRE), 2014, TASK FORC DEV COUNTR
   Fathalla MF, 2006, LANCET, V368, P2095, DOI 10.1016/S0140-6736(06)69483-X
   Frydman R, 2008, HUM REPROD, P85, DOI 10.1093/humrep/den163
   Gerrits T., 2012, FACTS VIEWS VIS OBGY, P1
   GREENHALL E, 1990, FERTIL STERIL, V54, P978
   Greil A. L, 1997, SOC SCI MED, V45, P1506
   Hamberger L, 1997, INT J GYNECOL OBSTET, V58, P149, DOI 10.1016/S0020-7292(97)00286-5
   Hammarberg K, 2013, REPROD BIOMED ONLINE, V26, P189, DOI 10.1016/j.rbmo.2012.11.009
   Henne MB, 2008, FERTIL STERIL, V89, P66, DOI 10.1016/j.fertnstert.2007.01.167
   Holton S, 2011, J POPUL RES, V28, P353, DOI 10.1007/s12546-011-9072-3
   Hovatta O, 2006, INT J GYNECOL OBSTET, V94, P287, DOI 10.1016/j.ijgo.2006.04.012
   Inhorn MC, 2009, INT J GYNECOL OBSTET, V106, P172, DOI 10.1016/j.ijgo.2009.03.034
   Johnson MH, 2014, REPROD BIOMED ONLINE, V28, P265, DOI 10.1016/j.rbmo.2014.01.001
   Johnson MH, 2000, ESSENTIAL REPROD
   Kato K, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-35
   Kawachiya S, 2006, FERTIL STERIL, V86, pS412, DOI 10.1016/j.fertnstert.2006.07.1137
   Kessler LM, 2013, FERTIL STERIL, V100, P1025, DOI 10.1016/j.fertnstert.2013.05.040
   KRAFT AD, 1980, AM J ORTHOPSYCHIAT, V50, P618, DOI 10.1111/j.1939-0025.1980.tb03324.x
   Lampic C, 2006, HUM REPROD, V21, P558, DOI 10.1093/humrep/dei367
   Langridge Paul, 2005, Nurs Times, V101, P47
   Larsen U, 2005, FERTIL STERIL, V83, P846, DOI 10.1016/j.fertnstert.2004.11.033
   LEKE RJI, 1993, ENVIRON HEALTH PERSP, V101, P73, DOI 10.2307/3431379
   Lopez-Regalado ML, 2014, EUR J OBSTET GYN R B, V178, P192, DOI 10.1016/j.ejogrb.2014.04.009
   LUNA F, 2002, CURRENT PRACTICES CO, P31
   Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P317, DOI 10.1093/humupd/dmh028
   Makuch MY, 2011, HUM REPROD, V26, P2054, DOI 10.1093/humrep/der158
   Makuch MY, 2010, HUM REPROD, V25, P430, DOI 10.1093/humrep/dep405
   Makuch Y, 2012, FACTS VIEWS VIS OBGY, V4, P221
   MENNING BE, 1980, FERTIL STERIL, V34, P313
   Nachtigall RD, 2006, FERTIL STERIL, V85, P871, DOI 10.1016/j.fertnstert.2005.08.066
   Nations U, 2000, MILLENNIUM DEV GOALS
   Obermeyer CM, 2005, CULT HEALTH SEX, V7, P443, DOI 10.1080/14789940500181495
   Okonofua FE, 1996, BRIT J OBSTET GYNAEC, V103, P957, DOI 10.1111/j.1471-0528.1996.tb09542.x
   Ombelet W, 2013, FACTS VIEWS VIS OBGY, V5, P161
   Ombelet W, 2008, HUM REPROD UPDATE, V14, P605, DOI 10.1093/humupd/dmn042
   Ombelet W, 2007, REPROD BIOMED ONLINE, V15, P257, DOI 10.1016/S1472-6483(10)60337-9
   Ombelet W, 2014, REPROD BIOMED ONLINE, V28, P267, DOI 10.1016/j.rbmo.2013.11.013
   Ombelet W, 2009, INT J GYNECOL OBSTET, V106, P168, DOI 10.1016/j.ijgo.2009.03.033
   Pandian Z, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003416.pub4
   Peterson BD, 2012, HUM REPROD, V27, P1375, DOI 10.1093/humrep/des011
   PLATT JJ, 1973, FERTIL STERIL, V24, P972
   Read SC, 2014, PATIENT EDUC COUNS, V94, P390, DOI 10.1016/j.pec.2013.10.025
   Roberts E, 2011, HUM REPROD, V26, P1202, DOI 10.1093/humrep/der007
   Rutstein SO, 2004, DHS COMP REPORTS, V6
   Sandelowski M, 1988, Health Care Women Int, V9, P147
   Schmidt L, 2009, HUM FERTIL, V12, P14, DOI 10.1080/14647270802331487
   SEIBEL MM, 1982, FERTIL STERIL, V37, P137
   Serour GI, 2009, INT J GYNECOL OBSTET, V106, P99, DOI 10.1016/j.ijgo.2009.03.041
   Shapiro C, 1993, INFERTILITY PREGNANC
   Soullier N, 2008, HUM REPROD, V23, P187, DOI 10.1093/humrep/dem352
   STEPTOE PC, 1978, LANCET, V2, P366
   Teramoto S, 2007, REPROD BIOMED ONLINE, V15, P134, DOI 10.1016/S1472-6483(10)60701-8
   *UN, 1995, INT C POP DEV CAIR E
   van Balen F, 2001, HUM REPROD, V16, P215, DOI 10.1093/humrep/16.2.215
   Van Balen F, 2002, INFERTILITY GLOBE NE, P79
   van Balen F, 2009, FACTS VIEWS VIS OBGY, V1, P106
   Van Blerkom J, 2014, REPROD BIOMED ONLINE, V28, P310, DOI 10.1016/j.rbmo.2013.11.012
   van Rooij FB, 2006, HUM REPROD, V21, P1832, DOI 10.1093/humrep/del046
   vanBalen F, 1996, PATIENT EDUC COUNS, V28, P247, DOI 10.1016/0738-3991(95)00852-7
   Vassard D, 2012, HUM REPROD, V27, P3502, DOI 10.1093/humrep/des353
   Vayena E., 2002, CURRENT PRACTICES CO
   Vayena E, 2009, FERTIL STERIL, V92, P413, DOI 10.1016/j.fertnstert.2009.02.011
   von Wolff M, 2014, REPROD BIOMED ONLINE, V29, P209, DOI 10.1016/j.rbmo.2014.04.013
   *WHO, 1987, FERTIL STERIL, V47, P944
   WIDGE A, 2002, CURRENT PRACTICES CO, P60
   World Health Organization, 1991, GEN PROGR MAT CHILD
NR 83
TC 14
Z9 16
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477-7827
J9 REPROD BIOL ENDOCRIN
JI Reprod. Biol. Endocrinol.
PD SEP 8
PY 2014
VL 12
AR 87
DI 10.1186/1477-7827-12-87
PG 7
WC Endocrinology & Metabolism; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA AS2MJ
UT WOS:000344114100001
PM 25201070
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Modesto, W
   Bahamondes, MV
   dos Santos, PS
   Fernandes, A
   Dal'Ava, N
   Bahamondes, L
AF Modesto, Waleska
   Valeria Bahamondes, M.
   dos Santos, Priscila Silva
   Fernandes, Arlete
   Dal'Ava, Natalia
   Bahamondes, Luis
TI Exploratory study of the effect of lifestyle counselling on bone mineral
   density and body composition in users of the contraceptive
   depot-medroxyprogesterone acetate
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Depot-medroxyprogesterone acetate; Bone mineral density; Body
   composition
ID VITAMIN-D; HORMONAL CONTRACEPTION; ORAL-CONTRACEPTIVES; 1ST-TIME USERS;
   WOMEN; RECOVERY; CALCIUM; MASS
AB Objectives To compare variations in bone mineral density (BMD) and body composition (BC) in depot-medroxyprogesterone acetate (DMPA) users and nonusers after providing counselling on healthy lifestyle habits.
   Methods An exploratory study in which women aged 18 to 40 years participated: 29 new DMPA users and 25 new non-hormonal contraceptive users. All participants were advised on healthy lifestyle habits: sun exposure, walking and calcium intake. BMD and BC were assessed at baseline and 12 months later. Statistical analysis included the Mann-Whitney test or Student's t-test followed by multiple linear regression analysis.
   Results Compared to the controls, DMPA users had lower BMD at vertebrae L1 and L4 after 12 months of use. They also had a mean increase of 2 kg in total fat mass and an increase of 2.2% in body fat compared to the non-hormonal contraceptive users. BMD loss at L1 was less pronounced in DMPA users with a calcium intake >= 1 g/day compared to DMPA users with a lower calcium intake.
   Conclusions DMPA use was apparently associated with lower BMD and an increase in fat mass at 12 months of use. Calcium intake >= 1 g/day attenuates BMD loss in DMPA users. Counselling on healthy lifestyle habits failed to achieve its aims.
C1 Univ Estadual Campinas, UNICAMP, Sch Med Sci, Human Reprod Unit,Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [09/53293-0,
   2011/01554-4]; National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The authors received financial support from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [grant # 09/53293-0] and the
   National Research Council (CNPq) [grant # 573747/2008-3]. WM has a
   fellowship from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [grant # 2011/01554-4].
CR Ahola R, 2010, J BIOMECH, V43, P1960, DOI 10.1016/j.jbiomech.2010.03.021
   Albertazzi P, 2006, CONTRACEPTION, V73, P577, DOI 10.1016/j.contraception.2006.02.004
   Babatunde OO, 2014, J BONE MINER METAB, V32, P305, DOI 10.1007/s00774-013-0497-y
   Berenson AB, 2004, OBSTET GYNECOL, V103, P899, DOI 10.1097/01.AOG.0000117082.49490.d5
   Berenson AB, 2001, OBSTET GYNECOL, V98, P576, DOI 10.1016/S0029-7844(01)01495-8
   Berenson AB, 2008, OBSTET GYNECOL, V112, P788, DOI 10.1097/AOG.0b013e3181875b78
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Clark MK, 2006, FERTIL STERIL, V86, P1466, DOI 10.1016/j.fertnstert.2006.05.024
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   Clark MK, 2004, FERTIL STERIL, V82, P1580, DOI 10.1016/j.fertnstert.2004.04.064
   Consensus Development Conference, 1991, OSTEOPOROSIS INT, V1, P114
   Cundy T, 1998, OBSTET GYNECOL, V92, P569, DOI 10.1016/S0029-7844(98)00270-1
   Feskanich D, 2003, AM J CLIN NUTR, V77, P504
   Frost HM, 2000, J PEDIATR ENDOCR MET, V13, P571, DOI 10.1515/JPEM.2000.13.6.571
   Kaunitz AM, 2006, CONTRACEPTION, V74, P90, DOI 10.1016/j.contraception.2006.03.010
   Michaelsson K, 2003, BONE, V32, P694, DOI 10.1016/S8756-3282(03)00048-6
   Murad MH, 2011, J CLIN ENDOCR METAB, V96, P2997, DOI 10.1210/jc.2011-1193
   Pludowski P, 2013, AUTOIMMUN REV, V12, P976, DOI 10.1016/j.autrev.2013.02.004
   Scholes D, 1999, OBSTET GYNECOL, V93, P233, DOI 10.1016/S0029-7844(98)00447-5
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648-200209000-00015
   Wanichsetakul P, 2002, CONTRACEPTION, V65, P407, DOI 10.1016/S0010-7824(02)00308-6
   Warensjo E, 2011, BMJ-BRIT MED J, V24, pd1473
   Wetmore CM, 2008, OSTEOPOROSIS INT, V19, P519, DOI 10.1007/s00198-007-0473-2
NR 23
TC 5
Z9 6
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD AUG
PY 2014
VL 19
IS 4
BP 244
EP 249
DI 10.3109/13625187.2014.924098
PG 6
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA AN0FJ
UT WOS:000340259000004
PM 24923792
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   Castro, S
   Marchi, NM
   Marcovici, M
   Andrade, LALA
   Fernandes, A
   Bahamondes, L
AF Bahamondes, M. Valeria
   Castro, Sara
   Marchi, Nadia M.
   Marcovici, Michele
   Andrade, Liliana A. L. A.
   Fernandes, Arlete
   Bahamondes, Luis
TI Human vaginal histology in long-term users of the injectable
   contraceptive depot-medroxyprogesterone acetate
SO CONTRACEPTION
LA English
DT Article
DE Injectable contraceptive; Vaginal histology; Reproductive age; Long-term
   users
ID HORMONAL CONTRACEPTION; HIV-INFECTION; NORTHERN THAILAND; LANGERHANS
   CELLS; RHESUS-MONKEYS; SOUTH-AFRICA; RISK-FACTORS; SEX WORKERS;
   EPITHELIUM; WOMEN
AB Objectives: Apparently, depot-medroxyprogesterone acetate (DMPA) increases a woman's risk of acquiring HIV. The objective of this study was to test whether the vaginal mucosal thickness and Langerhans cell counts were significantly different in long-term DMPA users compared with women users of an intrauterine device (IUD) who had never used DMPA.
   Study design: Cross-sectional study. Twenty-three DMPA users were matched with 23 nonusers controlled for age, body mass index (BMI; kg/m(2)), and duration of contraceptive use. Four groups of women were evaluated according to the duration of DMPA use: >1, <5; >= 5, <10; >= 10, <15 or >= 15 years. Estradiol (E-2) levels were compared between the two groups. Histologic sections of vaginal mucosal biopsies were evaluated to measure the mean epithelial thickness and S100 immunostained sections were used to count the number of Langerhans cells/mm.
   Results: Mean (+/- S.D.) E-2 levels were significantly lower in DMPA users (39.4 +/- 26.6 pg/mL) compared with nonusers (102.6 +/- 60.3 pg/mL) despite similar ages (42.3 +/- 7.4 and 42.4 +/- 7.4 years, respectively). Mean (+/- S.D.) vaginal thickness was 232.6 +/- 108.1 and 229.7 +/- 112.9 in DMPA users and nonusers, respectively. There were no differences in vaginal thickness or Langerhans cell count/mm between users and nonusers even after controlling for DMPA duration of use.
   Conclusions: Vaginal epithelial thinning or Langerhans cell count was not different between long-term DMPA users and copper-IUD users who had never used DMPA. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Bahamondes, M. Valeria; Castro, Sara; Marchi, Nadia M.; Marcovici, Michele; Fernandes, Arlete; Bahamondes, Luis] Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med Sci, Campinas, SP, Brazil.
   [Bahamondes, M. Valeria; Castro, Sara; Marchi, Nadia M.; Marcovici, Michele; Fernandes, Arlete; Bahamondes, Luis] Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
   [Andrade, Liliana A. L. A.] Univ Estadual Campinas, Dept Pathol, Sch Med Sci, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/22361-0];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant #2011/22361-0
   and from the National Research Council (CNPq), grant #573747/2008-3. M.
   Marcovici is a fellow from the Scientific Initiation Program of the
   Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP), Brazil.
CR Baeten JM, 2007, AIDS, V21, P1771, DOI 10.1097/QAD.0b013e328270388a
   Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Blish CA, 2011, AM J REPROD IMMUNOL, V65, P302, DOI 10.1111/j.1600-0897.2010.00930.x
   BULTERYS M, 1994, AIDS, V8, P1585, DOI 10.1097/00002030-199411000-00010
   Connor JP, 1999, GYNECOL ONCOL, V75, P130, DOI 10.1006/gyno.1999.5559
   DALY CC, 1994, GENITOURIN MED, V70, P110
   Fraser I S, 1981, Med J Aust, V1, P3
   Heffron R, 2013, AIDS, V27, P261, DOI 10.1097/QAD.0b013e32835ad473
   Heffron R, 2012, LANCET INFECT DIS, V12, P19, DOI 10.1016/S1473-3099(11)70247-X
   Heffron R, 2010, SEX TRANSM DIS, V37, P621, DOI 10.1097/OLQ.0b013e3181e1a162
   Hild-Petito S, 1998, AIDS RES HUM RETROV, V14, pS125
   Hu JJ, 1998, LAB INVEST, V78, P435
   Ildgruben AK, 2003, OBSTET GYNECOL, V102, P571, DOI 10.1016/S0029-7844(03)00618-5
   Jain AK, 2012, CONTRACEPTION, V86, P645, DOI 10.1016/j.contraception.2012.03.008
   Kapiga SH, 1998, AIDS, V12, P75, DOI 10.1097/00002030-199801000-00009
   Kaunitz AM, 2002, J REPROD MED, V47, P785
   Kiddugavu M, 2003, AIDS, V17, P233, DOI 10.1097/00002030-200301240-00014
   Kilmarx PH, 1998, AIDS, V12, P1889, DOI 10.1097/00002030-199814000-00021
   Lavreys L, 2004, AIDS, V18, P695, DOI 10.1097/00002030-200403050-00017
   Martin HL, 1998, J INFECT DIS, V178, P1053
   Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084
   Mauck CK, 1999, CONTRACEPTION, V60, P15, DOI 10.1016/S0010-7824(99)00058-X
   Miller L, 2000, OBSTET GYNECOL, V96, P431, DOI 10.1016/S0029-7844(00)00906-6
   Morrison CS, 2007, AIDS, V21, P85, DOI 10.1097/QAD.0b013e3280117c8b
   Morrison CS, 2012, AIDS, V26, P497, DOI 10.1097/QAD.0b013e32834fa13d
   Myer L, 2007, INT J EPIDEMIOL, V36, P166, DOI 10.1093/ije/dyl251
   Nagachinta T, 1997, AIDS, V11, P1765, DOI 10.1097/00002030-199714000-00014
   REHLE T, 1992, INFECTION, V20, P328, DOI 10.1007/BF01710677
   Ungchusak K, 1996, J ACQ IMMUN DEF SYND, V12, P500, DOI 10.1097/00042560-199608150-00010
   Wand H, 2012, AIDS, V26, P375, DOI 10.1097/QAD.0b013e32834f990f
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
   Wieser F, 2001, FERTIL STERIL, V75, P1234, DOI 10.1016/S0015-0282(01)01796-4
   Wilcher R, 2013, CURR OPIN HIV AIDS, V8, P490, DOI 10.1097/COH.0b013e3283632bd7
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 34
TC 19
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD AUG
PY 2014
VL 90
IS 2
BP 117
EP 122
DI 10.1016/j.contraception.2014.01.024
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AL8DI
UT WOS:000339367700003
PM 24613369
DA 2020-12-01
ER

PT J
AU Dal'Ava, N
   Bahamondes, L
   Bahamondes, MV
   Bottura, BF
   Monteiro, I
AF Dal'Ava, Natalia
   Bahamondes, Luis
   Bahamondes, M. Valeria
   Bottura, Bruna F.
   Monteiro, Ilza
TI Body weight and body composition of depot medroxyprogesterone acetate
   users
SO CONTRACEPTION
LA English
DT Article
DE Body mass; Fat mass; Lean mass; DMPA; Hormonal contraceptives;
   Dual-energy X-ray absorptiometry
ID COPPER IUD; RESISTANCE; INCREASE; FAT
AB Objectives: Weight gain is a concern with the contraceptive depot-medroxyprogesterone acetate (DMPA); however, this issue remains controversial. The objective of this study was to compare body weight (BW) and body composition (BC) in DMPA and copper intrauterine device (IUD) users at baseline and after one year of use.
   Study Design: We enrolled new DMPA users and age and weight matched new IUD users into this prospective study. Weight and height were measured, BC (fat and lean mass) was evaluated using dual-energy X-ray absorptiometry, and physical activity was assessed at baseline and at 12 months. Student's paired t test and the,Wilcoxon paired test for matched samples were used.
   Results: Ninety-seven women were enrolled for the study; 26 matched pairs continued using the initial method for at least one year, and completed the baseline and 12 month assessments. An increase of 1.9 kg occurred in BW (p=.02) in DMPA users at 12 months of use, resulting from an increase in fat mass of 1.6 kg (p=.03). Weight remained stable in IUD users; however, there was an increase in lean mass at 12 months of use (p=.001). The number of women practicing physical activity increased in this group. There was a significant difference between the groups regarding the variation in the percentage of central fat (p=.04).
   Conclusion: Weight gain in the DMPA group after the first year of use resulted from an increase in fat mass. Weight remained stable in the IUD group; however, an increase in lean mass and a reduction in localized abdominal fat mass occurred, possibly because more users were practicing physical activity. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Dal'Ava, Natalia] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Dal'Ava, N (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM na_taliads@hotmail.com
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/15595-4];
   Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant
   #2009/15595-4, and the Brazilian National Research Council (CNPq), grant
   573747/2008-3.
CR Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Bakry S, 2008, ARCH GYNECOL OBSTET, V278, P1, DOI 10.1007/s00404-007-0497-z
   Balasch J, 2003, HUM REPROD UPDATE, V9, P207, DOI 10.1093/humupd/dmg017
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Buppasiri P., 2012, PROGESTIN ONLY CONTR
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   De Cetina TEC, 2001, CONTRACEPTION, V63, P143
   Friendly M., 1995, SAS SYST STAT GRAPH
   Guilbert ER, 2009, CONTRACEPTION, V79, P167, DOI 10.1016/j.contraception.2008.10.016
   Haider S, 2007, CLIN OBSTET GYNECOL, V50, P898, DOI 10.1097/GRF.0b013e318159c20a
   Hajikazemi E, 2004, INT CONGR SER, V1271, P315, DOI 10.1016/j.ics.2004.05.067
   Hassan DF, 2003, CONTRACEPTION, V68, P27, DOI 10.1016/S0010-7824(03)00079-9
   Irving BA, 2008, MED SCI SPORT EXER, V40, P1863, DOI 10.1249/MSS.0b013e3181801d40
   Ismail I, 2012, OBES REV, V13, P68, DOI 10.1111/j.1467-789X.2011.00931.x
   Karastergiou K, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-13
   Le YCL, 2009, OBSTET GYNECOL, V114, P279, DOI 10.1097/AOG.0b013e3181af68b2
   Lopez LM, 2011, COCHRANE DB SYST REV, V13
   Lopez LM, 2013, COCHRANE DATABASE SY
   O'Leary VB, 2006, J APPL PHYSIOL, V100, P1584, DOI 10.1152/japplphysiol.01336.2005
   Ogden Cynthia L, 2012, NCHS Data Brief, P1
   OPAS. Organizacao Pan-Americana da Saude, 2003, DOENC CRON OB ESTR M
   Pantoja M, 2010, CONTRACEPTION, V81, P107, DOI 10.1016/j.contraception.2009.07.008
   Wajchenberg BL, 2000, ENDOCR REV, V21, P697, DOI 10.1210/er.21.6.697
   Westhoff C, 2007, CONTRACEPTION, V75, P261, DOI 10.1016/j.contraception.2006.12.009
   Word Health Organization, 2003, NUTR CONTR GLOB OB
   Wright SM, 2012, ABDOM IMAGING, V37, P730, DOI 10.1007/s00261-012-9862-x
NR 26
TC 11
Z9 11
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD AUG
PY 2014
VL 90
IS 2
BP 182
EP 187
DI 10.1016/j.contraception.2014.03.011
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AL8DI
UT WOS:000339367700013
PM 24780631
DA 2020-12-01
ER

PT J
AU Modesto, W
   Bahamondes, MV
   Bahamondes, L
AF Modesto, Waleska
   Valeria Bahamondes, M.
   Bahamondes, Luis
TI A randomized clinical trial of the effect of intensive versus
   non-intensive counselling on discontinuation rates due to bleeding
   disturbances of three long-acting reversible contraceptives
SO HUMAN REPRODUCTION
LA English
DT Article
DE counselling; long-acting contraceptive methods; copper intrauterine
   device; implant; levonorgestrel-releasing intrauterine system
ID INTRAUTERINE SYSTEM MIRENA(R); IMPLANON(R); PERFORMANCE; ACCEPTABILITY;
   SATISFACTION; CONTINUATION; WOMEN
AB Does intensive counselling before insertion and throughout the first year of use have any influence on discontinuation rates due to unpredictable menstrual bleeding in users of three long-acting reversible contraceptives (LARCs)?
   Intensive counselling had a similar effect to routine counselling in terms of discontinuation rates due to unpredictable menstrual bleeding in new users of the contraceptives.
   Contraceptive efficacy and satisfaction rates are very high with LARCs, including the etonogestrel (ENG)-releasing implant, the levonorgestrel-releasing intrauterine system (LNG-IUS) and the TCu380A intrauterine device (IUD). However, unpredictable menstrual bleeding constitutes the principal reason for premature discontinuation, particularly in the cases of the ENG-implant and the LNG-IUS.
   A randomized clinical trial was conducted between 2011 and 2013, and involved 297 women: 98 ENG-implant users, 99 LNG-IUS users and 100 TCu380A IUD users.
   Women accepting each contraceptive method were randomized into two groups after the women chose their contraceptive method. Group I received routine counselling at the clinic, including information on safety, efficacy and side effects, as well as what to expect regarding bleeding disturbances. Group II received 'intensive counselling'. In addition to the information provided to those in Group I, these women also received leaflets on their chosen method and were seen by the same three professionals, the most experienced at the clinic, throughout the year of follow-up. These three professionals went over all the information provided at each consultation. Women in both groups were instructed to return to the clinic after 45 (+/- 7) days and at 6 and 12 (+/- 1) months after insertion. They were instructed to record all bleeding episodes on a menstrual calendar specifically provided for this purpose. Additionally, satisfaction with the method was evaluated by a questionnaire completed by the women after 12 months of use of the contraceptive method.
   There were no significant differences between the intensive and routine counselling groups on the discontinuation rates due to unpredictable menstrual bleeding of the three contraceptives under evaluation. The 1-year cumulative discontinuation rates due to menstrual bleeding irregularities were 2.1, 2.7 and 4.0% and the continuation rates were 82.6, 81.0 and 73.2%, for the ENG-implant, the LNG-IUS or the TCu380A IUD users, respectively. The main reasons for discontinuation of the methods were weight gain in users of the ENG-implant and expulsion of the TCu380A.
   The main limitations are that we cannot assure generalization of the results to another settings and that the routine counselling provided by our counsellors may already be appropriate for the women attending the clinic and so consequently intensive counselling including written leaflets was unable to influence the premature discontinuation rate due to unpredictable menstrual bleeding. Additionally, counselling could discourage some women from using the LARC methods offered in the study and consequently those women may have decided on other contraceptives.
   Routine counselling may be sufficient for many women to help reduce premature discontinuation rates and improve continuation rates and user satisfaction among new users of LARC methods.
   The trial was registered at clinicaltrials.gov (NCT01392157).
   The study was partially funded by the Fundacao de Apoio a Pesquisa do Estado de Sao Paulo (FAPESP) grant # 2012/01379-0, the Brazilian National Research Council (CNPq) grant #573747/2008-3 and by Merck (MSD), Brazil under an unrestricted grant. The LNG-IUS were donated by the International Contraceptive Access Foundation (ICA) and the copper IUD by Injeflex, Sao Paulo, Brazil. L.B. has occasionally served on the Board of MSD, Bayer and Vifor.
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Human Reprod Unit, Dept Obstet & Gynaecol, Sch Med Sci, BR-13084971 Campinas, SP, Brazil.
   Univ Campinas UNICAMP, Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Human Reprod Unit, Dept Obstet & Gynaecol, Sch Med Sci, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/01379-0];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]; MSD, Brazil
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) under grant #
   2012/01379-0, from the National Research Council (CNPq) under grant #
   573747/2008-3 and from an unrestricted grant from MSD, Brazil. The
   LNG-IUS were donated by the International Contraceptive Access
   Foundation (ICA) and the copper IUD by Injeflex, Sao Paulo, Brazil.
CR Agrawal A, 2005, J FAM PLAN REPROD H, V31, P310, DOI 10.1783/147118905774480581
   ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0
   Backman T, 2002, OBSTET GYNECOL, V99, P608, DOI 10.1016/S0029-7844(01)01764-1
   Baldaszti E, 2003, CONTRACEPTION, V67, P87, DOI 10.1016/S0010-7824(02)00482-1
   Bitzer J, 2013, EUR J CONTRACEP REPR, V18, P372, DOI 10.3109/13625187.2013.819077
   Croxatto H B, 2000, Eur J Contracept Reprod Health Care, V5 Suppl 2, P21
   Croxatto HB, 1999, HUM REPROD, V14, P976, DOI 10.1093/humrep/14.4.976
   Croxatto HB, 2002, CONTRACEPTION, V65, P21, DOI 10.1016/S0010-7824(01)00294-3
   DARCANGUES C, 1989, CONTRACEPTION, V40, P531
   Davie JE, 1996, CLIN THER, V18, P150, DOI 10.1016/S0149-2918(96)80187-1
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   Ferreira JM, 2014, CONTRACEPTION, V89, P17, DOI 10.1016/j.contraception.2013.09.012
   Gemzell-Danielsson K, 2011, ACTA OBSTET GYN SCAN, V90, P869, DOI 10.1111/j.1600-0412.2011.01180.x
   Harvey C, 2009, CONTRACEPTION, V80, P527, DOI 10.1016/j.contraception.2009.05.132
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Kalmuss D, 1996, FAM PLANN PERSPECT, V28, P256, DOI 10.2307/2136054
   Lakha F, 2006, CONTRACEPTION, V74, P287, DOI 10.1016/j.contraception.2006.05.072
   Mansour D, 2011, CONTRACEPTION, V83, P202, DOI 10.1016/j.contraception.2010.08.001
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Peterson HB, 2005, NEW ENGL J MED, V353, P2169, DOI 10.1056/NEJMcp044148
   Rubenstein J, 2011, EUR J CONTRACEP REPR, V16, P225, DOI 10.3109/13625187.2011.561939
   Sheng J, 2009, CONTRACEPTION, V79, P189, DOI 10.1016/j.contraception.2008.11.004
   Smith A, 2002, J FAM PLAN REPROD H, V28, P193, DOI 10.1783/147118902101196540
   Suhonen S, 2004, CONTRACEPTION, V69, P407, DOI 10.1016/j.contraception.2003.11.008
   Bahamondes MV, 2012, CONTRACEPTION, V86, P244, DOI 10.1016/j.contraception.2011.12.005
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   Wong RC, 2009, CONTRACEPTION, V80, P452, DOI 10.1016/j.contraception.2009.03.021
NR 27
TC 37
Z9 37
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD JUL
PY 2014
VL 29
IS 7
BP 1393
EP 1399
DI 10.1093/humrep/deu089
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA AK0SV
UT WOS:000338126500009
PM 24812309
OA Green Accepted, Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Mansour, D
   Fiala, C
   Kaunitz, AM
   Gemzell-Danielsson, K
AF Bahamondes, Luis
   Mansour, Diana
   Fiala, Christian
   Kaunitz, Andrew M.
   Gemzell-Danielsson, Kristina
TI Comment on 'Practical advice for avoidance of pain associated with
   insertion of intrauterine contraceptives': authors' response
SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
LA English
DT Letter
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Fac Med Sci, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Mansour, Diana] Newcastle Gen Hosp, New Croft Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Fiala, Christian] Gynmed Clin, Vienna, Austria.
   [Fiala, Christian; Gemzell-Danielsson, Kristina] Karolinska Inst, Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.
   [Kaunitz, Andrew M.] Univ Florida, Coll Med Jacksonville, Dept Obstet & Gynecol, Jacksonville, FL USA.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Fac Med Sci, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br; Diana.Mansour@nuth.nhs.uk;
   christian.fiala@aon.at; andrew.kaunitz@jax.ufl.edu;
   kristina.gemzell@ki.se
RI Kaunitz, Andrew/AAL-8448-2020
OI Fiala, Christian/0000-0001-6451-7349
CR Bahamondes L, 2014, J FAM PLAN REPROD H, V40, P54, DOI 10.1136/jfprhc-2013-100636
   Goldthwaite L, 2014, CONTRACEPTI IN PRESS
   GUILLEBAUD J, 1983, RES CLIN FORUMS, V5, P69
   Guillebaud J, 2014, J FAM PLAN REPROD H, V40, P150, DOI 10.1136/jfprhc-2014-100904
   Ylikorkala O, 1978, LANCET, V312, P393
NR 5
TC 1
Z9 1
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1471-1893
EI 2045-2098
J9 J FAM PLAN REPROD H
JI J. Fam. Plan. Reprod. Health Care
PD JUL
PY 2014
VL 40
IS 3
DI 10.1136/jfprhc-2014-100925
PG 1
WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical
SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences
GA AK1PI
UT WOS:000338186800019
PM 24939488
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Yu, J
   Le, HH
   Connolly, M
   Bahamondes, L
   Cecatti, JG
   Hu, X
AF Yu, J.
   Le, H. H.
   Connolly, M.
   Bahamondes, L.
   Cecatti, J. G.
   Hu, X.
TI BURDEN OF UNINTENDED PREGNANCIES TO PUBLIC HEALTH SYSTEM IN BRAZIL
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Yu, J.] Merck, Whitehouse Stn, NJ USA.
   [Le, H. H.] Univ Groningen, Groningen, Netherlands.
   [Connolly, M.] Unit PharmacoEpidemiol & PharmacoEcon, Groningen, Netherlands.
   [Bahamondes, L.; Cecatti, J. G.] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Hu, X.] Merck Sharp & Dohme Ltd, West Point, PA 19486 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD MAY
PY 2014
VL 17
IS 3
MA PIH23
BP A158
EP A158
DI 10.1016/j.jval.2014.03.920
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1OG
UT WOS:000341082000865
OA Bronze
DA 2020-12-01
ER

PT J
AU Nunes, FR
   Ferreira, JM
   Bahamondes, L
AF Nunes, Fabiana R.
   Ferreira, Jessica M.
   Bahamondes, Luis
TI Prevalence of fibromyalgia and quality of life in women with and without
   endometriosis
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Article
DE Endometriosis; fibromyalgia; quality of life
ID WOLFE ET-AL; PRELIMINARY DIAGNOSTIC-CRITERIA; RETROGRADE MENSTRUATION;
   AUTOIMMUNE; ARTICLE; CLASSIFICATION; MULTICENTER; SEVERITY; BURDEN; PAIN
AB The objectives of the study were to assessed if there is any difference in the prevalence of fibromyalgia and in quality of life (QoL) between women with and without endometriosis. A cross-sectional study was conducted in 2011-2013, involving 257 women with surgically and histopathologically confirmed endometriosis and 253 women with no history of endometriosis and no endometriosis-related symptoms. Women were recruited both at the family planning and endometriosis clinic, Department of Obstetrics and Gynecology, University of Campinas, Brazil. The Short Form 36 questionnaire (SF-36) was used to assess QoL, while the 1990 and 2010 American College of Rheumatology (ACR) criteria were used to evaluate fibromyalgia. According to the 1990 ACR criteria, there were no cases of fibromyalgia in either group. Nevertheless, according to the 2010 ACR criteria, four women, two with endometriosis and two without the disease, were diagnosed with fibromyalgia. Scores were significantly lower in all the domains of the QoL questionnaire for the women with endometriosis compared to those without the disease. This study reports no difference in the prevalence of fibromyalgia between women with and without endometriosis; however QoL was poorer among women with endometriosis when compared to women without the disease.
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   [Bahamondes, Luis] Univ Campinas UNICAMP, Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX None of the authors declared any conflict of interest. The study was
   partially funded (grant 573747/2008-3) by the Brazilian National
   Research Council (CNPq).
CR Canis M, 1997, FERTIL STERIL, V67, P817
   Ciconelli R. M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005
   De Graaff AA, 2013, HUM REPROD, V28, P2677, DOI 10.1093/humrep/det284
   Gao X, 2006, CURR MED RES OPIN, V22, P1787, DOI 10.1185/030079906X121084
   HALME J, 1984, OBSTET GYNECOL, V64, P151
   Haun MVA, 1999, REV BRAS REUMATOL, V39, P221, DOI [DOI 10.1590/S0482-50042006000100006, 10.1590/S0482-50042006000100006]
   Laursen BS, 2005, EUR J PAIN, V9, P267, DOI 10.1016/j.ejpain.2004.07.003
   Lebovic DI, 2001, FERTIL STERIL, V75, P1, DOI 10.1016/S0015-0282(00)01630-7
   LIU DTY, 1986, BRIT J OBSTET GYNAEC, V93, P859, DOI 10.1111/j.1471-0528.1986.tb07995.x
   Marques A, 2004, J REPROD MED, V49, P115
   Matalliotakis I, 2012, J OBSTET GYNAECOL, V32, P291, DOI 10.3109/01443615.2011.644358
   Minson FP, 2012, REV BRAS GINECOL OBS, V34, P11, DOI 10.1590/S0100-72032012000100003
   Nnoaham KE, 2011, FERTIL STERIL, V96, P366, DOI 10.1016/j.fertnstert.2011.05.090
   Nothnick WB, 2001, FERTIL STERIL, V76, P223, DOI 10.1016/S0015-0282(01)01878-7
   Pasoto SG, 2005, AM J REPROD IMMUNOL, V53, P85, DOI 10.1111/j.1600-0897.2005.00252.x
   Petrelluzzi KFS, 2008, STRESS, V11, P390, DOI 10.1080/10253890701840610
   Petta CA, 2007, HUM REPROD, V22, P2693, DOI 10.1093/humrep/dem267
   SAMPSON JA, 1927, AM J OBSTET GYNECOL, V14, P442
   Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073
   Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715
   Smythe HA, 2011, J RHEUMATOL, V38, P975, DOI 10.3899/jrheum.110142
   Staud R, 2010, ARTHRIT CARE RES, V62, P1675, DOI 10.1002/acr.20290
   Thompson EN, 2010, ARTHRIT CARE RES, V62, P1674, DOI 10.1002/acr.20292
   Toda K, 2011, J RHEUMATOL, V38, P2075, DOI 10.3899/jrheum.110343
   Vanderschueren S, 2010, ARTHRIT CARE RES, V62, P1675, DOI 10.1002/acr.20293
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WHEELER JM, 1989, J REPROD MED, V34, P41
   WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140
   Yunus MB, 2012, JCR-J CLIN RHEUMATOL, V18, P71, DOI 10.1097/RHU.0b013e318247b7da
NR 30
TC 11
Z9 12
U1 0
U2 9
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0951-3590
EI 1473-0766
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD APR
PY 2014
VL 30
IS 4
BP 307
EP 310
DI 10.3109/09513590.2013.876401
PG 4
WC Endocrinology & Metabolism; Obstetrics & Gynecology
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA AF5GP
UT WOS:000334742300013
PM 24410333
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Mansour, D
   Fiala, C
   Kaunitz, AM
   Gemzell-Danielsson, K
AF Bahamondes, Luis
   Mansour, Diana
   Fiala, Christian
   Kaunitz, Andrew M.
   Gemzell-Danielsson, Kristina
TI Comment on 'Practical advice for avoidance of pain associated with
   insertion of intrauterine contraceptives': authors' response
SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
LA English
DT Letter
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Dept Obstet & Gynaecol, Fac Med Sci, Campinas, SP, Brazil.
   [Mansour, Diana] Newcastle Gen Hosp, New Croft Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Fiala, Christian] Gynmed Clin, Vienna, Austria.
   [Fiala, Christian; Gemzell-Danielsson, Kristina] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
   [Kaunitz, Andrew M.] Univ Florida, Dept Obstet & Gynecol, Coll Med Jacksonville, Jacksonville, FL USA.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Dept Obstet & Gynaecol, Fac Med Sci, Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Kaunitz, Andrew/AAL-8448-2020
OI Fiala, Christian/0000-0001-6451-7349
CR Bahamondes L, 2014, J FAM PLAN REPROD H, V40, P54, DOI 10.1136/jfprhc-2013-100636
   Pillai M, 2014, J FAM PLAN REPROD H, V40, P151, DOI 10.1136/jfprhc-2013-100848
NR 2
TC 0
Z9 0
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1471-1893
EI 2045-2098
J9 J FAM PLAN REPROD H
JI J. Fam. Plan. Reprod. Health Care
PD APR
PY 2014
VL 40
IS 2
BP 152
EP U82
DI 10.1136/jfprhc-2014-100874
PG 2
WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical
SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences
GA AD3XK
UT WOS:000333179600020
PM 24648536
OA Bronze, Green Published
DA 2020-12-01
ER

PT J
AU Taylor, DJ
   Lendvay, A
   Halpern, V
   Bahamondes, LG
   Fine, PM
   Ginde, SY
   Wheeless, A
   Raymond, EG
AF Taylor, Douglas J.
   Lendvay, Anja
   Halpern, Vera
   Bahamondes, Luis G.
   Fine, Paul M.
   Ginde, Savita Y.
   Wheeless, Angie
   Raymond, Elizabeth G.
TI A single-arm study to evaluate the efficacy, safety and acceptability of
   pericoital oral contraception with levonorgestrel
SO CONTRACEPTION
LA English
DT Article
DE Pericoital oral contraception; Levonorgestrel; Single-arm study
ID POSTCOITAL CONTRACEPTION; D-NORGESTREL; MG
AB Background: An oral dose of 0.75 mg levonorgestrel (LNG) taken shortly after sex was marketed as a routine, nonemergency contraceptive method until the 1990s. Because a hormonal method used only at the time of intercourse may be desirable for women who have infrequent sex, we conducted a study to reevaluate the potential of pericoital LNG as a primary means of contraception.
   Methods: We enrolled women aged 18-45 years in Brazil and the USA who expected to have sex 1-4 days per month for 6.5 months. Participants were instructed to take one tablet 0.75 mg LNG within 24 h before or after sex, with no more than one dose in any 24-h period. The primary efficacy measure was the Pearl Index among women aged 18-35 years.
   Results: The study was stopped after 72 of the planned 300 participants were enrolled due to slow recruitment and related feasibility considerations. In the primary analysis, three pregnancies occurred during 13.4 woman-years of follow-up, resulting in a Pearl Index of 22.4 (95% confidence interval, 4.6-65.4). No serious adverse events were reported, and vaginal bleeding patterns were generally acceptable.
   Conclusions: Our estimated Pearl Index was noticeably higher than expected from previous research of LNG for pericoital contraception. Although the regimen was safe and generally acceptable, the study was challenged by slow enrollment and curtailed person-years of follow-up, resulting in poor precision for the estimated treatment effect. Future research may inform whether our results are symptomatic of the regimen, study design or characteristics of the populations from which we recruited.
   Implications: Our study failed to confirm prior data suggesting that 0.75 mg LNG for pericoital contraception could be more effective than typical use of barrier methods among women having infrequent sex. Characterizing populations most likely to adhere to, and benefit from, pericoital regimens is essential to future research on these methods. (c) 2014 Elsevier Inc. All rights reserved.
C1 [Taylor, Douglas J.; Lendvay, Anja; Halpern, Vera; Wheeless, Angie] FHI 360, Durham, NC 27713 USA.
   [Bahamondes, Luis G.] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Fine, Paul M.] Planned Parenthood Gulf Coast Inc, Houston, TX 77023 USA.
   [Ginde, Savita Y.] Planned Parenthood Rocky Mt, Denver, CO 80207 USA.
   [Raymond, Elizabeth G.] Gynu Hlth Projects, New York, NY 10010 USA.
RP Halpern, V (corresponding author), FHI 360, Durham, NC 27713 USA.
EM vhalpern@fhi360.org
FU Laboratoire HRA Pharma; William and Flora Hewlett Foundation
FX The study was funded by Laboratoire HRA Pharma and a grant to FHI 360 by
   the William and Flora Hewlett Foundation. The authors thank Laneta
   Dorflinger (FHI 360) and scientists at Laboratoire HRA Pharma for their
CR BHATTACHARJEE S K, 1987, Contraception, V36, P275
   CANZLER E, 1984, ZBL GYNAKOL, V106, P1182
   Chernev T, 1995, Plan Parent Eur, V24, P25
   Halpern V, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007595.pub2
   Hatcher RA., 2011, CONTRACEPTIVE TECHNO
   HE CH, 1991, INT J GYNECOL OBSTET, V36, P43
   KESSERU E, 1973, CONTRACEPTION, V7, P367, DOI 10.1016/0010-7824(73)90139-X
   Kliment V, 1986, Cesk Gynekol, V51, P103
   LARRANAGA A, 1975, INT J FERTIL, V20, P156
   Lerkiatbundit S, 2000, J CLIN PHARM THER, V25, P185
   MOGGIA A, 1974, J REPROD MED, V13, P58
   Raymond EG, 2011, OBSTET GYNECOL, V117, P673, DOI 10.1097/AOG.0b013e318209dc25
   Seregely G, 1982, Ther Hung, V30, P72
   von Hertzen H, 2000, CONTRACEPTION, V61, P303, DOI 10.1016/S0010-7824(00)00116-5
NR 14
TC 6
Z9 6
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD MAR
PY 2014
VL 89
IS 3
BP 215
EP 221
DI 10.1016/j.contraception.2013.11.013
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AE4HW
UT WOS:000333944500012
PM 24388695
DA 2020-12-01
ER

PT J
AU Ferreira, JM
   Nunes, FR
   Modesto, W
   Goncalves, MP
   Bahamondes, L
AF Ferreira, Jessica M.
   Nunes, Fabiana R.
   Modesto, Waleska
   Goncalves, Mayara P.
   Bahamondes, Luis
TI Reasons for Brazilian women to switch from different contraceptives to
   long-acting reversible contraceptives
SO CONTRACEPTION
LA English
DT Article
DE Contraceptive methods; Decision making; Hormonal contraceptives; Brazil
   switchers
ID UNINTENDED PREGNANCY; INTRAUTERINE SYSTEM; UNITED-STATES; IUD; COST
AB Objectives: Long-acting reversible contraceptives (LARCs) include the copper-releasing intrauterine device (IUD), the levonorgestrel-releasing intrauterine system (LNG-IUS) and implants. Despite the high contraceptive efficacy of LARCs, their prevalence of use remains low in many countries. The objective of this study was to assess the main reasons for switching from contraceptive methods requiring daily or monthly compliance to LARC methods within a Brazilian cohort.
   Study Design: Women of 18-50 years of age using different contraceptives and wishing to switch to a LARC method answered a questionnaire regarding their motivations for switching from their current contraceptive. Continuation rates were evaluated 1 year after method initiation. Sample size was calculated at 1040 women. Clinical performance was evaluated by life table analysis. The cutoff date for analysis was May 23, 2013.
   Results: Overall, 1167 women were interviewed; however, after 1 year of use, the medical records of only 1154 women were available for review. The main personal reason for switching, as reported by the women, was "fear of becoming pregnant" while the main medical reasons were nausea and vomiting and unscheduled bleeding. No pregnancies occurred during LARC use, and the main reasons for discontinuation were expulsion (in the case of the IUD and LNG-IUS) and a decision to undergo surgical sterilization (in the case of the etonogestrel-releasing implant). Continuation rate was similar to 95.0/100 women/year for the three methods.
   Conclusions: Most women chose a LARC method for its safety and for practical reasons, and after 1 year of use, most women continued with the method. (C) 2014 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, UNICAMP, Sch Med Sci, Human Reprod Unit,Dept Obstet & Gynecol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Ferreira, Jessica/I-3350-2018
OI Ferreira, Jessica/0000-0003-2153-0353
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/01380-9];
   National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant # 2012/01380-9
   and from the National Research Council (CNPq), grant #573747/2008-3.
CR Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Black K, 2012, EUR J CONTRACEP REPR, V17, P340, DOI 10.3109/13625187.2012.700744
   Blumenthal PD, 2011, HUM REPROD UPDATE, V17, P121, DOI 10.1093/humupd/dmq026
   Blumenthal PD, 2013, CONTRACEPTION, V87, P170, DOI 10.1016/j.contraception.2012.10.002
   Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, 2012, OBSTET GYNECOL, V120, P983, DOI DOI 10.1097/AOG.0B013E3182723B7D
   Dempsey AR, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.014
   Eisenberg D, 2013, J ADOLESCENT HEALTH, V52, pS59, DOI 10.1016/j.jadohealth.2013.01.012
   Eisenberg DL, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.04.012
   Espey E, 2011, OBSTET GYNECOL, V117, P705, DOI 10.1097/AOG.0b013e31820ce2f0
   Finer LB, 2012, FERTIL STERIL, V98, P893, DOI 10.1016/j.fertnstert.2012.06.027
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   Kaunitz AM, 2012, CONTRACEPTION, V86, P452, DOI 10.1016/j.contraception.2012.07.018
   Madden T, 2010, CONTRACEPTION, V81, P112, DOI 10.1016/j.contraception.2009.08.002
   Mavranezouli I, 2008, HUM REPROD, V23, P1338, DOI 10.1093/humrep/den091
   Nault AM, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.10.876
   Pantoja M, 2010, CONTRACEPTION, V81, P107, DOI 10.1016/j.contraception.2009.07.008
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Population Reference Bureau, 2008, FAM PLANN WORLDW 200
   Short M, 2012, EUR J CONTRACEP REPR, V17, P79, DOI 10.3109/13625187.2011.636088
   Sivin I, 2007, CONTRACEPTION, V75, pS70, DOI 10.1016/j.contraception.2007.01.016
   Steiner MJ, 2007, AM J OBSTET GYNECOL, V197, P118, DOI 10.1016/j.ajog.2007.03.049
   Sundstrom B, 2012, CONTRACEPTION, V86, P4, DOI 10.1016/j.contraception.2011.10.016
   Trussell J, 2013, CONTRACEPTION, V87, P154, DOI 10.1016/j.contraception.2012.07.016
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Wellings K, 2007, CONTRACEPTION, V76, P208, DOI 10.1016/j.contraception.2007.05.085
   Wilson EK, 2013, J ADOLESCENT HEALTH, V52, P278, DOI 10.1016/j.jadohealth.2012.05.004
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 28
TC 17
Z9 17
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JAN
PY 2014
VL 89
IS 1
BP 17
EP 21
DI 10.1016/j.contraception.2013.09.012
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 275EM
UT WOS:000328659100005
PM 24156884
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Mansour, D
   Fiala, C
   Kaunitz, AM
   Gemzell-Danielsson, K
AF Bahamondes, Luis
   Mansour, Diana
   Fiala, Christian
   Kaunitz, Andrew M.
   Gemzell-Danielsson, Kristina
TI Practical advice for avoidance of pain associated with insertion of
   intrauterine contraceptives
SO JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; NULLIPAROUS WOMEN; MISOPROSTOL PRIOR;
   DEVICE INSERTION; EXPERIENCE; SYSTEM; IUD
AB Few studies in the scientific literature provide clear direction on the prevention or management of pain associated with intrauterine contraceptive (IUC) placement. Those that have been published have studied small numbers of women and fail to provide definitive conclusions. There are also no guidelines available detailing recognised standard approaches to this problem. The consensus recommendations in this review focus primarily on non-pharmacological and often non-evidence-based interventions. This review includes general considerations, practical recommendations for both routine and more difficult cases and guidance on the optimal choice of instruments. General considerations, including pre-insertion counselling, the setting for the procedure, the confidence and technique of the provider and the interplay between the provider and assistant, can influence women's level of anxiety and, in turn, influence their perception of pain and their overall experience. Further studies are required to refine the optimal strategy for managing pain associated with IUC insertion.
C1 [Bahamondes, Luis] Univ Campinas UNICAMP, Dept Obstet & Gynaecol, Fac Med Sci, BR-13084971 Campinas, SP, Brazil.
   [Mansour, Diana] Newcastle Hosp, New Croft Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Fiala, Christian] Gynmed Clin, Vienna, Austria.
   [Fiala, Christian; Gemzell-Danielsson, Kristina] Karolinska Inst, Dept Womens & Childrens Hlth, Karolinska Univ Hosp, Stockholm, Sweden.
   [Kaunitz, Andrew M.] Univ Florida, Coll Med Jacksonville, Dept Obstet & Gynecol, Jacksonville, FL USA.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Dept Obstet & Gynaecol, Fac Med Sci, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Kaunitz, Andrew/AAL-8448-2020
OI Fiala, Christian/0000-0001-6451-7349
FU Bayer Health
FX Bayer Health funded the medical writing of this study.
CR Allen R. H., 2009, COCHRANE DB SYST REV, V3
   [Anonymous], 2010, CONTRACEPTION, V81, P367, DOI 10.1016/j.contraception.2010.01.010
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Brockmeyer A, 2008, EUR J CONTRACEP REPR, V13, P248, DOI 10.1080/02699200802253706
   Centers for Disease Control and Prevention, 2010, MMWR EARL REL US MED, V59
   CHI I, 1986, CONTRACEPTION, V34, P483, DOI 10.1016/0010-7824(86)90057-0
   Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group The American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P983
   Dijkhuizen K, 2011, HUM REPROD, V26, P323, DOI 10.1093/humrep/deq348
   *FAC SEX REPR HLTH, 2007, FSRH GUID NOV 2007 I
   FAUNDES A, 1993, ANN MED, V25, P149, DOI 10.3109/07853899309164159
   Fiala C, 2007, INT J GYNECOL OBSTET, V99, pS168, DOI 10.1016/j.ijgo.2007.09.005
   Gemzell-Danielsson K, 2013, HUM REPROD UPDATE, V19, P419, DOI 10.1093/humupd/dmt022
   GUPTA JK, 1990, LANCET, V335, P1238, DOI 10.1016/0140-6736(90)91303-R
   Heikinheimo O, 2010, CONTRACEPTION, V81, P481, DOI 10.1016/j.contraception.2010.01.020
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Lassner K J, 1995, Bull Pan Am Health Organ, V29, P206
   Maguire K, 2012, CONTRACEPTION, V86, P214, DOI 10.1016/j.contraception.2012.01.005
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   McNicholas CP, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.09.018
   Murty J, 2003, J FAM PLAN REPROD H, V29, P150, DOI 10.1783/147118903101197539
   Nadelberg R., 2007, PARACERVICAL BLOCK
   National Institute for Health and Care Excellence, 2011, CLIN KNOWL SUMM UK M
   Saav I, 2007, HUM REPROD, V22, P2647, DOI 10.1093/humrep/dem244
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   World Health Organization, 2010, MED EL CONTR US
   Zhou LF, 2003, PHARMACOEPIDEM DR S, V12, P371, DOI 10.1002/pds.875
NR 27
TC 28
Z9 29
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1471-1893
EI 2045-2098
J9 J FAM PLAN REPROD H
JI J. Fam. Plan. Reprod. Health Care
PD JAN
PY 2014
VL 40
IS 1
BP 54
EP 60
DI 10.1136/jfprhc-2013-100636
PG 7
WC Family Studies; Obstetrics & Gynecology; Social Sciences, Biomedical
SC Family Studies; Obstetrics & Gynecology; Biomedical Social Sciences
GA 276IZ
UT WOS:000328745300013
PM 24076534
OA Other Gold, Green Published
DA 2020-12-01
ER

PT J
AU Munuce, MJ
   Cicare, J
   Zumoffen, C
   Caille, A
   Ghersevich, S
   Bahamondes, L
AF Jose Munuce, Maria
   Cicare, Juliana
   Zumoffen, Carlos
   Caille, Adriana
   Ghersevich, Sergio
   Bahamondes, Luis
TI Effects of ulipristal acetate on sperm DNA fragmentation during in vitro
   incubation
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Spermatozoa; Ulipristal acetate; Sperm chromatin dispersion test; DNA
   fragmentation
ID HUMAN-SPERMATOZOA; PROGESTERONE-RECEPTOR; HYDROGEN-PEROXIDE;
   MALE-INFERTILITY; LIPID-PEROXIDATION; ACROSOME REACTION; OXIDATIVE
   STRESS; SUPEROXIDE ANION; CAPACITATION; FERTILIZATION
AB Objective Ulipristal acetate (UPA) acts as an emergency contraceptive by inhibiting ovulation. This study explores possible additional effects on the fragmentation of sperm DNA during in vitro incubation.
   Methods Motile spermatozoa from healthy donors were selected by swim-up and incubated under capacitating conditions in control medium or with UPA (1, 10, 100, 1,000 or 10,000 ng/ml). In some experiments, 200 mu M of H2O2 were added to induce oxidative stress. The sperm chromatin dispersion test was performed to analyse DNA integrity (400 cells; 1000X). Lipid peroxidation (thiobarbituric acid assay), induced-acrosome reaction (AR) and sperm vitality (Eosin Y) were also evaluated in spermatozoa exposed to UPA and/or H2O2.
   Results During sperm incubation, the percentage of fragmented DNA increased significantly, from 15.0 +/- 1.3 to 41.0 +/- 4.5% (p < 0.001). In the presence of UPA, DNA fragmentation decreased significantly (p < 0.05), in a dose-dependent manner. At 100 and 1000 ng/ml, UPA also counteracted the effect of H2O2 and prevented DNA fragmentation. No effect on sperm vitality, lipid peroxidation or induced-AR was found with any treatment.
   Conclusions During in vitro sperm capacitation DNA fragmentation increased but the latter was counteracted in the presence of UPA, which possibly acted as a scavenger of reactive oxygen species produced by spermatozoa.
C1 [Jose Munuce, Maria; Cicare, Juliana; Zumoffen, Carlos; Caille, Adriana; Ghersevich, Sergio] Fed Univ Rosario, Sch Biochem & Pharmaceut Sci, Clin Biochem Div, Lab Reprod Studies, Rosario, Santa Fe, Argentina.
   [Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Human Reprod Unit,Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Bahamondes, Luis] Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and the writing of the text. The study
   received partial funding (grant 573747/2008-3) from the Brazilian
   National Research Council (CNPq).
CR Agarwal A, 2003, HUM REPROD UPDATE, V9, P331, DOI 10.1093/humupd/dmg027
   Aitken RJ, 1998, BIOL REPROD, V59, P1037, DOI 10.1095/biolreprod59.5.1037
   Aitken RJ, 1995, REPROD FERT DEVELOP, V7, P659, DOI 10.1071/RD9950659
   AITKEN RJ, 1987, J REPROD FERTIL, V81, P459
   Ali AA, 2003, THERIOGENOLOGY, V59, P939, DOI 10.1016/S0093-691X(02)01125-1
   ALVAREZ JG, 1987, J ANDROL, V8, P338
   Baker MA, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-67
   Baldi E, 2009, MOL CELL ENDOCRINOL, V308, P39, DOI 10.1016/j.mce.2009.02.006
   Bejarano I, 2008, FERTIL STERIL, V90, P1340, DOI 10.1016/j.fertnstert.2007.08.069
   BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376
   BLACKMORE PF, 1991, BIOCHEM BIOPH RES CO, V181, P331, DOI 10.1016/S0006-291X(05)81422-6
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120
   Calamera JC, 2001, ANDROLOGIA, V33, P79, DOI 10.1046/j.1439-0272.2001.00409.x
   Collins JA, 2008, FERTIL STERIL, V89, P823, DOI 10.1016/j.fertnstert.2007.04.055
   Dalzell LH, 2004, FERTIL STERIL, V82, P1443, DOI 10.1016/j.fertnstert.2004.04.053
   de Lamirande E, 1998, J ANDROL, V19, P215
   de Lamirande E, 2012, J ANDROL, V33, P1025, DOI 10.2164/jandrol.111.015982
   DELAMIRANDE E, 1992, J ANDROL, V13, P379
   DELAMIRANDE E, 1993, FERTIL STERIL, V59, P1291
   DELAMIRANDE E, 1992, J ANDROL, V13, P368
   DELAMIRANDE E, 1993, INT J ANDROL, V16, P21
   DELAMIRANDE E, 1995, HUM REPROD, V10, P15, DOI 10.1093/humrep/10.suppl_1.15
   Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628
   Dona G, 2011, HUM REPROD, V26, P3264, DOI 10.1093/humrep/der321
   Elger W, 2000, STEROIDS, V65, P713, DOI 10.1016/S0039-128X(00)00178-1
   Evenson DP, 2008, FERTIL STERIL, V90, P1229, DOI 10.1016/j.fertnstert.2007.10.066
   Ford WCL, 2004, HUM REPROD UPDATE, V10, P387, DOI 10.1093/humupd/dmh034
   Gemzell-Danielsson K, 2010, INT J WOMENS HEALTH, V2, P53
   Goncalves FS, 2010, REPROD DOMEST ANIM, V45, P129, DOI 10.1111/j.1439-0531.2008.01272.x
   Gosalvez J, 2011, ANDROLOGIA, V43, P373, DOI 10.1111/j.1439-0272.2010.01022.x
   Greco E, 2005, J ANDROL, V26, P349, DOI 10.2164/jandrol.04146
   Grunewald S, 2008, INT J ANDROL, V31, P325, DOI 10.1111/j.1365-2605.2007.00768.x
   Lozano GM, 2009, J REPROD DEVELOP, V55, P615, DOI 10.1262/jrd.20250
   Fernandez JL, 2011, METHODS MOL BIOL, V682, P291, DOI 10.1007/978-1-60327-409-8_21
   Makker K, 2009, INDIAN J MED RES, V129, P357
   Menezo YJR, 2007, REPROD BIOMED ONLINE, V14, P418, DOI 10.1016/S1472-6483(10)60887-5
   Munuce MJ, 2012, EUR J CONTRACEP REPR, V17, P428, DOI 10.3109/13625187.2012.725877
   Oosterhuis GJE, 2000, FERTIL STERIL, V74, P245, DOI 10.1016/S0015-0282(00)00623-3
   OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4
   ROYERE D, 1991, MOL REPROD DEV, V28, P177, DOI 10.1002/mrd.1080280211
   Sheweita SA, 2005, CURR DRUG METAB, V6, P495, DOI 10.2174/138920005774330594
   Storey BT, 1997, MOL HUM REPROD, V3, P203, DOI 10.1093/molehr/3.3.203
   WARD WS, 1991, BIOL REPROD, V44, P569, DOI 10.1095/biolreprod44.4.569
   WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301
   World Health Organization WHO, 2010, LAB MAN EX PROC HUM
   Yanagimachi R., 1988, P135
NR 47
TC 7
Z9 7
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1362-5187
EI 1473-0782
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD OCT
PY 2013
VL 18
IS 5
BP 355
EP 363
DI 10.3109/13625187.2013.813930
PG 9
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA 220WO
UT WOS:000324618100005
PM 23879383
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bahamondes, MV
   Modesto, W
   Tilley, IB
   Magalhaes, A
   Silva, JLPE
   Amaral, E
   Mishell, DR
AF Bahamondes, Luis
   Valeria Bahamondes, M.
   Modesto, Waleska
   Tilley, Ian B.
   Magalhaes, Alvicler
   Pinto e Silva, Joao Luiz
   Amaral, Eliana
   Mishell, Daniel R., Jr.
TI Effect of hormonal contraceptives during breastfeeding on infant's milk
   ingestion and growth
SO FERTILITY AND STERILITY
LA English
DT Article
DE Breastfeeding; combined oral contraceptives; contraceptive implant;
   hormonal contraceptives; levonorgestrel-releasing intrauterine system;
   deuterium
ID TOTAL-BODY WATER; RANDOMIZED-CONTROLLED-TRIAL; LONG-TERM INFLUENCE;
   DEUTERIUM-OXIDE; FERTILITY REGULATION; INTRAUTERINE-DEVICE; NURSING
   WOMEN; LACTATION; POSTPARTUM; MOTHERS
AB Objective: To measure infants' breast milk intake and infant growth when their mothers initiated either combined oral contraceptive (COC), levonorgestrel-releasing intrauterine system, or etonogestrel-releasing implant, or copper intrauterine device (IUD) as a reference group.
   Design: Prospective trial.
   Setting: University-based hospital.
   Patient(s): On postpartum day 42, 40 women initiated a contraceptive method according to their choice.
   Intervention(s): Deuterium (D2O; 0.5 g/kg mother's weight) was ingested by mothers on postpartum days 42, 52, and 63 as a marker of total body fluid.
   Main Outcome Measure(s): Infants' milk intake from 42 to 63 postpartum days was assessed by measurement of D2O levels in infants' saliva and infant growth by measuring their body weight, height, and tibia length. Women recorded all infant feed and changes of diapers wet with urine. Breastfeeding continuation was assessed at 6 months postpartum.
   Result(s): Infant mean milk intake, mean growth increase, mean number of breastfeeding episodes, daily wet diaper changes, and mean duration of exclusively breastfeeding (similar to 5 months) were similar in the four groups.
   Conclusion(s): Use of a COC, the two progestin-only contraceptives, or copper IUD did not affect the amount of infant milk intake and growth up to 9 weeks of age. The incidence of full breastfeeding and breastfeeding continuation was similar with contraceptive hormonal use and no use.
C1 [Bahamondes, Luis; Valeria Bahamondes, M.; Modesto, Waleska; Pinto e Silva, Joao Luiz; Amaral, Eliana] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Magalhaes, Alvicler] Univ Estadual Campinas, Inst Chem, Campinas, SP, Brazil.
   [Tilley, Ian B.; Mishell, Daniel R., Jr.] Univ So Calif, Keck Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
EM bahamond@caism.unicamp.br
RI Magalhaes, Alvicler/C-4676-2008; Magalhaes, Alvicler/AAB-3894-2019
OI Magalhaes, Alvicler/0000-0001-7439-8400; Magalhaes,
   Alvicler/0000-0001-7439-8400; Amaral, Esbelta Teresa/0000-0001-8781-491X
FU World Health OrganizationWorld Health Organization; Fundacao de Apoio a
   Pesquisa do Estado de Sao Paulo (FAPEP) [2010/09194-4]; Conselho
   Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX L.B. has received grants from the World Health Organization and is a
   board member of Bayer. M.V.B. has had travel paid for by the World
   Health Organization. W.M. has nothing to disclose. I.B.T. has nothing to
   disclose. A.M. has nothing to disclose. J.L.P.e.S. has nothing to
   disclose. E.A. has nothing to disclose. D.R.M. has nothing to disclose.;
   Funded in part by grant no. 2010/09194-4 from the Fundacao de Apoio a
   Pesquisa do Estado de Sao Paulo (FAPEP) and grant no. 573747/2008-3 from
   the Conselho Nacional de Pesquisa (CNPq).
CR [Anonymous], 1988, STUD FAMILY PLANN, V19, P361
   Brito MB, 2009, CONTRACEPTION, V80, P519, DOI 10.1016/j.contraception.2009.05.124
   BUTTE NF, 1988, AM J CLIN NUTR, V47, P815
   BUTTE NF, 1991, BRIT J NUTR, V65, P3, DOI 10.1079/BJN19910060
   Centers for Disease Control and Prevention, 2012, UPD CDCS US MED EL C
   Centers for Disease Control and Prevention, 2009, BREASTF US CHILDR BO
   Cisse Aita Sarr, 2002, Food and Nutrition Bulletin, V23, P138
   COWARD WA, 1979, LANCET, V2, P13
   COWARD WA, 1982, HUM NUTR-CLIN NUTR, V36, P141
   CROXATTO HB, 1983, CONTRACEPTION, V27, P13, DOI 10.1016/0010-7824(83)90052-5
   DIAZ S, 1983, CONTRACEPTION, V27, P1, DOI 10.1016/0010-7824(83)90051-3
   Espey E, 2012, OBSTET GYNECOL, V119, P5, DOI 10.1097/AOG.0b013e31823dc015
   Ettyang GA, 2005, ANN NUTR METAB, V49, P110, DOI 10.1159/000084744
   Gurtcheff SE, 2011, OBSTET GYNECOL, V117, P1114, DOI 10.1097/AOG.0b013e3182165ee8
   Halderman LD, 2002, AM J OBSTET GYNECOL, V186, P1250, DOI 10.1067/mob.2002.123738
   KAERN T, 1967, BRIT MED J, V3, P644, DOI 10.1136/bmj.3.5566.644
   Kapp N, 2010, CONTRACEPTION, V82, P17, DOI 10.1016/j.contraception.2010.02.002
   Kapp N, 2010, CONTRACEPTION, V82, P10, DOI 10.1016/j.contraception.2010.02.001
   KHALED MA, 1987, AM J CLIN NUTR, V45, P1
   Ministerio da Saude Brasil, PESQ PREV AL MAT NAS
   PERALTA O, 1983, CONTRACEPTION, V27, P27, DOI 10.1016/0010-7824(83)90053-7
   Queenan JT, 2012, OBSTET GYNECOL, V119, P1, DOI 10.1097/AOG.0b013e31823f3c6d
   REBOUCHE CJ, 1987, AM J CLIN NUTR, V45, P373
   Reinprayoon D, 2000, CONTRACEPTION, V62, P239, DOI 10.1016/S0010-7824(00)00173-6
   Shaamash AH, 2005, CONTRACEPTION, V72, P346, DOI 10.1016/j.contraception.2005.04.004
   Taneepanichskula S, 2006, CONTRACEPTION, V73, P368, DOI 10.1016/j.contraception.2005.10.010
   TANKEYOON M, 1984, Contraception, V30, P505, DOI 10.1016/0010-7824(84)90001-5
   WANG J, 1973, J LAB CLIN MED, V82, P170
   World Health Organization Reproductive Health and Research, 2010, MED EL CRIT CONTR US
NR 29
TC 15
Z9 18
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD AUG
PY 2013
VL 100
IS 2
BP 445
EP 450
DI 10.1016/j.fertnstert.2013.03.039
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 194KW
UT WOS:000322633200032
PM 23623474
DA 2020-12-01
ER

PT J
AU Santos, ARG
   Bahamondes, MV
   Hidalgo, MM
   Atti, A
   Bahamondes, L
   Monteiro, I
AF Gouvea Santos, Ana Raquel
   Valeria Bahamondes, M.
   Margarete Hidalgo, M.
   Atti, Ana
   Bahamondes, Luis
   Monteiro, Ilza
TI Pain at insertion of the levonorgestrel-releasing intrauterine system in
   nulligravida and parous women with and without cesarean section
SO CONTRACEPTION
LA English
DT Article
DE Levonorgestrel-releasing intrauterine system; Insertion; Mirena;
   Nulligravidas; Parous women
ID NULLIPAROUS WOMEN; CONTRACEPTION; DEVICE; GYNECOLOGISTS; ATTITUDES;
   IBUPROFEN; TRIAL; STILL; RISK
AB Background: Despite the high contraceptive effectiveness and noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS) in nulligravidas, there are still concerns related to the use of this device. Pain at insertion is one of the limitations to the increased use of intrauterine contraceptives. The aim of the study was to evaluate the ease of insertion and occurrence of pain at insertion of the LNG-IUS in nulligravidas (women who never became pregnant) compared to parous women with and without cesarean section (c-section). We also assessed the difficulty at insertion in each group.
   Methods: Three groups of new acceptors of the LNG-IUS were studied: one with 23 nulligravida women, one with 28 parous women who had undergone at least one c-section and one with 23 parous women who had no previous c-section. Pain at insertion was evaluated by using a pain visual analogue score (VAS). The ease of insertion was defined as easy or difficult by health care providers (HCPs) and classified according to the cause of difficulty: tight cervix, anatomically distorted uterus or pain.
   Results: Almost all women reported pain at insertion, regardless of parity and form of delivery. The mean VAS was 6.6 for nulligravida women, 5.2 for parous women with c-section and 5.9 for parous women with no c-section. Although 93% of the women reported pain at insertion, they also reported a willingness to insert a new LNG-IUS again if needed. The most common difficulties were a tight cervix in nulligravidas, an anatomically distorted uterus in parous women with c-section and pain in parous women without c-section. There was no failure of insertion in any group. HCPs reported that it was easier to perform insertion in parous women who had undergone only vaginal deliveries than nulligravid women or parous women with a prior c-section.
   Conclusions: Although almost all women reported pain at insertion, they also reported a willingness to insert a new LNG-IUS if needed. This attitude reflects high satisfaction with the LNG-IUS. The type of difficulty at insertion was related to parity and type of delivery. The LNG-IUS was able to be inserted in all women; however, it was easier to do in parous women without c-section than nulligravid women or those with a prior C-section. (C) 2013 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Monteiro, I (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM ilza@unicamp.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The study was partially funded (grant 573747/2008-3) by the Brazilian
   National Research Council (CNPq).
CR [Anonymous], 2010, CONTRACEPTION, V81, P367, DOI 10.1016/j.contraception.2010.01.010
   [Anonymous], 2006, PESQ NAC DEM SAUD CR
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Black KI, 2010, AUST NZ J OBSTET GYN, V50, P184, DOI 10.1111/j.1479-828X.2010.01136.x
   Brockmeyer A, 2008, EUR J CONTRACEP REPR, V13, P248, DOI 10.1080/02699200802253706
   Chor J, 2012, CONTRACEPTION, V85, P558, DOI 10.1016/j.contraception.2011.10.015
   d'Arcangues C, 2007, CONTRACEPTION, V75, pS2, DOI 10.1016/j.contraception.2006.12.024
   de Vaate AJMB, 2010, J MINIM INVAS GYN, V17, P133, DOI 10.1016/j.jmig.2009.09.009
   Duenas JL, 1996, CONTRACEPTION, V53, P23, DOI 10.1016/0010-7824(95)00025-9
   Fabres C, 2003, J ULTRAS MED, V22, P265
   Gibbons L, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.02.026
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Lete I, 1998, Eur J Contracept Reprod Health Care, V3, P190
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   Ofili-Yebovi D, 2008, ULTRASOUND OBST GYN, V31, P72, DOI 10.1002/uog.5200
   Osser OV, 2009, ULTRASOUND OBST GYN, V34, P90, DOI 10.1002/uog.6395
   Petersen KR, 1991, ADV CONTRACEPT, V7, P331
   Ramirez Hidalgo A, 2000, Eur J Contracept Reprod Health Care, V5, P198
   SIVIN I, 1990, CONTRACEPTION, V42, P361, DOI 10.1016/0010-7824(90)90046-X
   Stanwood NL, 2002, OBSTET GYNECOL, V99, P275, DOI 10.1016/S0029-7844(01)01726-4
   Stubbs E, 2008, CAN FAM PHYSICIAN, V54, P560
   Tinelli A, 2006, EUR J CONTRACEP REPR, V11, P197, DOI 10.1080/13625180600759755
   Veldhuis H M, 2004, Eur J Gen Pract, V10, P82
   Wang CB, 2009, ULTRASOUND OBST GYN, V34, P85, DOI 10.1002/uog.6405
   Wellings K, 2007, CONTRACEPTION, V76, P208, DOI 10.1016/j.contraception.2007.05.085
   *WHO, 1997, INTR DEV TECHN MAN G
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
   WOODFORDE JM, 1972, J PSYCHOSOM RES, V16, P173, DOI 10.1016/0022-3999(72)90041-4
   World Health Organization, 2010, MED EL CRIT CONTR US
NR 30
TC 16
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUL
PY 2013
VL 88
IS 1
BP 164
EP 168
DI 10.1016/j.contraception.2012.10.015
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 173NK
UT WOS:000321086000027
PM 23507169
DA 2020-12-01
ER

PT J
AU Gemzell-Danielsson, K
   Mansour, D
   Fiala, C
   Kaunitz, AM
   Bahamondes, L
AF Gemzell-Danielsson, K.
   Mansour, D.
   Fiala, C.
   Kaunitz, A.M.
   Bahamondes, L.
TI Management of pain associated with the insertion of intrauterine
   contraceptives
SO HUMAN REPRODUCTION UPDATE
LA English
DT Article
DE intrauterine contraception; pain; algesia; local anaesthesia; cervical
   priming
ID INJECTABLE LOCAL-ANESTHESIA; VAGINAL MISOPROSTOL; NULLIPAROUS WOMEN;
   DEVICE INSERTION; RANDOMIZED-TRIAL; CLINICAL-PERFORMANCE; IUD INSERTION;
   EVACUATION; SYSTEM; EXPERIENCE
AB BACKGROUND:
   Most intrauterine contraception (IUC) placements do not require pain relief. However, small proportions of nulliparous (approximate to 17%) and parous (approximate to 11%) women experience substantial pain that needs to be proactively managed. This review critically evaluates the evidence for pain management strategies, formulates evidence-based recommendations and identifies data gaps and areas for further research.
   METHODS:A PubMed literature search wasundertaken. Relevant articles on management of pain associated with IUC insertion, published in English between 1980 and November 2012, were identified using the following search terms: 'intrauterine contraception', 'insertion' and 'pain'.
   RCTs were included; further relevant articles were also identified and included as appropriate.
   RESULTS: Seventeen studies were identified and included: 12 RCTs and one non-randomized study of pre insertion oral analgesia, cervical
   priming and local anaesthesia; one systematic review and one RCT on post-insertion analgesia and two non-randomized studies on non pharma cological interventions. There was no conclusive evidence that any prophylactic pharmacological intervention reduces pain associated with IUC insertion. However,most of the regimens studied were adopted from hysteroscopy or abortion and effectiveness in specific subsets of women has not been studied adequately. Asystematicreviewfoundnon-steroidalanti-inflammatoryagents(NSAID)to be effective in reactively treating post insertion pain, but no benefit was found with prophylactic use.
   CONCLUSIONS: No prophylactic pharmacological intervention has been adequately evaluated to support routine use for pain reduction
   during or after IUC insertion. Women's anxiety about the procedure may contribute to higher levels of perceived pain, which highlights the importance of counselling, and creating a trustworthy, unhurried and professional atmosphere in which the experience of the provider also has a
   major role; a situation frequently referred to as 'verbal anaesthesia'.
C1 [Gemzell-Danielsson, K.; Fiala, C.] Karolinska Univ Hosp, Karolinska Inst, Dept Women & Childrens Hlth, SE-17176 Stockholm, Sweden.
   [Mansour, D.] New Croft Ctr, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England.
   [Fiala, C.] Gynmed Clin, Vienna, Austria.
   [Kaunitz, A.M.] Univ Florida, Coll Med Jacksonville, Dept Obstet & Gynecol, Jacksonville, FL 32209 USA.
   [Bahamondes, L.] Univ Estadual Campinas, UNICAMP, Fac Med Serv, Dept Obstet & Gynaecol, BR-13084971 Campinas, SP, Brazil.
RP Gemzell-Danielsson, K (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Women & Childrens Hlth, SE-17176 Stockholm, Sweden.
EM kristina.gemzell@ki.se
RI Kaunitz, Andrew/AAL-8448-2020
OI Fiala, Christian/0000-0001-6451-7349
FU Bayer HealthCareBayer AGBayer Healthcare Pharmaceuticals
FX The assistance provided by Sonya Haslam in preparing the manuscript was
   funded by Bayer HealthCare. No other funding was provided for the study.
CR Allen RH, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007373.pub2
   [Anonymous], 2011, Eur J Contracept Reprod Health Care, V16 Suppl 1, pS1, DOI 10.3109/13625187.2011.607690
   Aronsson A, 2004, HUM REPROD, V19, P81, DOI 10.1093/humrep/deh005
   *ASS REPR HLTH PRO, NEW DEV INTR CONTR U
   Bacon L, 2011, J FAM PLAN REPROD H, V37, P253, DOI 10.1136/jfprhc-2011-100186
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   Bailit JL, 2004, AM J OBSTET GYNECOL, V191, P800, DOI 10.1016/j.ajog.2004.01.051
   Barber EL, 2011, OBSTET GYNECOL, V118, P29, DOI 10.1097/AOG.0b013e31821e5f65
   Brockmeyer A, 2008, EUR J CONTRACEP REPR, V13, P248, DOI 10.1080/02699200802253706
   Caliskan E, 2007, EUR J CONTRACEP REPR, V12, P372, DOI 10.1080/13625180701549758
   CHI I, 1986, CONTRACEPTION, V34, P483, DOI 10.1016/0010-7824(86)90057-0
   CHI I C, 1989, Advances in Contraception, V5, P101, DOI 10.1007/BF01849478
   Chor J, 2012, CONTRACEPTION, V85, P558, DOI 10.1016/j.contraception.2011.10.015
   Cooper NAM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1130
   Dijkhuizen K, 2011, HUM REPROD, V26, P323, DOI 10.1093/humrep/deq348
   Eady A, 2011, J FAM PLAN REPROD H, V37, P254, DOI 10.1136/jfprhc-2011-100183
   Edelman AB, 2011, CONTRACEPTION, V84, P234, DOI 10.1016/j.contraception.2011.01.016
   Gemzell-Danielsson K, 2012, CONTRACEPTION, V86, P631, DOI 10.1016/j.contraception.2012.06.002
   GOLDSTUCK ND, 1983, CONTRACEPT DELIV SYS, V4, P33
   Gray S, 2011, J FAM PLAN REPROD H, V37, P189, DOI 10.1136/jfprhc-2011-0129
   Grimes DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006034.pub2
   GUPTA JK, 1990, LANCET, V335, P1238, DOI 10.1016/0140-6736(90)91303-R
   Heikinheimo O, 2010, CONTRACEPTION, V81, P481, DOI 10.1016/j.contraception.2010.01.020
   HEPBURN S, 1980, CONTRACEPT DELIV SYS, V1, P371
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   Hubacher D, 2006, AM J OBSTET GYNECOL, V195, P1272, DOI 10.1016/j.ajog.2006.08.022
   Hutt S, 2011, J FAM PLAN REPROD H, V37, P253, DOI 10.1136/jfprhc-2011-100203
   Hutt S, 2011, J FAM PLAN REPROD H, V37, P59, DOI 10.1136/jfprhc.2010.0037
   Jabir MM, 2009, SAUDI MED J, V30, P82
   Jones K, 2011, J FAM PLAN REPROD H, V37, P253, DOI 10.1136/jfprhc-2011-100184
   Karabayirli S, 2012, J MINIM INVAS GYN, V19, P581, DOI 10.1016/j.jmig.2012.04.004
   KURZ KH, 1983, CONTRACEPT DELIV SYS, V4, P27
   Lassner K J, 1995, Bull Pan Am Health Organ, V29, P206
   Maguire K, 2012, CONTRACEPTION, V86, P214, DOI 10.1016/j.contraception.2012.01.005
   Marions L, 2011, EUR J CONTRACEP REPR, V16, P126, DOI 10.3109/13625187.2011.558222
   McNicholas CP, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.09.018
   Meckstroth KR, 2006, OBSTET GYNECOL, V108, P582, DOI 10.1097/01.AOG.0000230398.32794.9d
   Mody SK, 2012, CONTRACEPTION, V86, P704, DOI 10.1016/j.contraception.2012.06.004
   Murty J, 2003, J FAM PLAN REPROD H, V29, P150, DOI 10.1783/147118903101197539
   NEWTON JR, 1977, CONTRACEPTION, V16, P523, DOI 10.1016/0010-7824(77)90075-0
   Oloto EJ, 1996, BRIT J FAM PLAN, V22, P117
   Peipert JF, 2011, OBSTET GYNECOL, V117, P1105, DOI 10.1097/AOG.0b013e31821188ad
   Saav I, 2007, HUM REPROD, V22, P2647, DOI 10.1093/humrep/dem244
   Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017
   Singh K, 1999, BRIT J OBSTET GYNAEC, V106, P266, DOI 10.1111/j.1471-0528.1999.tb08241.x
   Singh K, 1999, OBSTET GYNECOL, V94, P431, DOI 10.1016/S0029-7844(99)00272-0
   Singh K, 1998, OBSTET GYNECOL, V92, P795, DOI 10.1016/S0029-7844(98)00281-6
   Singh K, 1999, HUM REPROD, V14, P1635, DOI 10.1093/humrep/14.6.1635
   Stavrou EP, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-8
   Suhonen S, 2004, CONTRACEPTION, V69, P407, DOI 10.1016/j.contraception.2003.11.008
   Swenson C, 2012, OBSTET GYNECOL, V120, P341, DOI 10.1097/AOG.0b013e31825d9ec9
   Tang OS, 2007, INT J GYNECOL OBSTET, V99, pS160, DOI 10.1016/j.ijgo.2007.09.004
   THIERY M, 1985, Advances in Contraception, V1, P167, DOI 10.1007/BF01849798
   Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021
   Villar J, 2006, LANCET, V367, P1819, DOI 10.1016/S0140-6736(06)68704-7
   Ward K, 2011, CONTRACEPTION, V84, P594, DOI 10.1016/j.contraception.2011.03.011
   Winner B, 2012, NEW ENGL J MED, V366, P1998, DOI 10.1056/NEJMoa1110855
NR 57
TC 31
Z9 32
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1355-4786
EI 1460-2369
J9 HUM REPROD UPDATE
JI Hum. Reprod. Update
PD JUL-AUG
PY 2013
VL 19
IS 4
BP 419
EP 427
DI 10.1093/humupd/dmt022
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 165DP
UT WOS:000320463500008
PM 23670222
OA Green Published, Bronze
DA 2020-12-01
ER

PT J
AU Bahamondes, L
AF Bahamondes, Luis
TI "Is lipid profile determination necessary in women wishing to use oral
   contraceptives?" by Machado RB et al. Reply
SO CONTRACEPTION
LA English
DT Letter
C1 Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Sao Paulo, Brazil.
EM bahamond@caismunicamp.br
CR Berenson AB, 2009, OBSTET GYNECOL, V114, P786, DOI 10.1097/AOG.0b013e3181b76bea
   Committee on Gynecologic Practice American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P1527, DOI 10.1097/01.AOG.0000423818.85283.bd
   Machado RB, 2013, CONTRACEPTION, V87, P801, DOI 10.1016/j.contraception.2012.12.003
   Tepper NK, 2013, CONTRACEPTION, V87, P645, DOI 10.1016/j.contraception.2012.08.009
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2013
VL 87
IS 6
BP 864
EP 864
DI 10.1016/j.contraception.2013.01.003
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 152RZ
UT WOS:000319550100024
PM 23375354
DA 2020-12-01
ER

PT J
AU Munuce, MJ
   Zumoffen, C
   Cicare, J
   Caille, A
   Ghersevich, S
   Bahamondes, L
AF Munuce, Maria Jose
   Zumoffen, Carlos
   Cicare, Juliana
   Caille, Adriana
   Ghersevich, Sergio
   Bahamondes, Luis
TI Effect of exposure to ulipristal acetate on sperm function
SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE
LA English
DT Article
DE Spermatozoa; Ulipristal acetate; Acrosomal reaction; Sperm function
ID PROTEIN-TYROSINE PHOSPHORYLATION; COMPLETE ACROSOME REACTION;
   PROGESTERONE-RECEPTOR; HUMAN SPERMATOZOA; EMERGENCY CONTRACEPTION;
   CELL-SURFACE; MOUSE SPERMATOZOA; FOLLICULAR-FLUID; CAPACITATION; RU486
AB Objective A pill containing ulipristal acetate (UPA) is used for emergency contraception (EC). Considering that, following its intake, spermatozoa may be exposed to UPA in the female genital tract we intended to evaluate sperm functions after incubation with this compound.
   Methods Motile spermatozoa were selected by swim-up and were incubated under capacitating conditions with UPA (at concentrations of 1, 10, 100, 1,000, and 10,000 ng/ml) or control medium. The main outcome measures were sperm vitality, sperm protein tyrosine phosphorylation (TyrP), spontaneous acrosomal reaction (AR), and human follicular fluid (hFF)-induced AR.
   Results Sperm vitality and TyrP pattern were similar between spermatozoa exposed to UPA or control. In addition, spontaneous AR ranged from 14.0. +/- 1.5% to 18.0. +/- 1.9% after exposure to UPA or control medium without significant differences, and UPA did not prevent hFF-induced AR.
   Conclusions Incubation of sperm with UPA at concentrations around the expected plasma levels after ingestion of this EC pill (similar to 100-200 ng/ml) did not modify the signal transduction of TyrP involved in sperm capacitation. Moreover, UPA showed no agonist effect on progesterone receptors because it did not induce AR. Considering that progesterone in hFF is essential for AR induction, and UPA did not prevent the hFF-induced AR, an antagonist action of UPA on the AR is unlikely.
C1 [Munuce, Maria Jose; Zumoffen, Carlos; Cicare, Juliana; Caille, Adriana; Ghersevich, Sergio] Natl Univ Rosario, Sch Biochem & Pharmaceut Sci, Clin Biochem Area, Lab Reprod Studies, Rosario, Argentina.
   [Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Bahamondes, Luis] Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Saude da mulher, Inct/J-9403-2013
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The study received partial funding (grant 573747/2008-3) from the
   Brazilian National Research Council (CNPq).
CR Ambhaikar M, 1998, MOL HUM REPROD, V4, P413, DOI 10.1093/molehr/4.5.413
   Bahamondes L, 2011, EXPERT OPIN EMERG DR, V16, P373, DOI 10.1517/14728214.2011.536761
   Baldi E, 2009, MOL CELL ENDOCRINOL, V308, P39, DOI 10.1016/j.mce.2009.02.006
   BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282
   BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376
   BLACKMORE PF, 1991, BIOCHEM BIOPH RES CO, V181, P331, DOI 10.1016/S0006-291X(05)81422-6
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Bouchard P, 2011, GYNECOL ENDOCRINOL, V27, P1120, DOI 10.3109/09513590.2012.638754
   Bouchard P, 2011, FERTIL STERIL, V96, P1175, DOI 10.1016/j.fertnstert.2011.08.021
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   CALVO L, 1989, FERTIL STERIL, V52, P1048
   Croxtall JD, 2012, DRUGS, V72, P1075, DOI 10.2165/11209400-000000000-00000
   Durand M, 2001, CONTRACEPTION, V64, P227, DOI 10.1016/S0010-7824(01)00250-5
   Emiliozzi C, 1997, BIOL REPROD, V56, P674, DOI 10.1095/biolreprod56.3.674
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Guidobaldi HA, 2012, REPRODUCTION, V143, P587, DOI 10.1530/REP-11-0478
   Hermanny A, 2012, EXPERT REV OBSTET GY, V7, P123
   Jaiswal BS, 1999, MOL HUM REPROD, V5, P214, DOI 10.1093/molehr/5.3.214
   Jaiswal BS, 1998, FEBS LETT, V427, P309, DOI 10.1016/S0014-5793(98)00455-4
   Jang S, 2002, J BIOCHEM MOL BIOL, V35, P604
   Kohn FM, 1997, HUM REPROD, V12, P714, DOI 10.1093/humrep/12.4.714
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leonhardt SA, 2002, EXP BIOL MED, V227, P969
   Lishko PV, 2011, NATURE, V471, P387, DOI 10.1038/nature09767
   LUCONI M, 1995, MOL CELL ENDOCRINOL, V108, P35, DOI 10.1016/0303-7207(95)92576-A
   Munuce MJ, 2004, ANDROLOGIA, V36, P395, DOI 10.1111/j.1439-0272.2004.00638.x
   Munuce MJ, 2003, FERTIL STERIL, V80, P939, DOI 10.1016/S0015-0282(03)01114-2
   OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4
   Richardson AR, 2012, CLIN THER, V34, P24, DOI 10.1016/j.clinthera.2011.11.012
   SERRES C, 1994, BIOCHEM BIOPH RES CO, V204, P1009, DOI 10.1006/bbrc.1994.2563
   Stratton P, 2010, FERTIL STERIL, V93, P2035, DOI 10.1016/j.fertnstert.2008.12.057
   TESARIK J, 1992, FERTIL STERIL, V58, P784
   TESARIK J, 1993, ENDOCRINOLOGY, V133, P328, DOI 10.1210/en.133.1.328
   Tomes CN, 1998, MOL HUM REPROD, V4, P17, DOI 10.1093/molehr/4.1.17
   Urner F, 2003, REPRODUCTION, V125, P17, DOI 10.1530/rep.0.1250017
   VISCONTI PE, 1995, DEVELOPMENT, V121, P1139
   VISCONTI PE, 1995, DEVELOPMENT, V121, P1129
   WANG C, 1995, CONTRACEPTION, V51, P215, DOI 10.1016/0010-7824(95)00020-B
   World Health Organization WHO, 2010, LAB MAN EX PROC HUM
   Yanagimachi R., 1988, P135
   YANG J, 1994, P NATL ACAD SCI USA, V91, P529, DOI 10.1073/pnas.91.2.529
   Zumoffen CM, 2010, HUM REPROD, V25, P1504, DOI 10.1093/humrep/deq063
NR 42
TC 15
Z9 16
U1 0
U2 3
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1362-5187
J9 EUR J CONTRACEP REPR
JI Eur. J. Contracept. Reprod. Health Care
PD DEC
PY 2012
VL 17
IS 6
BP 428
EP 437
DI 10.3109/13625187.2012.725877
PG 10
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA 041QW
UT WOS:000311417300004
PM 23157703
DA 2020-12-01
ER

PT J
AU Gemzell-Danielsson, K
   Cho, S
   Inki, P
   Mansour, D
   Reid, R
   Bahamondes, L
AF Gemzell-Danielsson, Kristina
   Cho, SiHyun
   Inki, Pirjo
   Mansour, Diana
   Reid, Robert
   Bahamondes, Luis
TI Use of contraceptive methods and contraceptive recommendations among
   health care providers actively involved in contraceptive counseling -
   results of an international survey in 10 countries
SO CONTRACEPTION
LA English
DT Article
DE Contraception; Counseling; Health care providers
ID FEMALE PHYSICIANS; PERCEPTIONS; WOMEN
AB Background: This study was conducted to determine the personal choices of contraceptive methods among an international sample of contraception health care professionals (HCPs) and to determine if these choices are concordant with their recommendations to women.
   Study Design: In an anonymous online survey, 1001 HCPs actively involved in contraceptive counseling [obstetrician/gynecologists (OB/GYNs), general practitioners (GPs) and midwives (only in Sweden)] from 10 countries (Australia, Brazil, Canada, France, Germany, Korea, Mexico, Spain, Sweden and the United Kingdom) were asked about their personal use of contraceptive methods and their recommendations to women in two different clinical scenarios: for spacing between children (Group A) and after completion of the family (Group B).
   Results: The largest HCP group was OB/GYNs (67.1%), followed by GPs (31.4%) and midwives (1.5%). A total of 42.7% of respondents were male, and 57.3% were female. The majority of respondents were aged 36-45 years (38.9%) or 46-55 years (42.8%), 79.7% had children, and 53.9% were currently using contraception (by themselves or by their partners). Among 540 contraceptive users, the three most common methods were the levonorgestrel-releasing intrauterine system (LNG-IUS; 29.3%), combined oral contraceptives (COCs; 20.0%) and condoms (17.0%). OB/GYNs were more likely to be using the LNG-IUS than GPs (p=.014). Gender did not seem to influence contraceptive preference. Reasons for these choices were largely influenced by family situation and high contraceptive efficacy (for the LNG-IUS) or side effects caused by other methods (for condoms). The top contraceptive recommendation was COCs for Group A and the LNG-IUS for Group B. HCPs currently using COCs and the LNG-IUS were more likely to recommend these methods than other contraceptive methods for Group A and Group B, respectively.
   Conclusions: The most popular contraceptive method in this sample of HCPs was the LNG-IUS. Choice of contraceptive method was driven by family situation, age and profession. It appears that, in this sample, personal contraceptive use influences contraceptive recommendations. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Gemzell-Danielsson, Kristina] Karolinska Inst, Karolinska Univ Hosp, Div Obstet & Gynecol, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden.
   [Cho, SiHyun] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Obstet & Gynecol, Seoul 135720, South Korea.
   [Inki, Pirjo] Bayer Healthcare Pharmaceut, D-13342 Berlin, Germany.
   [Mansour, Diana] New Croft Ctr, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England.
   [Reid, Robert] Queens Univ, Div Reprod Endocrinol & Infertil, Kingston, ON K7L 4V7, Canada.
   [Bahamondes, Luis] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
RP Gemzell-Danielsson, K (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Div Obstet & Gynecol, Dept Womens & Childrens Hlth, S-17176 Stockholm, Sweden.
EM kristina.gemzell@ki.se
RI Saude da mulher, Inct/J-9403-2013
OI Cho, SiHyun/0000-0003-2718-6645
FU Bayer HealthcareBayer AGBayer Healthcare Pharmaceuticals
FX This study was partially funded by Bayer Healthcare; however, the
   authors did not receive any honorarium or assistance in manuscript
   preparation.
CR Benson LS, 2012, CONTRACEPTION, V85, P198, DOI 10.1016/j.contraception.2011.05.021
   Cibula David, 2008, Eur J Contracept Reprod Health Care, V13, P362
   CUMMINGS KM, 1987, AM J PREV MED, V3, P69
   Dehlendorf C, 2010, CONTRACEPTION, V81, P292, DOI 10.1016/j.contraception.2009.11.006
   Erviti J, 2010, QUAL HEALTH RES, V20, P778, DOI 10.1177/1049732310362983
   Frank E, 2003, MENOPAUSE, V10, P133, DOI 10.1097/00042192-200310020-00004
   Frank E, 1999, OBSTET GYNECOL, V94, P666, DOI 10.1016/S0029-7844(99)00424-X
   HYMAN DJ, 1992, PUBLIC HEALTH REP, V107, P441
   Lee DY, 2010, GYNECOL OBSTET INVES, V70, P154, DOI 10.1159/000316263
   LEWIS CE, 1991, ANN INTERN MED, V114, P54, DOI 10.7326/0003-4819-114-1-54
   Mattila-Lindy S, 1997, WOMEN HEALTH, V26, P15
   Rowen TS, 2011, CONTRACEPTION, V83, P459, DOI 10.1016/j.contraception.2010.09.011
   Viberga I, 2006, ACTA OBSTET GYN SCAN, V85, P583, DOI 10.1080/00016340600590451
   Wiebe ER, 2006, CONTRACEPTION, V73, P623, DOI 10.1016/j.contraception.2006.02.001
   ZBELLA EA, 1986, CONTRACEPTION, V33, P423, DOI 10.1016/S0010-7824(86)80001-4
NR 15
TC 26
Z9 26
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
J9 CONTRACEPTION
JI Contraception
PD DEC
PY 2012
VL 86
IS 6
BP 631
EP 638
DI 10.1016/j.contraception.2012.06.002
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 038SZ
UT WOS:000311195700005
PM 22770797
DA 2020-12-01
ER

PT J
AU Dal'Ava, N
   Bahamondes, L
   Bahamondes, MV
   Santos, AD
   Monteiro, I
AF Dal'Ava, Natalia
   Bahamondes, Luis
   Valeria Bahamondes, M.
   Santos, Allan de Oliveira
   Monteiro, Ilza
TI Body weight and composition in users of levonorgestrel-releasing
   intrauterine system
SO CONTRACEPTION
LA English
DT Article
DE Body composition; Fat mass; Levonorgestrel-releasing intrauterine system
ID DEPOT MEDROXYPROGESTERONE ACETATE; LONG-TERM USERS; COPPER IUD; BONE;
   DENSITY; WOMEN
AB Background: There is little information about body weight and body composition (BC) among users of the levonorgestrel-releasing intrauterine system (LNG-IUS). The aim of this study was to evaluate body weight and BC in LNG-IUS users compared to users of the TCu380A intrauterine device (IUD).
   Study Design: A prospective study was done with 76 new users of both contraceptive methods. Women were paired by age (+/- 2 years) and body mass index (BMI, kg/m(2), +/- 2). Body weight and BC (% lean mass and % fat mass) were evaluated by a trained professional at baseline and at 1 year of contraceptive use. The BC measurements were obtained using Lunar DXA equipment. Weight and BC were evaluated in each woman at baseline and at 12 months and analyzed as the mean change within each woman. Then, the changes in weight and BC for each woman were calculated and then compared between LNG-IUS and TCu380A IUD users (paired data for each woman). The central-to-peripheral fat ratio was calculated by dividing trunk fat by the upper and lower limb fat.
   Results: There were no significant differences at time of IUD insertion between LNG-IUS and TCu380A IUD users regarding age (mean +/- SD) (34.4 +/- 7.5 vs. 33.9 +/- 8.0 years), BMI (25.3 +/- 4.1 vs. 25.9 +/- 4.1) and number of pregnancies (1.9 +/- 0.2 vs. 1.7 +/- 0.2), respectively. Mean body weight gain of 2.9 kg was observed among LNG-IUS users at 12 months (p=.0012), whereas the body weight of TCu380A IUD users only increased by 1.4 kg (p=.067). There was no significant difference in body weight change between the two groups of users at 12 months. The variation in the central-to-peripheral fat ratio was the same between the two groups (-1.6% vs. -0.2%; p=.364). LNG-IUS users showed a 2.5% gain in fat mass (p=.0009) and a 1.4% loss of lean mass, whereas TCu380A IUD users showed a loss of 1.3% of fat mass (p=.159) and gain of 1.0% of lean mass (p=.120). TCu380A IUD users gained more lean mass than LNG-IUS users (p=.0270), although there was no significant difference between the two groups after 12 months of use.
   Conclusions: Although an increase in mean fat mass among LNG-IUS users at 12 months of use was observed, it should be noted that an increase of body weight was also observed in both groups after 1 year of insertion of the device. However, a study with a larger number of women and long-term evaluation is necessary to evaluate these body changes. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Dal'Ava, Natalia; Bahamondes, Luis; Valeria Bahamondes, M.; Monteiro, Ilza] Univ Campinas UNICAMP, Dept Obstet & Gynecol, Human Reprod Unit, Sch Med, BR-13083887 Campinas, SP, Brazil.
   [Santos, Allan de Oliveira] Univ Campinas UNICAMP, Dept Radiol, Sch Med, BR-13083887 Campinas, SP, Brazil.
RP Dal'Ava, N (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM na_taliads@hotmail.com
RI monteiro, ilza m u/F-4871-2014; Saude da mulher, Inct/J-9403-2013
OI monteiro, ilza m u/0000-0002-9536-0564; Santos,
   Allan/0000-0002-9192-6946
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/15595-4];
   Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study was partially financed by the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP, award #2009/15595-4) and by the
   Brazilian National Research Council (CNPq, award #573747/2008-3).
CR ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0
   Backman T, 2000, BRIT J OBSTET GYNAEC, V107, P335, DOI 10.1111/j.1471-0528.2000.tb13228.x
   Bahamondes L, 2006, HUM REPROD, V21, P1316, DOI 10.1093/humrep/dei457
   Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Bahamondes L, 2008, EXPERT REV MED DEVIC, V5, P437, DOI 10.1586/17434440.5.4.437
   Bahamondes MV, 2010, HUM REPROD, V25, P1158, DOI 10.1093/humrep/deq043
   Balasch J, 2003, HUM REPROD UPDATE, V9, P207, DOI 10.1093/humupd/dmg017
   Beatty Megan N, 2009, Ther Clin Risk Manag, V5, P561
   Berenson AB, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.052
   Crosignani PG, 2008, HUM REPROD UPDATE, V14, P197, DOI 10.1093/humupd/dmn003
   Hassan DF, 2003, CONTRACEPTION, V68, P27, DOI 10.1016/S0010-7824(03)00079-9
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248
   Schindler AE, 2008, MATURITAS, V61, P171, DOI 10.1016/j.maturitas.2008.11.013
   Sheng J, 2009, CONTRACEPTION, V79, P189, DOI 10.1016/j.contraception.2008.11.004
   Westhoff C, 2007, CONTRACEPTION, V75, P261, DOI 10.1016/j.contraception.2006.12.009
   Yela Daniela Angerame, 2006, Rev. Assoc. Med. Bras., V52, P32, DOI 10.1590/S0104-42302006000100019
NR 18
TC 18
Z9 18
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2012
VL 86
IS 4
BP 350
EP 353
DI 10.1016/j.contraception.2012.01.017
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 011FO
UT WOS:000309150600006
PM 22445431
DA 2020-12-01
ER

PT J
AU Marchi, NM
   Castro, S
   Hidalgo, MM
   Hidalgo, C
   Monteiro-Dantas, C
   Villarroeal, M
   Bahamondes, L
AF Marchi, Nadia M.
   Castro, Sara
   Margarete Hidalgo, M.
   Hidalgo, Creusa
   Monteiro-Dantas, Cecilia
   Villarroeal, Marina
   Bahamondes, Luis
TI Management of missing strings in users of intrauterine contraceptives
SO CONTRACEPTION
LA English
DT Article
DE Levonorgestrel-releasing intrauterine system; Copper-IUD; Missing
   strings
ID UTERINE PERFORATION; NULLIPAROUS WOMEN; DEVICE; IUD; REMOVAL; SYSTEM;
   INSERTION; CAVITY
AB Background: A common question among health care professionals is how to manage nonvisible strings in users of intrauterine contraceptives (IUCs) at repeat follow-up visits. This study assessed the position of the IUCs in women who consulted repeatedly with nonvisible IUC strings.
   Study Design: The medical records of the clinic were reviewed to identify new acceptors and switchers who had an IUC inserted between 1990 and 2009. All women were identified whose IUC string could not be visualized at the external os of the cervix by the health care professional at any given follow-up visit, even after attempting a standard maneuver of sweeping the strings from the cervical canal using a cervical brush or trying to visualize the strings in the cervical canal using colposcopy. Data were also retrieved on the use of ultrasonography and/or pelvic X-ray to assess IUC position, as well as data from any subsequent visits at which the IUC strings were nonvisible.
   Results: The medical charts of 14,935 patients using an IUC were reviewed, and 750 women (5.0%) presenting for the first time with missing IUC strings at any follow-up visit were identified. Ultrasound scans showed the IUC to be in situ in 735 cases (98.0%), while 9 women (1.2%) had expelled the device and, in 5 cases (0.7%), the device was found in the pelvis following uterine perforation. IUC strings were missing on a second occasion in 297 cases. The device was found to be in situ in 295 cases (99.3%) and had been expelled in 2 (0.7%). At subsequent consultations, (between 1 and 18 years after the first consultation), strings were missing in 113, 55, 19 and 5 cases. In 111 (98.2%), 54(98.2%), 18 (94.7%) and 5 (100%) of these cases, respectively, the IUC was found to be in situ, while in the remaining cases, the device had been expelled.
   Conclusions: Missing TUC strings are an uncommon finding, and ultrasonography confirmed that the device was in situ in the majority of these cases. For women with persistent missing IUC strings after one ultrasound scan that has verified appropriate intrauterine position, given the 2.4% likelihood that expulsion may have occurred at the time of subsequent visits, repeating the ultrasound (if available) should be considered for at least one (and possibly two) additional women's visit. (C) 2012 Elsevier Inc. All rights reserved.
C1 Univ Campinas UNCAMP, Dept Obstet & Gynecol, Human Reprod Unit, Sch Med Sci, BR-13084971 Campinas, SP, Brazil.
   Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Saude da mulher, Inct/J-9403-2013
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study was partially funded (grant 573747/2008-3) by the Brazilian
   National Research Council (CNPq).
CR ANTEBY SO, 1984, ENDOSCOPY, V16, P146, DOI 10.1055/s-2007-1018561
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes M Valeria, 2011, Contraception, V84, pe11, DOI 10.1016/j.contraception.2011.05.012
   BenRafael Z, 1996, OBSTET GYNECOL, V87, P785, DOI 10.1016/0029-7844(96)00009-9
   Blanas K, 2010, EUR J CONTRACEP REPR, V15, P441, DOI 10.3109/13625187.2010.514081
   BOUNDS W, 1992, BRIT J OBSTET GYNAEC, V99, P915, DOI 10.1111/j.1471-0528.1992.tb14442.x
   CHI IC, 1993, CONTRACEPTION, V48, P81, DOI 10.1016/0010-7824(93)90001-N
   d'Arcangues C, 2007, CONTRACEPTION, V75, pS2, DOI 10.1016/j.contraception.2006.12.024
   Faundes D, 2000, CONTRACEPTION, V62, P165, DOI 10.1016/S0010-7824(00)00167-0
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   Harrison-Woolrych M, 2003, CONTRACEPTION, V67, P53, DOI 10.1016/S0010-7824(02)00417-1
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hubacher D, 2007, CONTRACEPTION, V75, pS8, DOI 10.1016/j.contraception.2006.12.005
   LUUKKAINEN T, 1995, CONTRACEPTION, V52, P269, DOI 10.1016/0010-7824(95)00210-2
   Meirik O, 2009, CONTRACEPTION, V80, P133, DOI 10.1016/j.contraception.2009.02.006
   MISHELL DR, 1973, AM J OBSTET GYNECOL, V116, P1092, DOI 10.1016/0002-9378(73)90942-3
   Prabhakaran S, 2011, CONTRACEPTION, V83, P102, DOI 10.1016/j.contraception.2010.07.004
   ROKE CM, 1988, CONTRACEPTION, V37, P555, DOI 10.1016/0010-7824(88)90002-9
   Sivin I, 2007, CONTRACEPTION, V75, pS70, DOI 10.1016/j.contraception.2007.01.016
   Tugrul S, 2005, CONTRACEPTION, V71, P149, DOI 10.1016/j.contraception.2004.08.015
   Bahamondes MV, 2011, INT J GYNECOL OBSTET, V113, P50, DOI 10.1016/j.ijgo.2010.10.013
   Van Houdenhoven K, 2006, CONTRACEPTION, V73, P257, DOI 10.1016/j.contraception.2005.08.013
   Vilos GA, 2010, J MINIM INVAS GYN, V17, P805, DOI 10.1016/j.jmig.2010.07.014
   Waldron K, 1982, Aust Fam Physician, V11, P40
   Zhou LF, 2003, PHARMACOEPIDEM DR S, V12, P371, DOI 10.1002/pds.875
NR 25
TC 21
Z9 21
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2012
VL 86
IS 4
BP 354
EP 358
DI 10.1016/j.contraception.2012.01.018
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 011FO
UT WOS:000309150600007
PM 22459233
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   de Lima, Y
   Teich, V
   Bahamondes, L
   Monteiro, I
AF Valeria Bahamondes, M.
   de Lima, Yuri
   Teich, Vanessa
   Bahamondes, Luis
   Monteiro, Ilza
TI Resources and procedures in the treatment of heavy menstrual bleeding
   with the levonorgestrel-releasing intrauterine system (LNG-IUS) or
   hysterectomy in Brazil
SO CONTRACEPTION
LA English
DT Article
DE Pharmacoeconomics; Levonorgestrel-releasing intrauterine system; Mirena;
   Heavy menstrual bleeding; Hysterectomy
ID COST-EFFECTIVENESS; MENORRHAGIA; ABLATION; WOMEN; UTILITY; TRIAL
AB Background: Heavy menstrual bleeding (HMB) is the most common complaint of women seeking gynecological care. Treatments included surgical or medical options including hysterectomy and the levonorgestrel-releasing intrauterine system (LNG-IUS) due to the profound suppression of endometrial growth that intrauterine LNG exerts which results in amenorrhea or in a reduction of blood loss.
   Objective: The study was conducted to evaluate the resources and procedures involved in inserting an LNG-IUS compared to performing hysterectomy in women with HMB in a public sector hospital in Brazil.
   Study design: Two cohorts of women were studied: women who accepted an LNG-IUS (n=124) and matched women who underwent hysterectomy on the same day (n=122). We evaluate the number of procedures carried out in each group of women, including those performed before the decision was made to insert an LNG-IUS or to perform hysterectomy, the insertion of the device itself and the surgical procedure, in addition to the procedures and complications registered up to I year after LNG-IUS insertion or hysterectomy.
   Results: Age and the duration of HMB were significantly lower in the LNG-IUS acceptors than women at the hysterectomy group. The numbers of gynecological consultations and Pap smears were similar in both groups; however, women in the hysterectomy group also underwent laboratory tests, ultrasonography, chest X-ray and electrocardiogram. In the hysterectomy group, the main complications were hemorrhage (six), bladder/bowel perforation (four), complications with anesthesia (one), ureteral reimplantation required (one) and abdominal pain (two). At I year, HMB was controlled in 83.1% of women in the LNG-IUS group, and 106 women continued with the device.
   Conclusions: Both treatments were effective in HMB control. Fewer resources and complications were observed in LNG-IUS acceptors when compared to hysterectomy. The LNG-IUS represents a good strategy for reducing the number of hysterectomies and the resources required for women with HMB. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Valeria Bahamondes, M.; de Lima, Yuri; Bahamondes, Luis; Monteiro, Ilza] Univ Campinas UNICAMP, Sch Med Sci, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
   [Valeria Bahamondes, M.; de Lima, Yuri; Bahamondes, Luis; Monteiro, Ilza] Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
   [Teich, Vanessa] MedInsight, BR-04564040 Sao Paulo, Brazil.
RP Bahamondes, MV (corresponding author), Univ Campinas UNICAMP, Sch Med Sci, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
EM vbahamondes@cemicamp.org.br
RI Saude da mulher, Inct/J-9403-2013; monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Brazilian
   National Research Council (CNPq) grant 573747/2008-3.
CR Altman D, 2007, LANCET, V370, P1494, DOI 10.1016/S0140-6736(07)61635-3
   Andersson K, 1997, BRIT J OBSTET GYNAEC, V104, P614
   Barnard K, 2003, J WOMENS HEALTH, V12, P911, DOI 10.1089/154099903770948140
   Blumenthal PD, 2006, CONTRACEPTION, V74, P249, DOI 10.1016/j.contraception.2006.03.024
   Blumenthal PD, 2011, INT J GYNECOL OBSTET, V112, P171, DOI 10.1016/j.ijgo.2010.08.025
   Bourdrez P, 2004, FERTIL STERIL, V82, P160, DOI 10.1016/j.fertnstert.2003.12.025
   Brown PM, 2006, BJOG-INT J OBSTET GY, V113, P797, DOI 10.1111/j.1471-0528.2006.00944.x
   CAMERON IT, 1989, BAILLIERE CLIN OB GY, V3, P315, DOI 10.1016/S0950-3552(89)80024-0
   Clegg JP, 2007, CURR MED RES OPIN, V23, P1637, DOI 10.1185/030079907X199709
   Cote I, 2002, OBSTET GYNECOL, V100, P683, DOI 10.1016/S0029-7844(02)02094-X
   DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3
   Farquhar C, 2009, COCHRANE DB SYST REV, V7
   Fraser IS, 2010, CONTRACEPTION, V82, P396, DOI 10.1016/j.contraception.2010.05.005
   HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455
   Halmesmaki K, 2004, HUM REPROD, V19, P378, DOI 10.1093/humrep/deh055
   Heliovaara-Peippo S, 2010, BJOG-INT J OBSTET GY, V117, P602, DOI 10.1111/j.1471-0528.2010.02505.x
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   Kaunitz AM, 2010, OBSTET GYNECOL, V116, P625, DOI 10.1097/AOG.0b013e3181ec622b
   Lete I, 2011, EUR J OBSTET GYN R B, V154, P71, DOI 10.1016/j.ejogrb.2010.08.019
   LUUKKAINEN T, 1995, CONTRACEPTION, V52, P269, DOI 10.1016/0010-7824(95)00210-2
   MIDDLETON LJ, 2010, BMJ C, V3929, P341
   National Institute for Clinical Excellence, 2007, HEAV MENSTR BLEED
   New Zealand: National Health Committee and National Health Committee Working Party, GUID MAN HEAV MENSTR
   PAKARINEN P, 1995, HUM REPROD, V10, P2390
   World Health Organization, 2010, MED EL CRIT CONTR US
   You JHS, 2006, HUM REPROD, V21, P1878, DOI 10.1093/humrep/del088
NR 26
TC 6
Z9 7
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2012
VL 86
IS 3
BP 244
EP 250
DI 10.1016/j.contraception.2011.12.005
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 999AX
UT WOS:000308282600011
PM 22459236
DA 2020-12-01
ER

PT J
AU Makuch, MY
   Duarte-Osis, MJ
   de Padua, KS
   Petta, C
   Bahamondes, L
AF Makuch, Maria Y.
   Duarte-Osis, Maria J.
   de Padua, Karla S.
   Petta, Carlos
   Bahamondes, Luis
TI Opinion and experience of Brazilian women regarding menstrual bleeding
   and use of combined oral contraceptives
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Amenorrhea; Brazilian women; Combined oral contraceptives; Menstruation;
   Perspectives
ID INDUCED AMENORRHEA; SUPPRESSION; ATTITUDES; MENSES; ACCEPTABILITY;
   PERSPECTIVE; SYMPTOMS; PILLS
AB Objective: To describe the opinion and experience of Brazilian women regarding menstruation and the use of combined oral contraceptives (COCs) to control monthly bleeding and induce amenorrhea. Methods: Women attending regional public healthcare clinics for non-gynecologic conditions, and female members of staff from university schools unrelated to the field of medicine completed a questionnaire. Results: Of the 1111 women interviewed, 64.3% reported disliking menstruation. The desired frequency of bleeding was never (65.3%), less than monthly (18.2%), and every month or more often (16.5%). More than 60% of the women reported that they would use COCs to control menstrual bleeding, 82.0% would use COCs to reduce the amount of bleeding experienced, and 86.1% would use COCs to induce amenorrhea. When compared with women who disliked menstruation, those who reported that they liked to experience monthly bleeding had fewer years of schooling (OR1.98; 95% CI, 1.30-2.97), low socioeconomic status (OR 1.66; 95%Cl, 1.12-2.46), fewer days of menstruation each month (OR 1.62; 95%Cl, 1.11-2.36), and 1 or more child (OR 1.13; 95%Cl, 1.01-1.26). Conclusion: Many of the women surveyed disliked monthly menstruation and were interested in the use of COCs to control menstrual bleeding and induce amenorrhea. (C) 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Makuch, Maria Y.; Duarte-Osis, Maria J.; de Padua, Karla S.] Ctr Res Reprod Hlth, Campinas, SP, Brazil.
   [de Padua, Karla S.] Univ Estadual Campinas, Womens Hosp Prof Dr Jose Aristodemo Pinotti CAISM, Campinas, SP, Brazil.
   [Petta, Carlos; Bahamondes, Luis] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   [Petta, Carlos; Bahamondes, Luis] Natl Inst Hormones & Womens Hlth, Campinas, SP, Brazil.
RP Makuch, MY (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM mmakuch@cemicamp.org.br
RI Saude da mulher, Inct/J-9403-2013
FU Bayer, Brazil
FX The present study was partially funded by Bayer, Brazil. The sponsor was
   not involved in the development of the protocol, the collection and
   analysis of the data, or in the preparation of the manuscript.
CR Andrist LC, 2004, CONTRACEPTION, V70, P359, DOI 10.1016/j.contraception.2004.06.008
   Andrist Linda C, 2004, J Am Acad Nurse Pract, V16, P31
   Aubeny E, 2007, REPROD HEALTH MATTER, V15, P183, DOI 10.1016/S0968-8080(07)29285-7
   Barr Laboratories, 2002, BARR SEAS NDA ACC FI
   Brazilian Association of Research Institutions, 2011, EC CLASS CRIT BRAS 2
   do Amaral MCE, 2005, CONTRACEPTION, V72, P157, DOI 10.1016/j.contraception.2005.02.013
   Edelman AB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub2
   Edelman A, 2007, CONTRACEPTION, V75, P450, DOI 10.1016/j.contraception.2007.02.005
   Ferrero S, 2006, CONTRACEPTION, V73, P537, DOI 10.1016/j.contraception.2006.01.004
   Fruzzetti F, 2008, EUR J CONTRACEP REPR, V13, P153, DOI 10.1080/13625180701800672
   Glasier AF, 2003, CONTRACEPTION, V67, P1, DOI 10.1016/S0010-7824(02)00474-2
   Hardy E, 2009, CONTRACEPTION, V80, P266, DOI 10.1016/j.contraception.2009.06.010
   Kaunitz AM, 2000, CONTRACEPTION, V62, P277, DOI 10.1016/S0010-7824(00)00182-7
   Lin K, 2007, J WOMENS HEALTH, V16, P1171, DOI 10.1089/jwh.2007.0332
   Makuch MY, 2011, CONTRACEPTION, V84, P622, DOI 10.1016/j.contraception.2011.03.010
   Pillai M, 2010, BJOG-INT J OBSTET GY, V117, P216, DOI 10.1111/j.1471-0528.2009.02372.x
   Powell-Dunford N, 2009, AVIAT SPACE ENVIR MD, V80, P971, DOI 10.3357/ASEM.2566.2009
   Powell-Dunford NC, 2011, WOMEN HEALTH ISS, V21, P86, DOI 10.1016/j.whi.2010.08.006
   RUTTER W, 1988, MED J AUSTRALIA, V149, P417, DOI 10.5694/j.1326-5377.1988.tb120701.x
   Snow R, 2007, CONTRACEPTION, V76, P23, DOI 10.1016/j.contraception.2007.03.008
   Sulak PJ, 2004, CONTRACEPTION, V70, P281, DOI 10.1016/j.contraception.2004.04.007
   Sulak PJ, 1997, OBSTET GYNECOL, V89, P179, DOI 10.1016/S0029-7844(96)00488-7
   Trego LL, 2010, WOMEN HEALTH ISS, V20, P287, DOI 10.1016/j.whi.2010.03.002
   Wiegratz I, 2004, CONTRACEPTION, V69, P37, DOI 10.1016/j.contraception.2003.09.004
   1981, STUD FAM PLANN, V12, P3
NR 25
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD APR
PY 2012
VL 117
IS 1
BP 5
EP 9
DI 10.1016/j.ijgo.2011.11.018
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 921XY
UT WOS:000302512600002
PM 22285856
DA 2020-12-01
ER

PT J
AU Hermanny, A
   Bahamondes, MV
   Fazano, F
   Marchi, NM
   Ortiz, ME
   Genghini, MHRR
   Croxatto, HB
   Bahamondes, L
AF Hermanny, Alexia
   Bahamondes, M. Valeria
   Fazano, Francisco
   Marchi, Nadia M.
   Ortiz, Maria Elena
   Genghini, Maria Heloisa R. R.
   Croxatto, Horacio B.
   Bahamondes, Luis
TI In vitro assessment of some sperm function following exposure to
   levonorgestrel in human fallopian tubes
SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY
LA English
DT Article
DE Emergency contraception; Levonorgestrel; Acrosome reaction; Fallopian
   tubes; Human spermatozoa
ID EMERGENCY CONTRACEPTION; ACROSOME REACTION; HUMAN SPERMATOZOA;
   PROGESTERONE; MECHANISMS; REGIMENS; CONTACT; OVIDUCT
AB Background: The mechanism of action of levonorgestrel (LNG) as emergency contraception (EC) remains a subject of debate and its effect on sperm function has been only partially explained. The aim of this study was to assess whether LNG at a similar dose to those found in serum following oral intake for EC could affect spermatozoa when exposed to human fallopian tubes in vitro.
   Methods: Fifteen mini-laparotomies were performed, the side on which ovulation occurred was recorded, and both tubes were removed and perfused with a suspension containing 1 x 10(6) motile spermatozoa, with or without LNG. Following 4-hour incubation, the tubes were sectioned to separate the isthmus and the ampulla. Each segment was flushed and the material was evaluated to quantify the number of motile sperm, the number of spermatozoa adhering to the oviductal epithelium and the acrosome reaction (AR) rate.
   Results: The addition of LNG did not significantly alter the number of recovered motile spermatozoa either at the isthmus or at the ampulla, nor did it have any effect on the number of recovered spermatozoa adhered to the human tubal epithelium. Furthermore, LNG did not affect the AR rate. No significant differences were found even when the side on which ovulation occurred was taken into account.
   Conclusions: In a similar dose to that observed in serum following oral intake for EC, LNG had no effect on the number of motile spermatozoa recovered from the human fallopian tubes in vitro, on their adhesion to the tubal epithelium, distribution or AR rate. The possible effect of LNG as EC on sperm function remains poorly understood.
C1 [Hermanny, Alexia; Bahamondes, M. Valeria; Fazano, Francisco; Marchi, Nadia M.; Genghini, Maria Heloisa R. R.; Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   [Ortiz, Maria Elena] Inst Chileno Med Reprod ICMER, Santiago, Chile.
   [Croxatto, Horacio B.] Univ Santiago Chile, Fac Quim & Biol, Dept Biol, Santiago, Chile.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Funda ao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/07866-2];
   Brazilian Conselho Nacional de Pesquisa e Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq) [573747/2008-3]
FX A.H was a fellow at the Funda ao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) and partial financial support was obtained from this
   institution under grant #2007/07866-2 and also from the Brazilian
   Conselho Nacional de Pesquisa e Desenvolvimento Cientifico e Tecnologico
   (CNPq) under grant #573747/2008-3.
CR Aitken RJ, 1998, BIOL REPROD, V58, P186, DOI 10.1095/biolreprod58.1.186
   Bahamondes L, 2003, CONTRACEPTION, V68, P55, DOI 10.1016/S0010-7824(03)00105-7
   Baldi E, 2000, FRONT BIOSCI-LANDMRK, V5, pE110, DOI 10.2741/baldi
   Baldi E., 1998, FRONT BIOSCI, V3, P1051
   BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376
   BLACKMORE PF, 1991, J BIOL CHEM, V266, P18655
   BRAY C, 1999, REPROD MED REV, V7, P81
   Brito KS, 2005, CONTRACEPTION, V72, P225, DOI 10.1016/j.contraception.2005.04.005
   Calogero AE, 2000, HUM REPROD, V15, P28, DOI 10.1093/humrep/15.suppl_1.28
   CROSS NL, 1988, BIOL REPROD, V38, P235, DOI 10.1095/biolreprod38.1.235
   Croxatto HB, 2001, CONTRACEPTION, V63, P111, DOI 10.1016/S0010-7824(01)00184-6
   Croxatto Horacio B, 2002, Reprod Biomed Online, V4, P160
   De Jonge C, 2005, HUM REPROD UPDATE, V11, P205, DOI 10.1093/humupd/dmi010
   do Nascimento JAA, 2007, HUM REPROD, V22, P2190, DOI 10.1093/humrep/dem119
   Durand M, 2001, CONTRACEPTION, V64, P227, DOI 10.1016/S0010-7824(01)00250-5
   Flesch FM, 2000, BBA-REV BIOMEMBRANES, V1469, P197, DOI 10.1016/S0304-4157(00)00018-6
   ISRAEL R, 1972, AM J OBSTET GYNECOL, V112, P1043, DOI 10.1016/0002-9378(72)90178-0
   Johansson E, 2002, HUM REPROD, V17, P1472, DOI 10.1093/humrep/17.6.1472
   Kervancioglu ME, 2000, FERTIL STERIL, V74, P780, DOI 10.1016/S0015-0282(00)01514-4
   KESSERU E, 1974, CONTRACEPTION, V10, P411, DOI 10.1016/0010-7824(74)90041-9
   Luconi M, 1998, J CLIN ENDOCR METAB, V83, P877, DOI 10.1210/jc.83.3.877
   Nikkanen V, 2000, CONTRACEPTION, V61, P401, DOI 10.1016/S0010-7824(00)00125-6
   Noe G, 2010, CONTRACEPTION, V81, P414, DOI 10.1016/j.contraception.2009.12.015
   OEHNINGER S, 1994, HUM REPROD, V9, P1322, DOI 10.1093/oxfordjournals.humrep.a138702
   Orihuela PA, 1999, BIOL REPROD, V60, P908, DOI 10.1095/biolreprod60.4.908
   Ortiz ME, 2009, P 21 REUN BIEN ASS L, P43
   OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4
   PACEY AA, 1995, HUM REPROD, V10, P360, DOI 10.1093/oxfordjournals.humrep.a135943
   Rodriguez-Martinez H, 2007, THERIOGENOLOGY, V68, pS138, DOI 10.1016/j.theriogenology.2007.03.018
   Sauber K, 1995, J ANDROL, V16, P226
   SMITH TT, 1990, BIOL REPROD, V42, P450, DOI 10.1095/biolreprod42.3.450
   Suarez SS, 2006, HUM REPROD UPDATE, V12, P23, DOI 10.1093/humupd/dmi047
   SUELDO CE, 1993, FERTIL STERIL, V60, P137
   Tremblay D, 2001, CONTRACEPTION, V64, P327, DOI 10.1016/S0010-7824(01)00276-1
   von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3
   WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301
   WILLIAMS M, 1993, HUM REPROD, V8, P2019, DOI 10.1093/oxfordjournals.humrep.a137975
   World Health Organisation (WHO), 2010, WHO LAB MAN EX HUM S
   Yanagimachi R., 1988, P135
   Yeung WSB, 2002, CONTRACEPTION, V66, P453, DOI 10.1016/S0010-7824(02)00408-0
NR 40
TC 8
Z9 8
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7827
J9 REPROD BIOL ENDOCRIN
JI Reprod. Biol. Endocrinol.
PD JAN 30
PY 2012
VL 10
AR 8
DI 10.1186/1477-7827-10-8
PG 9
WC Endocrinology & Metabolism; Reproductive Biology
SC Endocrinology & Metabolism; Reproductive Biology
GA 911JT
UT WOS:000301713800001
PM 22289514
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Makuch, MY
   Osis, MJD
   Petta, CA
   de Padua, KS
   Bahamondes, L
AF Makuch, Maria Y.
   Osis, Maria Jose D.
   Petta, Carlos A.
   de Padua, Karla Simonia
   Bahamondes, Luis
TI Menstrual bleeding: perspective of Brazilian women
SO CONTRACEPTION
LA English
DT Article
DE Menstruation; Perspectives; Attitudes
ID CONTRACEPTION; ACCEPTABILITY; AMENORRHEA; ATTITUDES; MENSES
AB Background: Menstrual patterns, induced amenorrhea and the use of some contraceptive methods which induce non-bleeding are issues under debate among health professionals and women. The objective of the study was to describe perspectives and attitudes of Brazilian women regarding menstruation and its interference in daily activities.
   Study Design: A semistructured questionnaire was applied to nonpregnant, nonlactating women between 18 and 45 years old, who were menstruating, consulting at public health services for other complaints than gynecological or reproductive health care, and staff members and teachers of public universities in one city of each geographic region of Brazil and the Federal District.
   Results: Of the 885 women interviewed, 51.5% were aged 20-29 years, almost 60% reported normal frequency of bleeding, 22% and 43% reported interference of menstruation in their school activities and in the relationship with their partner, respectively. The value attributed to each interference (<5; >= 5; in a scale up to 10) was >5 for more than 60% of the women in all evaluated domains. The most common reason for disliking menstruation was inconvenient and/or discomfort, and for liking menstruation were feeling healthy and confirmation of not being pregnant. The variables associated to liking menstruation were attending <8 years of school and low economic class, having more than one child and no history of premenstrual tension.
   Conclusion: A great proportion of the interviewed women disliked having menstruation even when they did not present menstrual-related problems. However, some women still preferred monthly menstruation because they felt healthy and it was a free pregnancy test. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Makuch, Maria Y.; Osis, Maria Jose D.; de Padua, Karla Simonia] Ctr Res Reprod Hlth CEMICAMP, BR-13084971 Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Saude da mulher, Inct/J-9403-2013
FU Bayer Schering Pharma, BrazilBayer AG
FX The study was partially funded by Bayer Schering Pharma, Brazil. The
   sponsor was not involved in the development of the protocol, the
   collection and analysis of the data, or in the preparation of the
   manuscript.
CR Andrist Linda C, 2004, J Am Acad Nurse Pract, V16, P31
   [Anonymous], 1981, Stud Fam Plann, V12, P3
   *ASS REPR HLTH PRO, 2002, EXT REG OR CONTR
   *BRAZ ASS RES I, EC CLASS CRIT BRAS 2
   Carpenter JS, 2001, J PAIN SYMPTOM MANAG, V22, P979, DOI 10.1016/S0885-3924(01)00353-0
   den Tonkelaar I, 1999, CONTRACEPTION, V59, P357, DOI 10.1016/S0010-7824(99)00043-8
   do Amaral MCE, 2005, CONTRACEPTION, V72, P157, DOI 10.1016/j.contraception.2005.02.013
   Edelman A, 2007, CONTRACEPTION, V75, P450, DOI 10.1016/j.contraception.2007.02.005
   Ferrero S, 2006, CONTRACEPTION, V73, P537, DOI 10.1016/j.contraception.2006.01.004
   Garcia SG, 1997, INT FAM PLAN PERSPEC, V23, P52, DOI 10.2307/2950824
   Glasier AF, 2003, CONTRACEPTION, V67, P1, DOI 10.1016/S0010-7824(02)00474-2
   Hardy E, 2009, CONTRACEPTION, V80, P266, DOI 10.1016/j.contraception.2009.06.010
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   Hubacher D, 2009, CONTRACEPTION, V80, P113, DOI 10.1016/j.contraception.2009.02.008
   *I APPL RES EC, 2001, REP HUM DEV BRAZ BRA
   Jensen JT, 2008, DRUG TODAY, V44, P183, DOI 10.1358/dot.2008.44.3.1197950
   Kaunitz AM, 2000, CONTRACEPTION, V62, P277, DOI 10.1016/S0010-7824(00)00182-7
   Kriplani A, 2007, INT J GYNECOL OBSTET, V97, P190, DOI 10.1016/j.ijgo.2007.01.009
   Miller L, 2001, OBSTET GYNECOL, V98, P771, DOI 10.1016/S0029-7844(01)01555-1
   Petta CA, 2010, INT J GYNECOL OBSTET, V108, P40, DOI 10.1016/j.ijgo.2009.07.041
   RUTTER W, 1988, MED J AUSTRALIA, V149, P417, DOI 10.5694/j.1326-5377.1988.tb120701.x
   Sadana R, 1999, SOC SCI MED, V49, P343, DOI 10.1016/S0277-9536(98)00444-4
   Sanchez-Borrego R, 2008, CONTRACEPTION, V77, P114, DOI 10.1016/j.contraception.2007.05.082
   SHORT RV, 1996, CONTRACEPTIVES FUTUR, P3
   Snow R, 2007, CONTRACEPTION, V76, P23, DOI 10.1016/j.contraception.2007.03.008
   SNOW RC, 1997, REPROD HEALTH MATTER, V5, P36
   Wiegratz I, 2004, CONTRACEPTION, V69, P37, DOI 10.1016/j.contraception.2003.09.004
NR 27
TC 16
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD DEC
PY 2011
VL 84
IS 6
BP 622
EP 627
DI 10.1016/j.contraception.2011.03.010
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 857JF
UT WOS:000297714100013
PM 22078192
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bahamondes, V
   Schiola, A
   Silva, AP
   Santoni, NB
   Moura, M
   Salem, J
   Clarck, L
   Teich, V
AF Bahamondes, L.
   Bahamondes, V
   Schiola, A.
   Silva, A. P.
   Santoni, N. B.
   Moura, M.
   Salem, J.
   Clarck, L.
   Teich, V
TI RESOURCE USE AND ASSOCIATED COSTS FOR THE TREATMENT OF HEAVY MENSTRUAL
   BLEEDING WITH LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM (LNG-IUS)
   VERSUS HYSTERECTOMY: THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)
   PERSPECTIVE
SO VALUE IN HEALTH
LA English
DT Meeting Abstract
C1 [Bahamondes, L.; Bahamondes, V] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Schiola, A.] Bayer Mexico SA CV, Mexico City, DF, Mexico.
   [Silva, A. P.; Santoni, N. B.] Bayer Brazil, Sao Paulo, Brazil.
   [Moura, M.; Salem, J.; Clarck, L.; Teich, V] MedInsight Evidencias, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
J9 VALUE HEALTH
JI Value Health
PD NOV
PY 2011
VL 14
IS 7
BP A558
EP A558
DI 10.1016/j.jval.2011.08.1651
PG 1
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA 876KT
UT WOS:000299107101703
OA Bronze
DA 2020-12-01
ER

PT J
AU Modesto, WO
   Bahamondes, L
AF Modesto, Waleska Oliveira
   Bahamondes, Luis
TI Relationship Between Chronic Pelvic Pain and Functional Constipation in
   Women of Reproductive Age
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE chronic pelvic pain; constipation
ID EPIDEMIOLOGY; PREVALENCE; ADHESIONS; SYMPTOMS; ETIOLOGY
AB OBJECTIVE: To evaluate the effect of functional constipation on women with and without chronic pelvic pain (CPP).
   STUDY DESIGN: One hundred women ages 18-50 were separated into three groups: (A) women without CPP, (B) women with CPP but without functional constipation, and (C) women with CPP with functional constipation according to Rome III criteria. All participants were followed over 3 months, completing a questionnaire on pain and constipation daily. CPP was evaluated using a visual analog scale (VAS).
   RESULTS: In Group A, 16 of 31 women complained of lumpy or hard stools; 13 had symptoms of functional constipation. In Group B, 4 of 19 women had lumpy or hard stools. In Group C, 46 of 50 reported straining or incomplete bowel movements and 49 reported lumpy or hard stools. Regarding CPP, no significant differences were found in VAS pain score between Groups B and C; no changes were found in VAS pain score throughout the 12-week evaluation period. The most common diagnoses associated with CPP were idiopathic pain, endometriosis, and pelvic adhesions.
   CONCLUSION: Functional constipation was significantly more prevalent in women with CPP than women without CPP; however, it does not appear to have a role in worsening the pain. (J Reprod Med 2011;56:425-430)
C1 Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med Sci, Sao Paulo, Brazil.
   Univ Estadual Campinas, Natl Inst Hormones & Womens Hlth, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
EM bahamond@caism.unicamp.br
FU Brazilian Conselho Nacional de Pesquisa (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX Waleska Oliveira Modesto is a fellow of the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo, and partial financial support came from
   the Brazilian Conselho Nacional de Pesquisa (CNPq) grant 573747/2008-3.
CR CAMPBELL F, 1994, BRIT J ANAESTH, V73, P571, DOI 10.1093/bja/73.5.571
   Cheng CY, 2008, WOMEN HEALTH ISS, V18, P267, DOI 10.1016/j.whi.2008.02.004
   Cheong Y, 2006, BEST PRACT RES CL OB, V20, P695, DOI 10.1016/j.bpobgyn.2006.04.004
   Child TJ, 2001, DRUGS, V61, P1735, DOI 10.2165/00003495-200161120-00005
   Garrigues V, 2004, AM J EPIDEMIOL, V159, P520, DOI 10.1093/aje/kwh072
   Gunter J, 2003, OBSTET GYNECOL SURV, V58, P615, DOI 10.1097/01.OGX.0000083225.90017.01
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   Leung FW, 2007, DIGEST DIS SCI, V52, P313, DOI 10.1007/s10620-006-9298-7
   Lewis Linda A, 2007, Surg Technol Int, V16, P137
   Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061
   MENZIES D, 1990, ANN ROY COLL SURG, V72, P60
   Mertz H, 1999, AM J GASTROENTEROL, V94, P131
   Meurs-Szojda MM, 2011, COLORECTAL DIS, V13, P67, DOI 10.1111/j.1463-1318.2009.02055.x
   Nagle A, 2004, AM J SURG, V187, P464, DOI 10.1016/j.amjsurg.2003.12.036
   Paterson LQP, 2009, J SEX MED, V6, P215, DOI 10.1111/j.1743-6109.2008.01063.x
   Peters AAW, 2007, BEST PRACT RES CL GA, V21, P445, DOI 10.1016/j.bpg.2007.01.005
   Soligo M, 2006, AM J OBSTET GYNECOL, V195, P50, DOI 10.1016/j.ajog.2005.12.046
   Stewart WF, 1999, AM J GASTROENTEROL, V94, P3530, DOI 10.1111/j.1572-0241.1999.01642.x
   Thompson WG, 1999, GUT, V45, P43
   Toglia MR, 2009, OBSTET GYN CLIN N AM, V36, P659, DOI 10.1016/j.ogc.2009.08.004
   Zondervan K, 2000, BEST PRACT RES CL OB, V14, P403, DOI 10.1053/beog.1999.0083
NR 22
TC 2
Z9 2
U1 0
U2 4
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
EI 1943-3565
J9 J REPROD MED
JI J. Reprod. Med.
PD SEP-OCT
PY 2011
VL 56
IS 9-10
BP 425
EP 430
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 829CF
UT WOS:000295552300013
PM 22010528
DA 2020-12-01
ER

PT J
AU Viola, AS
   Castro, S
   Marchi, NM
   Bahamondes, MV
   Viola, CFM
   Bahamondes, L
AF Viola, Alexandre S.
   Castro, Sara
   Marchi, Nadia M.
   Bahamondes, M. Valeria
   Viola, Carolina F. M.
   Bahamondes, Luis
TI Long-term assessment of forearm bone mineral density in postmenopausal
   former users of depot medroxyprogesterone acetate
SO CONTRACEPTION
LA English
DT Article
DE Bone mineral density; Depot medroxyprogesterone acetate; Menopause
ID HORMONAL CONTRACEPTION; OSTEOPOROTIC FRACTURES; ORAL-CONTRACEPTIVES;
   WOMEN; ADOLESCENTS; RECOVERY; COHORT; HEALTH; DMPA; MASS
AB Background: There are many controversies on the association between depot medroxyprogesterone acetate (DMPA) and bone mineral density (BMD). This study reevaluated BMD in postmenopausal women who had used DMPA as a contraceptive until they reached menopause and compared them with non-users. BMD had previously been measured in these women either at 1 year or 2-3 years after menopause and was reassessed in these women 2 years later. Therefore, comparisons were made between the first and third years and between the second to third and fourth to fifth years after menopause.
   Study Design: BMD was reevaluated using dual-energy X-ray absorptiometry at two parts of the non-dominant forearm up to 5 years after menopause in 79 women between 46 and 61 years old: 24 former DMPA users and 55 former copper intrauterine device (IUD) users.
   Results: With respect to the former DMPA users, only the BMD measurement at the distal radius in the first year (mean SEM, 0.425 +/- 0.017) was significantly higher than the third-year measurement (0.406 +/- 0.017) (p<.015). No significant differences were found at the ultradistal radius. There were no significant differences between the groups of former DMPA and IUD users with respect to BMD measurements either at the distal radius or at the ultradistal radius. There was a direct relationship between higher body mass index (kg/m(2)) and higher BMD at the distal radius between the first and third years. At the ultradistal radius, there was an indirect relationship between older age and lower BMD between the first and third years in both groups.
   Conclusions: No statistically significant differences were found in forearm BMD measurements between postmenopausal women who had been long-term users of DMPA and those who had been long-term users of an IUD until menopause. Evaluation of BMD after the menopause showed slightly higher values in former DMPA users compared with non-users. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Bahamondes, Luis] Univ Estadual Campinas, Sch Med Sci, Human Reprod Unit, Dept Obstet & Gynecol, Sao Paulo, Brazil.
   Natl Inst Hormones & Womens Hlth, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018; Saude da mulher, Inct/J-9403-2013;
   Juliato, Cassia R T/D-4447-2012
OI Fernandes, Arlete/0000-0001-5872-0017; Juliato, Cassia R
   T/0000-0003-3197-1195
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX This study received partial financial support from the Brazilian
   National Research Council (CNPq) through Grant No. 573747/2008-3.
CR Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021
   Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Beksinska ME, 2009, CONTRACEPTION, V79, P345, DOI 10.1016/j.contraception.2008.11.009
   Berenson AB, 2004, OBSTET GYNECOL, V103, P899, DOI 10.1097/01.AOG.0000117082.49490.d5
   Cromer BA, 2004, J ADOLESCENT HEALTH, V35, P434, DOI 10.1016/j.jadohealth.2004.07.005
   CUNDY T, 1994, BRIT MED J, V308, P247, DOI 10.1136/bmj.308.6923.247
   Cundy T, 2002, AM J OBSTET GYNECOL, V186, P978, DOI 10.1067/mob.2002.122420
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   DUFF G, 2004, 392004 HSS MD
   Fraser I S, 1981, Med J Aust, V1, P3
   Guilbert ER, 2009, CONTRACEPTION, V79, P167, DOI 10.1016/j.contraception.2008.10.016
   Harel Z, 2010, J PEDIATR ADOL GYNEC, V23, P23, DOI 10.1016/j.jpag.2009.04.008
   Harel Z, 2010, CONTRACEPTION, V81, P281, DOI 10.1016/j.contraception.2009.11.003
   Jones T, 1998, BRIT J RHEUMATOL, V37, P539
   Kaunitz AM, 2005, CONTRACEPTION, V72, P165, DOI 10.1016/j.contraception.2005.05.011
   Kaunitz AM, 2002, J REPROD MED, V47, P785
   Kaunitz AM, 2008, CONTRACEPTION, V77, P67, DOI 10.1016/j.contraception.2007.10.005
   Kaunitz AM, 2009, CONTRACEPTION, V80, P7, DOI 10.1016/j.contraception.2009.02.005
   LAPPE JM, 1997, OSTEOPOROSIS INT, V12, P35
   Lara-Torre Eduardo, 2004, J Pediatr Adolesc Gynecol, V17, P17, DOI 10.1016/j.jpag.2003.11.017
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Orr-Walker BJ, 1998, CLIN ENDOCRINOL, V49, P615, DOI 10.1046/j.1365-2265.1998.00582.x
   Picard D, 2004, J CLIN DENSITOM, V7, P111, DOI 10.1385/JCD:7:1:111
   Rahman M, 2010, OBSTET GYNECOL, V115, P35, DOI 10.1097/AOG.0b013e3181c4e864
   Renner RM, 2010, WOMENS HEALTH, V6, P339, DOI [10.2217/whe.10.17, 10.2217/WHE.10.17]
   Sanches L, 2009, CONTRACEPTION, V79, P159, DOI 10.1016/j.contraception.2008.11.007
   Scholes D, 2004, CONTRACEPTION, V69, P99, DOI 10.1016/j.contraception.2003.10.005
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648-200209000-00015
   Tang OS, 2000, CONTRACEPTION, V62, P161, DOI 10.1016/S0010-7824(00)00168-2
   Tolaymat LL, 2009, CURR OPIN OBSTET GYN, V21, P396, DOI 10.1097/GCO.0b013e32832c9cc6
   *US FDA, 2004, BLACK BOX WARN DEP C
   Walsh JS, 2010, FERTIL STERIL, V93, P697, DOI 10.1016/j.fertnstert.2008.10.004
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
NR 33
TC 14
Z9 14
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD AUG
PY 2011
VL 84
IS 2
BP 122
EP 127
DI 10.1016/j.contraception.2010.11.007
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 798JA
UT WOS:000293200500003
PM 22018135
DA 2020-12-01
ER

PT J
AU Makuch, MY
   de Padua, KS
   Petta, CA
   Osis, MJD
   Bahamondes, L
AF Makuch, Maria Y.
   de Padua, Karla Simonia
   Petta, Carlos A.
   Duarte Osis, Maria Jose
   Bahamondes, Luis
TI Inequitable access to assisted reproductive technology for the
   low-income Brazilian population: a qualitative study
SO HUMAN REPRODUCTION
LA English
DT Article
DE assisted reproductive technology; equity; access; social class; public
   healthcare
ID DEVELOPING-COUNTRIES; INFERTILITY PREVALENCE; SERVICES; HEALTH; CARE;
   FERTILITY; CHILDREN; AFRICA; IVF
AB BACKGROUND: In Brazil, access to infertility care, including assisted reproductive technology (ART) is restricted. This is a second report of a study which evaluated the availability and access of low-income couples to ART services. The objective was to assess the perspective of health professionals and patients with respect to access to ART procedures within the public health network
   METHODS: Qualitative case studies were conducted in five centres offering ART in the public sector. Semi-structured interviews were conducted with 19 health professionals based at these centres and 48 patients (men and women). Data were analysed using thematic content analysis.
   RESULTS: All services implemented ART procedures using resources already available. In all except one centre, patients had to pay for the drugs used for the procedures and, in some cases, a fee to cover operative costs and supplies. These charges were incompatible with the financial possibilities of the majority of the low-income Brazilian population. The waiting time for access to ART varied between 3 months and 6 years. In the perspective of both patients and health professionals, the government should help centres to offer ART procedures at no cost to low-income populations.
   CONCLUSIONS: The low-income Brazilian population has limited access to ART procedures at the public services. The implementation of ART services cannot be based only on initiatives of the professionals involved but must be part of public health policies. One possible solution is to provide ART at lower cost, making it accessible for a large part of the population.
C1 [Makuch, Maria Y.; de Padua, Karla Simonia; Duarte Osis, Maria Jose] Ctr Res Reprod Hlth Campinas CEMICAMP, BR-13084971 Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Natl Inst Hormones & Women Hlth, Campinas, SP, Brazil.
RP Makuch, MY (corresponding author), Ctr Res Reprod Hlth Campinas CEMICAMP, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM mmakuch@cemicamp.org.br
RI Saude da mulher, Inct/J-9403-2013
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/00055-9]; Conselho
   Nacional de Pesquisa (CNPq), BrazilNational Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study was partially supported by the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP), award # 07/00055-9 and the Conselho
   Nacional de Pesquisa (CNPq), Brazil under award # 573747/2008-3.
CR Amorim C, 2007, LANCET, V369, P1373, DOI 10.1016/S0140-6736(07)60498-X
   Blackwell RE, 2001, FERTIL STERIL, V75, P749, DOI 10.1016/S0015-0282(01)01673-9
   Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046
   Brkovich AM, 1998, J PSYCHOSOM OBST GYN, V19, P218, DOI 10.3109/01674829809025700
   Daar A. S., 2002, CURRENT PRACTICES CO
   Dhont N, 2011, HUM REPROD, V26, P623, DOI 10.1093/humrep/deq373
   Dyer SJ, 2007, J PSYCHOSOM OBST GYN, V28, P69, DOI 10.1080/01674820701409959
   Dyer SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/humrep/17.6.1663
   *EHSRE, 2007, TASK FORC INF DEV CO
   Fathalla MF, 2006, LANCET, V368, P2095, DOI 10.1016/S0140-6736(06)69483-X
   Frydman R, 2008, HUM REPROD, P85, DOI 10.1093/humrep/den163
   Greil A. L, 1997, SOC SCI MED, V45, P1506
   Hovatta O, 2006, INT J GYNECOL OBSTET, V94, P287, DOI 10.1016/j.ijgo.2006.04.012
   HUBERMAN AM, 1994, DATA MANAGE, P428
   Huyser C, 2008, HUM REPROD, P77, DOI 10.1093/humrep/den139
   Inhorn C. M., 2002, INFERTILITY GLOBE NE, P3
   Inhorn MC, 2009, INT J GYNECOL OBSTET, V106, P172, DOI 10.1016/j.ijgo.2009.03.034
   Inhorn MC, 2003, SOC SCI MED, V56, P1837, DOI 10.1016/S0277-9536(02)00208-3
   Jones HW, 2009, FERTIL STERIL, V91, P2295, DOI 10.1016/j.fertnstert.2008.03.006
   Larsen U, 2005, FERTIL STERIL, V83, P846, DOI 10.1016/j.fertnstert.2004.11.033
   Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P317, DOI 10.1093/humupd/dmh028
   Makuch MY, 2010, HUM REPROD, V25, P430, DOI 10.1093/humrep/dep405
   *MIN SAUD, 2005, AR TECN SAUD MULH DI
   MINAYO MCS, 1998, DESAFIO CONHECIMENTO
   Nachtigall RD, 2006, FERTIL STERIL, V85, P871, DOI 10.1016/j.fertnstert.2005.08.066
   Nygren K, 2008, HUM REPROD, P5, DOI 10.1093/humrep/den218
   Okonofua FE, 1996, BRIT J OBSTET GYNAEC, V103, P957, DOI 10.1111/j.1471-0528.1996.tb09542.x
   OMBELET W, 2008, ESHRE MONOGR, V1, P1
   Ombelet W, 2008, HUM REPROD UPDATE, V14, P605, DOI 10.1093/humupd/dmn042
   Ombelet W, 2007, REPROD BIOMED ONLINE, V15, P257, DOI 10.1016/S1472-6483(10)60337-9
   Ombelet W, 2009, INT J GYNECOL OBSTET, V106, P168, DOI 10.1016/j.ijgo.2009.03.033
   Patton M. Q., 2002, QUALITATIVE RES EVAL
   Pilcher H, 2006, NATURE, V442, P975, DOI 10.1038/442975a
   Santos IS, 2008, CIENC SAUDE COLETIVA, V13, P1431, DOI 10.1590/S1413-81232008000500009
   Schmidt L, 2009, HUM FERTIL, V12, P14, DOI 10.1080/14647270802331487
   *SEN FED, 1988, CONST
   TURATO ER, 2003, TRATADO METODOLOGIA, P312
   UN, 1994, INT C POP DEV CAIR E
   United Nations, 2000, MILL DEV GOALS
   van Balen F, 2001, HUM REPROD, V16, P215, DOI 10.1093/humrep/16.2.215
   van Balen F, 2009, FACTS VIEWS VIS OBGY, V1, P106
   vanBalen F, 1996, PATIENT EDUC COUNS, V28, P247, DOI 10.1016/0738-3991(95)00852-7
   Vayena E, 2002, CURRENT PRACTICES CO
   Vayena E, 2009, FERTIL STERIL, V92, P413, DOI 10.1016/j.fertnstert.2009.02.011
   World Health Organization, 1991, INF TAB AV DAT PREV
NR 45
TC 12
Z9 12
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2011
VL 26
IS 8
BP 2054
EP 2060
DI 10.1093/humrep/der158
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 793QD
UT WOS:000292837300016
PM 21613314
OA Bronze
DA 2020-12-01
ER

PT J
AU Marchi, NM
   de Alvarenga, AT
   Osis, MJD
   Godoy, HMD
   Guimaraes, MCB
   Bahamondes, L
AF Marchi, Nadia Maria
   de Alvarenga, Augusta Thereza
   Duarte Osis, Maria Jose
   de Aguiar Godoy, Helena Maria
   Borges Guimaraes, Maria Ceclia
   Bahamondes, Luis
TI Consequences of Vasectomy: experience of men who underwent the surgery
   in Campinas (Sao Paulo), Brazil
SO SAUDE E SOCIEDADE
LA Portuguese
DT Article
DE Public Health; Sexual and Reproductive Health; Vasectomy
ID REGRET
AB Objective: To describe the experience of men who had a vasectomy at least one year before at public healthcare services at Campinas, State of Sao Paulo. Methodological procedures: descriptive study with a qualitative and a quantitative component. In the qualitative stage, 10 semi-structured interviews were performed with men selected according to purposeful criteria of level of schooling and number of children. Then, a structured form was provided for 202 men, drawn from the complete list of those who had had a vasectomy between 1998 and 2004. A thematic analysis of the content of the semi-structured interviews was carried out. The quantitative data were keyboarded and a descriptive analysis was conducted. Results: It was observed that 97% of the men were satisfied because they had undergone the surgery and only a few of them mentioned undesired effects. Among the few dissatisfied men, only one had had vasectomy reversal because he lived with a new partner and wanted to have children; among the others, dissatisfaction was due to the pain caused by the surgical procedure. The majority of the interviewees attributed to vasectomy changes for the best in their health, body, general relationship with their families and wives, in their sexual life and economic situation. The idea that prevailed was that vasectomy had brought only benefits. The possibility of regret was mentioned by the interviewees as something that would not happen to them. Conclusion: The results of this study allowed to verify that men who decide to have a vasectomy tend to see the method as a factor of positive changes, mainly in the sexual life and in the relationship with the partner and family in general.
C1 [Marchi, Nadia Maria] Univ Estadual Campinas, Ambulatorio Reprod Humana, Dept Tocoginecol, Fac Ciencias Med, Campinas, SP, Brazil.
   [de Alvarenga, Augusta Thereza] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, Brazil.
   [Duarte Osis, Maria Jose] FCM UNICAMP, Dept Pesquisas Sociais, Ctr Pesquisas Saude Reprod Campinas Cemicamp, Campinas, SP, Brazil.
   [Duarte Osis, Maria Jose] FCM UNICAMP, Dept Tocoginecol, Campinas, SP, Brazil.
   [de Aguiar Godoy, Helena Maria; Borges Guimaraes, Maria Ceclia] Prefeitura Municipal Campinas, Ambulatorio Planejamento Familiar, Campinas, SP, Brazil.
   [Bahamondes, Luis] Univ Estadual Campinas, Dept Tocoginecol, Fac Ciencias Med, UNICAMP, BR-13081970 Campinas, SP, Brazil.
RP Marchi, NM (corresponding author), Rua Vital Brasil 200, BR-13083888 Campinas, SP, Brazil.
EM nmarchi@uol.com.br; atal@usp.br; mjosis@cemicamp.org.br;
   helenamagodoy@gmail.com; ceciliaguimaraes2010@hotmail.com;
   bahamond@caism.unicamp.br
CR ARILHA M., 1999, QUESTOES SAUDE REPRO, P455
   ARRUDA J. M., 1987, PNSMIPF BRAS 1986 RI
   BANDEIRA L., 1999, SAUDE SEXUAL REPRODU, P180
   [BEMFAM-Sociedade Civil Bem Estar Familiar no Brasil MACRO Internacional], 1997, PROGR PESQ DEM SAUD
   Berquó Elza, 2003, Cad. Saúde Pública, V19, pS441, DOI 10.1590/S0102-311X2003000800025
   Bertero Eduardo, 2005, Int. braz j urol., V31, P452, DOI 10.1590/S1677-55382005000500006
   Brasil. Conselho Nacional de Saude, 1996, BIOETICA S, V4, P15
   de Carvalho LEC, 2007, CAD SAUDE PUBLICA, V23, P2906, DOI 10.1590/S0102-311X2007001200012
   Duarte Graciana Alves, 2003, Cad. Saúde Pública, V19, P207, DOI 10.1590/S0102-311X2003000100023
   ENGLE P.L., 1998, FARMILIA MIRA NUEVAS, P49
   Glasier A, 2010, CONTRACEPTION, V82, P453, DOI 10.1016/j.contraception.2010.03.016
   Hofmeyer DG, 2002, J SEX MARITAL THER, V28, P339, DOI 10.1080/00926230290001466
   HOWARD G, 1982, BRIT MED J, V285, P490, DOI 10.1136/bmj.285.6340.490
   Jamieson DJ, 2002, OBSTET GYNECOL, V99, P1073, DOI 10.1016/S0029-7844(02)01981-6
   Labrecque M, 2010, CONTRACEPTION, V82, P556, DOI 10.1016/j.contraception.2010.05.003
   Manhoso FR, 2005, INT NURS REV, V52, P101, DOI 10.1111/j.1466-2435.2005.00247.x
   Marchi NM, 2010, INT NURS REV, V57, P254, DOI 10.1111/j.1466-7657.2009.00761.x
   Marchi Nádia Maria, 2003, Cad. Saúde Pública, V19, P1017, DOI 10.1590/S0102-311X2003000400024
   Melville C, 2008, OBSTET GYNAECOL REPR, V18, P330, DOI DOI 10.1016/j.ogrm.2008.09.003
   MILLER WB, 1991, J NERV MENT DIS, V179, P602, DOI 10.1097/00005053-199110000-00003
   MINAYO MCS, 1998, DESAFIO CONHECIMENTO
   MINELLA L. S., 1998, CAD SAUDE PUBLICA, V14, P69
   Ministerio da Saude, 2008, PESQ NAC DEM SAUD CR
   Osis M J, 1999, Cad Saude Publica, V15, P521, DOI 10.1590/S0102-311X1999000300009
   OSIS M. J. D., 2001, THESIS U SAO PAULO S, P196
   Osis Maria José Duarte, 2006, Cad. Saúde Pública, V22, P2481, DOI 10.1590/S0102-311X2006001100023
   PHILLIBER SG, 1985, STUD FAMILY PLANN, V16, P1, DOI 10.2307/1965814
   Pile JM, 2009, UROL CLIN N AM, V36, P295, DOI 10.1016/j.ucl.2009.05.006
   Potts JM, 1999, J UROLOGY, V161, P1835, DOI 10.1016/S0022-5347(05)68819-2
   Rodrigues A., 2003, European Urology Supplements, V2, P121, DOI 10.1016/S1569-9056(03)80477-3
   Rungby J A, 1994, Ugeskr Laeger, V156, P2377
   SEIDEL J, 1998, ETHNOGRAPH VERSION 5
   SERRUYA S, 1996, MULHERES ESTERILIZAD
   SMITH A., 2009, J SEXUAL MED MALDEN, V7, P736
   Sonfield Adam, 2010, GUTTMACHER POLICY RE, V2
   THONNEAU P, 1990, INT J ANDROL, V13, P419, DOI 10.1111/j.1365-2605.1990.tb01050.x
NR 36
TC 1
Z9 1
U1 0
U2 1
PU UNIV SAO PAULO, FAC SAUDE PUBLICA
PI SAO PAULO
PA AV DR ARNALDO 715, PREDIO DA BIBLIOTECA 2 ANDAR SALA 2, SAO PAULO, SP
   01246 904, BRAZIL
SN 0104-1290
J9 SAUDE SOC-SAO PAULO
JI Saude Soc.
PD JUL-SEP
PY 2011
VL 20
IS 3
BP 568
EP 578
DI 10.1590/S0104-12902011000300004
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 831IS
UT WOS:000295724000004
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   Portugal, PM
   Brolazo, EM
   Simoes, JA
   Bahamondes, L
AF Valeria Bahamondes, M.
   Portugal, Priscila Mendes
   Brolazo, Eliane Melo
   Simoes, Jose Antonio
   Bahamondes, Luis
TI Use of a lactic acid plus lactoserum intimate liquid soap for external
   hygiene in the prevention of bacterial vaginosis recurrence after
   metronidazole oral treatment
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA English
DT Article
DE Bacterial vaginosis; lactic acid, treatment; recurrence
ID CLINICAL-TRIAL; FOLLOW-UP; THERAPY; GEL; VARIABILITY; PLACEBO
AB Objective: To determine the recurrence of bacterial vaginosis (BV) after the use of a lactic acid plus lactoserum liquid soap starting immediately after the treatment with oral metronidazole and the quality of life of the participants. Methods: A total of 123 women with diagnosis of BV with at least three of the following criteria: 1) homogeneous vaginal discharge without inflammation of the vagina or vulva; 2) vaginal pH >4.5; 3) positive Whiff test; and 4) "clue cells" in more than 20% of the epithelial cells in the vagina. A Nugent score > 4 in the vaginal bacterioscopy was also used. After BV diagnosis, metronidazole 500 mg was administered orally bid during 7 days. Patients cured of BV were then instructed to use 7.5 to 10 mL of a lactic acid plus lactoserum liquid soap once-a-day for hygiene of the external genital region. Three subsequent control visits after starting the hygiene treatment (30, 60, and 90 days; +/- 5 days) were scheduled. A questionnaire was applied in the form of visual analogue scale (VAS) in all the visits regarding: 1) level of comfort at the genital region; 2) malodorous external genitalia; 3) comfort in sexual intercourse; 4) satisfaction with intimate hygiene; and 5) self-esteem. Results: Ninety two (74.8%) women initiated the use of a lactic acid plus lactoserum liquid soap at visit 1. At visit 2, 3, and 4 there were 84,62 and 42 women available for evaluation, respectively. The rate of recurrence of BV was 19.0%, 24.2% and 7.1%, respectively in the three visits and vaginal candidiasis was observed in five treated women. Quality of life was evaluated in the 42 women who completed the four visits schedule and there were significant improvement in the five domains assessed. Conclusion: A lactic acid plus lactoserum liquid soap for external intimate hygiene may be an option for the prevention of BV recurrence after treatment and cure with oral metronidazole.
C1 [Valeria Bahamondes, M.; Portugal, Priscila Mendes; Brolazo, Eliane Melo; Simoes, Jose Antonio; Bahamondes, Luis] Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Med Sch,UNICAMP, Campinas, SP, Brazil.
   [Valeria Bahamondes, M.; Portugal, Priscila Mendes; Brolazo, Eliane Melo; Simoes, Jose Antonio; Bahamondes, Luis] Natl Inst Hormones & Women Hlth, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Sanofi-aventisSanofi-Aventis; Sanofi-aventis, Sao Paulo,
   BrazilSanofi-Aventis
FX This study was financed by an unrestricted grant by Sanofi-aventis; This
   study was financed by an unrestricted grant by Sanofi-aventis, Sao
   Paulo, Brazil.
CR Alfonsi GA, 2004, J FAM PRACTICE, V53, P650
   AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9
   ANDERSCH B, 1986, GYNECOL OBSTET INVES, V21, P19, DOI 10.1159/000298923
   BOEKE AJP, 1993, GENITOURIN MED, V69, P388
   Boris J, 1997, Infect Dis Obstet Gynecol, V5, P297, DOI 10.1002/(SICI)1098-0997(1997)5:4<297::AID-IDOG7>3.0.CO;2-U
   Bradshaw CS, 2006, J INFECT DIS, V194, P828, DOI 10.1086/506621
   Bradshaw CS, 2006, J INFECT DIS, V193, P1478, DOI 10.1086/503780
   British Association for Sexual Health and HIV, 2006, NAT GUID MAN BACT VA
   Camargo Rodrigo Pauperio Soares de, 2005, Sao Paulo Med. J., V123, P108, DOI 10.1590/S1516-31802005000300004
   *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P70
   Decena DCD, 2006, J OBSTET GYNAECOL RE, V32, P243, DOI 10.1111/j.1447-0756.2006.00383.x
   do Lago RF, 2003, CONTRACEPTION, V68, P105, DOI 10.1016/S0010-7824(03)00109-4
   Ferris DG, 2006, J AM BOARD FAM MED, V19, P368, DOI 10.3122/jabfm.19.4.368
   Gray RH, 2001, AM J OBSTET GYNECOL, V185, P1209, DOI 10.1067/mob.2001.118158
   Guaschino S, 2008, Minerva Ginecol, V60, P353
   Hay P, 2009, CURR OPIN INFECT DIS, V22, P82, DOI 10.1097/QCO.0b013e32832180c6
   HILLIER S, 1999, SEXUALLY TRANSMITTED, P563
   Holley RL, 2004, SEX TRANSM DIS, V31, P236, DOI 10.1097/01.OLQ.0000118423.20985.E7
   Livengood CH, 1999, SEX TRANSM DIS, V26, P137, DOI 10.1097/00007435-199903000-00003
   Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127
   Ness RB, 2006, SEX TRANSM DIS, V33, P381, DOI 10.1097/01.olq.0000204748.89222.33
   NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991
   Simoes JA, 2006, INT J GYNECOL OBSTET, V94, P28, DOI 10.1016/j.ijgo.2006.04.013
   Sobel JD, 2006, AM J OBSTET GYNECOL, V194, P1283, DOI 10.1016/j.ajog.2005.11.041
   SOBEL JD, 1993, J INFECT DIS, V167, P783, DOI 10.1093/infdis/167.3.783
   Soper, 1999, Curr Infect Dis Rep, V1, P393, DOI 10.1007/s11908-999-0048-9
   SPIEGEL CA, 2000, PRINCIPLES PRACTICE, V2, P2383
   2006, MMWR MORB MORTAL WKL, V55, P50
NR 28
TC 14
Z9 17
U1 0
U2 5
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD JUL-AUG
PY 2011
VL 57
IS 4
BP 415
EP 420
DI 10.1590/S0104-42302011000400015
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 807AM
UT WOS:000293862100014
PM 21876923
OA DOAJ Gold, Green Published
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bahamondes, MV
   Fernandes, AMD
   Monteiro, I
AF Bahamondes, Luis
   Bahamondes, Maria Valeria
   dos Santos Fernandes, Arlete Maria
   Monteiro, Ilza
TI Emerging female contraceptives
SO EXPERT OPINION ON EMERGING DRUGS
LA English
DT Review
DE emergency contraception; intrauterine system; oral contraception; spray;
   vaginal ring
ID RANDOMIZED-CONTROLLED-TRIAL; PROGESTERONE-RECEPTOR MODULATORS;
   CONTAINING ORAL-CONTRACEPTIVES; BLEEDING-SIGNALED REGIMEN; LOW-DOSE
   MIFEPRISTONE; G ETHINYL ESTRADIOL; 30 MU-G; EMERGENCY CONTRACEPTION;
   OVARIAN-FUNCTION; INTRAUTERINE SYSTEM
AB Areas covered: Women need contraception for almost 30 years of their life. Currently available contraceptives are highly effective with few side effects. This review provides information on emerging female contraceptives including some registered and others at different stages of development. Research efforts aim to reduce costs, improve acceptability and refine ''forgettable'' reversible methods. Although developing and testing a new method is laborious and expensive, many new contraceptives are currently under development including different routes of administration.
   Expert opinion: New methods should be affordable, simple to use and suitable for many women. Much work remains to be done and new methods that act on the fusion process between both gametes are desirable without affecting the hormonal milieu.
C1 [Bahamondes, Luis; Bahamondes, Maria Valeria; dos Santos Fernandes, Arlete Maria; Monteiro, Ilza] Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Campinas UNICAMP, Sch Med, Dept Obstet & Gynecol, POB 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Fernandes, Arlete/I-7561-2018; monteiro, ilza m u/F-4871-2014
OI Fernandes, Arlete/0000-0001-5872-0017; monteiro, ilza m
   u/0000-0002-9536-0564
FU MerckMerck & Company; Bayer Schering PharmaBayer AG
FX L Bahamondes and I Monteiro are recipients of research support grants
   from Merck and Bayer Schering Pharma.
CR Abrams LS, 2002, BRIT J CLIN PHARMACO, V53, P141, DOI 10.1046/j.0306-5251.2001.01532.x
   Abrams LS, 2001, CONTRACEPTION, V64, P287, DOI 10.1016/S0010-7824(01)00273-6
   Abrams LS, 2001, J CLIN PHARMACOL, V41, P1301, DOI 10.1177/00912700122012887
   Ahrendt HJ, 2006, CONTRACEPTION, V74, P451, DOI 10.1016/j.contraception.2006.07.004
   Ahrendt HJ, 2009, CONTRACEPTION, V80, P436, DOI 10.1016/j.contraception.2009.03.018
   [Anonymous], 2004, MED EL CRIT CONTR US
   ASTEDT B, 1979, BRIT J OBSTET GYNAEC, V86, P732
   Attardi BJ, 2002, MOL CELL ENDOCRINOL, V188, P111, DOI 10.1016/S0303-7207(01)00743-2
   Audet MC, 2001, JAMA-J AM MED ASSOC, V285, P2347, DOI 10.1001/jama.285.18.2347
   Bahamondes L, 2003, J REPROD MED, V48, P637
   Bajos N, 2003, HUM REPROD, V18, P994, DOI 10.1093/humrep/deg215
   Bannemerschult R, 1997, CONTRACEPTION, V56, P285, DOI 10.1016/S0010-7824(97)00157-1
   Barreiros FA, 2010, CONTRACEPTION, V81, P223, DOI 10.1016/j.contraception.2009.10.007
   Bata MS, 2006, J CLIN PHARMACOL, V46, P925, DOI 10.1177/0091270006289483
   BENRAFAEL Z, 1986, J CLIN ENDOCR METAB, V63, P1106, DOI 10.1210/jcem-63-5-1106
   Blithe DL, 2003, STEROIDS, V68, P1013, DOI 10.1016/S0039-128X(03)00118-1
   Bongaarts J, 2002, STUD FAMILY PLANN, V33, P24, DOI 10.1111/j.1728-4465.2002.00024.x
   Brache V, 2000, CONTRACEPTION, V61, P199, DOI 10.1016/S0010-7824(00)00092-5
   Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157
   Brache V, 2001, CONTRACEPTION, V63, P257, DOI 10.1016/S0010-7824(01)00199-8
   Brache V, 2007, CONTRACEPTION, V76, P111, DOI 10.1016/j.contraception.2007.04.005
   Brache V, 2009, CONTRACEPTION, V79, P150, DOI 10.1016/j.contraception.2008.08.010
   Brenner RM, 2005, SEMIN REPROD MED, V23, P74, DOI 10.1055/s-2005-864035
   Brenner RM, 2003, STEROIDS, V68, P1033, DOI 10.1016/S0039-128X(03)00120-X
   Brenner RM, 2002, REPRODUCTION, V124, P167, DOI 10.1530/reprod/124.2.167
   Brenner RM, 2010, CONTRACEPTION, V81, P336, DOI 10.1016/j.contraception.2009.11.004
   CHANG MC, 1978, AM J OBSTET GYNECOL, V132, P217, DOI 10.1016/0002-9378(78)90928-6
   Chwalisz K, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-S1-S8
   Cibula D, 2010, HUM REPROD UPDATE, V16, P631, DOI 10.1093/humupd/dmq022
   Coggins C, 2000, SEX TRANSM INFECT, V76, P480, DOI 10.1136/sti.76.6.480
   Creinin MD, 2006, OBSTET GYNECOL, V108, P1089, DOI 10.1097/01.AOG.0000239440.02284.45
   Daulaire N, 2002, PROMISES KEEP TOLL U, P1
   DIAZ S, 1995, CONTRACEPTION, V51, P33, DOI 10.1016/0010-7824(94)00006-I
   Dinger J, 2010, J FAM PLAN REPROD H, V36, P123, DOI 10.1783/147118910791749416
   DUIJKERS I, 2010, 14 WORLD C GYN END F
   Duijkers IJM, 2010, EUR J CONTRACEP REPR, V15, P314, DOI 10.3109/13625187.2010.504313
   DUSTERBERG B, 1982, MATURITAS, V4, P315, DOI 10.1016/0378-5122(82)90064-0
   Edelman AB, 2010, CONTRACEPTION, V81, P496, DOI 10.1016/j.contraception.2010.01.004
   Elger W, 2000, STEROIDS, V65, P713, DOI 10.1016/S0039-128X(00)00178-1
   Elias CJ, 1997, CONTRACEPTION, V56, P387, DOI 10.1016/S0010-7824(97)00176-5
   ENDRIKAT J, 1995, CONTRACEPTION, V52, P229, DOI 10.1016/0010-7824(95)00191-C
   Endrikat J, 2008, CONTRACEPTION, V78, P218, DOI 10.1016/j.contraception.2008.05.004
   Guazzelli CAF, 2009, CONTRACEPTION, V80, P430, DOI 10.1016/j.contraception.2009.05.004
   Fine P, 2010, OBSTET GYNECOL, V115, P257, DOI 10.1097/AOG.0b013e3181c8e2aa
   Finer LB, 2006, PERSPECT SEX REPRO H, V38, P90, DOI 10.1363/3809006
   Fraser I, 2009, INT J GYNECOL OBS S2, V107, P5183
   Fraser IS, 2007, CONTRACEPTION, V76, P432, DOI 10.1016/j.contraception.2007.08.006
   Fraser IS, 2005, CONTRACEPTION, V72, P40, DOI 10.1016/j.contraception.2004.12.015
   Gainer EE, 2003, STEROIDS, V68, P1005, DOI 10.1016/S0039-128X(03)00130-2
   Gilliam ML, 2010, OBSTET GYNECOL, V115, P503, DOI 10.1097/AOG.0b013e3181cf45dc
   Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8
   Goodman AL, 1996, REPROD ENDOCRINOLOGY, P548
   Grimes D, 1998, LANCET, V352, P428
   Grimes DA, 2010, FERTIL STERIL, V93, P1731, DOI 10.1016/j.fertnstert.2009.12.054
   Grimes DA, 2009, CONTRACEPTION, V80, P497, DOI 10.1016/j.contraception.2009.06.005
   HAUKKAMAA M, 1991, CONTRACEPTION, V44, P269, DOI 10.1016/0010-7824(91)90017-A
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hoffmann H, 1999, DRUGS TODAY, V35, P105
   Huber J, 2000, Eur J Contracept Reprod Health Care, V5, P25, DOI 10.1080/13625180008500375
   Hugon-Rodin J, 2010, ANN NY ACAD SCI, V1205, P230, DOI 10.1111/j.1749-6632.2010.05688.x
   Jensen J, 2009, FERTIL STERIL, V92, pS32
   Jesam C, 2010, HUM REPROD, V25, P368, DOI 10.1093/humrep/dep392
   Jick SS, 2010, CONTRACEPTION, V81, P452, DOI 10.1016/j.contraception.2009.12.016
   KIVINEN S, 1996, EUR J CONTRACEP REPR, V1, P183
   Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7
   LAHTEENMAKI P, 1981, CONTRACEPTION, V23, P63
   Luukkainen T, 2000, STEROIDS, V65, P699, DOI 10.1016/S0039-128X(00)00177-X
   LUUKKAINEN T, 1991, ANN NY ACAD SCI, V626, P43, DOI 10.1111/j.1749-6632.1991.tb37898.x
   Meirik O, 2003, HUM REPROD UPDATE, V9, P49, DOI 10.1093/humupd/dmg004
   Merkatz R, 2010, 11 C EUR SOC CONTR R
   Merkatz RB, 2009, CLIN PHARMACOL THER, V85, P553, DOI 10.1038/clpt.2009.29
   Moore C, 1999, DRUGS TODAY, V35, P53
   Moreau C, 2006, CONTRACEPTION, V74, P476, DOI 10.1016/j.contraception.2006.07.008
   Mueck AO, 2009, GYNECOL ENDOCRINOL, V11, P1
   Nahum GG, 2008, OBSTET GYNECOL, V111, p15S
   Narvekar N, 2004, J CLIN ENDOCR METAB, V89, P2491, DOI 10.1210/jc.2003-031945
   Nayak NR, 2007, CONTRACEPTION, V75, pS104, DOI 10.1016/j.contraception.2007.01.024
   Odlind V, 1996, Eur J Contracept Reprod Health Care, V1, P319, DOI 10.3109/13625189609150677
   Oettel M., 1995, Drugs of Today, V31, P517
   Oettel M, 1999, EUR J CONTRACEP REPR, V4, P2
   Palacios S, 2010, EUR J OBSTET GYN R B, V149, P57, DOI 10.1016/j.ejogrb.2009.11.001
   Pall M, 2001, HUM REPROD, V16, P1323, DOI 10.1093/humrep/16.7.1323
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Piaggio G, 1999, LANCET, V353, P721, DOI 10.1016/S0140-6736(98)05718-3
   *POP REF BUR, 2009, WORLD POP DAT SHEET
   *POP REF BUR STAFF, 2004, POPUL B, V59, P1
   Richards JS, 2001, ENDOCRINOLOGY, V142, P2184, DOI 10.1210/en.142.6.2184
   Ross JA, 2002, INT FAM PLAN PERSPEC, V28, P138, DOI 10.2307/3088256
   Roy G, 2010, SEMIN REPROD MED, V28, P126, DOI 10.1055/s-0030-1248137
   Samsioe G, 2004, CLIMACTERIC, V7, P347, DOI 10.1080/13697130400012239
   Santelli JS, 2007, AM J PUBLIC HEALTH, V97, P150, DOI 10.2105/AJPH.2006.089169
   Sicat BL, 2003, PHARMACOTHERAPY, V23, P472, DOI 10.1592/phco.23.4.472.32120
   Sitruk-Ware R, 2006, CONTRACEPTION, V73, P215, DOI 10.1016/j.contraception.2005.08.019
   Sitruk-Ware R, 2010, 11 C EUR SOC CONTR R
   Sitruk-Ware R, 2007, CONTRACEPTION, V75, P454, DOI 10.1016/j.contraception.2007.02.003
   Sivin I, 2005, CONTRACEPTION, V71, P122, DOI 10.1016/j.contraception.2004.08.010
   Sivin I, 2004, CONTRACEPTION, V69, P137, DOI 10.1016/j.contraception.2003.10.003
   Spona J, 1997, CONTRACEPTION, V56, P185, DOI 10.1016/S0010-7824(97)00123-6
   Stratton P, 2010, FERTIL STERIL, V93, P2035, DOI 10.1016/j.fertnstert.2008.12.057
   Szarewski A, 2002, EUR J CONTRACEP REPR, V7, P31
   Trussell J, 1998, CONTRACEPTION, V57, P363, DOI 10.1016/S0010-7824(98)00042-0
   Urdl W, 2005, EUR J OBSTET GYN R B, V121, P202, DOI 10.1016/j.ejogrb.2005.01.021
   VICTOR A, 1976, CONTRACEPTION, V14, P215, DOI 10.1016/0010-7824(76)90089-5
   von Hertzen H, 1998, LANCET, V352, P1939, DOI 10.1016/S0140-6736(05)60440-0
   von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3
   Weisberg E, 2005, CONTRACEPTION, V72, P46, DOI 10.1016/j.contraception.2004.12.014
   WOLF JP, 1989, FERTIL STERIL, V52, P1055
   Woolcock JG, 2008, FERTIL STERIL, V90, P2269, DOI 10.1016/j.fertnstert.2007.10.060
   Xu B, 2007, MATURITAS, V56, P142, DOI 10.1016/j.maturitas.2006.07.003
   Zeun S, 2009, EUR J CONTRACEP REPR, V14, P221, DOI 10.1080/13625180902850039
NR 110
TC 1
Z9 1
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8214
EI 1744-7623
J9 EXPERT OPIN EMERG DR
JI Expert Opin Emerg. Drugs
PD JUN
PY 2011
VL 16
IS 2
BP 373
EP 387
DI 10.1517/14728214.2011.536761
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 768UY
UT WOS:000290965100011
PM 21235423
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   Monteiro, I
   Canteiro, R
   Fernandes, AD
   Bahamondes, L
AF Valeria Bahamondes, M.
   Monteiro, Ilza
   Canteiro, Renata
   Fernandes, Arlete dos Santos
   Bahamondes, Luis
TI Length of the endometrial cavity and intrauterine contraceptive device
   expulsion
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article
DE Endometrial length; Expulsion rate; Intrauterine contraceptive device;
   Levonorgestrel-releasing intrauterine system
ID COPPER-T IUD; LEVONORGESTREL-RELEASING IUD; NULLIPAROUS WOMEN;
   PERFORMANCE; EXPERIENCE; INSERTION; TCU380A; TRIAL; RISK; AGE
AB Objective: To evaluate the correlation between endometrial cavity length and expulsion rate in acceptors of the TCu380A intrauterine device (IUD) or the levonorgestrel-releasing intrauterine system (LNG-IUS). Methods: The study included 235 nulligravida and parous women who received a TCu380A IUD or LNG-IUS and who were observed for up to 1 year. The length of the uterine cavity was measured by uterine sounding and ultrasonography. Results: The endometrial cavity was shorter than 3.2 cm in 2 LNG-IUS users and at least 3.2 cm long in 87 LNG-IUS users, with expulsions occurring in 0 (0.0%) and 2 (2.3%) of these women, respectively (P > 0.999). Among the TCu380A IUD users, the endometrial cavity was shorter than 3.6 cm in 63 women and at least 3.6 cm long in 83 women, with expulsions occurring in 3 (4.8%) and 5 (6.0%) of these women, respectively (P > 0.999). The mean length of the endometrial cavity-evaluated via ultrasonography-among the 10 women whose devices were expelled was 3.9 +/- 0.3 cm, compared with 3.9 +/- 0.0 cm in those who retained their devices (P = 0.799). Conclusion: The present results do not support the hypothesis of an association between uterine length and risk of intrauterine contraceptive expulsion. (C) 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Valeria Bahamondes, M.] Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Univ Campinas UNICAMP, Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, MV (corresponding author), Univ Campinas UNICAMP, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM vbahamondes@cemicamp.org.br
RI monteiro, ilza m u/F-4871-2014; Fernandes, Arlete/I-7561-2018
OI monteiro, ilza m u/0000-0002-9536-0564; Fernandes,
   Arlete/0000-0001-5872-0017
FU Brazilian National Research Council (CNPq)National Council for
   Scientific and Technological Development (CNPq) [573747/2008-3]
FX The present study was partially funded (grant 573747/2008-3) by the
   Brazilian National Research Council (CNPq).
CR ANTEBY E, 1993, OBSTET GYNECOL, V81, P112
   Bahamondes L, 1995, HUM REPROD, V10, P2917, DOI 10.1093/oxfordjournals.humrep.a135819
   Bahamondes L, 2005, CONTRACEPTION, V72, P337, DOI 10.1016/j.contraception.2004.12.026
   Bahamondes L, 1999, ADV CONTRACEPT, V15, P275, DOI 10.1023/A:1006780005535
   Canteiro R, 2010, CONTRACEPTION, V81, P515, DOI 10.1016/j.contraception.2010.01.006
   DIAZ J, 1993, CONTRACEPTION, V48, P23, DOI 10.1016/0010-7824(93)90062-C
   FAUNDES A, 1993, ANN MED, V25, P149, DOI 10.3109/07853899309164159
   Haugan T, 2007, CONTRACEPTION, V75, P171, DOI 10.1016/j.contraception.2006.09.005
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hubacher D, 2007, CONTRACEPTION, V75, pS8, DOI 10.1016/j.contraception.2006.12.005
   Johnson BA, 2005, AM FAM PHYSICIAN, V71, P95
   KULIER R, 2006, COCHRANE DB SYST REV, V3
   KURZ KH, 1984, CONTRACEPTION, V29, P495, DOI 10.1016/S0010-7824(84)80011-6
   LUUKKAINEN T, 1995, CONTRACEPTION, V52, P269, DOI 10.1016/0010-7824(95)00210-2
   Meirik O, 2009, CONTRACEPTION, V80, P133, DOI 10.1016/j.contraception.2009.02.006
   Merki-Feld GS, 2008, EUR J OBSTET GYN R B, V137, P92, DOI 10.1016/j.ejogrb.2007.02.003
   MISHELL DR, 1973, AM J OBSTET GYNECOL, V116, P1092, DOI 10.1016/0002-9378(73)90942-3
   O'Brien PA, 2008, CONTRACEPTION, V77, P318, DOI 10.1016/j.contraception.2007.12.011
   Petersen K R, 1991, Acta Eur Fertil, V22, P225
   Petta CA, 1996, CONTRACEPTION, V54, P287, DOI 10.1016/S0010-7824(96)00181-3
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   SIVIN I, 1979, STUD FAMILY PLANN, V10, P263, DOI 10.2307/1965507
   Sivin I, 2007, CONTRACEPTION, V75, pS70, DOI 10.1016/j.contraception.2007.01.016
   Wu SC, 2000, CONTRACEPTION, V61, P91, DOI 10.1016/S0010-7824(00)00087-1
   ZHANG J, 1992, CONTRACEPTION, V46, P427, DOI 10.1016/0010-7824(92)90146-K
   Zhou LF, 2003, PHARMACOEPIDEM DR S, V12, P371, DOI 10.1002/pds.875
NR 26
TC 10
Z9 11
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0020-7292
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
PD APR
PY 2011
VL 113
IS 1
BP 50
EP 53
DI 10.1016/j.ijgo.2010.10.013
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 756KL
UT WOS:000290010000010
PM 21272883
DA 2020-12-01
ER

PT J
AU Mansour, D
   Bahamondes, L
   Critchley, H
   Darney, P
   Fraser, IS
AF Mansour, Diana
   Bahamondes, Luis
   Critchley, Hilary
   Darney, Philip
   Fraser, Ian S.
TI The management of unacceptable bleeding patterns in
   etonogestrel-releasing contraceptive implant users
SO CONTRACEPTION
LA English
DT Review
DE Progestogen only contraceptives; Contraceptive implants; Progestogen
   implants; Etonogestrel implants; Irregular bleeding; Unpredictable
   bleeding; Bleeding irregularity; Bleeding pattern
ID DEPOT-MEDROXYPROGESTERONE ACETATE; INTRAUTERINE SYSTEM; IDIOPATHIC
   MENORRHAGIA; CONTROLLED-TRIAL; NORPLANT(R) USE; LEVONORGESTREL; WOMEN;
   ENDOMETRIUM; SECONDARY; EFFICACY
AB The aim of this guidance is to review the management of unacceptable vaginal bleeding patterns in etonogestrel (ENG)-releasing contraceptive implant users concentrating, where possible, on the evidence for pharmacological treatments and identifying a pragmatic approach where this is not possible.
   This article was developed in accordance with methodology used for producing Royal College of Obstetricians and Gynaecologists' Green Top Guidelines.
   The Cochrane Library (including the Cochrane Database of Systematic Reviews, DARE and EMBASE) and Medline (1966-2010) were searched using the relevant MeSH terms, including all subheadings, and this was combined with a keyword search. Search words included "progestogen only contraceptives," "contraceptive implants," "progestogen implants," "etonogestrel implants," "irregular bleeding," "unpredictable bleeding," "bleeding irregularity" and "bleeding pattern," and the search was limited to humans and English language. Enquiries for relevant information were also made to the pharmaceutical industry and researchers for missing studies.
   Although this is not a systematic review, two of the authors (D.M., I.S.F.), qualitatively assessed those papers reporting quantitative results involving treatments given either to stop or prevent bleeding in ENG or levonorgestrel contraceptive implants users. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Mansour, Diana] New Croft Ctr, Sexual Hlth Serv, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England.
   [Bahamondes, Luis] Univ Estadual Campinas, UNICAMP, Sch Med, Dept Obstet & Gynaecol,Human Reprod Unit, BR-13081970 Campinas, SP, Brazil.
   [Bahamondes, Luis] Natl Inst Hormones & Women Hlth, BR-13081970 Campinas, SP, Brazil.
   [Critchley, Hilary] Univ Edinburgh, Queens Med Res Inst, Div Reprod & Dev Sci, Edinburgh EH16 4TJ, Midlothian, Scotland.
   [Darney, Philip] Univ Calif San Francisco, San Francisco Gen Hosp, Bixby Ctr Global Reprod Hlth, San Francisco, CA 94941 USA.
   [Fraser, Ian S.] Univ Sydney, Queen Elizabeth II Res Inst Mothers & Infants, Dept Obstet & Gynaecol, Sydney, NSW 2006, Australia.
RP Mansour, D (corresponding author), New Croft Ctr, Sexual Hlth Serv, Market St E, Newcastle Upon Tyne NE1 6ND, Tyne & Wear, England.
EM diana.mansour@newcastle-pct.nhs.uk
RI Saude da mulher, Inct/J-9403-2013
FU Merck Sharp Dohme Limited; Medical Research CouncilMedical Research
   Council UK (MRC) [G1002033] Funding Source: researchfish
FX The authors have received an educational grant from Merck Sharp & Dohme
   Limited to cover their time and expenses in writing this article. The
   content is the total responsibility of the authors, and the MSD Company
   has had no input into any aspect of the review. All authors have been
   members of national and international pharmaceutical advisory boards and
   received honoraria for lecturing, expenses for attending scientific
   conferences and research grants from a number of pharmaceutical
   companies.
CR Abdel-Aleem H, 2005, CONTRACEPTION, V72, P432, DOI 10.1016/j.contraception.2005.05.015
   Abdel-Aleem H, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003449.pub2
   ALEXANDER NJ, 1992, JOINT WHO NIH S END, P1
   AlvarezSanchez F, 1996, AM J OBSTET GYNECOL, V174, P919, DOI 10.1016/S0002-9378(96)70326-5
   Andolsek L, 1982, REPR HLTH CAR INT S
   Buasang Kritsana, 2009, Journal of the Medical Association of Thailand, V92, P301
   Cheng L, 2000, HUM REPROD, V15, P1969, DOI 10.1093/humrep/15.9.1969
   Crawford P, 2002, CNS DRUGS, V16, P263, DOI 10.2165/00023210-200216040-00005
   Cupp EW, 1980, MAL, V84, P362
   d'Arcangues C, 2004, CONTRACEPTION, V70, P451, DOI 10.1016/j.contraception.2004.05.012
   DARCANGUES C, 1992, STEROID HORMONES AND UTERINE BLEEDING, P81
   dArcangues C, 1996, HUM REPROD, V11, pU5
   Darney P, 2009, FERTIL STERIL, V91, P1646, DOI 10.1016/j.fertnstert.2008.02.140
   Davie JE, 1996, CLIN THER, V18, P150, DOI 10.1016/S0149-2918(96)80187-1
   De Cetina TEC, 2001, CONTRACEPTION, V63, P143
   DIAZ S, 1990, CONTRACEPTION, V42, P97
   DICZFALUSY E, 1980, WHO S STER CONTR MEC
   Faculty of Sexual and Reproductive Health Care, 2009, UK MED EL CRIT CONTR
   Faculty of Sexual and Reproductive Healthcare, 2009, MAN UNSCH BLEED WOM
   Findlay JK, 1996, HUM REPROD, V11, P179, DOI 10.1093/humrep/11.suppl_2.179
   Fraser IS, 1999, BEST PRACT RES CL OB, V13, P203, DOI 10.1053/beog.1999.0018
   Fraser IS, 2000, CONTRACEPTION, V61, P241, DOI 10.1016/S0010-7824(00)00100-1
   Gemzell-Danielsson K, 2010, HUM REPROD, V25, P354, DOI 10.1093/humrep/dep426
   Glasier AF, 2002, FERTIL STERIL, V77, P366, DOI 10.1016/S0015-0282(01)02997-1
   Graesslin O, 2008, EUR J CONTRACEP REPR, V13, P4, DOI 10.1080/13625180801942754
   Grossman MP, 2006, CONTRACEPTION, V73, P562, DOI 10.1016/j.contraception.2006.01.016
   Guttinger A, 2007, CONTRACEPTION, V75, pS93, DOI 10.1016/j.contraception.2007.01.015
   Halpern V, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004317.pub2
   Harvey C, 2009, CONTRACEPTION, V80, P527, DOI 10.1016/j.contraception.2009.05.132
   Hickey M, 2005, E SCHERING RES FDN W, V52, P191
   HICKEY M, 2001, REPROD MED REV, V9, P153
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hubacher D, 2009, CONTRACEPTION, V80, P113, DOI 10.1016/j.contraception.2009.02.008
   Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x
   Kaewrudee S, 1999, CONTRACEPTION, V60, P25, DOI 10.1016/S0010-7824(99)00059-1
   Lasseter R. H., 2007, MATLAB SIMPOWERSYSTE, V1, P305
   Livingstone M, 2002, HUM REPROD UPDATE, V8, P60, DOI 10.1093/humupd/8.1.60
   Magalhaes J, 2007, CONTRACEPTION, V75, P193, DOI 10.1016/j.contraception.2006.11.004
   Mansour D, 2008, EUR J CONTRACEP REPR, V13, P13, DOI 10.1080/13625180801959931
   Mishell DR, 1996, J REPROD MED, V41, P381
   *NAT I HLTH CLIN E, 2005, LONG ACT REV CONTR
   National Institute for Health and Clinical Excellence, 2007, HEAV MENSTR BLEED CL
   Phaliwong Paweena, 2004, Journal of the Medical Association of Thailand, V87, pS64
   Phupong V, 2006, CONTRACEPTION, V73, P253, DOI 10.1016/j.contraception.2005.09.012
   Power J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001326.pub2
   Reuter S, 2003, EUR J CONTRACEP REPR, V8, P27
   ROGERS P, 2000, HUM REPROD S3, V15, P1
   Rosenberg MJ, 1996, AM J OBSTET GYNECOL, V174, P628, DOI 10.1016/S0002-9378(96)70440-4
   SCHERING AG, 2002, PRODUCT MONOGRAPH MI
   SHAABAN MM, 1984, CONTRACEPTION, V30, P421, DOI 10.1016/0010-7824(84)90034-9
   Van Den Bosch T, 2002, ULTRASOUND OBST GYN, V20, P377, DOI 10.1046/j.1469-0705.2002.00816.x
   VIEGAS OAC, 1988, CONTRACEPTION, V38, P313, DOI 10.1016/0010-7824(88)90103-5
   Warner P, 2010, HUM REPROD, V25, P345, DOI 10.1093/humrep/dep377
   Weisberg E, 2006, HUM REPROD, V21, P295, DOI 10.1093/humrep/dei273
   Weisberg E, 2009, HUM REPROD, V24, P1852, DOI 10.1093/humrep/dep081
   WHITE JO, 1991, CONTRACEPTION, V43, P401, DOI 10.1016/0010-7824(91)90077-S
   Witjaksono J, 1996, HUM REPROD, V11, P109, DOI 10.1093/humrep/11.suppl_2.109
   Zheng SR, 1999, CONTRACEPTION, V60, P1, DOI 10.1016/S0010-7824(99)00053-0
NR 58
TC 45
Z9 50
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD MAR
PY 2011
VL 83
IS 3
BP 202
EP 210
DI 10.1016/j.contraception.2010.08.001
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 724GB
UT WOS:000287563000003
PM 21310280
DA 2020-12-01
ER

PT J
AU Canteiro, R
   Bahamondes, MV
   Fernandes, AD
   Espejo-Arce, X
   Marchi, NM
   Bahamondes, L
AF Canteiro, Renata
   Bahamondes, M. Valeria
   Fernandes, Arlete dos Santos
   Espejo-Arce, Ximena
   Marchi, Nadia M.
   Bahamondes, Luis
TI Length of the endometrial cavity as measured by uterine sounding and
   ultrasonography in women of different parities
SO CONTRACEPTION
LA English
DT Article
DE Endometrial length Nulligravida women; Parous women; Intrauterine device
ID NULLIPAROUS MEXICAN WOMEN; 3 DIFFERENT IUDS; CLINICAL-PERFORMANCE;
   ULTRASOUND; EXPERIENCE
AB Background: In view of current controversies regarding the need for new, shorter intrauterine devices (IUDs) that would reduce expulsion rates in nulligravida, endometrial cavity length was measured in women of different parities using uterine sounding and ultrasonography.
   Study Design: A cross-sectional descriptive study was performed including 570 women of 17-52 years of age, 260 of whom were nulligravida and 310 parous.
   Results: The difference in mean length between measurements taken by uterine sounding and ultrasonography was 0.28 cm. Mean endometrial cavity length was 3.84 +/- 0.03 cm (mean +/- S.E.M.) in nulligravida and 4.25 +/- 0.03 cm in parous women according to uterine sounding (p<.001) and 3.70 +/- 0.03 cm and 3.84 +/- 0.03 cm, respectively, according to ultrasonography (p=.006).
   Conclusions: By either technique, mean length of the endometrial cavity was >3.6 cm, the length of the most common IUDs, the TCu380A and the levonorgestrel-releasing intrauterine system. Therefore, the issue appears controversial for developing new, shorter IUDs, since current models fit most women, including nulligravida, albeit one third of the women of our sample showed endometrial length shorter than 3.2 cm. (C) 2010 Elsevier Inc. All rights reserved
C1 Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med Sci, BR-13084971 Sao Paulo, Brazil.
   Univ Estadual Campinas, Natl Inst Hormones & Womens Hlth, BR-13084971 Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Saude da mulher, Inct/J-9403-2013; Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Sao Paulo Foundation for the Support of Research (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2003108391-7];
   National Research Council (CNN) [573747/2008-3]
FX This study received partial financial support from the Sao Paulo
   Foundation for the Support of Research (FAPESP), grant #2003108391-7 and
   from the National Research Council (CNN) grant #573747/2008-3.
CR Brockmeyer A, 2008, EUR J CONTRACEP REPR, V13, P248, DOI 10.1080/02699200802253706
   Du R G, 1988, Shengzhi Yu Biyun, V8, P52
   Hubacher D, 2007, CONTRACEPTION, V75, pS8, DOI 10.1016/j.contraception.2006.12.005
   KULIER R, 2006, COCHRANE DB SYST REV, V3
   KURZ KH, 1984, CONTRACEPTION, V29, P495, DOI 10.1016/S0010-7824(84)80011-6
   KURZ KH, 1981, CONTRACEPT DELIV SYS, V2, P21
   Lete I, 1998, Eur J Contracept Reprod Health Care, V3, P190
   MISHELL DR, 1973, AM J OBSTET GYNECOL, V116, P1092, DOI 10.1016/0002-9378(73)90942-3
   Otero-Flores JB, 2003, CONTRACEPTION, V67, P273, DOI 10.1016/S0010-7824(02)00519-X
   PETERSON JC, 1991, COMMUN SOIL SCI PLAN, V22, P225, DOI 10.1080/00103629109368410
   Petta CA, 1996, CONTRACEPTION, V54, P287, DOI 10.1016/S0010-7824(96)00181-3
   Sivin I, 2004, CONTRACEPTION, V69, P259, DOI 10.1016/j.contraception.2003.10.012
   SIVIN I, 1979, STUD FAMILY PLANN, V10, P263, DOI 10.2307/1965507
   Suhonen S, 2004, CONTRACEPTION, V69, P407, DOI 10.1016/j.contraception.2003.11.008
   TANG D C, 1991, Advances in Contraception, V7, P29, DOI 10.1007/BF01850716
   Wang J G, 1988, Shengzhi Yu Biyun, V8, P11
   WITTMANN BK, 1976, BRIT J OBSTET GYNAEC, V83, P802, DOI 10.1111/j.1471-0528.1976.tb00748.x
NR 17
TC 21
Z9 21
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2010
VL 81
IS 6
BP 515
EP 519
DI 10.1016/j.contraception.2010.01.006
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 605MA
UT WOS:000278350500010
PM 20472119
DA 2020-12-01
ER

PT J
AU Marchi, NM
   de Alvarenga, AT
   Osis, MJD
   Godoy, HMD
   Domeni, MFSES
   Bahamondes, L
AF Marchi, N. M.
   de Alvarenga, A. T.
   Osis, M. J. D.
   de Aguiar Godoy, H. M.
   Simoes e Silva Domeni, M. F.
   Bahamondes, L.
TI Vasectomy within the public health services in Campinas, Sao Paulo,
   Brazil
SO INTERNATIONAL NURSING REVIEW
LA English
DT Article
DE Contraception; Family Planning; Family Planning Services; Men; Vasectomy
ID WOMEN
AB Objective:
   To describe some of the characteristics of men who underwent a vasectomy in the public health network of Campinas, Sao Paulo, Brazil.
   Methods:
   A descriptive study including 202 men randomly selected from a list of all the men vasectomized between 1998 and 2004 in the public health network.
   Results:
   Most of the men were 30 years of age or older when vasectomized, had completed elementary school and had two or more children of both sexes. Most of the men came from the lowest income segment of the population: 47.6% in 1998-1999 and 61.3% in 2003-2004. Although the men knew various contraceptive methods, 51.2% reported that their partners were using combined oral contraceptives at the time of surgery. Most men initially sought information on vasectomy at health-care clinics where care was provided by a multidisciplinary team; most received counselling, however, 47.9% of the men waited more than 4 months for the vasectomy.
   Conclusions:
   The profile of the vasectomized men in this study appears to indicate that the low-income population from Campinas, Sao Paulo, Brazil has access to vasectomy; however, the waiting time for vasectomy reveals that difficulties exist in obtaining this contraceptive method in the public health service.
C1 [Marchi, N. M.; Bahamondes, L.] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, Campinas, SP, Brazil.
   [Osis, M. J. D.] Campinas Reprod Hlth Res Ctr CEMICAMP, Social Res Dept, Campinas, SP, Brazil.
   [de Aguiar Godoy, H. M.; Simoes e Silva Domeni, M. F.] Campinas Municipal Family Planning Clin, Campinas, SP, Brazil.
   [de Alvarenga, A. T.] Univ Sao Paulo, Sch Publ Hlth, Dept Womens & Child Healthcare, Sao Paulo, Brazil.
RP Marchi, NM (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM nmarchi@uol.com.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/069837]
FX This study was partially funded by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), Grant 2004/069837. The authors would like
   to thank Maria Helena de Souza for her assistance in the statistical
   analysis of these data, Karla Simonia de Padua and Veronica Barros for
   their help in preparing the tables and for reviewing the manuscript, and
   Adriana Barros for her collaboration in the data collection.
CR Altman D.G., 1991, PRACTICAL STAT MED R
   [BEMFAM-Sociedade Civil Bem Estar Familiar no Brasil MACRO Internacional], 1997, PROGR PESQ DEM SAUD
   BERQUO E, 2003, CAD SAUDE PUBLICA, V19, P5441
   *BRAZ MIN HLTH, 2008, NAT DEM HLTH SURV
   de Carvalho LEC, 2007, CAD SAUDE PUBLICA, V23, P2906, DOI 10.1590/S0102-311X2007001200012
   *DATASUS, 2009, SI MIN HLTH HOSP PRO
   Espejo X, 2003, REV SAUDE PUBL, V37, P583, DOI 10.1590/S0034-89102003000500006
   HARDY E, 1993, REV BRAS GINECOL OBS, V4, P70
   Kish L., 1965, SURVEY SAMPLING
   Manhoso FR, 2005, INT NURS REV, V52, P101, DOI 10.1111/j.1466-2435.2005.00247.x
   Marchi Nádia Maria, 2003, Cad. Saúde Pública, V19, P1017, DOI 10.1590/S0102-311X2003000400024
   MARCHI NM, 2005, VARONES LATINOAMERIC, P174
   MINELLA L. S., 1998, CAD SAUDE PUBLICA, V14, P69
   Osis Maria José Duarte, 2003, Cad. Saúde Pública, V19, P1399, DOI 10.1590/S0102-311X2003000500018
   Osis Maria José Duarte, 2006, Cad. Saúde Pública, V22, P2481, DOI 10.1590/S0102-311X2006001100023
   OSIS MJD, 1997, 4 LAT AM C SOC SCI M
   Penteado LG, 2001, STUD FAMILY PLANN, V32, P315, DOI 10.1111/j.1728-4465.2001.00315.x
   Rodrigues A., 2003, European Urology Supplements, V2, P121, DOI 10.1016/S1569-9056(03)80477-3
   SERRUYA S, 1996, MULHERES ESTERILIZAD
   VIANNA SA, 1997, AN 15 REUN AS LAT IN, P144
   Vieira Elisabeth Meloni, 2005, Cad. Saúde Pública, V21, P1785, DOI 10.1590/S0102-311X2005000600026
   VIEIRA EM, 1994, REV SAUDE PUBL, V28, P440, DOI 10.1590/S0034-89101994000600008
   Vieira EM, 2002, REV SAUDE PUBL, V36, P263, DOI 10.1590/S0034-89102002000300002
   Vieira EM, 1998, CAD SAUDE PUBLICA S1, V14, P59
   WALSH J, 1996, CONTRACEPTIVE CHOICE
NR 25
TC 4
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-8132
EI 1466-7657
J9 INT NURS REV
JI Int. Nurs. Rev.
PD JUN
PY 2010
VL 57
IS 2
BP 254
EP 259
DI 10.1111/j.1466-7657.2009.00761.x
PG 6
WC Nursing
SC Nursing
GA 597XS
UT WOS:000277796500019
PM 20579162
DA 2020-12-01
ER

PT J
AU Bahamondes, MV
   Monteiro, I
   Castro, S
   Espejo-Arce, X
   Bahamondes, L
AF Bahamondes, M. Valeria
   Monteiro, Ilza
   Castro, Sara
   Espejo-Arce, Ximena
   Bahamondes, Luis
TI Prospective study of the forearm bone mineral density of long-term users
   of the levonorgestrel-releasing intrauterine system
SO HUMAN REPRODUCTION
LA English
DT Article
DE bone mineral density; levonorgestrel-releasing intrauterine system;
   Mirena; contraception
ID HORMONAL CONTRACEPTION; POSTMENOPAUSAL WOMEN; HEALTHY WOMEN;
   OSTEOPOROSIS; PERFORMANCE; MENORRHAGIA; MASS
AB The levonorgestrel-releasing intrauterine system (LNG-IUS) induces amenorrhoea, and its effect on bone mineral density (BMD) may constitute a concern. This study evaluated BMD in long-term users of the LNG-IUS or intrauterine device (IUD).
   BMD was evaluated at the midshaft of the ulna and ultra-distal radius using dual-energy X-ray absorptiometry in 37 women at 7 or 10 years of use following placement of a second LNG-IUS. The groups were paired for duration of use, age, body mass index (BMI), ethnicity and number of pregnancies.
   The mean age of both LNG-IUS and IUD users at the 7th and 10th year was similar to 34 and 38 years, respectively. Mean BMI was similar to 25 in both groups, increasing to similar to 26 at the 10th year. Amenorrhoea occurred in 51.4 and 91.9% of LNG-IUS users at the 7th and 10th year, respectively. Estradiol levels in LNG-IUS users were normal at both evaluations. There were no differences in BMD (g/cm(2)) at the midshaft of the ulna nor ultra-distal radius between LNG-IUS and IUD users or between the 7th and 10th years of use in LNG-IUS users. A Z-score below -2SD at the ultra-distal radius was observed in only one LNG-IUS user and in none of the IUD users at the 10th year. Higher BMI and BMD at the seventh year and amenorrhoea were predictors of higher BMD at the 10th year.
   BMD at the midshaft of the ulna and ultra-distal radius in LNG-IUS users were similar to that of IUD users and remained unchanged between the 7th and the 10th years of use.
C1 [Bahamondes, M. Valeria] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Natl Inst Hormones & Womens Hlth, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, MV (corresponding author), Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM vbahamondes@cemicamp.org.br
RI monteiro, ilza m u/F-4871-2014; Saude da mulher, Inct/J-9403-2013
OI monteiro, ilza m u/0000-0002-9536-0564; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/083917]; Conselho
   Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX Partial. nancial support was received from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) under grant number 03/083917
   and also from the Conselho Nacional de Pesquisa (CNPq) under grant
   number 573747/2008-3.
CR [Anonymous], 2004, MED EL CRIT CONTR US
   Arfati JS, 2009, JOINT BONE SPINE, V76, P134, DOI 10.1016/j.jbspin.2008.09.014
   Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021
   Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Bahamondes L, 2006, HUM REPROD, V21, P1316, DOI 10.1093/humrep/dei457
   Bahamondes L, 2006, HUM REPROD, V21, P466, DOI 10.1093/humrep/dei358
   Bahamondes L, 2003, J REPROD MED, V48, P637
   Bahamondes L, 2008, EXPERT REV MED DEVIC, V5, P437, DOI 10.1586/17434440.5.4.437
   Berenson AB, 2004, OBSTET GYNECOL, V103, P899, DOI 10.1097/01.AOG.0000117082.49490.d5
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   Enriquez J, 2007, J ENDOCRINOL, V193, P493, DOI 10.1677/JOE-06-0038
   Guilbert ER, 2009, CONTRACEPTION, V79, P167, DOI 10.1016/j.contraception.2008.10.016
   Gur A, 2003, J BONE MINER METAB, V21, P234, DOI 10.1007/s00774-003-0415-9
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hidalgo MM, 2009, CONTRACEPTION, V80, P84, DOI 10.1016/j.contraception.2009.01.004
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   Jones T, 1998, BRIT J RHEUMATOL, V37, P539
   Kaunitz AM, 2009, OBSTET GYNECOL, V113, P1104, DOI 10.1097/AOG.0b013e3181a1d3ce
   Liu JH, 2005, AM J OBSTET GYNECOL, V192, P1316, DOI 10.1016/j.ajog.2004.12.067
   LUUKKAINEN T, 1995, CONTRACEPTION, V52, P269, DOI 10.1016/0010-7824(95)00210-2
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Monteiro I, 2002, CONTRACEPTION, V65, P325, DOI 10.1016/S0010-7824(02)00283-4
   MONTEIRODANTAS C, 2007, REPROD HLTH, V12, P11
   NAESSEN T, 1995, CONTRACEPTION, V52, P35, DOI 10.1016/0010-7824(95)00121-P
   Paton LM, 2003, AM J CLIN NUTR, V77, P707
   PECK WA, 1993, AM J MED, V94, P646
   Petitti DB, 2000, OBSTET GYNECOL, V95, P736, DOI 10.1016/S0029-7844(00)00782-1
   Picard D, 2004, J CLIN DENSITOM, V7, P111, DOI 10.1385/JCD:7:1:111
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648-200209000-00015
   Sitruk-Ware R, 2007, CONTRACEPTION, V75, pS155, DOI 10.1016/j.contraception.2007.01.010
   TAMAKI J, 2009, J BONE MINE IN PRESS
   Tang OS, 2000, CONTRACEPTION, V62, P161, DOI 10.1016/S0010-7824(00)00168-2
   Volpe A, 1997, Eur J Contracept Reprod Health Care, V2, P123
   Wetmore CM, 2008, OSTEOPOROSIS INT, V19, P519, DOI 10.1007/s00198-007-0473-2
   World Health Organization, 1994, WHO TECHN REP SER
NR 37
TC 26
Z9 28
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD MAY
PY 2010
VL 25
IS 5
BP 1158
EP 1164
DI 10.1093/humrep/deq043
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 584EG
UT WOS:000276732800011
PM 20185512
OA Bronze
DA 2020-12-01
ER

PT J
AU Pantoja, M
   Medeiros, T
   Baccarin, MC
   Morais, SS
   Bahamondes, L
   Fernandes, AMD
AF Pantoja, Marcia
   Medeiros, Tatiane
   Baccarin, Maria Carolina
   Morais, Sirlei Siani
   Bahamondes, Luis
   dos Santos Fernandes, Arlete Maria
TI Variations in body mass index of users of depot-medroxyprogesterone
   acetate as a contraceptive
SO CONTRACEPTION
LA English
DT Article
DE Depot-medroxyprogesterone acetate; contraception; Weight; Obesity
ID WEIGHT-GAIN; COPPER IUD; WOMEN; INCREASE; OBESE
AB Background: Weight gain is a frequent reason for discontinuing the contraceptive with depot-medroxyprogesterone acetate (DMPA).
   Study Design: This 3-year retrospective cohort study assessed body mass index (BMI; kg/m(2)) variations in 379 Current or past DMPA users compared to TCu380A intrauterine device (IUD) users matched for age and BMI, categorized into G1 (normal weight), G2 (overweight) or G3 (obese) according to baseline BMI. Variations in weight and BMI were evaluated using analysis of variance.
   Results: BMI increased progressively in all groups but significantly more in G1 and G2 DMPA users compared to nonusers and according to duration of use. In the G3 subgroup, weight trends were similar in the DMPA and IUD users.
   Conclusions: Normal and overweight women increased BMI with DMPA use; however, obese women did not increase weight. Weight increase in DMPA users could be associated with metabolic alterations related to duration of use in normal and overweight women and to alterations already present in obese women. Prospective studies are required to determine triggering factors. DMPA use :! 3 years was not associated with weight increase in women with BMI (kg/m(2)) >= 30. (C) 2010 Elsevier Inc. All rights reserved.
C1 [dos Santos Fernandes, Arlete Maria] Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Natl Inst Hormones & Women Hlth, BR-13084971 Campinas, SP, Brazil.
RP Fernandes, AMD (corresponding author), Univ Estadual Campinas, Sch Med Sci, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
EM arlete@fem.unicamp.br
RI Fernandes, Arlete/I-7561-2018
OI Fernandes, Arlete/0000-0001-5872-0017
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [03/083917]
FX The Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   Brazil, provided partial financial support under Award #03/083917.
CR ACOG (American Congress of Obstetricians and Gynecologists), 2006, OBSTET GYNECOL, V107, P1453, DOI DOI 10.1097/00006250-200606000-00055.PUBMED:16738183
   AMATAYAKUL K, 1980, CONTRACEPTION, V22, P605, DOI 10.1016/0010-7824(80)90087-6
   [Anonymous], 2020, MED EL CRIT CONTR US
   ARMITAGE P, 1985, STAT METHODS MED RES
   Bahamondes L, 2001, CONTRACEPTION, V64, P223, DOI 10.1016/S0010-7824(01)00255-4
   Bakry S, 2008, ARCH GYNECOL OBSTET, V278, P1, DOI 10.1007/s00404-007-0497-z
   Blanco-Molina A, 2009, THROMB HAEMOSTASIS, V101, P478, DOI 10.1160/TH08-10-0684
   Bonny AE, 2006, ARCH PEDIAT ADOL MED, V160, P40, DOI 10.1001/archpedi.160.1.40
   Clark MK, 2005, INT J OBESITY, V29, P1252, DOI 10.1038/sj.ijo.0803023
   Espey E, 2000, CONTRACEPTION, V62, P55, DOI 10.1016/S0010-7824(00)00144-X
   FOTHERBY K, 1982, CONTRACEPTION, V26, P51, DOI 10.1016/0010-7824(82)90171-8
   Fraser I S, 1981, Med J Aust, V1, P3
   Haider S, 2007, CLIN OBSTET GYNECOL, V50, P898, DOI 10.1097/GRF.0b013e318159c20a
   Hair J. F., 1998, MULTIVARIATE DATA AN
   Hassan DF, 2003, CONTRACEPTION, V68, P27, DOI 10.1016/S0010-7824(03)00079-9
   Kaunitz AM, 1996, INT J FERTIL MENOP S, V41, P69
   Mangan Sharon A, 2002, J Pediatr Adolesc Gynecol, V15, P79, DOI 10.1016/S1083-3188(01)00147-4
   Pelkman C, 2002, J REPROD MED, V47, P791
   SAID S, 1986, CONTRACEPTION, V34, P223, DOI 10.1016/0010-7824(86)90004-1
   Taneepanichskul S, 1998, CONTRACEPTION, V58, P149, DOI 10.1016/S0010-7824(98)00085-7
   Westhoff C, 2007, CONTRACEPTION, V75, P261, DOI 10.1016/j.contraception.2006.12.009
NR 21
TC 41
Z9 41
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD FEB
PY 2010
VL 81
IS 2
BP 107
EP 111
DI 10.1016/j.contraception.2009.07.008
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 549EY
UT WOS:000274030000004
PM 20103446
DA 2020-12-01
ER

PT J
AU Makuch, MY
   Petta, CA
   Osis, MJD
   Bahamondes, L
AF Makuch, Maria Y.
   Petta, Carlos A.
   Duarte Osis, Maria Jose
   Bahamondes, Luis
TI Low priority level for infertility services within the public health
   sector: a Brazilian case study
SO HUMAN REPRODUCTION
LA English
DT Article
DE infertility; inequity; low-income population; Brazil; public health
ID DISPARITIES; PREVALENCE; CHILDREN; CARE; MEN
AB In view of the lack of information on availability of public sector infertility services and in order to contribute to the debate on access to these services, we assessed the availability of public sector infertility services, including assisted reproduction technology (ART), in Brazil.
   We conducted a cross-sectional study with telephone interviews using a semi-structured questionnaire with Health Secretariats' authorities from the 26 States, the Federal District, 26 Municipal state capitals and another 16 cities with more than 500 000 inhabitants. Also, directors of 26 referral centres and teaching hospitals provide ART procedures supported by the state or university teaching hospitals.
   Authorities from 24/26 State Secretariats and the Federal District, from 39/42 cities and 26 directors of referral centres and teaching hospitals offering government-funded infertility care and ART were interviewed. In 19/25 states (76%) and 26/39 cities (66.7%), no infertility treatment was available free of charge. The most common reason for lack of services at the state and municipal levels was 'lack of any political decision to implement them', followed by 'lack of human and financial resources'. When ART was available, barriers to access included the fact that patients needed to purchase medication and the more than 1-year waiting list for treatment.
   Lack of political commitment results in inequity in the access of low-income couples in Brazil to infertility treatment, including ART.
C1 [Makuch, Maria Y.; Duarte Osis, Maria Jose] Ctr Res Reprod Hlth Campinas CEMICAMP, BR-13084971 Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Natl Inst Hormones & Women Hlth, Campinas, SP, Brazil.
   [Petta, Carlos A.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
RP Makuch, MY (corresponding author), Ctr Res Reprod Hlth Campinas CEMICAMP, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM mmakuch@cemicamp.org.br
RI Saude da mulher, Inct/J-9403-2013
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/00055-9]; Conselho
   Nacional de Pesquisa (CNPq), BrazilNational Council for Scientific and
   Technological Development (CNPq) [573747/2008-3]
FX This study was partially supported by the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP), award no. 07/00055-9 and the Conselho
   Nacional de Pesquisa (CNPq), Brazil under award no. 573747/2008-3.
CR Amorim C, 2007, LANCET, V369, P1373, DOI 10.1016/S0140-6736(07)60498-X
   Araoye Margaret O, 2003, West Afr J Med, V22, P190
   Blackwell RE, 2000, AM J OBSTET GYNECOL, V182, P891, DOI 10.1016/S0002-9378(00)70341-3
   Blackwell RE, 2001, FERTIL STERIL, V75, P749, DOI 10.1016/S0015-0282(01)01673-9
   Boivin J, 2007, HUM REPROD, V22, P1506, DOI 10.1093/humrep/dem046
   *BRAS MIN SAUD SEC, 2005, DIR SEX DIR REPR PRI
   Chambers GM, 2009, FERTIL STERIL, V91, P2281, DOI 10.1016/j.fertnstert.2009.04.029
   Collins J, 2001, SEMIN REPROD MED, V19, P279, DOI 10.1055/s-2001-18047
   Daar A. S., 2002, CURRENT PRACTICES CO
   de Mouzon J, 2009, HUM REPROD, V24, P2310, DOI 10.1093/humrep/dep098
   Dyer SJ, 2007, J PSYCHOSOM OBST GYN, V28, P69, DOI 10.1080/01674820701409959
   Dyer SJ, 2002, HUM REPROD, V17, P1663, DOI 10.1093/humrep/17.6.1663
   Fathalla MF, 2006, LANCET, V368, P2095, DOI 10.1016/S0140-6736(06)69483-X
   FATHALLA MF, 2002, CURRENT PRACTICES CO, P3
   Filetto JN, 2005, REPROD BIOMED ONLINE, V11, P458, DOI 10.1016/S1472-6483(10)61141-8
   Frydman R, 2008, HUM REPROD, P85, DOI 10.1093/humrep/den163
   GREENHALL E, 1990, FERTIL STERIL, V54, P978
   Grimes DA, 2006, LANCET, V368, P1908, DOI 10.1016/S0140-6736(06)69481-6
   GUNBY J, 2006, FERTIL STER IN PRESS
   Hamberger L, 1997, INT J GYNECOL OBSTET, V58, P149, DOI 10.1016/S0020-7292(97)00286-5
   Hammoud AO, 2009, FERTIL STERIL, V91, P1630, DOI 10.1016/j.fertnstert.2007.10.038
   Hardy E, 1996, CONTRACEPTION, V54, P159, DOI 10.1016/S0010-7824(96)00171-0
   HARDY E, 2002, CURRENT PRACTICES CO, P60
   Jones HW, 2009, FERTIL STERIL, V91, P2295, DOI 10.1016/j.fertnstert.2008.03.006
   King RB, 2006, FERTIL STERIL, V85, P842, DOI 10.1016/j.fertnstert.2006.01.007
   Larsen U, 2005, FERTIL STERIL, V83, P846, DOI 10.1016/j.fertnstert.2004.11.033
   LUNA F, 2002, CURRENT PRACTICES CO, P31
   Lunenfeld B, 2004, HUM REPROD UPDATE, V10, P317, DOI 10.1093/humupd/dmh028
   Makuch M Y, 2000, Cad Saude Publica, V16, P249, DOI 10.1590/S0102-311X2000000100027
   Nachtigall RD, 2006, FERTIL STERIL, V85, P871, DOI 10.1016/j.fertnstert.2005.08.066
   Ombelet W, 2008, HUM REPROD UPDATE, V14, P605, DOI 10.1093/humupd/dmn042
   Ombelet W, 2007, REPROD BIOMED ONLINE, V15, P257, DOI 10.1016/S1472-6483(10)60337-9
   *REP FED BRAS, 1988, CONST
   Santos IS, 2008, CIENC SAUDE COLETIVA, V13, P1431, DOI 10.1590/S1413-81232008000500009
   *UN, 1995, INT C POP DEV CAIR E
   United Nations, 2000, MILL DEV GOALS
   United Nations (UN), 2008, WORLD CONTR US 2007, P15
   van Balen F, 2001, HUM REPROD, V16, P215, DOI 10.1093/humrep/16.2.215
   Van Balen F, 2002, INFERTILITY GLOBE NE, P79
   VAYENA E, 2002, M GEN SWITZ WHO, P383
   *WHO, 2004, UNS AB GLOB REG EST
   *WHO, 1987, FERTIL STERIL, V47, P944
   WIDGE A, 2002, CURRENT PRACTICES CO, P60
   World Health Organization, 1991, INF TAB AV DAT PREV
NR 44
TC 18
Z9 18
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD FEB
PY 2010
VL 25
IS 2
BP 430
EP 435
DI 10.1093/humrep/dep405
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 545AI
UT WOS:000273703400020
PM 19920065
OA Bronze
DA 2020-12-01
ER

PT J
AU Bernardes, ND
   Marques, A
   Ganunny, C
   Bahamondes, L
AF Bernardes, Nicole de Oliveira
   Marques, Andrea
   Ganunny, Camila
   Bahamondes, Luis
TI Use of Intravaginal Electrical Stimulation for the Treatment of Chronic
   Pelvic Pain A Randomized, Double-Blind, Crossover Clinical Trial
SO JOURNAL OF REPRODUCTIVE MEDICINE
LA English
DT Article
DE clinical trial; intravaginal electrical stimulation; pelvic pain;
   physiotherapy (techniques); placebos
ID MANAGEMENT; PREVALENCE; WOMEN
AB OBJECTIVE: To assess the efficacy of intravaginal electrical stimulation (IVES) or placebo in women with chronic pelvic pain (CPP) with no apparent cause.
   STUDY DESIGN: A double-blind, crossover, randomized clinical trial in which 26 women were randomly allocated to active (group I, n = 15) or placebo (group II, n = 11.) IVES. All women underwent 10 30-minute, twice-Weekly sessions. The groups were then crossed over for a further 10 sessions. Pain was evaluated using a visual analog scale WAS) before and after each series.
   RESULTS: At the end of the first series, 5 of 11 women who initiated with the placebo had a VAS pain score >3 (p = 0.0253); however, when they crossed over to active IVES, only I had a VAS pain score >3 at the end of the series (p = 0.0143). In the 15 women who initiated with active IVES, 2 had a score >3 at the end of the series (P = 0.0005); however, when they crossed over to the placebo, 3 had a VAS pain score >3 at the end of treatment (p = 0.0833). After the 2 sessions, 54.6% who initiated With placebo and 80% who initiated with active IVES had a VAS pain score <3.
   CONCLUSION: Intravaginal electrical stimulation was more effective than a placebo in alleviating pain in women with CPP. (J Reprod Med 2010;55:19-24)
C1 Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   Natl Inst Hormones & Womens Hlth, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Sao Paulo State FoundationFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [03/08391-7]; Conselho Nacional de Pesquisa
   [573747/2008-3]
FX Supported in part by the Sao Paulo State Foundation for the Support of
   Research, award #03/08391-7, and Conselho Nacional de Pesquisa, award
   #573747/2008-3.
CR *ACOG COMM PRACT B, 2004, OBSTET GYNECOL, V103, P589
   Adamson GD, 2006, J MINIM INVAS GYN, V13, P578, DOI 10.1016/j.jmig.2006.08.015
   Bernardes NDO, 2005, J REPROD MED, V50, P267
   Butrick CW, 2007, CLIN OBSTET GYNECOL, V50, P412, DOI 10.1097/GRF.0b013e31804b195f
   Collett BJ, 2001, PAIN REV, V8, P95, DOI 10.1191/0968130201pr177ra
   Duffy S, 2001, INT J GYNECOL OBSTET, V74, pS3, DOI 10.1016/S0020-7292(01)00458-1
   Duleba A J, 1996, J Am Assoc Gynecol Laparosc, V3, P205, DOI 10.1016/S1074-3804(96)80004-1
   Everaert K, 2001, INT UROGYNECOL J PEL, V12, P9, DOI 10.1007/s001920170087
   FITZWATER JB, 2006, J MINIM INVAS GYN, V13, P578
   FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2
   Gelbaya TA, 2001, OBSTET GYNECOL SURV, V56, P757, DOI 10.1097/00006254-200112000-00002
   Gomel V, 2007, J MINIM INVAS GYN, V14, P521, DOI 10.1016/j.jmig.2007.01.004
   Grace Victoria, 2006, Health Care Women Int, V27, P585, DOI 10.1080/07399330600803725
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Howard F M, 1993, Obstet Gynecol Surv, V48, P357, DOI 10.1097/00006254-199306000-00001
   Howard FM, 2003, OBSTET GYNECOL, V101, P594, DOI 10.1016/S0029-7844(02)02723-0
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   *INT ASS STUD PAIN, 2008, CLIN UPDATES PAIN, V16, P1
   *INT PELV PAIN SOC, CHRON PELV PAIN PAT
   Jones B, 2003, DESIGN ANAL CROSS OV
   KAMES LD, 1990, PAIN, V41, P41, DOI 10.1016/0304-3959(90)91107-T
   Kaplan B., 1997, Clinical and Experimental Obstetrics and Gynecology, V24, P123
   KEEFE FJ, 1991, ADULT SPINE PRINCIPL, P185
   Khadilkar A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003008.pub3
   Lamvu G, 2006, AM J OBSTET GYNECOL, V195, P591, DOI 10.1016/j.ajog.2006.03.081
   Leserman J, 2006, AM J OBSTET GYNECOL, V195, P554, DOI 10.1016/j.ajog.2006.03.071
   Mathias SD, 1996, OBSTET GYNECOL, V87, P321, DOI 10.1016/0029-7844(95)00458-0
   Meadows E, 1999, Urol Nurs, V19, P33
   Nappi RE, 2003, J SEX MARITAL THER, V29, P103, DOI 10.1080/713847129
   Nnoaham KE, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003222.pub2
   Oosterhof Jan, 2006, J Headache Pain, V7, P196, DOI 10.1007/s10194-006-0309-z
   Pearce Chris, 2007, Br J Nurs, V16, P82
   PETERS AAW, 1991, OBSTET GYNECOL, V77, P740
   Petros PP, 2001, EUR J OBSTET GYN R B, V94, P264, DOI 10.1016/S0301-2115(00)00313-4
   POCOCK SJ, 1987, CLIN TRIALS PRACTICA
   PRICE DD, 1980, PAIN, V8, P137, DOI 10.1016/0304-3959(88)90001-2
   Reiter RC, 1998, CLIN OBSTET GYNECOL, V41, P422, DOI 10.1097/00003081-199806000-00023
   Selkowitz D, 1999, PHYS AGENTS REHABILI, P345
   STEEGE JF, 1998, CHRONIC PELVIC PAIN
   Stones W, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000387, DOI 10.1002/14651858.CD000387]
   SWANTON A, 2004, REV GYNAECOL PRACT, V4, P65
   Vincent K, 2009, POSTGRAD MED J, V85, P24, DOI 10.1136/pgmj.2008.073494
   Weijenborg PTM, 2007, PAIN, V132, pS117, DOI 10.1016/j.pain.2007.06.020
   Zondervan KT, 2001, BRIT J GEN PRACT, V51, P541
NR 44
TC 7
Z9 8
U1 0
U2 1
PU SCI PRINTERS & PUBL INC
PI ST LOUIS
PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA
SN 0024-7758
EI 1943-3565
J9 J REPROD MED
JI J. Reprod. Med.
PD JAN-FEB
PY 2010
VL 55
IS 1-2
BP 19
EP 24
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 569BS
UT WOS:000275571500004
PM 20337203
DA 2020-12-01
ER

PT J
AU Loreti, N
   Ambao, V
   Juliato, CT
   Machado, C
   Bahamondes, L
   Campo, S
AF Loreti, Nazareth
   Ambao, Veronica
   Juliato, Cassia Teatin
   Machado, Cecilia
   Bahamondes, Luis
   Campo, Stella
TI Carbohydrate complexity and proportion of serum FSH isoforms reflect
   pituitary-ovarian activity in perimenopausal women and depot
   medroxyprogesterone acetate users
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID FOLLICLE-STIMULATING-HORMONE; GONADOTROPIN-RELEASING-HORMONE; LONG-TERM
   USE; LONGITUDINAL ASSESSMENT; LACTATIONAL AMENORRHEA;
   LUTEINIZING-HORMONE; SEX; SECRETION; STEROIDS; ISOHORMONES
AB P>Background
   FSH is synthesized and secreted in multiple glycosylation variants with different oligosaccharide structures; the endocrine milieu regulates the composition of FSH carbohydrate moiety.
   Objectives
   To characterize serum FSH isoforms according to their sialic acid content and oligosaccharide complexity in regularly menstruating women and in depot medroxyprogesterone acetate (DMPA) users during the menopausal transition.
   Subjects and methods
   Ten regularly menstruating perimenopausal women aged 45-52, with mid-follicular phase FSH levels < 10 IU/l and 10 regularly menstruating women, aged 20-39, were included. Blood samples were collected on the ninth day of the menstrual cycle. Twenty DMPA users were divided into two groups (n = 10) according to age: DMPA(1), age range 20-39 and DMPA(2), age range 45-52. Blood samples were collected 90 +/- 5 days after the last injection of DMPA. Oestradiol (E-2), inhibin B (Inh B), Pro-alpha C levels and the relative abundance of FSH isoforms on the basis of charge (preparative isoelectric focusing) and carbohydrate complexity (Concanavalin A chromatography) were determined.
   Results
   Decreased Inh B and moderately elevated E-2 levels were observed in perimenopausal women associated with an increase in FSH sialylation and a decrease in its oligosaccharide complexity. DMPA induced changes in the hormonal profile and FSH molecular microheterogeneity; the secreted hormone was more heterogeneous and its oligosaccharides were less complex under this condition.
   Conclusion
   Serum FSH glycoforms with increased sialylation and decreased oligosaccharide complexity reflect the decline of the gonadal activity induced either by age or by the use of a DMPA as a contraceptive.
C1 [Loreti, Nazareth; Ambao, Veronica; Machado, Cecilia; Campo, Stella] Hosp Ninos Dr Ricardo Gutierrez, CONICET, Ctr Invest Endocrinol, Buenos Aires, DF, Argentina.
   [Juliato, Cassia Teatin; Bahamondes, Luis] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
RP Campo, S (corresponding author), Hosp Gen Ninos Ricardo Gutierrez, Ctr Invest Endocrinol, Gallo 1330,C1425EFD, Buenos Aires, DF, Argentina.
EM scampo@cedie.org.ar
RI Saude da mulher, Inct/J-9403-2013; Juliato, Cassia R T/D-4447-2012
OI Juliato, Cassia R T/0000-0003-3197-1195
FU The Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [03/08391-7]; Consejo Nacional de Investigaciones Cientificas y
   TecnicasConsejo Nacional de Investigaciones Cientificas y Tecnicas
   (CONICET); CONICET, ArgentinaConsejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
FX The authors are very grateful to the volunteers who participated in the
   study. This study received partial financial support from The Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), award #
   03/08391-7, Brazil and Consejo Nacional de Investigaciones Cientificas y
   Tecnicas, CONICET, Argentina. S. Campo is an established investigator
   from CONICET.
CR Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Bedecarras P, 1998, CLIN ENDOCRINOL, V49, P603
   Bousfield GR, 2007, MOL CELL ENDOCRINOL, V260, P40, DOI 10.1016/j.mce.2006.02.017
   Burger HG, 2005, MENOPAUSE, V12, P267, DOI 10.1097/01.GME.0000147172.21183.86
   CHENG CY, 1984, ENDOCRINOLOGY, V114, P1395, DOI 10.1210/endo-114-4-1395
   Creus S, 1996, CLIN ENDOCRINOL, V44, P181, DOI 10.1046/j.1365-2265.1996.646467.x
   DAHL KD, 1986, J CLIN ENDOCR METAB, V63, P792
   Damian-Matsumura P, 1999, J MOL ENDOCRINOL, V23, P153, DOI 10.1677/jme.0.0230153
   de Vet A, 2002, FERTIL STERIL, V77, P357, DOI 10.1016/S0015-0282(01)02993-4
   DICLEMENTE N, 1994, ENDOCRINE, V2, P553
   ESCOBAR ME, 1976, ACTA ENDOCRINOL-COP, V81, P351, DOI 10.1530/acta.0.0810351
   Fraser IS, 1981, MED J AUST         S, V1, P1
   GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114
   GROOME NP, 1995, J CLIN ENDOCR METAB, V80, P2926, DOI 10.1210/jc.80.10.2926
   Groome NP, 1996, J CLIN ENDOCR METAB, V81, P1401, DOI 10.1210/jc.81.4.1401
   Hall JE, 2007, SEMIN REPROD MED, V25, P344, DOI 10.1055/s-2007-984740
   JEPPSSON S, 1982, ACTA ENDOCRINOL-COP, V99, P339, DOI 10.1530/acta.0.0990339
   Juliato CT, 2007, CONTRACEPTION, V76, P282, DOI 10.1016/j.contraception.2007.06.005
   KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215
   NARASIMHAN S, 1979, CAN J BIOCHEM CELL B, V57, P83, DOI 10.1139/o79-011
   PADMANABHAN V, 1988, J CLIN ENDOCR METAB, V67, P465, DOI 10.1210/jcem-67-3-465
   Park SJ, 2002, EXP BIOL MED, V227, P455
   PHILLIPS DJ, 1994, J CLIN ENDOCR METAB, V79, P814, DOI 10.1210/jc.79.3.814
   Prior JC, 2005, ENDOCRINE, V26, P297, DOI 10.1385/ENDO:26:3:297
   RICHARDSON SJ, 1987, J CLIN ENDOCR METAB, V65, P1231, DOI 10.1210/jcem-65-6-1231
   Ulloa-Aguirre A, 1999, ENDOCRINE, V11, P205, DOI 10.1385/ENDO:11:3:205
   ULLOAAGUIRRE A, 1995, ENDOCR REV, V16, P765, DOI 10.1210/er.16.6.765
   ULLOAAGUIRRE A, 1984, BIOL REPROD, V30, P382, DOI 10.1095/biolreprod30.2.382
   ULLOAAGUIRRE A, 1992, J ENDOCRINOL, V134, P97, DOI 10.1677/joe.0.1340097
   ULLOAGUIRRE A, 1992, HUM REPROD, V7, P23, DOI 10.1093/oxfordjournals.humrep.a137550
   van Disseldorp J, 2008, J CLIN ENDOCR METAB, V93, P2129, DOI 10.1210/jc.2007-2093
   Velasquez EV, 2006, HUM REPROD, V21, P916, DOI 10.1093/humrep/dei411
   Velasquez EV, 2006, HUM REPROD, V21, P909, DOI 10.1093/humrep/dei410
   Walton WJ, 2001, J CLIN ENDOCR METAB, V86, P3675, DOI 10.1210/jc.86.8.3675
   Welt CK, 2006, HUM REPROD, V21, P2189, DOI 10.1093/humrep/del136
   Welt CK, 1999, J CLIN ENDOCR METAB, V84, P105, DOI 10.1210/jc.84.1.105
   WIDE L, 1986, ACTA ENDOCRINOL-COP, V112, P336, DOI 10.1530/acta.0.1120336
   WIDE L, 1984, J CLIN ENDOCR METAB, V58, P426, DOI 10.1210/jcem-58-3-426
   WIDE L, 1990, J CLIN ENDOCR METAB, V70, P271, DOI 10.1210/jcem-70-1-271
   WIDE L, 1989, J ENDOCRINOL, V123, P519, DOI 10.1677/joe.0.1230519
   WIDE L, 1994, CLIN ENDOCRINOL, V40, P783, DOI 10.1111/j.1365-2265.1994.tb02513.x
   Wise PM, 1999, ENDOCR REV, V20, P243, DOI 10.1210/er.20.3.243
   Wise PM, 1999, AM J PHYSIOL-ENDOC M, V277, pE965
   ZAMBRANO E, 1995, J CLIN ENDOCR METAB, V80, P1647, DOI 10.1210/jc.80.5.1647
NR 44
TC 9
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-0664
EI 1365-2265
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD OCT
PY 2009
VL 71
IS 4
BP 558
EP 565
DI 10.1111/j.1365-2265.2009.03559.x
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 492RJ
UT WOS:000269676600016
PM 19250269
DA 2020-12-01
ER

PT J
AU Hidalgo, MM
   Hidalgo-Regina, C
   Bahamondes, MV
   Monteiro, I
   Petta, CA
   Bahamondes, L
AF Hidalgo, Maria M.
   Hidalgo-Regina, Creusa
   Bahamondes, M. Valeria
   Monteiro, Ilza
   Petta, Carlos A.
   Bahamondes, Luis
TI Serum levonorgestrel levels and endometrial thickness during extended
   use of the levonorgestrel-releasing intrauterine system
SO CONTRACEPTION
LA English
DT Article
DE Levonorgestrel-releasing intrauterine system; Mirena (R);
   Levonorgestrel; Contraception
ID PLASMA-CONCENTRATIONS; BLEEDING PATTERNS; FOLLOW-UP; WOMEN; THERAPY;
   HYPERPLASIA; PERFORMANCE; MENORRHAGIA; MIRENA(R); ESTROGEN
AB Background: The levonorgestrel-releasing intrauterine system (LNG-FUS) is a contraceptive method approved for five years of use. However, there is some evidence that its life span may be longer. The aim of the study was to evaluate serum levonorgestrel (LNG) and estradiol (E-2) levels and endometrial thickness every 6 months from 7 to 8 1/2 years after insertion.
   Study Design: At the end of the approved 5-year life span, no replacement devices were available; therefore, 86 women were allowed to retain the same device for a further 2 years. At the 7-year follow-up visit, the women who consented were again allowed to retain the same device for a further 18 months and were followed-up at six-monthly intervals. At each visit, vaginal sonography was performed to measure endometrial thickness, and a blood sample was taken to measure LNG and E-2.
   Results: Eighty-four months after insertion, 67 women aged 34.3 +/- 0.8 years (mean+SEM) (range, 25-49 years) returned for follow-up. Mean +/- SEM LNG levels decreased from an initial 253 +/- 27 pg/mL (range, 86-760) during the first 2 months following insertion to 137 +/- 12 (range, 23-393) at 84 months and 119 +/- 9 pg/mL (range, 110-129) at 102 months of use (+/- SEM). At 84 months of use, mean +/- SEM endometrial thickness was 2.8 +/- 0.1 mm, increasing to 3.8 +/- 0.5 mm at 102 months of use. The incidence of amenorrhea decreased from 41.8% at 84 months to 31.5% at 102 months of use. No correlation was found between LNG levels and bleeding patterns; however, a weak correlation was found between high body mass index (kg/m(2)), high weight, and low serum LNG levels. E, levels were similar to those of the follicular phase of the menstrual cycle of regularly menstruating women.
   Conclusions: During extended use of the LNG-IUS, serum LNG levels were nearly half those found in the first 2 months of use (Wilcoxon signed rank test); serum E, levels were normal. Despite the very thin endometrium, menstrual bleeding was reinstated in many cases. At the end of its 5-year life span, there is a window for changing the LNG-IUS, and physicians and users should not be concerned about delaying replacement of the device for a short time beyond the approved life span; however, maintaining the same device long after its approved life span cannot be recommended. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Hidalgo, Maria M.; Hidalgo-Regina, Creusa; Bahamondes, M. Valeria; Monteiro, Ilza; Petta, Carlos A.; Bahamondes, Luis] Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014; Saude da mulher, Inct/J-9403-2013
OI monteiro, ilza m u/0000-0002-9536-0564; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/083917]
FX The authors would like to acknowledge the contribution of Dr. Rafael
   Barrientos Astigarra of MAGABI Pesquisa Clinica Farmaceutica, Sao Paulo,
   Brazil, for performing the LNG measurements and of the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo, Brazil, for providing partial
   financial support under Award #03/083917.
CR [Anonymous], 2004, MED EL CRIT CONTR US
   Bahamondes L, 2003, ACTA OBSTET GYN SCAN, V82, P580
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   DIAZ J, 1982, CONTRACEPTION, V26, P221, DOI 10.1016/0010-7824(82)90071-3
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   FAUNDES A, 1993, ANN MED, V25, P149, DOI 10.3109/07853899309164159
   Hampton NRE, 2005, HUM REPROD, V20, P2653, DOI 10.1093/humrep/dei085
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   JIA M C, 1992, Advances in Contraception, V8, P33, DOI 10.1007/BF01849346
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248
   Monteiro I, 2002, CONTRACEPTION, V65, P325, DOI 10.1016/S0010-7824(02)00283-4
   NILSSON CG, 1984, FERTIL STERIL, V41, P52
   NILSSON CG, 1980, ACTA ENDOCRINOL-COP, V93, P380, DOI 10.1530/acta.0.0930380
   NILSSON CG, 1978, CONTRACEPTION, V17, P569, DOI 10.1016/S0010-7824(78)80009-2
   NILSSON CG, 1980, CONTRACEPTION, V21, P225, DOI 10.1016/0010-7824(80)90003-7
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Raudaskoski T, 2002, BJOG-INT J OBSTET GY, V109, P136, DOI 10.1016/S1470-0328(02)01167-9
   RODRIGUEZ G, 1976, STUD FAMILY PLANN, V7, P42, DOI 10.2307/1964872
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   Theron HB, 2004, J CHROMATOGR B, V813, P331, DOI 10.1016/j.jchromb.2004.10.039
   Vereide AB, 2003, GYNECOL ONCOL, V91, P526, DOI 10.1016/j.ygyno.2003.07.002
NR 25
TC 45
Z9 46
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUL
PY 2009
VL 80
IS 1
BP 84
EP 89
DI 10.1016/j.contraception.2009.01.004
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 460JZ
UT WOS:000267185300014
PM 19501221
DA 2020-12-01
ER

PT J
AU Sanches, L
   Marchi, NM
   Castro, S
   Juliato, CT
   Villarroel, M
   Bahamondes, L
AF Sanches, Luciana
   Marchi, Nadia M.
   Castro, Sara
   Juliato, Cassia Teatin
   Villarroel, Marina
   Bahamondes, Luis
TI Forearm bone mineral density in postmenopausal former users of depot
   medroxyprogesterone acetate (vol 78, pg 365, 2008)
SO CONTRACEPTION
LA English
DT Correction
C1 [Sanches, Luciana; Marchi, Nadia M.; Castro, Sara; Juliato, Cassia Teatin; Villarroel, Marina; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynecol, Human Reprod Unit, Sch Med Sci, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Dept Obstet & Gynecol, Human Reprod Unit, Sch Med Sci, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Juliato, Cassia R T/D-4447-2012
OI Juliato, Cassia R T/0000-0003-3197-1195
CR Sanches L, 2008, CONTRACEPTION, V78, P365, DOI 10.1016/j.contraception.2008.07.013
NR 1
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD FEB
PY 2009
VL 79
IS 2
BP 159
EP 160
DI 10.1016/j.contraception.2008.11.007
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 397UN
UT WOS:000262687700016
DA 2020-12-01
ER

PT J
AU Sanches, L
   Marchi, NM
   Castro, S
   Juliato, CT
   Villarroel, M
   Bahamondes, L
AF Sanches, Luciana
   Marchi, Nadia M.
   Castro, Sara
   Juliato, Cassia Teatin
   Villarroel, Marina
   Bahamondes, Luis
TI Forearm bone mineral density in postmenopausal former users of depot
   medroxyprogesterone acetate
SO CONTRACEPTION
LA English
DT Article
DE Bone mineral density; Depot-medroxyprogesterone acetate; Menopause
ID LONG-TERM USERS; BLACK-BOX; CONTRACEPTION; RECOVERY; WOMEN;
   DEPO-PROVERA(R); INJECTION; HEALTH
AB Background: The aim of the study was to compare the bone mineral density (BMD) of postmenopausal women who had used depot-medroxyprogesterone acetate (DMPA) or a copper intrauterine device (IUD) as a comparison group until menopause.
   Study Design: BMD was measured using dual-energy X-ray absorptiometry at the nondominant forearm for up to 3 years following menopause in 135 women aged 43-58 years: 36 former DMPA users and 99 former IUD users.
   Results: Mean duration of use was (mean +/- SEM) 9.4 +/- 3.8 and 14.7 +/- 6.2 years for the DMPA and IUD groups, respectively. One year after menopause, mean distal radius BMD was 0.435 and 0.449 in DMPA and IUD users, respectively, and 0.426 and 0.447 at 2-3 years following menopause. Ultra-distal BMD was 0.369 and 0.384 in DMPA and IUD users, respectively, at 1 year, and 0.340 and 0.383 at 2-3 years.
   Conclusions: At 1 and 2-3 years following menopause, no significant differences were observed in the BMD of postmenopausal women aged 43-58 years, who had used DMPA or an IUD until menopause. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Sanches, Luciana; Marchi, Nadia M.; Castro, Sara; Juliato, Cassia Teatin; Villarroel, Marina; Bahamondes, Luis] Univ Estadual Campinas, Sch Med Sci, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med Sci, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/08391-7]
FX This study received partial financial support from the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) Grant No. 03/08391-7.
CR Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Clark MK, 2006, FERTIL STERIL, V86, P1466, DOI 10.1016/j.fertnstert.2006.05.024
   Cromer BA, 2005, AM J OBSTET GYNECOL, V192, P42, DOI 10.1016/j.ajog.2004.07.041
   Cromer BA, 2006, J ADOLESCENT HEALTH, V39, P296, DOI 10.1016/j.jadohealth.2006.03.011
   CUNDY T, 1994, BRIT MED J, V308, P247, DOI 10.1136/bmj.308.6923.247
   Cundy T, 2002, AM J OBSTET GYNECOL, V186, P978, DOI 10.1067/mob.2002.122420
   Curtis KM, 2006, CONTRACEPTION, V73, P470, DOI 10.1016/j.contraception.2005.12.010
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   Fraser I S, 1981, Med J Aust, V1, P3
   Gbolade BA, 2002, J FAM PLAN REPROD H, V28, P7
   Juliato CT, 2007, CONTRACEPTION, V76, P282, DOI 10.1016/j.contraception.2007.06.005
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   Kaunitz AM, 2005, CONTRACEPTION, V72, P165, DOI 10.1016/j.contraception.2005.05.011
   Kaunitz AM, 2008, CONTRACEPTION, V77, P67, DOI 10.1016/j.contraception.2007.10.005
   Kaunitz AM, 2006, CONTRACEPTION, V74, P90, DOI 10.1016/j.contraception.2006.03.010
   MARTIN A, 2003, J CLIN DENSITOM, V2, P381
   Merki-Feld GS, 2000, BRIT J OBSTET GYNAEC, V107, P863, DOI 10.1111/j.1471-0528.2000.tb11084.x
   Orr-Walker BJ, 1998, CLIN ENDOCRINOL, V49, P615, DOI 10.1046/j.1365-2265.1998.00582.x
   ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32
   Scholes D, 2002, EPIDEMIOLOGY, V13, P581, DOI 10.1097/00001648-200209000-00015
   *US FDA, 2004, BLACK BOX WARN ADD C
   Westhoff C, 2003, CONTRACEPTION, V68, P75, DOI 10.1016/S0010-7824(03)00136-7
   Wong PKK, 2007, CLIN SCI, V113, P233, DOI 10.1042/CS20060173
NR 23
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD NOV
PY 2008
VL 78
IS 5
BP 365
EP 369
DI 10.1016/j.contraception.2008.07.013
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 364GM
UT WOS:000260324200004
PM 18929732
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Diaz, J
   Marchi, NM
   Castro, S
   Villarroel, M
   Macaluso, M
AF Bahamondes, Luis
   Diaz, Juan
   Marchi, Nadia Maria
   Castro, Sara
   Villarroel, Marina
   Macaluso, Maurizio
TI Prostate-specific antigen in vaginal fluid after exposure to known
   amounts of semen and after condom use: comparison of self-collected and
   nurse-collected samples
SO HUMAN REPRODUCTION
LA English
DT Article
DE condoms; semen exposure; PSA; women
ID SEXUALLY-TRANSMITTED-DISEASE; FEMALE CONDOM; CONTRACEPTIVE EFFICACY;
   HUMAN-PAPILLOMAVIRUS; CLINICAL-TRIALS; TRANSMISSION; INTERCOURSE;
   PREVENTION; CHLAMYDIA; INFECTION
AB BACKGROUND: Prostate-specific antigen (PSA) in vaginal fluid indicates exposure to semen, and was used to assess condom effectiveness, although validity and reliability have not been fully evaluated. Our objective was to compare PSA in self-collected samples with samples collected by a nurse. METHODS: We conducted two studies, each with 100 women aged 18-48 years. In the first, a nurse exposed each participant to her partner's semen (10, 100 and 1000 mu l), and nurse and participant collected samples. In the second, each participant sampled before and after using two male condoms (MC) and two female condoms (FC); a nurse collected another sample afterwards. RESULTS: PSA concentration increased with semen exposure, but was lower in nurse-collected samples. Both procedures were sensitive, almost 100% after exposure to 100-1000 mu l of semen. PSA detection rates with MC and FC were 13% and 28% in self-collected samples, 8% and 9% in nurse-collected samples. Concordance between sample types was 93% with the MC (95% CI: 89%; 96%), 78% with the FC (95% CI: 72%; 84%). PSA decay between sampling times may explain higher values in self-collected samples. CONCLUSIONS: PSA is a highly sensitive surrogate endpoint for condom effectiveness studies. Self-collected and nurse-collected samples are equivalent, but sample collection timing is critical.
C1 [Bahamondes, Luis; Marchi, Nadia Maria; Castro, Sara; Villarroel, Marina] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   [Diaz, Juan] Populat Council, New York, NY 10017 USA.
   [Macaluso, Maurizio] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Macaluso, Maurizio/J-2076-2015
OI Macaluso, Maurizio/0000-0002-2977-9690
FU The Population Council, New York [AI06.40C-17/A]
FX This study received financial support from The Population Council, New
   York under award # AI06.40C-17/A.
CR ARMBRUSTER D, 1993, CLIN CHEM, V38, P181
   Arya A, 2008, EUR J OBSTET GYN R B, V139, P43, DOI 10.1016/j.ejogrb.2007.12.005
   Chen MP, 2007, SEX TRANSM DIS, V34, P557, DOI 10.1097/01.olq.0000258487.38309.b9
   Davis KR, 1999, FAM PLANN PERSPECT, V31, P272, DOI 10.2307/2991537
   FARR G, 1994, AM J PUBLIC HEALTH, V84, P1960, DOI 10.2105/AJPH.84.12.1960
   Feldblum PJ, 2001, AIDS, V15, P1037, DOI 10.1097/00002030-200105250-00012
   Fontanet AL, 1998, AIDS, V12, P1851, DOI 10.1097/00002030-199814000-00017
   French PP, 2003, SEX TRANSM DIS, V30, P433, DOI 10.1097/00007435-200305000-00010
   Galvao LW, 2005, CONTRACEPTION, V71, P130, DOI 10.1016/j.contraception.2004.08.008
   GRAVES HCB, 1985, NEW ENGL J MED, V312, P338, DOI 10.1056/NEJM198502073120603
   Holmes KK, 2004, B WORLD HEALTH ORGAN, V82, P454
   Jones HE, 2007, J CLIN MICROBIOL, V45, P1679, DOI 10.1128/JCM.02369-06
   Karwalajtys T, 2006, SEX TRANSM INFECT, V82, P337, DOI 10.1136/sti.2005.019430
   Lawson ML, 1998, SEX TRANSM DIS, V25, P427, DOI 10.1097/00007435-199809000-00009
   Macaluso M, 2003, AM J EPIDEMIOL, V157, P289, DOI 10.1093/aje/kwf212
   Macaluso M, 1999, CONTRACEPTION, V59, P195, DOI 10.1016/S0010-7824(99)00013-X
   Macaluso M, 2007, AM J EPIDEMIOL, V166, P88, DOI 10.1093/aje/kwm046
   Mauck CK, 2007, CONTRACEPTION, V75, P407, DOI 10.1016/j.contraception.2007.02.007
   *NAT I ALL INF DIS, 2001, WORKSH SUMM SCI EV C
   Pinkerton SD, 1997, SOC SCI MED, V44, P1303, DOI 10.1016/S0277-9536(96)00258-4
   Price D, 2006, J OBSTET GYNAECOL CA, V28, P1083, DOI 10.1016/S1701-2163(16)32337-4
   ROY S, 1994, BARRIER CONTRACEPTIV, P77
   Safaeian M, 2007, SEX TRANSM DIS, V34, P429, DOI 10.1097/01.olq.0000243623.67673.22
   Schachter J, 2003, J CLIN MICROBIOL, V41, P3784, DOI 10.1128/JCM.41.8.3784-3789.2003
   SOPER DE, 1993, SEX TRANSM DIS, V20, P137, DOI 10.1097/00007435-199305000-00003
   STEINER M, 2003, AM J EPIDEMIOL, V157, P300
   Trussell J, 1998, CONTRACEPTION, V58, P147, DOI 10.1016/S0010-7824(98)00094-8
   Walsh TL, 2003, CONTRACEPTION, V67, P139, DOI 10.1016/S0010-7824(02)00478-X
   Walsh TL, 1999, CONTRACEPTION, V60, P289, DOI 10.1016/S0010-7824(99)00098-0
   Warner L, 2006, SEX TRANSM DIS, V33, P36, DOI 10.1097/01.olq.0000187908.42622.fd
   Warner L, 2005, AM J EPIDEMIOL, V161, P765, DOI 10.1093/aje/kwi094
   Warner L, 2004, AM J EPIDEMIOL, V159, P242, DOI 10.1093/aje/kwh044
   WARNER L, 2004, CONTRACEPTIVE TECHNO, P331
   ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003
NR 34
TC 18
Z9 18
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD NOV
PY 2008
VL 23
IS 11
BP 2444
EP 2451
DI 10.1093/humrep/den283
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 361QT
UT WOS:000260142900007
PM 18664473
OA Bronze
DA 2020-12-01
ER

PT J
AU Nanda, K
   Amaral, E
   Hays, M
   Viscola, MAM
   Mehta, N
   Bahamondes, L
AF Nanda, Kavita
   Amaral, Eliana
   Hays, Melissa
   Viscola, Marco A. M.
   Mehta, Neha
   Bahamondes, Luis
TI Pharmacokinetic interactions between depot medroxyprogesterone acetate
   and combination antiretroviral therapy
SO FERTILITY AND STERILITY
LA English
DT Article
DE depot medroxyprogesterone acetate; contraception; HIV; antiretroviral
   therapy; pharmacokinetics
ID HIV-INFECTED WOMEN; METABOLISM; AMINOGLUTETHIMIDE; RADIOIMMUNOASSAY;
   CONTRACEPTION; CANCER
AB Objective: To evaluate the effect of an antiretroviral (ARV) therapy regimen containing zidovudine (AZT), lamivudine (3TC), and efavirenz (EFV) on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA).
   Design: Open-label, nonrandomized, clinical trial.
   Setting: University hospital clinic.
   Patient(s): Thirty HIV-infected women; 15 using ARV therapy (AZT, 3TC, and EFV) and 15 non-users of ARV therapy, followed biweekly for 12 weeks.
   Intervention(s): Single injection of DMPA (150 mg IM) for both groups.
   Main Outcome Measure(s): Pharmacokinetic parameters of DMPA by liquid chromatography with mass spectrometry, and ovulation by serum P.
   Result(s): Maximum serum concentrations of DMPA were reached at 14 days after injection. The area under the curve was similar in both groups, as were the minimum concentration, half-life, and clearance. Only I woman, not using ARV therapy, ovulated at 11 weeks after DMPA.
   Conclusion(s): Pharmacokinetics of DMPA were similar in HIV-infected women, regardless of ARV therapy use, suggesting that triple therapy with AZT, 3TC, and EFV is not likely to interfere with the contraceptive effectiveness of DMPA.
C1 [Nanda, Kavita; Hays, Melissa; Mehta, Neha] Family Hlth Int, Res Triangle Pk, NC 27709 USA.
   [Amaral, Eliana; Viscola, Marco A. M.; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynecol, Sch Med, Campinas, SP, Brazil.
RP Nanda, K (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.
EM knanda@fhi.org
OI Amaral, Esbelta Teresa/0000-0001-8781-491X; Nanda,
   Kavita/0000-0001-7650-2929
FU United States Agency for International Development (USAID)United States
   Agency for International Development (USAID) [AID/CCP-3079-A-00-5022-00,
   GPO-A-OO-05-00022-00]; Contraceptive and Reproductive Health
   Technologies Research and Utilization; University of North Carolina at
   Chapel Hill Center for AIDS Research [P30 A150410]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410, P30AI050410, P30AI050410, P30AI050410,
   P30AI050410, P30AI050410] Funding Source: NIH RePORTER
FX Support for this work was provided by funds from the United States
   Agency for International Development (USAID) (cooperative agreements
   nos. AID/CCP-3079-A-00-5022-00 and GPO-A-OO-05-00022-00), the
   Contraceptive and Reproductive Health Technologies Research and
   Utilization Program, and the University of North Carolina at Chapel Hill
   Center for AIDS Research (a National Institutes of Health-funded
   program; P30 A150410). The views expressed in this document, however, do
   not necessarily reflect those of USAID.
CR *BRAS MIN SAUD, 2006, REC TER ANT AD AD IN
   Chu JH, 2005, AM J EPIDEMIOL, V161, P881, DOI 10.1093/aje/kwi116
   Cohn SE, 2007, CLIN PHARMACOL THER, V81, P222, DOI 10.1038/sj.clpt.6100040
   Danel C, 2006, JAIDS-J ACQ IMM DEF, V42, P29, DOI 10.1097/01.qai.0000219777.04927.50
   de Souza A, 2004, J FAM PLAN REPROD H, V30, P190, DOI 10.1783/1471189041261393
   Fraser I S, 1981, Med J Aust, V1, P3
   Gilead Sciences, TEN PRESCR INF
   GUPTA C, 1979, J CLIN ENDOCR METAB, V48, P816, DOI 10.1210/jcem-48-5-816
   HALPENNY O, 1990, MED ONCOL TUMOR PHAR, V7, P241
   KARKKAINEN J, 1990, EUR J CANCER, V26, P975, DOI 10.1016/0277-5379(90)90624-3
   Kobayashi K, 2000, CLIN CANCER RES, V6, P3297
   LUNDGREN S, 1990, CANCER CHEMOTH PHARM, V27, P101, DOI 10.1007/BF00689091
   Mildvan D, 2002, J ACQ IMMUN DEF SYND, V29, P471, DOI 10.1097/00126334-200204150-00007
   ORTIZ A, 1977, J CLIN ENDOCR METAB, V44, P32, DOI 10.1210/jcem-44-1-32
   Ouellet D, 1998, BRIT J CLIN PHARMACO, V46, P111, DOI 10.1046/j.1365-2125.1998.00749.x
   *PHARM LTD, DEPOPROVERA 15 MG ML
   Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1
   Rossi AD, 2005, CONTRACEPTION, V71, P45, DOI 10.1016/j.contraception.2004.07.001
   *SCOTT INT GUID NE, 70 SCOTT INT GUID NE
   SHRIMANKER K, 1978, J STEROID BIOCHEM, V9, P359, DOI 10.1016/0022-4731(78)90631-3
   United States Department of Health and Human Services, GUID US ANT AG HIV 1
   US Food and Drug Administration, GUID IND BIOAV BIOEQ
   World Health Organization, 2002, SCAL ANT THER RES LT
NR 23
TC 37
Z9 39
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD OCT
PY 2008
VL 90
IS 4
BP 965
EP 971
DI 10.1016/j.fertnstert.2007.07.1348
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 358UQ
UT WOS:000259943400006
PM 17880953
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Bahamondes, MV
   Monteiro, I
AF Bahamondes, Luis
   Bahamondes, M. Valeria
   Monteiro, Ilza
TI Levonorgestrel-releasing intrauterine system: uses and controversies
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Editorial Material
DE levonorgestrel-releasing intrauterine system; LNG-IUS
ID THERMAL BALLOON ABLATION; MENSTRUAL BLOOD-LOSS; LONG-TERM USERS;
   ADMINISTERED PROGESTOGEN LEVONORGESTREL; RANDOMIZED COMPARATIVE TRIAL;
   HORMONE REPLACEMENT THERAPY; LNG-IUS; SYMPTOMATIC ENDOMETRIOSIS;
   IDIOPATHIC MENORRHAGIA; POSTMENOPAUSAL WOMEN
AB This article provides a perspective on the use of the levonorgestrel-releasing intrauterine system as a contraceptive method and as therapy in different situations, as well as presenting the corresponding controversies and unresolved issues. All studies have reported high contraceptive efficacy, an improvement in menstrual blood loss in women with idiopathic menorrhagia, menorrhagia due to thrombophilic diseases and fibroids, and excellent endometrial protection during postmenopausal estrogen therapy. Moreover, the device is able to reduce pelvic pain and clysmenorrhea as well as improve the staging of enclometriosis and adenomyosis, and to control, albeit partially, enclometrial hyperplasia. The expectation is that in years to come the number of hysterectomies and female sterilizations will fall due to increased use of the device, including use by patients with enclometriosis and HIV-positive women. It would also be desirable to develop a smaller device for postmenopausal women and nulligraviclas.
C1 [Bahamondes, Luis; Bahamondes, M. Valeria; Monteiro, Ilza] Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br; vbahamondes@cemicamp.org.br;
   ilza@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
CR ANDERSSON JK, 1990, BRIT J OBSTET GYNAEC, V97, P690, DOI 10.1111/j.1471-0528.1990.tb16240.x
   ANDERSSON K, 1992, OBSTET GYNECOL, V79, P963
   ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0
   ANDERSSON K, 1992, CONTRACEPTION, V46, P575, DOI 10.1016/0010-7824(92)90122-A
   Backman T, 2005, OBSTET GYNECOL, V106, P813, DOI 10.1097/01.AOG.0000178754.88912.b9
   Backman T, 2004, AM J OBSTET GYNECOL, V190, P50, DOI 10.1016/j.ajog.2003.07.021
   Bahamondes L, 2006, HUM REPROD, V21, P1316, DOI 10.1093/humrep/dei457
   Bahamondes L, 2003, J REPROD MED, V48, P637
   Bahamondes L, 2003, ACTA OBSTET GYN SCAN, V82, P580
   Banks E, 2004, BMJ-BRIT MED J, V328, P1291, DOI 10.1136/bmj.328.7451.1291
   Barrington JW, 2003, EUR J OBSTET GYN R B, V108, P72, DOI 10.1016/S0301-2115(02)00408-6
   BAVEJA R, 1989, Contraception, V39, P37
   Blumenfeld Z, 2007, SCAND J CLIN LAB INV, V67, P257, DOI 10.1080/00365510601113241
   Bragheto AM, 2007, CONTRACEPTION, V76, P195, DOI 10.1016/j.contraception.2007.05.091
   Brown PM, 2006, BJOG-INT J OBSTET GY, V113, P797, DOI 10.1111/j.1471-0528.2006.00944.x
   Busfield RA, 2006, BJOG-INT J OBSTET GY, V113, P257, DOI 10.1111/j.1471-0528.2006.00863.x
   Chan SSC, 2007, BJOG-INT J OBSTET GY, V114, P1510, DOI 10.1111/j.1471-0528.2007.01545.x
   Dhar KK, 2005, GYNECOL ONCOL, V97, P924, DOI 10.1016/j.ygyno.2004.10.031
   FAUNDES A, 1988, INT J GYNECOL OBSTET, V26, P429, DOI 10.1016/0020-7292(88)90341-4
   FAUNDES A, 1993, ANN MED, V25, P149, DOI 10.3109/07853899309164159
   Fedele L, 2001, FERTIL STERIL, V75, P485, DOI 10.1016/S0015-0282(00)01759-3
   Fedele Luigi, 2004, Expert Opin Emerg Drugs, V9, P167, DOI 10.1517/eoed.9.1.167.32945
   FOSTER PA, 1995, THROMB HAEMOSTASIS, V74, P784
   Gardner FJE, 2000, LANCET, V356, P1711, DOI 10.1016/S0140-6736(00)03204-9
   Giannopoulos T, 2004, GYNECOL ONCOL, V95, P762, DOI 10.1016/j.ygyno.2004.09.010
   Graff-Iversen S, 2002, CONTRACEPTION, V66, P7, DOI 10.1016/S0010-7824(02)00311-6
   Grigorieva V, 2003, FERTIL STERIL, V79, P1194, DOI 10.1016/S0015-0282(03)00175-4
   Guttinger A, 2007, CONTRACEPTION, V75, pS93, DOI 10.1016/j.contraception.2007.01.015
   Hampton NRE, 2005, HUM REPROD, V20, P2653, DOI 10.1093/humrep/dei085
   HAUKKAMAA M, 1986, AM J OBSTET GYNECOL, V154, P520, DOI 10.1016/0002-9378(86)90594-6
   Heikinheimo O, 2006, HUM REPROD, V21, P2857, DOI 10.1093/humrep/del264
   HEIKKILA M, 1982, CONTRACEPTION, V25, P279, DOI 10.1016/0010-7824(82)90051-8
   HEIKKILA M, 1982, CONTRACEPTION, V25, P41, DOI 10.1016/0010-7824(82)90017-8
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   Hurskainen R, 2001, LANCET, V357, P273, DOI 10.1016/S0140-6736(00)03615-1
   Inki P, 2002, ULTRASOUND OBST GYN, V20, P381, DOI 10.1046/j.1469-0705.2002.00805.x
   Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x
   Istre O, 2001, FERTIL STERIL, V76, P304, DOI 10.1016/S0015-0282(01)01909-4
   Kaunitz AM, 2007, CONTRACEPTION, V75, pS130, DOI 10.1016/j.contraception.2007.01.012
   Kingman CEC, 2004, BJOG-INT J OBSTET GY, V111, P1425, DOI 10.1111/j.1471-0528.2004.00305.x
   Koh SCL, 2007, J THROMB HAEMOST, V5, P133, DOI 10.1111/j.1538-7836.2006.02243.x
   Lahteenmaki P, 1998, BMJ-BRIT MED J, V316, P1122, DOI 10.1136/bmj.316.7138.1122
   Lessard T, 2008, CONTRACEPTION, V77, P30, DOI 10.1016/j.contraception.2007.09.009
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   Lockhat FB, 2004, HUM REPROD, V19, P179, DOI 10.1093/humrep/deh004
   LUKES AS, 2007, FERTIL STERIL
   Luukkainen T, 2000, STEROIDS, V65, P699, DOI 10.1016/S0039-128X(00)00177-X
   LUUKKAINEN T, 1987, CONTRACEPTION, V36, P169, DOI 10.1016/0010-7824(87)90012-6
   LUUKKAINEN T, 1991, ANN NY ACAD SCI, V626, P43, DOI 10.1111/j.1749-6632.1991.tb37898.x
   Magalhaes J, 2007, CONTRACEPTION, V75, P193, DOI 10.1016/j.contraception.2006.11.004
   Mansour D, 2007, CONTRACEPTION, V75, pS144, DOI 10.1016/j.contraception.2006.12.021
   Mattinson A, 2006, J FAM PLAN REPROD H, V32, P181, DOI 10.1783/147118906777888143
   Mercorio F, 2003, CONTRACEPTION, V67, P277, DOI 10.1016/S0010-7824(02)00522-X
   MILSOM I, 1991, AM J OBSTET GYNECOL, V164, P879, DOI 10.1016/S0002-9378(11)90533-X
   MISRA JS, 1995, ACTA CYTOL, V39, P45
   Monteiro I, 2002, CONTRACEPTION, V65, P325, DOI 10.1016/S0010-7824(02)00283-4
   Montz FJ, 2002, AM J OBSTET GYNECOL, V186, P651, DOI 10.1067/mob.2002.122130
   Munuce MJ, 2006, CONTRACEPTION, V73, P97, DOI 10.1016/j.contraception.2005.06.072
   Odlind V, 1996, Eur J Contracept Reprod Health Care, V1, P319, DOI 10.3109/13625189609150677
   Ortayli N, 2001, CONTRACEPTION, V63, P309, DOI 10.1016/S0010-7824(01)00212-8
   Pakarinen P, 2005, CONTRACEPTION, V72, P342, DOI 10.1016/j.contraception.2005.05.013
   Pakarinen P, 2003, CONTRACEPTION, V68, P31, DOI 10.1016/S0010-7824(03)00104-5
   Pakarinen P, 2001, SEMIN REPROD MED, V19, P365, DOI 10.1055/s-2001-18644
   Peloggia A, 2006, HUM REPROD, V21, P1129, DOI 10.1093/humrep/dei476
   Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Pisoni CN, 2006, LUPUS, V15, P877, DOI 10.1177/0961203306071706
   Prentice A, 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000346
   Raudaskoski T, 2002, BJOG-INT J OBSTET GY, V109, P136, DOI 10.1016/S1470-0328(02)01167-9
   RAUDASKOSKI TH, 1995, AM J OBSTET GYNECOL, V172, P114, DOI 10.1016/0002-9378(95)90095-0
   Reid PC, 2005, BJOG-INT J OBSTET GY, V112, P1121, DOI 10.1111/j.1471-0528.2005.00642.x
   Reid PC, 2005, BRIT MED J, V330, P938, DOI 10.1136/bmj.38376.505382.AE
   Reid PC, 2000, BRIT J OBSTET GYNAEC, V107, P320, DOI 10.1111/j.1471-0528.2000.tb13225.x
   Riphagen F E, 2000, Climacteric, V3, P199, DOI 10.1080/13697130008500114
   RODEGHIERO F, 1987, BLOOD, V69, P454
   Rogovskaya S, 2005, OBSTET GYNECOL, V105, P811, DOI 10.1097/01.AOG.0000156301.11939.56
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   Rossi AD, 2005, CONTRACEPTION, V71, P45, DOI 10.1016/j.contraception.2004.07.001
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   SCARSELLI G, 1988, European Journal of Gynaecological Oncology, V9, P284
   Schaedel ZE, 2005, AM J OBSTET GYNECOL, V193, P1361, DOI 10.1016/j.ajog.2005.05.002
   SILVERBERG SG, 1986, INT J GYNECOL PATHOL, V5, P235, DOI 10.1097/00004347-198609000-00005
   Sitruk-Ware R, 2004, MATURITAS, V47, P277, DOI 10.1016/j.maturitas.2004.01.001
   Sitruk-Ware R, 2007, CONTRACEPTION, V75, pS155, DOI 10.1016/j.contraception.2007.01.010
   Sitruk-Ware R, 2005, WOMENS HEALTH, V1, P171, DOI 10.2217/17455057.1.2.171
   SIVIN I, 1994, FERTIL STERIL, V61, P70
   SIVIN I, 1991, OBSTET GYNECOL, V78, P291
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   Soysal S, 2005, GYNECOL OBSTET INVES, V59, P29, DOI 10.1159/000080932
   Suhonen S, 1997, ACTA OBSTET GYN SCAN, V76, P145, DOI 10.3109/00016349709050071
   SUHONEN SP, 1995, AM J OBSTET GYNECOL, V172, P562, DOI 10.1016/0002-9378(95)90573-1
   Suvanto-Luukkonen E, 1999, FERTIL STERIL, V72, P161, DOI 10.1016/S0015-0282(99)00162-4
   TOIVONEN J, 1991, OBSTET GYNECOL, V77, P261, DOI 10.1097/00006250-199102000-00019
   Varila E, 2001, FERTIL STERIL, V76, P969, DOI 10.1016/S0015-0282(01)02846-1
   Vercellini P, 2003, FERTIL STERIL, V80, P305, DOI 10.1016/S0015-0282(03)00608-3
   Vercellini P, 1999, FERTIL STERIL, V72, P505, DOI 10.1016/S0015-0282(99)00291-5
   Vereide AB, 2003, GYNECOL ONCOL, V91, P526, DOI 10.1016/j.ygyno.2003.07.002
   Yela Daniela Angerame, 2006, Rev. Assoc. Med. Bras., V52, P32, DOI 10.1590/S0104-42302006000100019
NR 99
TC 13
Z9 15
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD JUL
PY 2008
VL 5
IS 4
BP 437
EP 445
DI 10.1586/17434440.5.4.437
PG 9
WC Engineering, Biomedical
SC Engineering
GA 325VX
UT WOS:000257617700010
PM 18573044
DA 2020-12-01
ER

PT J
AU Viola, AS
   Gouveia, D
   Andrade, L
   Aldrighi, JM
   Viola, CFM
   Bahamondes, L
AF Viola, Alexandre S.
   Gouveia, Daniela
   Andrade, Liliana
   Aldrighi, Jose M.
   Viola, Carolina F. M.
   Bahamondes, Luis
TI Prevalence of endometrial cancer and hyperplasia in non-symptomatic
   overweight and obese women
SO AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY
LA English
DT Article
DE cancer; endometrium; hyperplasia; obesity; overweight
ID BODY-MASS INDEX; SWEDISH TWIN REGISTRY; ENDOGENOUS HORMONES; FAT
   DISTRIBUTION; WEIGHT CHANGE; RISK-FACTORS; LIFE-STYLE; COHORT; HEALTH;
   SIZE
AB Background: Obesity is a public health problem and it is necessary to identify if non-symptomatic obese women must be submitted to endometrial evaluation.
   Aims: To determine the prevalence of endometrial hyperplasia and cancer in non-symptomatic overweight or obese women.
   Methods: A cross-sectional study was carried out in 193 women submitted to an endometrial biopsy using a Pipelle de Cornier. The findings were classified as normal, hyperplasia or cancer, and the results were compared to body mass index (BMI; kg/m(2)). For the purpose of statistical analysis, women were divided into two groups: women of reproductive age and postmenopausal women, and according to BMI as overweight or obese.
   Results: The prevalence of endometrial cancer and hyperplasia was 1.0% and 5.8% in women of reproductive age and 3.0% and 12.1% in postmenopausal women, respectively. According to logistic regression, being in the postmenopause increased the risk of endometrial hyperplasia and cancer to 1.19 (95% confidence interval (CI): 0.36-3.90), while being postmenopausal and severely obese increased the odds ratio (OR) to 1.58 (95%CI: 0.30-8.23) and being postmenopausal and morbidly obese increased the OR to 2.72 (95%CI: 0.65-11.5). No increase in risk was found in women of reproductive age who were either overweight or obese.
   Discussion: Our results show that non-symptomatic, severe or morbidly obese postmenopausal women have a high risk of developing endometrial hyperplasia or cancer; however, no such risk was found for women of reproductive age.
C1 [Viola, Alexandre S.; Viola, Carolina F. M.; Bahamondes, Luis] Univ Estadual Campinas, Fac Med Sci, Dept Obstet & Gynaecol, Campinas, SP, Brazil.
   [Andrade, Liliana] Univ Estadual Campinas, Fac Med Sci, Dept Pathol, Campinas, SP, Brazil.
   [Gouveia, Daniela; Aldrighi, Jose M.] Fac Med Sci Santa Casa Sao Paulo, Dept Obstet & Gynaecol, Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
CR AUSTIN H, 1991, CANCER RES, V51, P568
   Bianchini Franca, 2002, Obes Rev, V3, P5, DOI 10.1046/j.1467-789X.2002.00046.x
   *CDCP, 2002, BEH RISK FACT SURV S
   Chia VM, 2007, INT J GYNECOL CANCER, V17, P441, DOI 10.1111/j.1525-1438.2007.00790.x
   Chubak J, 2004, CANCER EPIDEM BIOMAR, V13, P1296
   CRISSMAN JD, 1981, OBSTET GYNECOL, V57, P699
   French SA, 1997, INT J OBESITY, V21, P217, DOI 10.1038/sj.ijo.0800390
   Friedenreich C, 2007, CANCER CAUSE CONTROL, V18, P399, DOI 10.1007/s10552-006-0113-8
   Furberg AS, 2003, INT J CANCER, V104, P669, DOI 10.1002/ijc.10974
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   *IARC, 2002, HDB CANC PREVENTION, V6
   *IBGE, 2007, EST NUTR PREC EST TO
   Jonsson F, 2003, INT J CANCER, V106, P594, DOI 10.1002/ijc.11266
   Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070
   Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531
   KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6
   Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6
   Kuriyama S, 2005, INT J CANCER, V113, P148, DOI 10.1002/ijc.20529
   LAVECCHIA C, 1982, INT J EPIDEMIOL, V11, P120, DOI 10.1093/ije/11.2.120
   LEMARCHAND L, 1991, INT J CANCER, V48, P807
   LEVI F, 1992, INT J CANCER, V50, P567, DOI 10.1002/ijc.2910500413
   Lukanova A, 2006, INT J CANCER, V118, P458, DOI 10.1002/ijc.21354
   Monteiro CA, 2000, EUR J CLIN NUTR, V54, P342, DOI 10.1038/sj.ejcn.1600960
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Ogden CL, 2007, GASTROENTEROLOGY, V132, P2087, DOI 10.1053/j.gastro.2007.03.052
   Oguma Y, 2005, OBES RES, V13, P945, DOI 10.1038/oby.2005.109
   OLSON SH, 1995, NUTR CANCER, V23, P141, DOI 10.1080/01635589509514370
   Potischman N, 1999, EPIDEMIOLOGY, V10, P76, DOI 10.1097/00001648-199901000-00014
   Schouten LJ, 2004, JNCI-J NATL CANCER I, V96, P1635, DOI 10.1093/jnci/djh291
   Soliman PT, 2005, OBSTET GYNECOL, V105, P575, DOI 10.1097/01.AOG.0000154151.14516.f7
   SWANSON CA, 1993, CANCER EPIDEM BIOMAR, V2, P321
   Terry P, 1999, INT J CANCER, V82, P38, DOI 10.1002/(SICI)1097-0215(19990702)82:1&lt;38::AID-IJC8&gt;3.0.CO;2-Q
   Trentham-Dietz A, 2006, INT J EPIDEMIOL, V35, P151, DOI 10.1093/ije/dyi226
   US Department of Health and Human Services and US Department of Agriculture, 2005, DIET GUID AM
   Weiderpass E, 2000, CANCER CAUSE CONTROL, V11, P185, DOI 10.1023/A:1008946825313
   *WHO, 1995, 854 WHO
   *WHO, 1997, GLOB EP OB
   World Health Organization, 2003, NUTR CONTR GLOB OB E
NR 38
TC 16
Z9 16
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0004-8666
J9 AUST NZ J OBSTET GYN
JI Aust. N. Z. J. Obstet. Gynaecol.
PD APR
PY 2008
VL 48
IS 2
BP 207
EP 213
DI 10.1111/j.1479-828X.2008.00845.x
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 279UW
UT WOS:000254381500014
PM 18366497
DA 2020-12-01
ER

PT J
AU Marchi, NM
   de Alvarenga, AT
   Osis, MJD
   Bahamondes, L
AF Marchi, N. M.
   de Alvarenga, A. T.
   Osis, M. J. D.
   Bahamondes, L.
TI Contraceptive methods with male participation: a perspective of
   Brazilian couples
SO INTERNATIONAL NURSING REVIEW
LA English
DT Article
DE Brazil; contraception; gender; male roles
AB Objective: To assess the perspectives of couples who requested vasectomy in a public health service on the use of male participation contraceptive methods available in Brazil: male condoms, natural family planning/calendar, coitus interruptus and vasectomy.
   Methods: A qualitative study with semi-structured interviews was held with 20 couples who had requested vasectomy at the Human Reproduction Unit of the Universidade Estadual de Campinas, Brazil. Data analysis was carried out through thematic content analysis.
   Findings: The couples did not, in general, know any effective contraceptive options for use by men and/or participating in their use, except for vasectomy. The few methods with male participation that they knew of were perceived to interfere in spontaneity and in pleasure of intercourse. Men accepted that condom use in extra-conjugal relations offered them protection from sexually transmitted diseases; that their wives might also participate in extra-marital relationships was not considered.
   Discussion: The few contraceptive options with male participation lead to difficulty in sharing responsibilities between men and women. On the basis of perceived gender roles, women took the responsibility for contraception until the moment when the situation became untenable, and they faced the unavoidable necessity of sterilization.
   Conclusion: Specific actions are necessary for men to achieve integral participation in relation to reproductive sexual health. These include education and discussions on gender roles, leading to greater awareness in men of the realities of sexual and reproductive health.
C1 [Marchi, N. M.; Bahamondes, L.] Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, Brazil.
   [de Alvarenga, A. T.] Univ Sao Paulo, Fac Saude Publ, Dept Saude Materno Infantil, Sao Paulo, Brazil.
   [Osis, M. J. D.] Ctr Pesquisas Saude Reprod Caminas Cemicamp, Coordinator Social Res Dept, Campinas, Brazil.
RP Marchi, NM (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM mjosis@cemicamp.org.br
RI Swaibu, Ramadhani A/H-3164-2011
CR ALCALA MJ, 1995, COMPROMISOS SALUD DE
   ALVARENGA A. T., 1998, SAUDE SOC, V7, P87
   Alves Rozilda Neves, 2002, Rev. Saúde Pública, V36, P32, DOI 10.1590/S0034-89102002000500006
   BADIANI R, 1998, AN 9 ENC NAC EST POP, P925
   BARZELATTO J, 1990, REPROD HLTH STRATEGY
   *BEMFAM MACRO INT, 1997, PESQ NAC SOBR DEM SA
   *BRAS, 1988, CONST REP FED BRAS, P113
   Carvalho MLO, 2001, REV SAUDE PUBL, V35, P23, DOI 10.1590/S0034-89102001000100004
   CECATTI JG, 1995, BIOETICA, V4, P15
   COGNA M, 1998, CAD SAUDE PUBLICA, V14, P81
   Duarte Graciana Alves, 2003, Cad. Saúde Pública, V19, P207, DOI 10.1590/S0102-311X2003000100023
   FIGUEROA J. G., 1995, CIENCIAS SOCIALES ME, P193
   Figueroa Perea J. G., 1998, CAD SAUDE PUBLICA, V14, P87, DOI DOI 10.1590/S0102-311X1998000500018
   Gomez CA, 1996, J SEX RES, V33, P355, DOI 10.1080/00224499609551853
   HARDY E, 1971, CUADERNOS MED SOCIAL, V12, P34
   Jimenez A L, 2001, Cad Saude Publica, V17, P55, DOI 10.1590/S0102-311X2001000100005
   Manhoso FR, 2005, INT NURS REV, V52, P101, DOI 10.1111/j.1466-2435.2005.00247.x
   MINAYO MCS, 2000, DESAFIO CONHECIMENTO
   *MINT SAUD SECR PO, 2005, BOL EP AIDS 1
   *NETW N CAR US, 1997, FAMILY HLTH INT, V17, P4
   OSIS M. J. M. D., 1998, CAD SAUDE PUBLICA, V14, P25
   Patton M., 1990, QUALITATIVE EVALUATI
   Piet-Pelon NJ, 1999, MEN BANGLADESH INDIA
   ROGOW D, 1991, MAN HOMBRE HOMME RES
   Schulhofer Stephen J., 1996, J CONT LEGAL ISSUES, V7, P78
   SOUZAS Raquel, 2001, SAUDE SOC, V10, P15
   VIEIRA EM, 1999, SAUDE SEXUALE REPROD, P324
   VILLELA W, 1999, SEXUALIDADES PELO AV, V34, P199
   ZAMBERLIN N, 1999, FEMINIDADES MASCULIN, P245
NR 29
TC 7
Z9 7
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-8132
EI 1466-7657
J9 INT NURS REV
JI Int. Nurs. Rev.
PD MAR
PY 2008
VL 55
IS 1
BP 103
EP 109
DI 10.1111/j.1466-7657.2007.00572.x
PG 7
WC Nursing
SC Nursing
GA 262KR
UT WOS:000253147900025
PM 18275543
DA 2020-12-01
ER

PT J
AU Lessard, T
   Simoes, JA
   Discacciati, MG
   Hidalgo, M
   Bahamondes, L
AF Lessard, Tricia
   Simoes, Jose A.
   Discacciati, Michelle G.
   Hidalgo, Margarete
   Bahamondes, Luis
TI Cytological evaluation and investigation of the vaginal flora of
   long-term users of the levonorgestrel-releasing intrauterine system
   (LNG-IUS)
SO CONTRACEPTION
LA English
DT Article
DE candidiasis; microbiological abnormalities; cytopathological
   abnormalities; papanicolaou; LNG-IUS; vaginal flora
ID BACTERIAL VAGINOSIS; MEDROXYPROGESTERONE ACETATE; CLINICAL-PERFORMANCE;
   CERVICAL CYTOLOGY; CONTRACEPTION; DEVICE; WOMEN; INFECTIONS; SMEARS;
   IUDS
AB Background: The study was conducted to evaluate the cytopathological findings and vaginal flora in cervical smear samples from women using the levonorgestrel-releasing intrauterine system (LNG-IUS) for a period of up to 7 years.
   Study Design: Postinsertion cytology examinations were conducted on 187 women who had an LNG-IUS inserted between April and September 1998 in the family planning clinic of the Universidade Estadual de Campinas.
   Results: During the 7 years of follow-up, a high frequency of candidiasis was found from the fourth through the seventh year of use in comparison to the first year of use. No significant results were found with respect to cytopathological abnormalities or other microbiological alterations following insertion of the LNG-IUS.
   Conclusion: Use of the LNG-IUS had no effect on cervical smears over the 7-year follow-up period; however, an increase occurred in the frequency of candidiasis. (c) 2008 Elsevier Inc. All rights reserved.
C1 [Lessard, Tricia; Simoes, Jose A.; Discacciati, Michelle G.; Hidalgo, Margarete; Bahamondes, Luis] Univ Estadual Campinas, Dept Obstet & Gynaecol, Sch Med, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Discacciati, Michelle Garcia/B-4608-2014
OI Discacciati, Michelle Garcia/0000-0003-3660-3826
CR ANDERSSON K, 1994, CONTRACEPTION, V49, P56, DOI 10.1016/0010-7824(94)90109-0
   AVONTS D, 1990, SEX TRANSM DIS, V17, P23
   Calzolari E, 2000, INT J GYNECOL OBSTET, V70, P341, DOI 10.1016/S0020-7292(00)00217-4
   CHICK P H, 1985, Clinical Reproduction and Fertility, V3, P81
   Darwish A, 2004, CONTRACEPTION, V69, P121, DOI 10.1016/j.contraception.2003.09.010
   DIAZ J, 1993, CONTRACEPTION, V47, P169, DOI 10.1016/0010-7824(93)90089-P
   Discacciati MG, 2006, DIAGN CYTOPATHOL, V34, P272, DOI 10.1002/dc.20418
   do Lago RF, 2003, CONTRACEPTION, V68, P105, DOI 10.1016/S0010-7824(03)00109-4
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Joesoef MR, 2001, CONTRACEPTION, V64, P169, DOI 10.1016/S0010-7824(01)00246-3
   Lockhat FB, 2004, HUM REPROD, V19, P179, DOI 10.1093/humrep/deh004
   Luukkainen T, 2001, SEMIN REPROD MED, V19, P355, DOI 10.1055/s-2001-18643
   LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248
   Miller L, 2000, OBSTET GYNECOL, V96, P431, DOI 10.1016/S0029-7844(00)00906-6
   Misra JS, 2003, DIAGN CYTOPATHOL, V29, P136, DOI 10.1002/dc.10326
   MISRA JS, 1995, ACTA CYTOL, V39, P45
   POWELL LC, 1971, AM J OBSTET GYNECOL, V110, P36, DOI 10.1016/0002-9378(71)90210-9
   SIVIN I, 1991, CONTRACEPTION, V44, P473, DOI 10.1016/0010-7824(91)90149-A
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Sturridge F, 1997, BRIT J OBSTET GYNAEC, V104, P285, DOI 10.1111/j.1471-0528.1997.tb11455.x
   TOIVONEN J, 1991, OBSTET GYNECOL, V77, P261, DOI 10.1097/00006250-199102000-00019
   Valente PT, 1998, CANCER CYTOPATHOL, V84, P328, DOI 10.1002/(SICI)1097-0142(19981225)84:6<328::AID-CNCR3>3.0.CO;2-Z
   *WHO, 1986, B WORLD HEALTH ORGAN, V64, P375
   *WHO, 1996, B WORLD HEALTH ORGAN, V74, P345
NR 24
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JAN
PY 2008
VL 77
IS 1
BP 30
EP 33
DI 10.1016/j.contraception.2007.09.009
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 245DL
UT WOS:000251915000005
PM 18082663
DA 2020-12-01
ER

PT J
AU Juliato, CT
   Fernandes, A
   Marchi, NM
   Castro, S
   Olivotti, B
   Bahamondes, L
AF Juliato, Cassia Teatin
   Fernandes, Arlete
   Marchi, Nadia Maria
   Castro, Sara
   Olivotti, Bruna
   Bahamondes, Luis
TI Usefulness of FSH measurements for determining menopause in long-term
   users of depot medroxyprogesterone acetate over 40 years of age
SO CONTRACEPTION
LA English
DT Article
DE depot medroxyprogesterone acetate; follicle-stimulating hormone;
   menopause
ID DISCONTINUATION; FERTILITY; PITUITARY; MECHANISM; RETURN; WOMEN
AB Objective: To assess the usefulness of follicle-stimulating hormone (FSH) measurements for determining menopause in 40-55-year-old users of depot medroxyprogesterone acetate (DMPA).
   Study Design: FSH levels were measured in 355 blood samples from 82 amenorrheic women during an 18-month period. Blood was collected every 90 days immediately prior to DMPA administration.
   Results: Using FSH values >35 mIU/mL as being in the post menopausal range, 32 women (39.0%) presented at least one FSH measurement in the postmenopausal range and 14 of them (43.7%) had more than one elevated FSH measurement and were considered postmenopausal. In five users (15.6%), only the last FSH measurement was within the postmenopausal range, and in 13 women (40.6%), FSH returned to normal values following one measurement that was within the postmenopausal range.
   Conclusions: The menopausal status in DMPA users in amenorrhea should be determined based on at least two consecutive high FSH evaluations, since, as shown here, 40.6% of the women with high FSH had a low FSH in the subsequent determination. FSH measurements should be done only in women 50 years old because there is a greater possibility of being in postmenopause. However, we do not recommend the interruption of DMPA use prior to the quantification of FSH. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Juliato, Cassia R T/D-4447-2012
OI Juliato, Cassia R T/0000-0003-3197-1195
CR Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   BAHAMONDES L, 2007, EXP REV OBSTET GYNEC, V2, P141
   Bastian LA, 2003, JAMA-J AM MED ASSOC, V289, P895, DOI 10.1001/jama.289.7.895
   Beksinska ME, 2003, CONTRACEPTION, V68, P339, DOI 10.1016/j.contraception.2003.08.003
   Burger HG, 1999, J STEROID BIOCHEM, V69, P31, DOI 10.1016/S0960-0760(98)00145-9
   Burger HG, 2002, RECENT PROG HORM RES, V57, P257, DOI 10.1210/rp.57.1.257
   Curtis KM, 2006, CONTRACEPTION, V73, P470, DOI 10.1016/j.contraception.2005.12.010
   FOTHERBY K, 1977, CONTRACEPTION, V16, P591, DOI 10.1016/0010-7824(77)90060-9
   FRANCHIMONT P, 1970, OBSTET GYNECOL, V36, P93
   Fraser IS, 1981, MED J AUST         S, V1, P1
   Harlow SD, 2006, J CLIN ENDOCR METAB, V91, P3432, DOI 10.1210/jc.2005-2810
   Harper AJ, 2001, FERTIL STERIL, V76, pS108, DOI 10.1016/S0015-0282(01)02318-4
   Kaunitz AM, 2001, AM J OBSTET GYNECOL, V185, pS32, DOI 10.1067/mob.2001.116525
   KORA S, 1975, FERTIL STERIL, V26, P121
   LOBO RA, 1984, OBSTET GYNECOL, V63, P1
   Mcdaniel E B, 1973, Asian Med J, V9, P133
   MCKINLAY SM, 1992, MATURITAS, V14, P103, DOI 10.1016/0378-5122(92)90003-M
   MORRISON JC, 1980, AM J OBSTET GYNECOL, V138, P99, DOI 10.1016/0002-9378(80)90017-4
   PARDTHAISONG T, 1980, LANCET, V1, P509
   PEREZPALACIOS G, 1981, ACTA ENDOCRINOL-COP, V97, P320, DOI 10.1530/acta.0.0970320
   PEREZPALACIOS G, 1981, J STEROID BIOCHEM, V15, P125, DOI 10.1016/0022-4731(81)90266-1
   Practice Committee of the American Society for Reproductive Medicine, 2006, Fertil Steril, V86, pS253
   Randolph JF, 2006, J CLIN ENDOCR METAB, V91, P3034, DOI 10.1210/jc.2006-0243
   SCHWALLIE PC, 1974, CONTRACEPTION, V10, P181, DOI 10.1016/0010-7824(74)90073-0
   SCHWARTZ D, 1982, NEW ENGL J MED, V306, P404, DOI 10.1056/NEJM198202183060706
   SHIDELER SE, 1989, MATURITAS, V11, P331, DOI 10.1016/0378-5122(89)90029-7
   World Health Organization, 2004, MAK PREGN SAF CRIT R, P1
NR 27
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD OCT
PY 2007
VL 76
IS 4
BP 282
EP 286
DI 10.1016/j.contraception.2007.06.005
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 218QJ
UT WOS:000250029700006
PM 17900438
DA 2020-12-01
ER

PT J
AU Bragheto, AM
   Caserta, N
   Bahamondes, L
   Petta, CA
AF Bragheto, Aristides M.
   Caserta, Nelson
   Bahamondes, Luis
   Petta, Carlos A.
TI Effectiveness of the levonorgestrel-releasing intrauterine system in the
   treatment of adenomyosis diagnosed and monitored by magnetic resonance
   imaging
SO CONTRACEPTION
LA English
DT Article
DE adenomyosis; levonorgestrel-releasing intrauterine system; magnetic
   resonance imaging
ID UTERINE JUNCTIONAL ZONE; HISTOPATHOLOGIC CORRELATION; ENDOVAGINAL US;
   UTERUS; ULTRASONOGRAPHY; MENORRHAGIA; DIFFUSE; WOMEN
AB Background: This study was conducted to evaluate the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on adenomyotic lesions diagnosed and monitored by magnetic resonance imaging (MRI).
   Study Design: LNG-IUS was inserted during menstrual bleeding in 29 women, 24 to 46 years of age, with MRI-diagnosed adenomyosis associated with menorrhagia and dysmenorrhea. Clinical evaluations were carried out at baseline and at 3 and 6 months postinsertion. MRI was performed at baseline and at 6 months postinsertion and was used to calculate junctional zone thickness (in mm), to define the junctional zone borders, to identify the presence of high-signal foci on T-2-weighted images and to calculate uterine volume (in mL).
   Results: A significant reduction of 24.2% in junctional zone thickness was observed (p <.0001); however, no significant decrease in uterine volume was observed (142.6 mL vs. 136.4 mL; p=.2077) between baseline and the 6-month evaluation. A significant decrease in pain score was observed at 3 and 6 months after insertion (p <.0001); however, six women continued to report pain scores > 3 at 6 months of observation. At 3 months of use, the most common bleeding pattern was spotting, and at 6 months of observation, oligomenorrhea was the most common pattern observed, although spotting was present in one third of the women.
   Conclusions: The insertion of an LNG-TUS led to a reduction in pain and abnormal bleeding associated with adenomyosis. MRI was useful for monitoring response of adenomyotic lesions to the LNG-fUS. (c) 2007 Elsevier Inc. All rights reserved.
C1 Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Univ Estadual Campinas, Sch Med, Dept Radiol, BR-13084971 Campinas, Brazil.
RP Petta, CA (corresponding author), Dept Obstet & Gynecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
EM cpetta@attglobal.net
CR ARNOLD LL, 1994, FERTIL STERIL, V61, P1165
   Bazot M, 2001, HUM REPROD, V16, P2427, DOI 10.1093/humrep/16.11.2427
   Bergholt T, 2001, HUM REPROD, V16, P2418, DOI 10.1093/humrep/16.11.2418
   BROSENS JJ, 1995, LANCET, V346, P558, DOI 10.1016/S0140-6736(95)91387-4
   Byun JY, 1999, RADIOGRAPHICS, V19, pS161, DOI 10.1148/radiographics.19.suppl_1.g99oc03s161
   Dueholm M, 2001, FERTIL STERIL, V76, P588, DOI 10.1016/S0015-0282(01)01962-8
   Fedele L, 1997, FERTIL STERIL, V68, P426, DOI 10.1016/S0015-0282(97)00245-8
   Fong YF, 1999, CONTRACEPTION, V60, P173, DOI 10.1016/S0010-7824(99)00075-X
   He Shu-ming, 2005, Zhonghua Fu Chan Ke Za Zhi, V40, P536
   Hendrickson M.R., 1980, SURG PATHOLOGY UTERI, P452
   Kang S, 1996, AM J ROENTGENOL, V166, P1145, DOI 10.2214/ajr.166.5.8615259
   Monteiro I, 2002, CONTRACEPTION, V65, P325, DOI 10.1016/S0010-7824(02)00283-4
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   NILSSON CG, 1986, FERTIL STERIL, V45, P805
   Reinhold C, 1999, RADIOGRAPHICS, V19, pS147, DOI 10.1148/radiographics.19.suppl_1.g99oc13s147
   Reinhold C, 1996, RADIOLOGY, V199, P151, DOI 10.1148/radiology.199.1.8633139
   REINHOLD C, 1997, MRI ABDOMEN PELVIS, P617
   TOGASHI K, 1989, RADIOLOGY, V171, P531, DOI 10.1148/radiology.171.2.2704819
   VANDERWALT LA, 1986, CLIN PHYSIOL BIOCH, V4, P217
   WOODFORDE JM, 1972, J PSYCHOSOM RES, V16, P173, DOI 10.1016/0022-3999(72)90041-4
NR 20
TC 69
Z9 80
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2007
VL 76
IS 3
BP 195
EP 199
DI 10.1016/j.contraception.2007.05.091
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 207NC
UT WOS:000249256800004
PM 17707716
DA 2020-12-01
ER

PT J
AU do Nascimento, JAA
   Seppala, M
   Perdigao, A
   Espejo-Arce, X
   Munuce, MJ
   Hautala, L
   Koistinen, R
   Andrade, L
   Bahamondes, L
AF do Nascimento, Josiane A. A.
   Seppala, Markku
   Perdigao, Antero
   Espejo-Arce, Ximena
   Munuce, Maria Jose
   Hautala, Laura
   Koistinen, Riitta
   Andrade, Liliana
   Bahamondes, Luis
TI In vivo assessment of the human sperm acrosome reaction and the
   expression of glycodelin-A in human endometrium after
   levonorgestrel-emergency contraceptive pill administration
SO HUMAN REPRODUCTION
LA English
DT Article
DE emergency contraception; levonorgestrel; human spermatozoa; acrosome
   reaction; glycodelin-A
ID HUMAN SPERMATOZOA; MENSTRUAL-CYCLE; CERVICAL-MUCUS; YUZPE REGIMEN;
   LUTEAL-PHASE; MECHANISM; MIFEPRISTONE; WOMEN; SERUM; TRIAL
AB BACKGROUND: The objectives were firstly to assess acrosome reaction (AR) status of spermatozoa following uterine flushing, secondly to measure levonorgestrel (LNG) levels in serum and in uterine flushing fluid and finally to measure endometrial glycodelin-A expression after administration of LNG as a form of emergency contraception (EC).
   METHODS: Forty-eight experiments were conducted on 15 regularly menstruating women. Four groups were formed based on different intercourse to treatment interval and treatment to recovery of spermatozoa and the biopsies.
   RESULTS: Twenty-four and forty-eight hours after treatment, there were 14.5 +/- 3.9 x 106 and 17.3 +/- 6.8 x 106 sperm recovered from the uterus, respectively. There were no differences between the AR rate and the endometrial glycodelin-A staining intensity in an LNG or placebo treated cycles. The LNG in uterine flushing medium represented 1.38% of the values observed in serum 24 h after the LNG intake.
   CONCLUSIONS: Twenty-four and forty-eight hours after administration of EC, neither the proportion of AR sperm, nor the glycodelin-A level was influenced by 1.5 mg of LNG. LNG did not impair the cervical mucus either because viable spermatozoa were found in the genital tract 36-60 h after coitus and 24-48 h after LNG intake. The mechanism of action of LNG as EC remains unknown.
C1 Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, BR-13084971 Campinas, SP, Brazil.
   Univ Helsinki, Cent Hosp, Biomedicum, Dept Clin Chem, Helsinki, Finland.
   Univ Nacl Rosario, Sch Biochem & Pharmaceut Sci, Dept Clin Biochem, Lab Reprod Studies, RA-2000 Rosario, Argentina.
   Univ Estadual Campinas, Sch Med, Dept Pathol, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
OI Hautala, Laura/0000-0002-5501-2792
CR Bahamondes L, 2003, CONTRACEPTION, V68, P55, DOI 10.1016/S0010-7824(03)00105-7
   BIELFELD P, 1992, ANDROLOGIA, V24, P83
   Brito KS, 2005, CONTRACEPTION, V72, P225, DOI 10.1016/j.contraception.2005.04.005
   CHENG L, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001324.PUB2
   CROSS NL, 1988, BIOL REPROD, V38, P235, DOI 10.1095/biolreprod38.1.235
   Croxatto HB, 2003, STEROIDS, V68, P1095, DOI 10.1016/j.steroids.2003.07.007
   Croxatto HB, 2001, CONTRACEPTION, V63, P111, DOI 10.1016/S0010-7824(01)00184-6
   Croxatto HB, 1996, REPROD ENDOCRINOLOGY, P385
   Devoto L, 2005, FERTIL STERIL, V84, P46, DOI 10.1016/j.fertnstert.2005.01.106
   Durand M, 2005, CONTRACEPTION, V71, P451, DOI 10.1016/j.contraception.2005.01.003
   Durand M, 2001, CONTRACEPTION, V64, P227, DOI 10.1016/S0010-7824(01)00250-5
   Gainer E, 2006, CONTRACEPTION, V74, P118, DOI 10.1016/j.contraception.2006.02.009
   Gemzell-Danielsson K, 2004, HUM REPROD UPDATE, V10, P341, DOI 10.1093/humupd/dmh027
   GOULD JE, 1984, BIOL REPROD, V31, P888, DOI 10.1095/biolreprod31.5.888
   Grimes D, 1998, LANCET, V352, P428
   Hapangama D, 2001, CONTRACEPTION, V63, P123, DOI 10.1016/S0010-7824(01)00186-X
   ISRAEL R, 1972, AM J OBSTET GYNECOL, V112, P1043, DOI 10.1016/0002-9378(72)90178-0
   Kamarainen M, 1996, AM J PATHOL, V148, P1435
   KESSERU E, 1974, CONTRACEPTION, V10, P411, DOI 10.1016/0010-7824(74)90041-9
   Mandelin E, 1997, HUM REPROD, V12, P2671, DOI 10.1093/humrep/12.12.2671
   Mandelin E, 2001, FERTIL STERIL, V76, P474, DOI 10.1016/S0015-0282(01)01969-0
   Marions L, 2002, OBSTET GYNECOL, V100, P65, DOI 10.1016/S0029-7844(02)02006-9
   MOGHISSI KS, 1973, OBSTET GYNECOL, V41, P585
   Munuce MJ, 2005, CONTRACEPTION, V72, P71, DOI 10.1016/j.contraception.2004.12.003
   Nikkanen V, 2000, CONTRACEPTION, V61, P401, DOI 10.1016/S0010-7824(00)00125-6
   PERLOFF WH, 1964, AM J OBSTET GYNECOL, V88, P439
   Seppala M, 2002, ENDOCR REV, V23, P401, DOI 10.1210/er.2001-0026
   Swahn ML, 1996, ACTA OBSTET GYN SCAN, V75, P738, DOI 10.3109/00016349609065738
   Theron HB, 2004, J CHROMATOGR B, V813, P331, DOI 10.1016/j.jchromb.2004.10.039
   Trussell J, 1999, OBSTET GYNECOL, V93, P872, DOI 10.1016/S0029-7844(98)00380-9
   von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3
   WILLIAMS M, 1993, HUM REPROD, V8, P925, DOI 10.1093/oxfordjournals.humrep.a138168
   World Health Organization, 1999, WHO LAB MAN EX HUM
   Yeung WSB, 2006, MOL CELL ENDOCRINOL, V250, P149, DOI 10.1016/j.mce.2005.12.038
   ZINAMAN M, 1989, BIOL REPROD, V41, P790, DOI 10.1095/biolreprod41.5.790
NR 35
TC 32
Z9 33
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD AUG
PY 2007
VL 22
IS 8
BP 2190
EP 2195
DI 10.1093/humrep/dem119
PG 6
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 205EK
UT WOS:000249096600017
PM 17537781
OA Bronze
DA 2020-12-01
ER

PT J
AU Petta, C
   Bragheto, A
   Caserta, N
   Bahamondes, L
AF Petta, C.
   Bragheto, A.
   Caserta, N.
   Bahamondes, L.
TI Effectiveness of the levonorgestrel IUS in the treatment of adenomyosis
   diagnosed and monitored by magnetic resonance imaging
SO HUMAN REPRODUCTION
LA English
DT Meeting Abstract
CT 23rd Annual Meeting of the
   European-Society-of-Human-Reproduction-and-Embryology
CY JUL 01-04, 2007
CL Lyon, FRANCE
SP European Soc Human Reprod & Embryol (ESHRE)
C1 [Petta, C.; Bragheto, A.; Caserta, N.; Bahamondes, L.] Univ Estadual Campinas, Campinas, SP, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD JUL
PY 2007
VL 22
SU 1
MA O-194 Oral
BP I79
EP I79
PG 1
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 293GA
UT WOS:000255322200186
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Petta, CA
   Fernandes, A
   Monteiro, I
AF Bahamondes, Luis
   Petta, Carlos A.
   Fernandes, Arlete
   Monteiro, Ilza
TI Use of the levonorgestrel-releasing intrauterine system in women with
   endometriosis, chronic pelvic pain and dysmenorrhea
SO CONTRACEPTION
LA English
DT Article; Proceedings Paper
CT 5th International Symposium on Intrauterine Devices and Systems for
   Womens Health
CY OCT 27-28, 2006
CL New York, NY
SP Populat Council, United Natl Populat Fund
DE endometriosis; adenomyosis; dysmenorrhea; pain; levonorgestrel-releasing
   intrauterine system (LNG-IUS (R))
ID ADMINISTERED PROGESTOGEN LEVONORGESTREL; LONG-TERM USERS;
   PERITONEAL-FLUID; SYMPTOMATIC ENDOMETRIOSIS; DEVICE; MANAGEMENT;
   STATEMENT; DENSITY; TRIAL; FLOW
AB Objectives: This report is a review of the medical literature on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS (R)) in women with endometriosis, adenomyosis, cyclic pelvic pain and dysmenorrhea.
   Material and Methods: A review was carried out using the MEDLINE and EMBASE databases to evaluate the use of LNG-IUS (R) in women with endometriosis and adenomyosis.
   Results: Nine studies were identified, only two of which were randomized clinical trials. One compared the insertion of LNG-IUS (R) after surgery with expectant conduct and the other compared the use of the device with a GnRH analogue (GnRH-a). All studies reported an improvement in pelvic pain and dysmenorrhea, and a reduction in menstrual bleeding. One study found an improvement in the staging of the disease at 6 months of use, and the studies that evaluated the use of LNG-IUS (R) in women with adenomyosis reported a reduction in uterine volume. Furthermore, the only study in which women were followed up for 3 years after insertion found improvement in pelvic pain at 12 months of use. However, there was no improvement after that period.
   Conclusions: The use of LNG-IUS (R) is an alternative for the medical treatment of women suffering from endometriosis, adenomyosis, chronic pelvic pain or dysmenorrhea, but experience is limited and long-term studies are necessary to reach definitive conclusions. However, for women who do not wish to become pregnant, this device offers the possibility of at least 5 years of treatment following one single intervention. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med, BR-13084971 Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Univ Estadual Campinas, Human Reprod Unit, Dept Obstet & Gynecol, Sch Med, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI monteiro, ilza m u/F-4871-2014
OI monteiro, ilza m u/0000-0002-9536-0564
CR *AM FERT SOC, 1985, FERTIL STERIL, V43, P351
   Bahamondes L, 2006, HUM REPROD, V21, P1316, DOI 10.1093/humrep/dei457
   Bahamondes L, 2003, J REPROD MED, V48, P637
   d'Arcangues C, 2006, CONTRACEPTION, V73, P443, DOI 10.1016/j.contraception.2006.01.002
   Fedele L, 1997, FERTIL STERIL, V68, P426, DOI 10.1016/S0015-0282(97)00245-8
   Fedele L, 2001, FERTIL STERIL, V75, P485, DOI 10.1016/S0015-0282(00)01759-3
   Fedele Luigi, 2004, Expert Opin Emerg Drugs, V9, P167, DOI 10.1517/eoed.9.1.167.32945
   Fong YF, 1999, CONTRACEPTION, V60, P173, DOI 10.1016/S0010-7824(99)00075-X
   Gambone JC, 2002, FERTIL STERIL, V78, P961, DOI 10.1016/S0015-0282(02)04216-4
   He Shu-ming, 2005, Zhonghua Fu Chan Ke Za Zhi, V40, P536
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hurskainen R, 2000, MOL HUM REPROD, V6, P1013, DOI 10.1093/molehr/6.11.1013
   Jarvela I, 1998, HUM REPROD, V13, P3379, DOI 10.1093/humrep/13.12.3379
   Kupker W, 1998, HUM REPROD UPDATE, V4, P719, DOI 10.1093/humupd/4.5.719
   Ling FW, 1999, OBSTET GYNECOL, V93, P51, DOI 10.1016/S0029-7844(98)00341-X
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   Lockhat FB, 2005, FERTIL STERIL, V83, P398, DOI 10.1016/j.fertnstert.2004.07.961
   Lockhat FB, 2004, HUM REPROD, V19, P179, DOI 10.1093/humrep/deh004
   Luukkainen T, 2000, STEROIDS, V65, P699, DOI 10.1016/S0039-128X(00)00177-X
   LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248
   Marques A, 2004, J REPROD MED, V49, P115
   Maruo T, 2001, HUM REPROD, V16, P2103, DOI 10.1093/humrep/16.10.2103
   McLaren J, 1996, J CLIN INVEST, V98, P482, DOI 10.1172/JCI118815
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   NILSSON CG, 1978, FERTIL STERIL, V29, P397
   NILSSON CG, 1980, CONTRACEPTION, V21, P225, DOI 10.1016/0010-7824(80)90003-7
   Odlind V, 1996, Eur J Contracept Reprod Health Care, V1, P319, DOI 10.3109/13625189609150677
   Oliveira-Ribeiro M, 2004, HUM REPROD, V19, P1778, DOI 10.1093/humrep/deh348
   PAKARINEN P, 1995, HUM REPROD, V10, P2390
   Peloggia A, 2006, HUM REPROD, V21, P1129, DOI 10.1093/humrep/dei476
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Prentice A, 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000346
   RAMEY JW, 1993, FERTIL STERIL, V60, P1
   Sitruk-Ware R, 2004, MATURITAS, V47, P277, DOI 10.1016/j.maturitas.2004.01.001
   Vercellini P, 1996, AM J OBSTET GYNECOL, V175, P396, DOI 10.1016/S0002-9378(96)70152-7
   Vercellini P, 2003, FERTIL STERIL, V80, P305, DOI 10.1016/S0015-0282(03)00608-3
   Vercellini P, 1999, FERTIL STERIL, V72, P505, DOI 10.1016/S0015-0282(99)00291-5
   Winkel CA, 2003, OBSTET GYNECOL, V102, P397, DOI 10.1016/S0029-7844(03)00474-5
   Zalel Y, 2002, HUM REPROD, V17, P2878, DOI 10.1093/humrep/17.11.2878
NR 39
TC 58
Z9 60
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2007
VL 75
IS 6
SU S
BP S134
EP S139
DI 10.1016/j.contraception.2006.12.008
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 177YU
UT WOS:000247189200023
PM 17531605
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Juliato, CT
   Villarreal, M
   Sobreira-Lima, B
   Simoes, JA
   Ferriandes, AMD
AF Bahamondes, Luis
   Juliato, Cassia Teatin
   Villarreal, Marina
   Sobreira-Lima, Bruno
   Simoes, Jose A.
   dos Santos Ferriandes, Arlete M.
TI Bone mineral density in users of two kinds of once-a-month combined
   injectable contraceptives
SO CONTRACEPTION
LA English
DT Article
DE bone mineral density; combined injectable contraceptives; contraception
ID DEPOT MEDROXYPROGESTERONE ACETATE; LONG-TERM USERS; POSTMENOPAUSAL
   WOMEN; ORAL-CONTRACEPTIVES; YOUNG-WOMEN; MASS; PROVERA; PREMENOPAUSAL;
   METAANALYSIS; CYCLOFEM(R)
AB Objective: The objective of this descriptive study was to compare bone mineral density (BMD) between users of two kinds of once-a-month combined injectable contraceptives (CICs) and control subjects. Subjects and
   Methods: This cross-sectional descriptive study included 97 women aged between 20 and 45 years using CICs containing either 25 mg of medroxyprogesterone acetate and 5 mg of estradiol cypionate for 12-82 months or 50 mg of norethindrone enanthate and 5 mg of estradiol valerate for 12-60 months, matched by age (1 year) and body mass index (BMI; kg/m(2)) (+/- 1) with users of the TCu 380A intrauterine device as control subjects. BMD was evaluated at the midshaft of the ulna and at the distal section of the radius of the nondominant forearm using double X-ray absorptiometry.
   Results: There was no difference in BNID between users of either CIC and nonusers at either section of the forearm studied. There was also no difference in BMD between users of the two CICs at either section of the forearm.
   Conclusions: Women aged between 20 and 45 years, currently using one of these two kinds of CICs, presented BMDs similar to those of control subjects paired by age and BMI. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, Sch Med, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Sao Paulo, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Sao Paulo, Brazil.
EM bahamond@caism.unicamp.br
RI Juliato, Cassia R T/D-4447-2012
OI Juliato, Cassia R T/0000-0003-3197-1195
CR AEDO AR, 1985, CONTRACEPTION, V31, P453, DOI 10.1016/0010-7824(85)90081-2
   [Anonymous], 2004, MED EL CRIT CONTR US
   Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Bahamondes L, 1999, FERTIL STERIL, V71, P849, DOI 10.1016/S0015-0282(99)00084-9
   Bahamondes L, 1997, CONTRACEPTION, V55, P307, DOI 10.1016/S0010-7824(97)00034-6
   Barad D, 2005, FERTIL STERIL, V84, P374, DOI 10.1016/j.fertnstert.2005.01.132
   BASSOL S, 1995, CONTRACEPTION, V51, P307, DOI 10.1016/0010-7824(95)00080-T
   Castelo-Branco C, 2001, J REPROD MED, V46, P875
   COOPER C, 1993, BONE, V14, P41, DOI 10.1016/8756-3282(93)90254-8
   Cromer BA, 1996, J PEDIATR-US, V129, P671, DOI 10.1016/S0022-3476(96)70148-8
   Doren M, 2003, HUM REPROD, V18, P1737, DOI 10.1093/humrep/deg315
   DUFF G, 2004, 392004 HSS MD
   Gbolade B, 1998, BRIT J OBSTET GYNAEC, V105, P790, DOI 10.1111/j.1471-0528.1998.tb10211.x
   Hall P, 1997, CONTRACEPTION, V56, P353, DOI 10.1016/S0010-7824(97)00185-6
   Kaunitz AM, 2000, OBSTET GYN CLIN N AM, V27, P741, DOI 10.1016/S0889-8545(05)70171-6
   Kaunitz AM, 2005, CONTRACEPTION, V72, P165, DOI 10.1016/j.contraception.2005.05.011
   KLEEREKOPER M, 1991, ARCH INTERN MED, V151, P1971, DOI 10.1001/archinte.151.10.1971
   LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7
   Lloyd T, 2004, J PEDIATR-US, V144, P776, DOI 10.1016/j.jpeds.2004.02.047
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Massai R, 2005, HUM REPROD, V20, P2764, DOI 10.1093/humrep/dei117
   Michaelsson K, 1999, LANCET, V353, P1481, DOI 10.1016/S0140-6736(98)09044-8
   Nappi C, 2003, CONTRACEPTION, V67, P355, DOI 10.1016/S0010-7824(03)00025-8
   Newton J. R., 1994, Journal of Obstetrics and Gynaecology (Abingdon), V14, pS1
   ORIOWO MA, 1980, CONTRACEPTION, V21, P415, DOI 10.1016/S0010-7824(80)80018-7
   Perrotti M, 2001, FERTIL STERIL, V76, P469, DOI 10.1016/S0015-0282(01)01936-7
   POLATTI F, 1995, CONTRACEPTION, V51, P221, DOI 10.1016/0010-7824(95)00036-A
   RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403
   Rickenlund A, 2004, J CLIN ENDOCR METAB, V89, P4364, DOI 10.1210/jc.2003-031334
   RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605
   SANG GW, 1994, CONTRACEPTION, V49, P361, DOI 10.1016/0010-7824(94)90033-7
   UPADHYAY U, 2005, POPULATION REPORTS M, V19
   *US FDA, 2004, BLACK BOX WARN DEP C
   von Kesseru E, 2000, CONTRACEPTION, V61, P317, DOI 10.1016/S0010-7824(00)00110-4
   *WHO, 2005, WHO STAT HORM CONTR
   World Health Organization, 1994, WHO TECHN REP SER
NR 36
TC 4
Z9 5
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD SEP
PY 2006
VL 74
IS 3
BP 259
EP 263
DI 10.1016/j.contraception.2006.03.019
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 078ES
UT WOS:000240085500011
PM 16904421
DA 2020-12-01
ER

PT J
AU Oliveira-Ribeiro, M
   Petta, CA
   Andrade, LALDA
   Hidalgo, MM
   Pellogia, A
   Bahamondes, L
AF Oliveira-Ribeiro, Marilia
   Petta, Carlos A.
   De Angelo Andrade, Liliana A. L.
   Hidalgo, Margarete M.
   Pellogia, Alessandra
   Bahamondes, Luis
TI Endometrial histology, microvascular density and caliber, and matrix
   metalloproteinase-3 in users of the Nestorone (R)-releasing
   contraceptive implant with and without endometrial breakthrough bleeding
SO CONTRACEPTION
LA English
DT Article
DE endometrial bleeding; subdermal progestin implant; Nestorone;
   leukocytes; MMP-3/microvessels
ID SERUM STEROID CONCENTRATIONS; OVARIAN-FUNCTION; PROGESTIN ST-1435;
   INTERSTITIAL COLLAGENASE; MENSTRUAL BREAKDOWN; VAGINAL RINGS;
   EXPRESSION; ESTRADIOL; PATTERNS; DISTURBANCES
AB Objective: This descriptive study evaluated endometrial histology, microvascular density and caliber, and quantification of matrix metalloproteinase (MMP-3) expression in long-term users of the Nestorone (R) (NES)-releasing implant who presented or not endometrial breakthrough bleeding (BTB).
   Methods: Endometrial biopsies were obtained from 32 healthy women with unpredictable BTB. The quantitative analysis was performed only in 20 samples.
   Results: The mean duration of use of the implant among the 14 women with BTB was 19.6 +/- 1.0 months, and the other six women had used the implant for 17.7 +/- 2.3 months (mean +/- S.E.M.). Histological analysis of the endometrial tissue showed a predominance of progestogenic pattern followed by atrophic and proliferative endometrium in both groups. Mucosal breakdown and glandular pseudostratification were observed in half of the cases. Endometrial vascular density was 73.1 +/- 10.0 and 57.5 +/- 24.1 vessels/mm(2), and maximum vessel diameter was 923.3 +/- 86.0 and 1038.0 +/- 404 mu m (mean S.E.M.) in the group with and without BTB, respectively, without significance, and the rate of cells expressing MMP-3 x 1000 counted stromal cells was 155.8 +/- 24.8 and 127.0 +/- 19.0 (mean +/- S.E.M.) in both groups, respectively, without significance.
   Conclusions: This study provides information about some endometrial aspects of women using NES in contraceptive implants. In addition, the endometrium was similar during long-tern use of NES-releasing contraceptive implants in women with and without endometrial bleeding. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Estadual Campinas, Sch Med, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
   Univ Estadual Campinas, Sch Med, Dept Pathol, BR-13084971 Campinas, SP, Brazil.
RP Petta, CA (corresponding author), Univ Estadual Campinas, Sch Med, Human Reprod Unit, Dept Obstet & Gynecol, BR-13084971 Campinas, SP, Brazil.
EM cpetta@attglobal.net
CR ALVAREZSANCHEZ F, 1992, CONTRACEPTION, V46, P387, DOI 10.1016/0010-7824(92)90101-X
   BARBOSA I, 1995, ADV CONTRACEPT, V11, P85, DOI 10.1007/BF01987274
   BELSEY E M, 1991, Advances in Contraception, V7, P257, DOI 10.1007/BF01849416
   BELSEY EM, 1986, CONTRACEPTION, V34, P253, DOI 10.1016/0010-7824(86)90006-5
   Brache V, 2001, CONTRACEPTION, V63, P257, DOI 10.1016/S0010-7824(01)00199-8
   Brache V, 2000, STEROIDS, V65, P687, DOI 10.1016/S0039-128X(00)00175-6
   COUTINHO E, 1978, CONTRACEPTION, V18, P411, DOI 10.1016/0010-7824(78)90026-4
   Critchley HOD, 1998, HUM REPROD, V13, P1218, DOI 10.1093/humrep/13.5.1218
   Croxatto HB, 2002, CONTRACEPTION, V65, P21, DOI 10.1016/S0010-7824(01)00294-3
   d'Arcangues C, 2000, HUM REPROD, V15, P24, DOI 10.1093/humrep/15.suppl_3.24
   DARCANGUES C, 1992, STEROID HORMONES AND UTERINE BLEEDING, P81
   FINA L, 1990, BLOOD, V75, P2417
   Findlay JK, 1996, HUM REPROD, V11, P179, DOI 10.1093/humrep/11.suppl_2.179
   FINN CA, 1986, BIOL REV, V61, P313, DOI 10.1111/j.1469-185X.1986.tb00657.x
   Fraser IS, 1996, HUM REPROD, V11, P165, DOI 10.1093/humrep/11.suppl_2.165
   Fraser IS, 2000, STEROIDS, V65, P665, DOI 10.1016/S0039-128X(00)00188-4
   Galant C, 2000, J CLIN ENDOCR METAB, V85, P4827, DOI 10.1210/jc.85.12.4827
   HAMPTON AL, 1994, J ENDOCRINOL, V141, pR1, DOI 10.1677/joe.0.141R001
   HAUKKAMAA M, 1991, CONTRACEPTION, V44, P269, DOI 10.1016/0010-7824(91)90017-A
   Hickey M, 1996, HUM REPROD, V11, P2009
   Hickey M, 1996, HUM REPROD, V11, P35, DOI 10.1093/humrep/11.suppl_2.35
   Hickey M, 1999, CONTRACEPTION, V59, P123, DOI 10.1016/S0010-7824(99)00012-8
   Irwin JC, 1996, J CLIN INVEST, V97, P438, DOI 10.1172/JCI118433
   Jeziorska M, 1996, J REPROD FERTIL, V107, P43
   JOHANNISSON E, 1990, CONTRACEPTION MECH E, P53
   Jones RL, 2000, HUM REPROD, V15, P162, DOI 10.1093/humrep/15.suppl_3.162
   Kokorine I, 1996, J CELL SCI, V109, P2151
   KURUNMAKI H, 1985, CONTRACEPTION, V31, P305, DOI 10.1016/0010-7824(85)90099-X
   LAHTEENMAKI P, 1981, CONTRACEPTION, V23, P63
   LAURIKKAROUTTI M, 1990, CONTRACEPTION, V42, P111, DOI 10.1016/0010-7824(90)90095-D
   LEES M, 1994, EUR J BIOCHEM, V223, P171, DOI 10.1111/j.1432-1033.1994.tb18980.x
   MARBAIX E, 1995, BIOCHEM J, V305, P1027, DOI 10.1042/bj3051027
   Marbaix E, 1996, P NATL ACAD SCI USA, V93, P9120, DOI 10.1073/pnas.93.17.9120
   Marbaix E, 2000, HUM REPROD, V15, P120, DOI 10.1093/humrep/15.suppl_3.120
   MAZUR MT, 1995, DIAGNOSIS ENDOMETRIA, P109
   McGavigan CJ, 2003, HUM REPROD, V18, P77, DOI 10.1093/humrep/deg023
   Nagase H, 1998, BIOL EXTRAC, P43
   NILSSON CG, 1984, FERTIL STERIL, V41, P52
   ODLIND V, 1984, UPSALA J MED SCI, V89, P151, DOI 10.3109/03009738409178475
   ODLIND V, 1990, CONTRACEPTION MECHAN, P5
   Oliveira-Ribeiro M, 2004, HUM REPROD, V19, P1778, DOI 10.1093/humrep/deh348
   Rhoton-Vlasak A, 2005, FERTIL STERIL, V83, P659, DOI 10.1016/j.fertnstert.2004.11.009
   RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461
   RODRIGUEZ G, 1976, STUD FAMILY PLANN, V7, P42, DOI 10.2307/1964872
   Salamonsen LA, 2000, HUM REPROD UPDATE, V6, P16, DOI 10.1093/humupd/6.1.16
   Salamonsen LA, 1999, J REPROD IMMUNOL, V44, P1
   Salamonsen LA, 1996, REPROD MED REV, V5, P185
   SILVERBERG SG, 1986, INT J GYNECOL PATHOL, V5, P235, DOI 10.1097/00004347-198609000-00005
   Sivin I, 2004, CONTRACEPTION, V69, P137, DOI 10.1016/j.contraception.2003.10.003
   Skinner JL, 1999, HUM REPROD, V14, P793, DOI 10.1093/humrep/14.3.793
   Song JY, 1996, HUM REPROD, V11, P1713
   SUHONEN S, 1992, FERTIL STERIL, V57, P1211
   Vincent AJ, 2000, HUM REPROD, V15, P135, DOI 10.1093/humrep/15.suppl_3.135
   WANG IYS, 1995, CONTRACEPTION, V51, P243, DOI 10.1016/0010-7824(95)00040-H
NR 54
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0010-7824
EI 1879-0518
J9 CONTRACEPTION
JI Contraception
PD JUN
PY 2006
VL 73
IS 6
BP 634
EP 640
DI 10.1016/j.contraception.2005.10.013
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 052BU
UT WOS:000238206500017
PM 16730498
DA 2020-12-01
ER

PT J
AU Bahamondes, L
   Espejo-Arce, X
   Hidalgo, MM
   Hidalgo-Regina, C
   Teatin-Juliato, C
   Petta, CA
AF Bahamondes, L
   Espejo-Arce, X
   Hidalgo, MM
   Hidalgo-Regina, C
   Teatin-Juliato, C
   Petta, CA
TI A cross-sectional study of the forearm bone density of long-term users
   of levonorgestrel-releasing intrauterine system
SO HUMAN REPRODUCTION
LA English
DT Article
DE bone mineral density; contraception; levonorgestrel-releasing
   intrauterine system; Mirena (R)
ID DEPOT MEDROXYPROGESTERONE ACETATE; FOLLOW-UP; OSTEOPOROTIC FRACTURES;
   OVARIAN-FUNCTION; MINERAL DENSITY; CLINICAL-TRIAL; WOMEN; CONTRACEPTION;
   IMPLANTS; ESTROGEN
AB BACKGROUND: There are concerns about the effect of hormonal contraceptives on bone mineral density (BMD), but there is currently no information available on the effect of the levonorgestrel-releasing intrauterine system (LNG-IUS) on BMD. The objective of this study was to compare the BMD of LNG-IUS users with that of controls using the TCu380A intrauterine device (IUD). MATERIALS AND METHODS: A cross-sectional study paired 53 women, aged 25-51 years, who had been using the LNG-IUS for 7 years, with 53 IUD users, according to age (+/- 1 year) and body mass index (BMI; kg/m(2)) (+/- 1). BMD was evaluated at the midshaft of the ulna and the distal radius of the nondominant forearm using double X-ray absorptiometry. RESULTS: Mean age of women was 34 years. BMI was slightly over 25 in both groups. Estradiol was normal. Mean BMD was 0.469 +/- 0.008 and 0.467 +/- 0.009 and 0.409 +/- 0.009 and 0.411 +/- 0.009 at the midshaft of the ulna and distal radius in LNG-IUS and IUD users, respectively, without significant differences. CONCLUSIONS: Women aged 25-51 years, using the LNG-IUS for 7 years, had a mean BMD similar to that of the control group of TCu380A IUD users.
C1 Univ Estadual Campinas, Sch Med, Dept Obstet & Gynaecol, Human Reprod Unit, Campinas, SP, Brazil.
RP Bahamondes, L (corresponding author), Caixa Postal 6181, BR-13084971 Campinas, SP, Brazil.
EM bahamond@caism.unicamp.br
RI Juliato, Cassia R T/D-4447-2012
OI Juliato, Cassia R T/0000-0003-3197-1195
CR [Anonymous], 2004, MED EL CRIT CONTR US
   Armitage P., 1971, STAT METHODS MED RES
   Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021
   Bahamondes L, 2000, CONTRACEPTION, V62, P23, DOI 10.1016/S0010-7824(00)00132-3
   Bahamondes L, 1999, FERTIL STERIL, V71, P849, DOI 10.1016/S0015-0282(99)00084-9
   Bahamondes L, 2003, J REPROD MED, V48, P637
   BAHAMONDES L, 2005, HUM REPROD ADV  1010
   BARBOSA I, 1995, ADV CONTRACEPT, V11, P85, DOI 10.1007/BF01987274
   CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505
   Cromer BA, 1996, J PEDIATR-US, V129, P671, DOI 10.1016/S0022-3476(96)70148-8
   Cundy T, 1998, OBSTET GYNECOL, V92, P569, DOI 10.1016/S0029-7844(98)00270-1
   CUNDY T, 1991, BRIT MED J, V303, P13, DOI 10.1136/bmj.303.6793.13
   Diaz J, 2000, CONTRACEPTION, V62, P59, DOI 10.1016/S0010-7824(00)00140-2
   Diaz S, 1999, HUM REPROD, V14, P2499, DOI 10.1093/humrep/14.10.2499
   DIAZ S, 1982, CONTRACEPTION, V25, P447, DOI 10.1016/0010-7824(82)90033-6
   DIAZ S, 1987, CONTRACEPTION, V35, P551, DOI 10.1016/S0010-7824(87)80016-1
   Gbolade B, 1998, BRIT J OBSTET GYNAEC, V105, P790, DOI 10.1111/j.1471-0528.1998.tb10211.x
   Hampton NRE, 2005, HUM REPROD, V20, P2653, DOI 10.1093/humrep/dei085
   Hidalgo M, 2002, CONTRACEPTION, V65, P129, DOI 10.1016/S0010-7824(01)00302-X
   Hurskainen R, 2004, JAMA-J AM MED ASSOC, V291, P1456, DOI 10.1001/jama.291.12.1456
   JIA M C, 1992, Advances in Contraception, V8, P33, DOI 10.1007/BF01849346
   Kaunitz AM, 2005, CONTRACEPTION, V72, P165, DOI 10.1016/j.contraception.2005.05.011
   Lockhat FB, 2005, HUM REPROD, V20, P789, DOI 10.1093/humrep/deh650
   LUUKKAINEN T, 1990, ANN MED, V22, P85, DOI 10.3109/07853899009147248
   Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254
   Monteiro I, 2002, CONTRACEPTION, V65, P325, DOI 10.1016/S0010-7824(02)00283-4
   NAESSEN T, 1995, CONTRACEPTION, V52, P35, DOI 10.1016/0010-7824(95)00121-P
   NILSSON CG, 1984, FERTIL STERIL, V41, P52
   NILSSON CG, 1982, CLIN ENDOCRINOL, V17, P529, DOI 10.1111/j.1365-2265.1982.tb01625.x
   Perrotti M, 2001, FERTIL STERIL, V76, P469, DOI 10.1016/S0015-0282(01)01936-7
   Petitti DB, 2000, OBSTET GYNECOL, V95, P736, DOI 10.1016/S0029-7844(00)00782-1
   Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
   Raudaskoski T, 2002, BJOG-INT J OBSTET GY, V109, P136, DOI 10.1016/S1470-0328(02)01167-9
   RAUDASKOSKI TH, 1995, AM J OBSTET GYNECOL, V172, P114, DOI 10.1016/0002-9378(95)90095-0
   ROBERTSON DN, 1983, CONTRACEPTION, V27, P483, DOI 10.1016/0010-7824(83)90045-8
   Ronnerdag M, 1999, ACTA OBSTET GYN SCAN, V78, P716, DOI 10.1034/j.1600-0412.1999.780810.x
   *US FDA, 2004, TALK PAP BLACK BOX W
   Volpe A, 1997, Eur J Contracept Reprod Health Care, V2, P123
   *WHO, 2005, WHO STAT HORM CONTR
   World Health Organization, 1994, WHO TECHN REP SER
NR 40
TC 25
Z9 26
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD MAY
PY 2006
VL 21
IS 5
BP 1316
EP 1319
DI 10.1093/humrep/dei457
PG 4
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 033AP
UT WOS:000236818600035
PM 16373404
OA Bronze
DA 2020-12-01
ER

PT J
AU Petta, CA
   Ribeiro, M
   Andrade, L
   Bahamondes, L
   Hidalgo, M
AF Petta, C. A.
   Ribeiro, M.
   Andrade, L.
   Bahamondes, L.
   Hidalgo, M.
TI Correlation between endometrial histology, microvascular density and
   calibre, matrix metalloproteinase-3 and bleeding pattern in women using
   intrauterine levonorgestrel
SO HUMAN REPRODUCTION
LA English
DT Meeting Abstract
C1 [Petta, C. A.; Ribeiro, M.; Andrade, L.; Bahamondes, L.; Hidalgo, M.] Univ Estadual Campinas, Dept Gynecol, Campinas, SP, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
J9 HUM REPROD
JI Hum. Reprod.
PD JUN
PY 2003
VL 18
SU 1
BP 44
EP 45
PG 3
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA V23AP
UT WOS:000208316000123
DA 2020-12-01
ER

EF